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ABSTRACT 
Introduction: HIV-infected and HIV-exposed-uninfected children have a heightened 
susceptibility to some vaccine preventable disease. There is a paucity of data on 
immunogenicity of vaccines in these children, including HIV-infected children who are 
initiated on early antiretroviral therapy (ART). We evaluated the effect of maternal HIV-
exposure and timing of ART in HIV-infected children on antibody responses to combined 
diphtheria-toxoid (DT) -tetanus-toxoid (TT)-whole cell pertussis (wP) and Haemophilus 
influenzae type b conjugate vaccine (HibCV); monovalent hepatitis B vaccine (HepB) and 
live-attenuated measles vaccine (MV).  
 
Methods: Samples obtained from children aged 6–12 weeks who had been enrolled into the 
CIPRA-SA study were analysed. Briefly, HIV-uninfected children born to HIV-uninfected 
(HIV-unexposed) and HIV-infected mothers (HEU). Additionally, we enrolled perinatally 
HIV-infected children with CD4+%≥25% randomized to deferred-ART (i.e. initiated when 
clinically or immunologically indicated per the then WHO recommended treatment criteria; 
ART-Def) or immediate-ART initiation (i.e. initiated on ART immediately upon confirmation 
of HIV-infection status at 4-10 weeks of age; ART-Immed). Children enrolled in the ART-
Immed arm were further randomized to interrupt ART at one-year (ART/12m) or two-years 
of age (ART/24m). Additionally, a convenience sample of HIV-infected children with 
CD4+<25% initiated on immediate-ART was enrolled (ART-CD4+<25%). Children received 
a primary series of DTwP-HibCV/HepB at 6, 10 and 14 weeks of age; and MV at 40 weeks of 
age. Booster dose of DTwP and MV was given at 15-18 months of age. Sampling time-points 
were: prior to the first dose of vaccine, four weeks after the third dose (18 weeks age), 24 
weeks after the third dose (39.3 weeks of age), at the time of the booster dose (15- 18 months 
age), two  to four weeks after the booster dose and at 24 months of age. Samples were 
analysed for antibodies for DT, TT, PT, FHA, HepB measured by Luminex microbead-
immunoassay; and MV antibodies were quantified by an indirect enzyme immunoassay.  
 
Results:  Antibody kinetics and response to primary series of DTwP-HibCV/HepB: 
Pre-vaccination GMCs were higher in HIV-unexposed than HEU children for TT, but lower 
for HepB, DT and FHA. Post-vaccination, sero-conversion, sero-protection and GMCs were 
similar in HEU and HIV-unexposed children for all vaccines. Furthermore, GMCs were 
higher in HIV-unexposed for TT, DT, HepB and FHA than in ART-Immed children; and for 
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TT, HepB and PT than in ART-Def children. Nevertheless, there was no difference in 
proportion of HIV-unexposed and HIV-infected children who developed sero-protective 
vaccine-specific antibody levels post-vaccination. The timing of ART initiation generally did 
not affect immune responses to vaccines between HIV-infected groups.  
 
Antibody kinetics and booster responses to DTwP-HibCV/HepB vaccines:  
Pre-booster GMCs were generally higher in HIV-unexposed than HIV-infected children for 
all vaccine epitopes. Post-booster and at 24 months of age the ART-Def group had lower 
GMCs (except to FHA), and were less likely to have sero-protective antibody levels 
compared to HIV-unexposed group. Also, post-booster and at 24 months of age, GMC were 
generally higher in HIV-unexposed than ART-Immed children, and a higher percentage of 
HIV-unexposed than ART-Immed children maintained antibody levels ≥1IU/ml to TT and 
DT at 24 months of age. The GMCs and percentage of children with sero-protective 
thresholds were similar pre-booster and at 24 months of age between HIV-unexposed and 
HEU children. 
 
Antibody kinetics and response to measles virus vaccine:  
At 7.3 weeks of age, the proportion with sero-protective titers was higher in HIV-unexposed 
(65.2%) compared to any HIV-infected group (range: 16.7% to 41.8%); but dropped to <17% 
in all Groups at age 19.6 weeks. Twenty-eight weeks following the first measles-vaccine, 
ART/12m were less likely to have sero-protective titers (79.3%) compared to HIV-unexposed 
(94.8%; p<0.001), ART-Def (95.7%; p=0.003) or ART/24m (92.1%; p=0.02). Although the 
proportion with sero-protective levels were similar between groups immediately post-booster 
dose, this was lower in HEU (79.6%; p=0.002) and ART/12m (80.3%; p=0.01) compared to 
HIV-unexposed (94.3%) 41-weeks later. 
 
Conclusion: Primary vaccination with DTwP-HibCV/HBV of HIV-infected children initiated 
on early-ART confers similar immunity compared to HIV-unexposed children. HIV-infected 
children had poor anamnestic responses, if ART was not initiated prior to primary 
vaccination. In contrast, the memory response and persistence of antibody to most vaccine 
epitopes were similar between HIV-unexposed and HEU children. Increased waning of 
vaccine induced immunity over a 24 month period in ART-Def, ART/12m and HEU children 
following MV booster-dose; indicating the need for further booster doses after two-years of 
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age in these children. I recommend close monitoring of HEU children, as this group makes up 
most children born to HIV-infected mothers and what facets of the immune system have been 
impacted by maternal exposure to HIV.  
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PREFACE 
The format presented for this thesis is the ―Divided block‖ as recommended by the University 
of the Witwatersrand. This thesis is divided into two parts: the first part is a background 
literature review and objectives, and study method description. The second part consists of 
results and discussion of the study objectives that are written as separate chapters. 
 
The thesis deals with the effects of human immunodeficiency virus exposure and timing of 
antiretroviral therapy initiation among HIV-infected infants on their immunological responses to 
childhood vaccines. Furthermore we aimed to identify factors that affect immune response to 
childhood vaccine in HIV-infected children.  
 
Chapter 1: The introductory chapter provides a synopsis of the burden of HIV-infection and 
how it has thus far affected immunization and the burden of vaccine preventable diseases 
globally and in sub-Saharan Africa. I also review studies that have been conducted and 
highlight the paucity of data surrounding the objectives of my research. 
 
Chapter 2: The literature review chapter provides an overview of the immune system and the 
dysfunctions that might result from HIV-infection. Furthermore I discuss ART treatment 
strategies of HIV in young children. I also discuss the public health of HIV-exposed 
uninfected children. In addition, the burden of vaccine preventable diseases in children under 
the age of five years, in particular diphtheria, tetanus, pertussis, measles, hepatitis B and 
Haemophilus influenzae type b are summarised. Also, I briefly describe the effects which the 
high HIV prevalence in sub-Saharan Africa has had on short and long-term immunogenicity 
of these vaccines. Furthermore, the detection methods (ELISA) that were historically used to 
assess immune response to vaccines and well as their short comings are discussed. The 
concluding statement of this chapter is the hypothesis and study rationale.  
 
Chapter 3: This chapter lists the study aims and details the primary and secondary objectives 
of the study. 
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Chapter 4: This chapter details the methods of the research. To address  the study objectives, 
the study was divided into two phases: Phase 1: I developed, validated and optimized the 
Luminex microbead immunoassay by using samples from a previous cohort(Madhi et al., 
2009), to determine which reference standard to use, the limits of detection, controls, required 
sample volume, antigen coating concentration, incubation times, sensitivity and specificity.  
 
Chapters‘5 to 8 present the results and brief discussion of my work. In chapter 5, the 
validation and optimization of Luminex microbead immunoassay is presented and answers 
objective (i). The results are a comparison of the conventional ELISA vs. the Luminex 
microbead immunoassay. Also, I show the superiority of the microbead immunoassay over 
the conventional ELISA. In Chapter 6, I present results of response to primary vaccine 
(Objective ii) and the short term persistence of antibodies to DTwP/HepB vaccines in HEU 
and HIV-infected either on immediate ART or not. I also show factors that may be 
responsible for response to primary vaccination in children born to HIV-infected mothers.  In 
Chapter 7, the effects of HIV-infected and ART treatment strategies on booster responses and 
persistence of antibodies to DTwP/HepB are presented (Objective iii). Furthermore, factors 
that may be associated with response to booster vaccination are analysed by mixed linear 
regression model. In chapter 8, the effects of HIV-exposure and ART treatment on immune 
response to measles vaccine are presented (Objective iv). In this chapter I evaluate immune 
responses to primary and booster vaccination, as well as factors associated with response to 
measles vaccine. 
 
Chapter 9: This chapter provides a summary of my research findings, a description of the 
study-limitations, and the implications of my research findings in formulating health policy. 
The thesis concludes with a summary of the findings and a conclusion. 
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CHAPTER 1: INTRODUCTION 
The burden of childhood mortality still remains one of the biggest challenges facing sub-
Saharan Africa, with the United Children‘s Fund most recent estimates indicating that one in 
every nine children dies before the age of five years (United Nations, 2015). In view of these 
recent developments, the majority of sub-Saharan African countries have not met the United 
Nations Millennium Development Goal (MGD) 4 aimed at reducing the mortality of children 
under the age of five years by 2015 compared to 1990 levels (United Nations, 2015). In South 
Africa, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) 
was identified as one of the five major causes of mortality in children under the age of five 
years in 2013, in addition to diarrhoeal diseases, pneumonia, preterm birth complications and 
birth asphyxia (Nannan et al., 2012, Massyn et al., 2015).   
 
One in three women aged 25 to 29 years, the biggest group of woman of child bearing age, 
were at  risk of contracting HIV in 2008 in South Africa (Shisana et al., 2009). Furthermore, 
there has been an epidemiological change between 2008 to 2012, which showed that the peak 
HIV prevalence for females had shifted from 25 to 29 year age group in 2008 to the 30 to 39 
year age group in 2012 (Shisana et al., 2014).  Furthermore,, in  2014/15  an estimated 91% of 
South African pregnant woman living with HIV were receiving some form of antiretroviral 
treatment (ART) for the prevention of mother-to-child-transmission (PMTCT)  (Massyn et al., 
2015). The steady increase in access to ART has resulted in HIV mother-to-child-
transmission rates dropping to <2% in 2014/15 (Massyn et al., 2015), however the prevalence 
of children born to HIV-infected women has remained unchanged over the past decade in 
South Africa. This has resulted in approximately one-third of newborns in South Africa being 
HIV-exposed in utero, albeit the majority are HIV-uninfected (Massyn et al., 2015).  
 
HIV-infected children demonstrate aberrations of both humoral and cell mediated immune 
responses (Resino et al., 2004, Letvin and Walker, 2003), and several abnormalities in B-
lymphocytes (Resino et al., 2004, Shearer et al., 2000). The dysfunction of the immune 
response is evident early on during the course of their HIV-infection, when individuals show 
a gradual loss of their T-lymphocytic proliferative responses (Gona et al., 2006, Letvin and 
Walker, 2003), progressive decline in total B-lymphocytes, with polyclonal hyper-gamma 
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globulinemia (Shearer et al., 2000), and loss of pathogen specific antibodies (Pensieroso et al., 
2009). This immunodeficiency state could impair immune responses to vaccines.    
 
With improving survival rates in children with HIV being observed as a result of increased 
access and early initiation of ART (Violari et al., 2008), the vaccine responses in this 
population of children needs to be considered (Miller and Rathore, 2012). It is important to 
understand the degree of immune compromise and prospective immune recovery of these 
children, to gain guidance in vaccine administration for these children (Miller and Rathore, 
2012). Vaccines have generally been found to be safe in HIV-infected children, with the 
notable exception of live-attenuated Bacillus Calmette-Guérin (BCG) (Jones et al., 2011). 
Although caution is raised with other live-attenuated vaccines, including oral polio vaccine 
and measles vaccine, there has been no documentation indicating an adverse safety profile for 
these vaccines in HIV-infected children (Moss et al., 2003). Immune response to vaccines 
among HIV-infected children in the pre-ART era was generally poor following  primary 
vaccination, for diphtheria (10-88% sero-protection) (Ryder, 1993, Borkowsky et al., 1992, 
Borkowsky et al., 1987, Tejiokem et al., 2007), tetanus (25-82% sero-protection) (Essajee et 
al., 1999, Zaccarelli-Filho et al., 2007, Tejiokem et al., 2007, Borkowsky et al., 1987, 
Pensieroso et al., 2009, Farquhar et al., 2009, Barbi et al., 1992, Rosenblatt et al., 2005), 
pertussis (23%-75% sero-positivity) (Tejiokem et al., 2009, de Martino et al., 1997, Tejiokem 
et al., 2007), hepatitis B (0-78% sero-protection) (Schoub, 2002, Bruguera et al., 1992, 
Zaccarelli-Filho et al., 2007, Zuin et al., 1992, Simani et al., 2009, Zuccotti et al., 1994) and 
measles (16-77% sero-protection) (Oxtoby et al., 1989, Krasinski and Borkowsky, 1989, 
Thaithumyanon, 2000, Rudy et al., 1994, Moss et al., 2007, Tejiokem et al., 2007, Palumbo et 
al., 1992). The lesser likelihood of inducing sero-protective antibody concentrations among 
HIV-infected children was particularly evident among those  with low CD4+ lymphocyte 
counts; with humoral and cellular immune responses often correlated with CD4+ lymphocyte 
count  (Tejiokem et al., 2007). In those children who demonstrated response, there was a 
greater waning of immunity to diphtheria-toxoid, tetanus-toxoid, whole-cell pertussis and 
measles vaccine over time when compared to their HIV-uninfected controls (Tejiokem et al., 
2007, Rosenblatt et al., 2005). Consequently, the high burden of HIV-infection in South 
Africa and other sub-Saharan African countries could increase the number of vaccine failures 
(either primary or secondary) and reduce the effectiveness of these vaccines (Burnett et al., 
2005).  
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Despite the success of reducing mother-to-child HIV transmission, HEU compared to HIV-
unexposed children in developed and developing countries have been found to have lower 
concentrations of specific antibody to vaccine-preventable diseases including to H. influenzae 
type b, pneumococcus, tetanus and pertussis (Gaensbaier et al., 2014, Jones et al., 2013, 
Madhi et al., 2013a, Jones et al., 2011, Madhi et al., 2005, Madhi et al., 2013b). The 
decreased antibody concentration observed in HEU children could be due to low 
concentration of specific antibodies in the HIV-infected mothers, compounded by reduced 
transplacental transfer of antibody from mother-to-child (Jones et al., 2013, Jones et al., 2011, 
Cumberland et al., 2007, de Moraes-Pinto et al., 1998, de Moraes-Pinto et al., 1996). On the 
other hand, response to primary vaccination in HEU children are similar (for diphtheria, 
tetanus, H. influenzae type b and BCG) (Jones et al., 2011, Reikie et al., 2013, Hesseling et 
al., 2015) or even increased (for pertussis, pneumococcal capsular polysaccharide, and 
measles) (Jones et al., 2011, Madhi et al., 2013a, Madhi et al., 2010) compared to HIV-
unexposed children.  Also, high percentage (>97%) of HEU children have  serological 
evidence of protection after combined measles, mumps and rubella immunization (Siberry et 
al., 2015). In addition, the fold-increase of antibody concentration from pre- to post 
vaccination is increased in HEU for pertussis (PT and FHA) and pneumococcus vaccine 
epitopes when compared to HIV-unexposed children (Jones et al., 2011). The robust immune 
response to vaccine epitopes observed in HEU children could be explained by the reduced 
interference of maternal antibody on the child immune response to vaccines, which has been 
reported for multiple vaccines.  
 
In contrast to the above, other studies have shown decreased antibody response in HEU 
children for hepatitis B, oral polio and BCG vaccines when compared to HIV-unexposed 
children (Abramczuk et al., 2011, Mazzola et al., 2011, Van Rie et al., 2006). Possibly due to 
ART exposure for the prevention of mother-to-child transmission at birth, and in utero 
exposure to HIV virion particle may affect the cytokine profile that is necessary for vaccine 
response and lower total B-lymphocyte population in HEU children (Hesseling et al., 2015, 
Kakkar et al., 2014, Abramczuk et al., 2011). Reduced thymus lymphocyte  output and 
functional defects of antigen presenting cells have also been reported in HEU children 
(Desmonde et al., 2016)  
 
Although these studies indicate significant differences and trends in vaccine specific 
responses in children born to HIV-infected woman, they have mainly evaluated immune 
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responses following the primary series of vaccines, without further follow-up. Others have 
mainly assessed re-vaccination in HIV-infected children while receiving ART, without 
evaluating the responses following the primary series (Zaccarelli-Filho et al., 2007, Rigaud et 
al., 2008, Ching et al., 2007, Fernandes et al., 2008, Abzug et al., 2009, Aurpibul et al., 2006). 
In all these studies, none evaluated the effect of the timing of initiation of ART among HIV-
infected children on immune responses to the primary series of vaccines; and longitudinal 
follow-up of the HIV-infected children to determine the specific effects of timing of ART 
initiation or interruption thereof on persistence of antibody and response to booster doses of 
vaccines has been limited. Furthermore, there is a paucity of data on immune response to 
childhood vaccines with regards to HEU children, especially in Africa.  
 
We set out to investigate vaccine specific immunoglobulin G (IgG) responses to diphtheria-
toxoid, tetanus-toxoid, whole cell pertussis, Hib conjugate vaccine (Analysed in a separate 
study and not part of this thesis), hepatitis B and measles vaccine in HIV-infected children 
initiated on ART immediately upon being diagnosed as being HIV-infected within 4-10 
weeks of age  (ART-Immed) or in whom it was only initiated following progression to the 
then WHO recommended criteria for ART initiation based on clinical or immunological 
progression. Also, we evaluated immune responses to these vaccines among HEU children 
and compared all groups to the immune responses observed in the cohort of HIV-unexposed 
uninfected children. These children had been enrolled into a longitudinal cohort study in 
which the immune responses to 7-valent pneumococcal conjugate vaccine had been evaluated 
(Madhi et al., 2010), and the HIV-infected children were also participants in the CHER study 
in which the different ART regimens was evaluated (Violari et al., 2008). 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Overview of immune system 
The immune system is composed of proteins and cells whose major role is to protect the skin, 
respiratory tract, intestinal tract and other areas of the body from  bacteria, fungi, parasites, 
viruses, cancer cells and toxins (Warrington et al., 2011). Immunity is the ability of the human 
body to respond to infection and maintain resistance to infectious diseases. Synchronization of 
the immune system, tissues and organs against potential pathogens is defined as an immune 
response. Therefore, the major role of the immune system is to confer protection by prevention 
and elimination of invading pathogens (Warrington et al., 2011). 
 
There are two major arms of the immune system, innate and adaptive immunity, that act as the 
host line of defence (Warrington et al., 2011). Innate immunity (non-specific) represents the first 
line of defence to potential pathogens. This defence mechanism is antigen-independent and is 
triggered by the host immediately or within hours of antigen exposure. Furthermore, it does not 
result in immunologic memory (Turvey and Broide, 2010). On the other hand, adaptive immunity 
is antigen-dependent and antigen-specific and therefore involves a lag time between exposure to 
the antigen and optimal immune response. This arm of immunity, could result in immunologic 
memory, which allows the host to mount a more rapid and efficient immune response to 
subsequent homotypic antigen exposure (Bonilla and Oettgen, 2010). The innate and adaptive 
arms of immunity are inter-dependent  as host defence mechanisms, with defects in either 
increasing susceptibility  to infectious diseases (Warrington et al., 2011).  
 
2.1.1 Innate immunity 
Innate immunity plays a key role (Fearon and Locksley, 1996) by recruiting immune cells to the 
site of infection and inducing an inflammatory response  through  production of cytokines 
(Warrington et al., 2011). The effectiveness of the immune response is dependent on information 
about the common pathogenic molecular patterns of pathogens that the innate immune response 
encounters (Kalinski et al., 2001, Bonilla and Oettgen, 2010). The availability of the common 
pathogenic molecular patterns allows the pathogen to be targeted selectively and for the effector 
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mechanisms to be targeted against the particular pathogen and  not harmful to the affected host 
tissue (Kalinski et al., 2001).  
 
Exposure of the innate system to a pathogen‘s antigen results in its activation and stimulates an  
adaptive immune response  (Ploegh, 1998, Turvey and Broide, 2010). Many organisms have 
evolved mechanisms to overcome the defences of innate immunity, thereby prompting the need 
for more adaptive defences.  
 
2.1.2 Adaptive immunity 
Adaptive immunity may be humoral or cell mediated (Bonilla and Oettgen, 2010), and develop 
over the lifetime of an individual in response to different antigen exposures, including that of 
potential  pathogens. Adaptive immunity is more specific in defence against infection and disease 
progression than innate immunity (Benjamin, 1996b), and can induce immunological long-term 
memory that offers protection against re-infection (Bonilla and Oettgen, 2010).   
In the event that adaptive immunity is compromised, illness or disease may occur. This could 
occur due to  an overactive immune response (known as hypersensitivity reactions), an 
inappropriate reaction to self (known as autoimmunity) or ineffective immune responses (known 
as immunodeficiency) (Warrington et al., 2011). There are five main properties that define the 
adaptive immune responses, as listed in Table 2.1.  
 
Table 2.1: Properties of adaptive immunity (Benjamin, 1996b). 
Property Significance for immunity to microbes 
Specificity Ability to discriminate among different antigenic 
epitopes presented to it and respond specifically to 
those epitopes  
Adaptiveness Ability to respond to antigenic epitopes to which 
the immune system is naïve 
Discrimination between self and ‗non-self‘ antigens Ability of the  immune system to recognize and 
respond only to non-self epitopes and avoid 
immune responses to the host antigenic structure 
Clonal Expansion The capacity to compete with rapidly proliferating 
microbes 
Memory Ability of memory cells being induced following 
antigenic exposure, which are able to elicit more 
rapid and robust response upon subsequent 
exposure to the same epitope 
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2.1.2.1 Cells involved in Adaptive immunity 
Lymphocytes are the major players in adaptive immunity. These cells include the effectors of 
cellular immune responses, the T-lymphocytes which mature in the thymus, and antibody 
producing B-lymphocytes which originate from the bone marrow (Bonilla and Oettgen, 2010). 
After their development in the primary lymphoid organs (thymus and bone marrow), they are 
transported to secondary lymphoid organs, which include lymph nodes and the spleen, and serve 
to capture circulating antigens from the lymph and blood, respectively (Bonilla and Oettgen, 
2010, Ploegh, 1998).  These cells play an important part in defining the adaptive immune 
response; and are produced and/or activated often under the direction of the innate immune 
system signals (cytokines and chemokines) stimulated  directly or indirectly by circulating 
antigens; or by pathogen activated cutaneous or mucosal antigen-presenting cells (APCs, for 
example macrophages, dendritic cells (DCs) and B-lymphocytes) (Bonilla and Oettgen, 2010, 
Ploegh, 1998).  
 
In the presence of antigen, T- and B-lymphocytes are activated, and after proliferation and 
maturation become effector cells. Effector B-lymphocytes produce antibodies, upon maturation 
they become plasma cells. On the other hand, effector T-lymphocytes produce a wide array of 
cytokines, which serve as signalling proteins that act to mediate the type of immune response 
required (Janeway et al., 2001b). T-lymphocytes are divided into three main classes. 1) Cytotoxic 
T-lymphocytes (CTLs), which are involved in the direct killing of infected host cells. CTLs that 
express the CD8+ molecule on their surfaces are referred to as CD8+ T-lymphocytes. These 
lymphocytes recognize intracellular antigen peptides presented on the MHC class I molecule, 
such as viruses, which results in the activation and killing action of these lymphocytes. The CTL 
killing action is through the release of various toxic molecules, such as perforin and granzymes, 
which induce apoptosis or cell death (Janeway et al., 2001b, Bonilla and Oettgen, 2010).   
2) T helper (Th) lymphocytes, which are involved in the activation of APCs. Th- lymphocytes are 
also known as CD4+ T-lymphocytes. They interact with major histocompatibility complex 
(MHC) class II molecules on antigen presenting cells (Janeway et al., 2001b). Two main classes 
of these cells exist. The first being Th1 cells, which are involved in mediating inflammatory 
responses, and the second is Th2 cells, which play an important role in humoral immunity 
through the activation of B-lymphocytes (Bonilla and Oettgen, 2010, Ridge et al., 1998, Rissoan 
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et al., 1999).   3) T regulatory (Treg) or suppressor lymphocytes, are involved in the control and 
regulation of the immune response (Romagnani, 2005).        
 
Two major forms of adaptive immunity exist, i.e. cell mediated and humoral immunity. Both 
forms are mediated by various cells and proteins and are intended to provide defence against 
extra- and intracellular organisms (Bonilla and Oettgen, 2010).  
 
2.1.2.2 T-lymphocytes and cell-mediated immunity 
Intracellular pathogens are eliminated from the host through cell mediated immunity, and this 
process is mediated by T-lymphocytes.  
 
i) Activation of T-lymphocytes by recognition of MHC associated peptides 
Mature T-lymphocytes express a unique antigen binding receptor on their membrane, known as 
the T-cell receptor (TCR) which is comprised of an α and β chain,  and requires the action of 
APCs to recognize specific antigens (Warrington et al., 2011). TCRs recognize displayed 
peptides and residues located around the peptide-binding cleft of MHC molecules. MHC 
molecules are expressed on the surface of APCs, and are divided into MHC class I which are 
found on all nucleated cells, or class II which are found on certain cells of the immune system, 
including DCs, macrophages and B-lymphocytes (Warrington et al., 2011). Extracellular antigens 
are taken up by either phagocytosis or endocytosis into vesicles of APCs, which process them 
into peptides, which are then displayed by MHC class II complexes (Figure 2.1). Antigens that 
are present within the cytoplasm are processed and displayed by MHC class I molecules 
(Janeway et al., 2001b).  
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Figure 2.1: T- and B-lymphocyte activation and function: Adaptive immunity (Warrington et 
al., 2011). APC: antigen presenting cell; MHC: major histocompatibility complex; TCR; T-
lymphocyte receptor. 
 
Mature MHC restricted T-lymphocytes express either CD4+ or CD8+ cell surface markers, 
which function as co-receptors of TCR and MHC binding. CD4+ T-lymphocytes recognize 
extracellular microbial antigens displayed on MHC class II molecules, and CD8+ T-lymphocytes 
recognize intracellular peptides displayed on MHC class I molecules (Janeway et al., 2001b).  
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ii) T-lymphocyte activation through co-stimulation 
Expression of B7.1 (CD80) and B7.2 (CD86) ligands (co-stimulatory molecules) appears to be 
crucial to the ability of professional APCs (DCs, B-lymphocytes and macrophages) to activate T-
lymphocytes (Lenschow et al., 1996), their expression is increased during APC encounter with 
microbes. These ligands are recognized by a receptor expressed on T-lymphocytes, called CD28. 
Ligation of CD28 (on T-lymphocytes) results in the production of an essential co-stimulatory 
signal that activates resting T-lymphocytes. B7-CD28 interaction co-stimulates the induction of 
interleukin (IL)-2, autocrine T-lymphocyte growth factor that rescues TCR-triggered cells from 
activation induced cell death and allows for their proliferation and acquisition of effector 
functions (Lenschow et al., 1996). In addition, another set of molecules that provide increased co-
stimulatory signals for T-lymphocytes are CD40 Ligand (CD40L) that bind to CD40 on APCs. 
This binding, results in stimulation or activation of APCs to express more B7 co-stimulation and 
secretion of cytokines, such as IL-12, which further enhances T-lymphocyte differentiation 
(Janeway et al., 2001b). 
 
CD8+ T-lymphocytes recognize antigen peptides from cytoplasmic proteins, such as viral 
proteins, in any nucleated cell. During intracellular infection, infected cells are taken up by 
specific APCs, like DCs, after which antigens are ―cross-presented‖. The same APCs may 
present viral antigens from the cytosol in MHC class I. Furthermore, CD4+ T-lymphocytes 
secrete cytokines that play a role in the activation of CD8+ T-lymphocytes leading to their clonal 
expansion and differentiation into effector and memory CTLs. Activation of CD8+ T-lymphocyte 
may explain the defective CTL responses observed in persons with HIV-infection that result in 
the destruction of CD4+ T-lymphocytes and not necessarily CD8+ T-lymphocytes. However this 
event is not necessarily true for all viral infections (Janeway et al., 2001d). 
 
iii) Cytokines and their role in T-lymphocyte activation 
Cytokines are a large set of proteins that function as mediators of immunity and inflammation; 
they are produced by CD4+ T-lymphocytes in response to antigen exposure and co-stimulation. 
Following CD4+ T lymphocyte activation, IL-2 is produced. The IL-2 cytokine up-regulates the 
ability of T-lymphocytes to proliferate and respond by regulating the expression of the IL-2 
receptor. CD4+ T-lymphocytes are dependent on IL-2 production, while CD8+ T-lymphocytes 
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do not produce IL-2 in response to antigen stimulation. It is suggested that antigen recognition 
rather than IL-2 production drives the proliferation of CD8+ T-lymphocytes (Janeway et al., 
2001d). 
 
iv) Th1 and Th2 lymphocytes  
CD4+ helper T-lymphocytes have an important role in establishing and maximizing the immune 
response, through the production of distinct sets of cytokines that possess certain functions. 
These lymphocytes have no cytotoxic or phagocytic activity, and are unable to kill infected cells 
or clear pathogens. Two main subsets of Th lymphocytes exist, Th1 and Th2. Th1 lymphocytes 
are involved in cell mediated responses, activating mononuclear phagocytes, natural killer cells 
and virally infected cells. This response is characterized by the capacity to make interferon 
gamma (INFγ) and IL-2, which activates the bactericidal activity of macrophages (Bonilla and 
Oettgen, 2010). An additional function of Th1 lymphocyte subset is to release cytokines that 
induce B-lymphocytes to make opsonizing and neutralizing antibodies. Furthermore, IFNγ 
stimulates the expression of MHC class II molecules and B7 co-stimulators on APCs, thus 
leading to increased T-lymphocyte responses (Janeway et al., 2001d, Warrington et al., 2011).  
 
The Th2 lymphocyte response is characterized by its involvement in humoral immunity by 
enhancement of B-lymphocyte production, as well as hypersensitivity and parasite-induced 
immune responses. Cytokines released by this subset of lymphocytes include IL-4, IL-5, IL10 
and IL-13 (Bonilla and Oettgen, 2010). IL-10 produced by Th2 lymphocytes plays a role in 
inhibition of macrophages. Furthermore, IL-4 and IL-10 regulate or suppress Th1 lymphocyte 
types (Janeway et al., 2001d). 
 
2.1.2.3 Humoral immunity 
Humoral immunity is an antibody mediated specific immunity, and functions to eliminate 
extracellular microbes. Humoral immune responses follow either direct recognition by B-
lymphocytes through de novo recognition of antigenic epitopes, or following presentation of the 
epitope after processing and presentation thereof  by Th-lymphocytes to B-lymphocytes (Bonilla 
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and Oettgen, 2010). One of the roles of humoral immunity is to defend the host against bacterial 
capsules rich in polysaccharides and lipids (Janeway et al., 2001d). 
 
i) An introduction to antibodies  
Activated B-lymphocytes produce antibodies which together with components of the complement 
pathway flag pathogens for recognition by T-lymphocytes for destruction (Ploegh, 1998). 
Antibodies are depicted by a Y-shaped molecule, and found in the components of blood or 
plasma, as well as extracellular fluid. An antibody is composed of two distinct regions: the 
constant region that holds one of five biochemically distinguishable forms, and a variable region 
that is composed of an unlimited  variety of different amino acid (aa) sequences that vary in 
structure and allow for antibodies to bind to a wide range of antigens (Janeway et al., 2001c).  
 
The variable region determines the binding specificity of an antibody. It consists of two identical 
regions, as a result has two identical antigen binding sites (Fab region). The constant region 
engages the effector functions of the antibody molecule and determines how the antibody will 
process the antigen once bound (Fc region). Furthermore, antibodies are constructed from paired 
heavy and light polypeptide chains, and the generic term immunoglobulin (Ig) is used to describe 
them. These polypeptide chains contribute to the variable and constant region, thus allowing the 
antibody molecule to have a two-fold symmetry. These chains combine to form the antigen-
binding specificity of the antibody molecule (Janeway et al., 2001c). 
 
ii) Antibody function 
There are three main ways in which antibodies can participate in host defence: neutralization, 
opsonization and complement activation (Janeway et al., 2001d). To enter cells, pathogens bind 
to specific molecules on target cell surfaces, antibodies can bind to the pathogen and prevent 
entry by neutralizing the pathogen. Neutralization is important in preventing bacterial toxins or 
viruses from entering the target host cell. Antibodies can also protect against bacteria that 
multiply extracellularly, by facilitating their uptake by phagocytes in two ways. In the first, 
bound antibodies coating the pathogen are recognized by Fc receptors on phagocytic cells that 
bind to the Fc region, which enhances phagocytosis through a process known as opsonization. 
Secondly, antibodies binding to the surface of the pathogen can activate proteins of the 
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complement system. Complement activation results in complement proteins binding to the 
pathogen surface, also leading to opsonization and subsequent  phagocytes and lysis of the 
pathogen (Janeway et al., 2001b). In addition to these functions, antibodies can participate in the 
process of antibody dependent cellular cytotoxicity, where natural killer cells bind Fc receptors 
resulting in lysis of the pathogen infected cell  and its eventual phagocytosis (Bonilla and 
Oettgen, 2010). 
 
Antibodies are produced after stimulation of B-lymphocytes by antigens. The portion of the 
antigen that binds specifically with the binding site of the receptor on a lymphocyte is termed an 
antigenic determinant (i.e. epitope) (Janeway et al., 2001c). The antigen-specific receptors on B- 
lymphocytes are immunoglobulin molecules allowing interaction of epitopes sized between 5-22 
aa residues (Singh et al., 2013). The size of an epitope that binds to specific T-lymphocyte is 
somewhat larger, since it contains an area that binds to MHC proteins of APCs and an area that 
binds specific receptors on the T-lymphocyte resulting in a tri-molecule complex. Therefore the 
size of the epitope is estimated to be 10-15 aa residues long (Singh et al., 2013).  
 
B-lymphocytes stimulated by an antigen then differentiate into antibody secreting cells (plasma 
cells), to produce antibodies of different heavy chain classes or isotypes (Table 2.2). There are a 
total of five known antibody isotypes produced by B-lymphocytes: IgA, IgD, IgE, IgG and IgM, 
each possessing their own class of heavy chains (α, δ, ε, γ, and μ) respectively (Table 2.2) 
(Stavnezer et al., 2008). IgG and IgA isotypes have been divided into further subclasses (e.g. 
IgG1-4 and IgA1-2) that differ in heavy chains. The differing heavy chains give rise to distinct 
conformations in the hinge and tail regions of antibodies so that each class and subclass is unique 
(Janeway et al., 2001b). 
 
Table 2.2: Main functions of human immunoglobulin antibodies (Warrington et al., 2011, 
Panda and Ding, 2015). 
Immunoglobulin isotype Function 
IgM First Ig expressed during B-lymphocyte 
development (primary response) 
Opsonizing antigen for destruction 
Complement fixation 
IgG Main Ig during secondary immune response 
Only antibody capable of crossing placental 
barrier 
Neutralization of toxins and viruses 
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Opsonizing antigen for destruction 
Complement fixation 
IgD Function unclear, but appears to play a role in 
homeostasis 
IgA Mucosal response 
Protects mucosal surfaces from toxins, viruses 
and bacteria through direct neutralization or 
prevention of binding to mucosal surface 
IgE Associated with hypersensitivity and allergic 
reactions 
Plays a role in immune response to parasites 
 
Antibody isotypes are able to enter the blood through a process of transduction and progress to 
the site of infection. This function allows antibodies to fight infection throughout the host‘s body. 
Based on the type of signals elicited by this response, B- and T-lymphocytes differentiate to a 
memory phenotype and obtain a particular effector function (Bonilla and Oettgen, 2010). These 
effector mechanisms are recalled whenever effector/memory lymphocytes are re-exposed to the 
specific epitope (Swain et al., 1991, Richter et al., 1999). Memory lymphocytes influence the 
immune responses to subsequent exposure to the same epitope  (Benjamin, 1996a). The ease with 
which memory lymphocytes are triggered, even at extremely low antigen concentrations may 
explain why immune responses tend to be dominated by memory lymphocytes from previous 
infections (Rogers et al., 2000). Memory lymphocytes of a certain responsive mode may direct 
the differentiation of new, naïve clonotypes of lymphocytes via cytokine secretion (Paul and 
Seder, 1994).  
 
The innate immune system generally induces the appropriate type of adaptive immune response 
to pathogens. Pre-existing memory lymphocytes can dramatically increase the chances of 
surviving following an infection, an example of this is seen with memory responses following 
vaccination (Borghans and De Boer, 2002). There are many advantages of memory lymphocytes, 
as they are not confined to lymphoid tissue and freely enter solid tissue, respond from anywhere 
and anytime where a specific epitope is encountered (Zinkernagel et al., 1997). Responses as a 
result of memory lymphocytes are typically faster than in primary immune responses, because 
memory lymphocytes are more sensitive to low concentration of antigen, have stringent 
requirements for co-stimulation and are primed for specific responses (Borghans and De Boer, 
2002).   
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iii) B-lymphocyte activation 
For an antigen to be immunogenic it must be exogenous to the host being exposed, must be of 
relatively high molecular weight and possess a certain degree of chemical complexity (Benjamin, 
1996a). Processing of antigens can be classified as either T-lymphocyte independent (TI) or T-
lymphocyte dependent (TD) in nature (Lesinski and Westerink, 2001, Bonilla and Oettgen, 
2010).  
 
iv) T-independent antigens 
TI  immune responses are associated with a less important role of T-lymphocytes in inducing B-
lymphocyte production of epitope specific antibodies or their differentiation (Bonilla and 
Oettgen, 2010). TI immune responses are also not associated with inducing differentiation of B- 
or T-lymphocytes into memory cells. TI antigens are generally polysaccharide epitopes and  can 
either be Th1 or Th2 based on their interaction with B-lymphocytes (Lesinski and Westerink, 
2001). Antigens such as lipopolysaccharides are known potent B-lymphocyte mitogens. They 
function by non-specific, polyclonal activation of most B-lymphocytes; they do not induce 
memory-lymphocytes or isotype switching of antibodies. In contrast, Th2 antigens are capsular 
polysaccharides; they do not function as B-lymphocyte mitogens and can only activate mature B-
lymphocytes (Lesinski and Westerink, 2001). 
 
v) T-dependent antigens 
Conversely, antigens eliciting TD immune responses, include peptides or proteins, and involve 
B-lymphocyte stimulation though Th1 lymphocytes. TD antigens are presented to T-lymphocytes 
by APCs in conjunction with MHC molecules (Bonilla and Oettgen, 2010). The activation of T-
lymphocytes results in cytokine production and an array of immunologic reactions. Epitope 
recognition by Th1 lymphocytes result in their differentiation as well as presentation of epitopes 
and stimulation of B-lymphocytes. This consequently induces immunoglobulin production 
including maturation and production of high affinity antibodies of varying isotypes and 
differentiation into memory B- and T-lymphocyte sub-populations (Bonilla and Oettgen, 2010, 
Lesinski and Westerink, 2001).  
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vi) Immunopathology 
Defects or malfunctions in either innate or adaptive immunity can occur as a result of 
hypersensitivity reactions, autoimmunity and immunodeficiency (Warrington et al., 2011). As 
part of this section, immunodeficiency will be reviewed. Immunodeficiency often refers to the 
immune system‘s inability to fight infectious disease. Immunodeficiency disorders can be 
classified into two forms: 1) primary congenital defect (primary immunodeficiency) or 2) 
acquired from a secondary source (secondary immunodeficiency), such as bacterial or viral 
infections, malnutrition or treatment with immunosuppressive drugs. A number of diseases can 
cause direct or indirect impairment of the immune system such as leukaemia and multiple 
myeloma. Immunodeficiency is also the hallmark of AIDS, which is caused by HIV-infection 
(Warrington et al., 2011).  
 
The adaptive immune system is designed to ward off infection and allow for the maintenance of 
good health. However, the immune system is often challenged by organisms that have developed 
a number of mechanisms to overcome the protective mechanisms of immunity, one such 
pathogen is HIV. 
 
2.2 THE HIV PANDEMIC 
2.2.1 The status of HIV/AIDS pandemic  
In 2014, an estimated 36.9 million individuals globally were living with HIV (UNAIDS, 2015). 
On average there was a 35% decreases in new infections globally since 2000, including a 58% 
decrease in children at the end of 2014 (UNAIDS, 2015). At the same time AIDS related deaths 
decreased by 42% since the peak in 2004 (UNAIDS, 2015).  
 
Sub-Saharan Africa is a region with the highest HIV prevalence worldwide and HIV/AIDS 
remains a leading cause of death including in South African children (UNAIDS, 2015). It is 
estimated that more than 3 million children under the age of 15 years were infected with HIV 
worldwide, including 91% of whom live in sub-Saharan Africa, in 2007 (UNAIDS, 
2015)(UNAIDS, 2013). Furthermore, in 2007 there were an estimated 1 800 new HIV-infections 
daily in children through mother-to-child transmission (UNAIDS, 2007, UNAIDS, 2015). 
Approximately 29.5% of the 1.1 million children born each year in South Africa were born to 
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HIV-infected women (South African Department of Health, 2005; Theron, 2007). In 2007, there 
were an estimated 93 000 children who were infected with HIV through peri-natal transmission 
and a further 21 000 who were subsequently infected by HIV through breast milk exposure 
(UNICEF, 2008), with an   estimated 14.6% receiving adequate antiretroviral treatment for the 
prevention of mother-to-child transmission in 2007 (South African Department of Health, 2005; 
Theron, 2007; (UNICEF, 2008).  The estimated mortality rate of HIV-infected children in South 
Africa, in the absence of antiretroviral treatment programmes, was 50% within the first two years 
of life (UNICEF, 2008). However, this had decreased by 18% in 2008 due to improved 
antiretroviral mother-to-child transmission programme (UNAIDS, 2009)(UNAIDS, 2015). 
Despite all progress made in reducing mother-to-child HIV transmission through peri-partum 
antiretroviral programmes, paediatric HIV-infection remains a public-health problem in African 
countries (Buchanan et al., 2014). 
 
2.3 HIV PATHOGENESIS AND IMMUNOLOGICAL ABERRATIONS 
HIV has continued to be a major health problem worldwide, owing to the intricate nature of its 
interaction with the immune system. HIV has remained an enigma that cleverly uses the host 
machinery to survive. Its ability to evade the hosts‘ defences at both levels, innate and adaptive, 
allows it to replicate and transmit from one host to another. HIV-infection leads to immune 
dysfunction and subsequent depletion of the immune system. In the past 3 decades there has been 
extensive progress on the understanding the immunopathogenesis of HIV-infection. 
 
2.3.1 Structure of HIV  
HIV-1 and HIV-2 belonging to the family Retroviridae within the subfamily Lentivirinae 
(Fanales-Belasio et al., 2010). Of these two, HIV-1 is more prevalent, and has established global 
epidemics, while HIV-2 is more prevalent in West African nations (Janeway et al., 2001a, 
Fanales-Belasio et al., 2010).  
 
The structure of the HIV-1 consists of an internal core particle made up of 1200 molecules of 
capsid protein (p24 gag) surrounded by a lipid envelope (env) spiked with 75 trimers of a highly 
glycosylated protein, gp160, wrapped around a scaffold made of the matrix protein (p17 gag) 
(Cosson, 1990, Hill et al., 1996). The gp160 env molecules are made of two non-covalently 
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linked polypeptide chains. The trans-membrane chain, gp41, that anchors the spikes in the lipid 
bilayer of the envelope, maintains their trimeric structure, and plays a major role in fusion of the 
virus and cell membranes (Bugge et al., 1990, Eckert and Kim, 2001). The external chain, gp120, 
carries the important antigenic determinants of the virus and binds CD4+ receptor with either 
CXCR-4 (T-lymphocyte-tropic) or CCR-5 (macrophage-tropic) co-receptors (Kwong et al., 1998, 
Wyatt and Sodroski, 1998).  
 
2.3.2 Viral entry and life cycle 
Cellular tropism is defined as the ability of HIV to enter target cell types and is determined by the 
expression of specific receptors on the surfaces of those particular cells. HIV is known to bind 
mainly to cells such as macrophages, DCs and CD4+ T-lymphocytes (Janeway et al., 2001a).  
 
HIV first infects macrophages that carry the HIV to the lymph nodes, where they encounter 
follicular dendritic cells (FDCs). FDCs remove the HIV from the macrophages and contain the 
virus within the lymph nodes. The FDCs come into contact with CD4+
 
T-lymphocytes (naïve), 
resulting in T-lymphocyte infection. Therefore, HIV changes from macrophage (M)-tropic to 
CD4+ T-lymphocyte (T)-tropic because the T-lymphocytes have the appropriate receptor and co-
receptors necessary for establishment of infection (Alcamo, 1997). HIV adsorbs to primary 
(CD4+) target cells by interaction of gp120, CD4+ and CC-chemokine co-receptor 5 (CCR5) or 
CX-chemokine co-receptor 4 (CXCR4). This results in conformational changes that expose gp41, 
which fuses with the cellular membrane resulting in a passage way and the nucleocapsid is 
deposited inside the cytoplasm of the target cell (Strauss and Strauss, 2002). 
 
The capsid is uncoated by cellular enzymes, releasing the diploid single stranded (ss)-RNA and 
reverse transcriptase. Reverse transcriptase, reverse transcribes ss-RNA to double stranded-
deoxyribonucleic acid (ds-DNA) that is transported to the nucleus of the infected cell. Integration 
occurs with the aid of the integrase enzyme, where the ds-DNA is inserted randomly into the host 
cell genome (to be known as provirus). After integration, the provirus is able to undergo 
transcription and translation. The proteins made initially are very long precursor proteins that 
must be spliced to size by the viral protease. Finally, mature infectious virions are released by 
budding to complete the life cycle (Strauss and Strauss, 2002).  HIV can alternatively cause latent 
infection through the integrated provirus, this has been observed to occur in memory CD4+ T-
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lymphocytes and macrophages, thus serving as important reservoirs of infection (Sierra et al., 
2005). 
 
2.2.3 Immune response following HIV-infection 
Infected individuals develop several immunological responses to HIV, including neutralizing 
antibodies, antibody-dependent cell-mediated cytotoxicity and HIV-specific CTLs. A quarter of 
HIV-infected individuals develop broadly neutralizing antibodies targeting a number of 
conserved epitopes on the viral envelope (Euler et al., 2010). Neutralizing antibodies may play a 
role in the control of HIV in the blood after primary infection (Eley, 2003). In general, many viral 
infections are not cleared but rather controlled by an effective immune response (Eley, 2003). 
Both specific CD4+ Lymphocytes and CD8+ CTLs are required to limit replication during viral 
infections (McMichael et al., 2010). 
 
However, during the advanced stages of infection, neutralizing antibodies do not influence the 
viraemia. This is probably because of successive waves of viral escape as a means of escaping 
immune pressure (Moore et al., 2013). Antibody-dependent cell-mediated cytotoxicity is present 
throughout infection and is primarily directed against gp120 (Fouda et al., 2011). Expression of 
several cytokines is altered during HIV-infection. In in vitro experiments, cytokines such as IFN-
α and IFN-β suppress HIV replication, whereas transforming growth factor (TGF) - β, IL-4, IL-
10, IL-13 and IFN-γ may either induce or suppress HIV expression (McMichael et al., 2010). The 
altered cytokine network may therefore influence viral replication (Fauci, 1996). 
In the early stages of HIV disease, specific CD8+ CTLs restrict viral replication and limit CD4+ 
cell suppression (McMichael et al., 2010). Anti-HIV specific CD8+ CTLs are activated via 
surface expressed T-lymphocyte receptors after encountering HIV-specific antigens that are 
presented in association with MHC class I molecules, on the surface of target cells. 
Consequently, CTLs lyse infected cells either by secreting proteases, granuzyme A and B, and 
perforin or via Fas-mediated killing (Cocchi et al., 1995). CD8+ CTL further induces non-lytic 
inhibition of viral replication by MHC restricted release of β-chemokines including MIP-1α, 
MIP-1β and RANTES (Fauci, 1996). 
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2.3.4 Immunopathogenesis of HIV-infection 
HIV directly infects and replicates within cells of the immune system particularly macrophages 
and CD4+ T-lymphocytes, resulting in abnormalities of both humoral and cell mediated immune 
responses (Resino et al., 2004, Letvin and Walker, 2003), as well as in B-lymphocytes (Resino et 
al., 2004, Shearer et al., 2000, Lane et al., 1983). The dysfunction of the immune response 
becomes apparent early on during HIV-infection, when individuals show a gradual loss of their T 
lymphocytic proliferative responses (Gona et al., 2006, Letvin and Walker, 2003, Palumbo et al., 
1992, Borkowsky et al., 1992), progressive decline in total B-lymphocytes, with polyclonal 
hyperglobulinemia (Lane et al., 1983, Shearer et al., 2000), impaired reactivity to immunization 
(Arpadi et al., 1996, Pensieroso et al., 2009) and loss of specific antibodies (Pensieroso et al., 
2009, al-Attar et al., 1995). In addition HIV viral replication may impair immune function 
through immunosuppressive effects of viral proteins and by a state of hyper activation that leads 
to immunosuppression and accelerated apoptosis (Letvin and Walker, 2003). The consequences 
of this is the loss of CD4+ T-lymphocytes; increased risk of susceptibility to infections or poor 
immune response due to defective antigen processing by macrophages and dendritic cells; 
defective immunological memory; failure to prime memory cells or failure of primed B-
lymphocytes differentiation into memory cells; loss of immunological memory of T- and B-
lymphocytes after priming i.e. clonal deletion or depletion (Resino et al., 2004, Obaro et al., 
2004).  
 
2.4 ACCESS TO ANTIRETROVIRAL THERAPY  
The global estimates of ART coverage in HIV-infected children (23%) in 2009 was similar to 
that of HIV-infected adults (UNAIDS, 2012, UNAIDS, 2009). There has been a steady increase 
in access and ART treatment of HIV-infected adults and children since 2003, with a 10-fold 
increase in usage having been reported by 2008 (UNAIDS, 2009). It is estimated that ART 
coverage in HIV-infected children in South Africa increased from an estimated 7% in 2004 to 
44% in 2010 (UNAIDS, 2011). The improved access in antiretroviral treatment programme, 
including changes to triple therapy in HIV-infected pregnant women (Goga et al., 2015), has 
reduced the vertical transmission of HIV to newborns of HIV-infected women to 2.5% in 2010 
(Barron et al., 2013, Goga et al., 2015). In addition, improved access to ART of HIV-infected 
children, particularly when initiated early in life, results in improved survival among HIV-
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infected children (Violari et al., 2008). ART has been shown to dramatically change the current 
course of HIV-infection by drastically reducing viral load and enabling the recovery of the 
immune system of children and adults (Resino et al., 2004, Valdez, 2002). In developed 
countries, where children have access to ART, 80% are still alive by the age of 6 years (WHO, 
2005). Resino and colleagues reported that immune reconstitution due to ART in HIV-infected 
children seemed to be a consequence of a decrease in activation of naïve T-lymphocyte 
reconstitution (Resino et al., 2004). This immune system restoration supports normalization of 
immune parameters such as cytokine production, lymphoproliferative response and 
immunoglobulin levels in plasma (Pensieroso et al., 2009). ART treated children have shown 
improved numbers of CD4+ T-lymphocytes, including increased levels of both naïve and 
memory cells (Melvin, 1997, van Rossum, 2000). 
 
However, additional challenges faced by HIV-infected children include the faster progression of 
HIV/AIDS illness; a prevailing immature immune system; greater difficulties in accessing ART 
programmes; and delayed initiation of ART. These factors are thought to contribute to faster 
progression to AIDS and death in HIV-infected children (UNAIDS, 2008). A multi-centered 
study in South Africa, however, indicated that early diagnosis and early initiation of ART within 
eight weeks of birth was able to delay HIV-related disease progression by 75% and reduce 
childhood mortality rates by 76% (Violari et al., 2008). This study was instrumental in the WHO 
revising its recommendation on the timing of initiation of ART in HIV-infected children in 2010 
(WHO, 2010a). In an older group of Zambian HIV-infected children, a combination of ART and 
co-trimoxazole prophylaxis was associated with a six-fold decrease in mortality among HIV-
infected children (Walker et al., 2007). HIV-infected children, especially in the absence of ART, 
rapidly develop progressive deterioration of various arms of their immune system (Moss et al., 
2003). The resultant immunodeficiency in these children renders them highly susceptible to 
potentially fatal infections (Arrazola et al, 1995), increasing the need for strategies aimed at 
preventing infectious diseases in these children. 
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2.5 PREVENTION OF MOTHER-TO-CHILD TRANSMISSION (PMTCT) 
PROGRAMMES 
Prior to implementation and routine use of ART, the rate of HIV transmission from mother-to-
child ranged from 15 to 25% among children who were formula-fed and from 25 to 40% among 
children who were breast-fed (Luzuriaga and Mofenson, 2016). In the absence of preventative 
measures, an HIV-infected women has a one in three chance of transmitting the virus to her 
offspring (UNAIDS, 2010). Almost half of the children who acquire HIV in utero will die before 
the age of 2 years without effective treatment (UNAIDS, 2010). In order to decrease the rate of 
transmission from an infected mother to her child, PMTCT programme along with increased 
access to ART need to be implemented (Country progress report on the declaration of 
commitment on HIV/AIDS 2010 report, 2010). Therefore, with the administration of ART during 
pregnancy and delivery to both mother and child, the risk of transmitting the virus from mother-
to-child has decreased to less than 2% (UNAIDS, 2016, Massyn et al., 2015).  
 
South Africa, along with Botswana, Mozambique, Namibia, Swaziland and Uganda, have thus 
far achieved above 90% coverage of ART to prevent mother to child transmission (UNAIDS, 
2016). Coverage of ART for PMTCT in South Africa and Namibia was reported to be >95%, 
whereas other African countries such as Nigeria and Côte d‘Ivoire have reported coverage of less 
than 30% (UNAIDS, 2016). The national PMTCT programme in South Africa was established 
and initiated in 2001, which was then followed by the initiation of the ART schedule in 2004. 
The original PMTCT programme involved using a single dose nevirapine (NVP) regime, 
amended in 2008 to combination/dual therapy including AZT and NVP, as recommended by the 
WHO (DOH, 2009).  
 
Due to the increased mortality observed in HIV-infected women and children, PMTCT and ART 
programmes were accelerated and modified to address this. During the course of April 2010, 
revisions of the PMTCT programme in keeping with the guidelines stipulated by WHO, stated 
that all HIV-infected women with a CD4+ cell count less than 350 cells/μl should be considered 
eligible for ART. Pregnant women, who tested HIV positive, would receive treatment at 14 
weeks gestation rather than in the final trimester. Previously, a CD4+ count of 200 cells/μl served 
as the guideline for therapy initiation in pregnant mothers (DOH, 2010). These changes highlight 
constant improvements to decrease the spread of HIV from the infected mother to child. In 
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addition, it has been reported that along with a functioning health system, PMTCT programmes 
and interventions may be able to eliminate HIV-infection in children (Sprague et al., 2010). 
 
2.6 HIV-EXPOSED UNINFECTED (HEU) CHILDREN 
2.6.1 The increasing number of HEU children 
Out of the 1 million children born in South Africa, approximately 300 000 of these children are 
exposed to HIV in utero (DOH, 2009).  Several studies have reported increased morbidity and 
mortality in HEU children due to infectious agents (Newell et al., 2004, McNally et al., 2007, 
Filteau, 2011, Slogrove et al., 2010). Increased morbidity and mortality in HEU is believed to be 
multifactorial, including low-birth weight, failure to thrive, exposure to ART, inadequate clinical 
follow-up and reduced breastfeeding have been shown to be contributing risk factors (Filteau, 
2011). Furthermore, HEU children experience abnormalities in the physiologic development of 
the immune system (Clerici et al., 2000). A major challenge exists in identifying the underlying 
mechanisms of immune dysfunction HEU children. Different pathogens interact differently with 
the maternal immune system; therefore, their mechanisms of interaction with the fetal immune 
system are different (Dauby et al., 2012). However, some mechanisms have been postulated to be 
common, such as the activation of adaptive immune responses by microbial epitopes either free or 
complexed with immunoglobulins (May et al., 2009), crossing the placenta (Malhotra et al., 1997, 
Pit et al., 2000, Attallah et al., 2003, Broen et al., 2007, Kuhn et al., 2002, Koumbi et al., 2010). 
Innate immune responses can be triggered by infection of the placenta with parasites such as 
plasmodium (Broen et al., 2007) and schistosoma (Kurtis et al., 2011), or by microbial products 
inducing inflammatory responses in the placenta or after transfer to the fetus (Lucchi et al., 2011, 
Diouf et al., 2004, Dauby et al., 2012).  
 
McNally et al. and others have reported heightened susceptibility of HEU children to severe 
infections caused by opportunistic pathogens such as Pneumocystis jirovecii or Mycobacterium 
tuberculosis, and the more common early life pathogens such as cytomegalovirus and group A 
streptococcus, which rarely occur in HIV-unexposed children (McNally et al., 2007, Slogrove et 
al., 2010, Heresi et al., 2007).  The results of these studies suggest that prenatal or perinatal 
factors that are associated with maternal HIV-infection increase the susceptibility of children to 
infectious diseases in different parts of the world (Dauby et al., 2012).  
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Furthermore, several other factors besides maternal HIV-infection have been implicated in the 
increased susceptibility of HEU children to infectious diseases. They include increased exposure 
to pathogens as a result of maternal HIV associated disease, poor socio-economic status, and 
absence of breastfeeding as a recommended measure to prevent MTCT and toxicity associated 
with antenatal antiretroviral prophylaxis (Dauby et al., 2012). In addition, the role played by 
alterations in passive and acquired immunity has been suggested by several studies (Miles et al., 
2010, Neilsen et al., 2001, Kuhn et al., 2001, Rich et al., 1997, Chougnet et al., 2000, Farquhar et 
al., 2005, Jones et al., 2011, de Moraes-Pinto et al., 1996, Embree et al., 2001). HEU children 
have lower CD4+ T-lymphocyte counts compared to HIV-unexposed children in the first few 
months of life (Miles et al., 2010, Embree et al., 2001). The low CD4+ T-lymphocyte counts in 
HEU children has been associated with low thymic output, decreased cloning efficiency of 
proginator cells, and increased serum concentrations of IL-7 (Neilsen et al., 2001). Furthermore,  
altered in-vitro T-lymphocyte activation was detected in HEU neonates with an increased 
production of IL-10 and decreased production of IL-2 after polyclonal stimulation (Kuhn et al., 
2001, Rich et al., 1997). Decreased production of IL-12 by cord blood lymphocytes in HEU 
children also suggests that the function of antigen presenting cells might be altered in them. 
(Chougnet et al., 2000) Furthermore, HEU children have reduced transfer of maternal antibodies 
across the placenta compared to HIV-unexposed children (Farquhar et al., 2005, de Moraes-Pinto 
et al., 1996, Jones et al., 2011).  
 
The mechanisms behind the immune dysregulation among HEU children is  yet to be fully 
elucidated,  but may involve the transfer of non-infectious HIV virion particles with 
immunosuppressive properties across the placenta, or the activation of the maternal immune 
system with transfer of soluble mediators or maternal cells across the placenta (Dauby et al., 
2012). Also, although maternal  ART has been highly successful in the  PMTCT programme, 
maternal ART exposure has been shown to have negative effects on  foetal and childhood 
development in HEU children (Noguera et al., 2004). A common side effect of ART exposure 
(zidovudine) in HEU children is mitochondrial dysfunction (Noguera et al., 2004), although this 
was not evident in another study (European-Collaborative-Study., 2005). Studies have also 
shown an association of in utero ART exposure with abnormal T-lymphocyte counts, CD8+ CTL 
counts, abnormal neutrophil and red blood cell counts in the first few years of life (Bunders et al., 
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2005, Feiterna-Sperling et al., 2007, Pacheco et al., 2003, Le Chenadec et al., 2003). Even though 
the effects of ART should be carefully examined, the benefits of maternal ART far outweigh its 
side effects, however, the increased infectious diseases morbidity among HEU children require 
on-going monitoring (Thea et al., 1997, Marinda et al., 2007).   
 
The integrity of the immune system of HEU children can be evaluated in vivo by use of vaccine 
induced responses as a model of controlled antigen exposure. Results suggest that HEU children, 
have antibody and T-lymphocyte responses to vaccines that are similar to those in HIV-
unexposed children (Helfand et al., 2008, Mansoor et al., 2009, Jones et al., 2011, Reikie et al., 
2013). Furthermore, some studies also reported that HEU children have increased antibody 
responses to vaccines such as pertussis, pneumococcus and H. Influenzae type b compared to 
HIV-unexposed children (Reikie et al., 2013, Jones et al., 2011, Madhi et al., 2005). This could 
be due to less interference from maternal-acquired antibody to the vaccine epitopes (Jones et al., 
2011, Reikie et al., 2013). In contrast, other studies have reported sub-optimal responses to oral 
polio, tetanus, hepatitis B, and BGC vaccines (Abramczuk et al., 2011, Van Rie et al., 2006, 
Mazzola et al., 2011, Sanz-Ramos et al., 2013).  Possibly due to exposure to ART at birth, in 
utero exposure to HIV may affect the cytokine profile that is necessary for vaccine response and 
lower total B-lymphocyte population in HEU children (Hesseling et al., 2015, Kakkar et al., 
2014, Abramczuk et al., 2011). The discrepancy in results in HEU children needs to be further 
evaluated especially now in the era where ART for prevention of mother to child transmission is 
being scaled up. 
 
2.7 PREVENTION OF INFECTION IN EARLY LIFE (MATERNAL ANTIBODIES) 
2.7.1 Role of maternal antibodies 
Neonates have a relatively incompetent immune system in relation to their ability to respond to 
infections. Therefore, the innate mechanisms play a key role in protecting the neonate against 
potential pathogens. Neonates are also endowed with maternal antibodies that are important for 
protection against infections in the first months of life  (Siegrist, 1998). Placental antibody 
transfer generally occurs between 28-32 weeks gestational age (Malek, 2003). Naturally acquired 
antibodies have been shown to be variable in both level and rate of deterioration (Glezen, 2003, 
Palfi and Selbing, 1998). By the time of birth, passively acquired neonatal IgG exceeds maternal 
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concentrations (Saji et al., 1999, Leuridan and Van Damme, 2007). These maternal antibodies 
against pathogen-specific antigens disappear during the first months of life while the neonate‘s 
own immune system develops (Saji et al., 1999, Palfi and Selbing, 1998, Offit et al., 2002, 
Leuridan and Van Damme, 2007). The interval between the loss of protection once maternal 
antibodies have disappeared and protection by vaccination should be as narrow as possible for all 
vaccine-preventable diseases, because of the risk of early infection (Glezen, 2003). Therefore the 
amount of maternal antibody  transferred to the child determines the length of protection, as well 
as response to vaccination (de Moraes-Pinto et al., 1998).  
 
2.7.2 Mechanisms of maternal antibody transfer 
Immunoglobulin G subclasses are the only antibody subclass (predominantly IgG1 and IgG3) 
that can cross the placenta. This transfer is an active, selective and intracellular process, which 
usually occurs within the third  trimester (Englund, 2007). This transfer occurs through the 
contact of maternal blood with cells of the placenta that contain Fc receptors. These Fc receptors 
bind IgG molecules circulating through the blood. Antibody molecules that are attached to the 
receptors are taken up by placental cells through a process called receptor-mediated endocytosis. 
Following this, they are subsequently transported across the cell in vesicles, which are then 
released into the foetal blood by exocytosis. Other antibody subclasses or isotypes are unable to 
be transferred due to the structural inability to bind specific Fc receptors. IgG is also secreted into 
breast milk, which also offers protection against mucosal pathogens (Janeway et al., 2001d) 
(Englund, 2007). A number of factors have been described that may influence the effectiveness 
of maternal antibody transfer, some of which include placental abnormalities, total IgG 
concentration in maternal blood, vaccine-antigen type, gestational age of child, as well as time 
duration of maternal vaccination and delivery (Englund, 2007, van den Berg et al., 2010). 
 
2.7.3 How maternal antibodies influence the child’s immune response 
At primary vaccination, most children still have high levels of maternal antibodies. Studies have 
raised concerns on the interference of maternal antibodies with immune response to vaccination. 
The extent of this effect is vaccine antigen specific (Glezen, 2003, Jones et al., 2014). For 
example, 25-56% decrease in antibody response to whole cell pertussis vaccine was observed in 
the presence of maternal antibodies (Englund et al., 1995). However in the same study this effect 
was not observed when acellular pertussis vaccine was utilised (Englund et al., 1995). Other 
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antigens that have shown the negative effects of maternal antibodies are the oral and inactivated 
polio vaccines given at birth. The response was further decreased in breastfed babies (Warren et 
al., 1964, Simoes et al., 1985). Immune response to diphtheria-toxoid was shown to be decreased 
in children who had antibody levels >0.1IU/ml prior to vaccination, however, when a booster was 
given at 12 months of age there was no difference in response between children with high 
maternal derived antibodies and those who had low antibodies (Bjorkholm et al., 1995). Similar 
results were shown for Hib and tetanus toxoid vaccines (Nohynek et al., 1999). These studies 
suggest that passively acquired antibodies play a role in suppressing antibody responses to 
immunization during early childhood, but do not influence responses to booster vaccinations. 
No evidence exists to suggest that maternal cellular immune response can be transferred to the 
child.  
 
The exact mechanism by which transferred maternal antibodies in children interfere with their 
immune response to vaccines is still unclear. However, there is a suggestion that the interference 
may be epitope specific, and mainly affects B-lymphocyte responses (Siegrist, 2003). It may be 
related to maternal antibody to vaccine antigen ratio at the time of immunization, which may 
result in epitope masking. The concept of epitope masking refers to maternal antibodies that 
disguise vaccine antigenic epitopes, therefore preventing binding of the child‘s B-lymphocytes to 
these epitopes; Figure 2.2. It has been suggested that to overcome the epitope masking effect, 
would be to increase the dose of vaccine antigen, thereby increasing the number of antigenic 
epitopes that will allow sufficient binding of child‘s B-lymphocytes (Siegrist, 2003). However, 
recent data from a cotton rat model of measles virus vaccination suggests that the inhibitory 
effect of maternally derived IgG on infant B-lymphocyte responses to vaccination is mediated 
through cross-linking of the inhibitory receptor FcγRIIB to the B-lymphocytes receptor by 
antibody-antigen complexes  (Kim et al., 2011) and not through epitope masking as suggested by 
Siegrist (Siegrist, 2003); resulting in inhibition of B-lymphocyte activation and therefore 
antibody secretion (Kim et al., 2011).  No human studies have been performed to prove this 
observation. 
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Figure 2.2: The dual effects of maternal antibodies on response to immunization by children. 
The presence of maternal antibodies inhibits B-lymphocyte responses to masked epitope, but 
not to the generation of memory B-lymphocytes. Secondly, maternal antibodies also play a role 
in increasing T-lymphocyte responses by enhancing antigen capture and presentation (Lambert 
et al., 2005). 
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2.7.4 HIV and its effects on maternal antibody transfer 
Studies have suggested that HIV impairs the transport of IgG from an infected mother to her 
foetus (de Moraes-Pinto et al., 1998, Farquhar and John-Steward, 2003). Thus, a child born to an 
HIV-infected woman may be deprived from early protection against disease. In addition, the 
effective transfer on antibody is dependent on the integrity of the placenta. Diseases such as 
malaria and HIV have shown a negative impact on transplacental antibody transfer (Farquhar, 
2004, Englund, 2007).  In the case of malaria, Fc receptors impairment seems to play a role in 
decreased antibody transfer (Englund, 2007). On the other hand, increased levels of specific HIV 
antibodies present in maternal blood during the final trimester may obstruct the Fc receptors, thus 
inhibiting the active transport of antibodies (Farquhar, 2004).  
 
In South Africa, significantly lower concentrations of maternal antibodies against pertussis, 
tetanus, Hib and pneumococcus were observed in HEU compared to HIV-unexposed children 
(Jones et al., 2011).  In addition, HIV-infected women had significantly low levels of antibodies 
to PRP (Hib vaccine epitope) and pneumococcus compared to HIV-uninfected woman. However, 
the levels to tetanus and pertussis were similar between HIV-infected and -uninfected women 
(Jones et al., 2011). Similarly, a study on Streptococcus pneumoniae specific IgG transfer in 
Malawi showed a low transplacental maternal S. pneumoniae antibody transfer in children born 
to HIV-infected woman (de Moraes-Pinto et al., 1998). However the presence of IgG antibodies 
to tetanus toxoid and measles were not reduced (Farquhar and John-Steward, 2003, de Moraes-
Pinto et al., 1998). On the contrary a study conducted in Kenya showed that maternal HIV-
infection was associated with a 52% reduction of tetanus antibodies in children after adjusting for 
maternal vaccination. The study concluded that HIV interferes with the transfer of maternal 
antibodies (Cumberland et al., 2007). These observations are not unique to bacterial antibody 
transfer, as similar findings have been observed for antibodies targeting viral epitopes. A 
Zambian study showed a decrease in measles antibody transfer from HIV-infected mother to her 
offspring, resulting in both HIV-infected and HEU children being more susceptible to measles 
infection by 6 months of age (Scott et al., 2007).  These results were further supported by studies 
conducted in Kenya and Brazil, which also showed lower  measles virus antibodies in cord blood  
of children born to HIV-infected woman  (Scott et al., 2005, de Moraes-Pinto et al., 1993). 
There is limited understanding on the role of HIV viral load mechanism associated with antibody 
transfer. Although Jones et al (2011) found a 23% reduction in the transplacental transfer for PRP 
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antibody, 40% for pertussis (PT and FHA) and 27% for tetanus antibody, there was no 
association between maternal CD4+ count or HIV viral load and placental transfer (Jones et al., 
2011). In contrast, Farquhar et al (Farquhar et al., 2005), showed a positive correlation with 
maternal viral load and reduced transfer of maternal antibodies.  
 
Other studies have shown that mothers with hypergammaglobulinaemia transferred lower levels 
of antibodies to their children (Hartter et al., 2000). This was confirmed in a Malawian study that 
showed that maternal HIV-infection and hypergammaglobulinaemia were independently 
associated with reduced transfer of IgG antibodies to S. pneumoniae (de Moraes-Pinto et al., 
1996). Hypergammaglobulinaemia is often associated with HIV-infection and Hartter et al 
(2000) has proposed that during hypergammaglobulinaemia, IgG antibodies compete for 
available receptors (Hartter et al., 2000). They also observed that despite German mothers having 
half the IgG measles antibody concentration than detected in Nigerian mothers, they still 
transferred a higher amount of measles antibody to their foetuses (Hartter et al., 2000). 
 
2.8 VACCINATION FOR THE PREVENTION OF DISEASE 
Acquired immunity can be induced either through passive or active immunization. Passive 
immunization includes the transfer or administration of externally derived antibodies (polyclonal 
or monoclonal) with the aim of preventing infection in exposed individuals (Warrington et al., 
2011). It can occur through transplacental transfer of maternal antibodies to either the developing 
foetus , or in colostrum and milk during breastfeeding (Horzinek and Thiry, 2009, Offit et al., 
2002). However, maternally acquired antibodies have a short life-span, usually declining during 
the first few months of life (Offit et al., 2002, Siegrist et al., 1998, Siegrist and Lambert, 1998). 
More importantly, maternally acquired antibodies offer limited immunologic protection (Offit et 
al., 2002). Alternatively, immediate protection can be achieved by injecting antibody in the form 
of  serum, immunoglobulin or monoclonal antibodies  (Horzinek and Thiry, 2009). The latter is 
used when there is a high risk of infection and limited time for the body to develop its own 
immune response, or to reduce the symptoms of chronic or immunosuppressive diseases 
(Warrington et al., 2011).  
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Active immunization refers to administration of an antigen (attenuated pathogens, inactivated 
organism or toxin) so as to induce the production of antibodies against a specific target  
(Horzinek and Thiry, 2009, Warrington et al., 2011). The next section details the immune 
response to vaccines. 
 
2.8.1 The burden of vaccine preventable diseases 
On a global scale; persistence of vaccine-preventable diseases; including morbidity and mortality 
due to measles, diphtheria, tetanus, pertussis, hepatitis B and H. influenzae type b remain high,  
(Gentile et al., 2010) especially in low-income settings.  Despite the significant progress  in 
reducing the death among children under 5 years of age, the  progress has lagged in many  low-
middle income countries, including due to vaccine preventable diseases (Gentile et al., 2010, 
Offit, 2014). Included among these are death due to diphtheria, tetanus, pertussis, hepatitis B , 
Hib  and measles (Offit, 2014). Deaths attributable to vaccine preventable diseases among 
children younger than 5 years of age, varies regionally and globally ranging between 25 000 for 
diphtheria to 371 000 for invasive Hib disease; Table 2.3.  
 
Table 2.3: Worldwide reported incidence, estimated worldwide incidence and prevalence, and 
deaths of diphtheria, tetanus, pertussis, Hepatitis B, H. influenzae type b disease and measles.  
Disease Worldwide 
incidence 
(cases/year) 
Estimated actual  worldwide 
incidence/prevalence 
Deaths Reference 
Diphtheria 4729 Incidence: 50 000 25 000 (Offit, 2014) 
Tetanus
 
8473 Incidence: 500 000-1 million 72 600-200 000 (Ergonul et al., 
2016) 
Pertussis 117 889 Incidence: 30-50 million 300 000 (Offit, 2014) 
Hepatitis B 6-10 million Prevalence: 400 million >686 000  (WHO, 2016a) 
Hib disease 3 million Incidence: 8.13 million 371 000  (Watt et al., 2009) 
Measles 244 704 Incidence: 344 000 114 900 (Offit, 2014) 
 
Some of the most striking annual rates of infection worldwide include 138 million cases of 
rotavirus, 80 million cases of varicella and 40 million cases of pertussis (Offit, 2014). The annual 
deaths due to  vaccine-preventable diseases include one million deaths from hepatitis B, 1.6 
million deaths from pneumococcus, 450,000 deaths from rotavirus (Offit, 2014).
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Although  South Africa reportedly has a  high immunization coverage (94-97% in 2015 for 
DTP3, Hib3, HepB3 and MV1) since the inception of the EPI in South Africa in 1995 (WHO, 
2016b),  outbreaks of vaccine-preventable diseases that have been observed over the last 10 
years. One such disease is measles which  occurred between 2008 to 2010, with many cases 
occurring among  children exposed to maternal HIV and were too young to have been vaccinated 
at 9 months of age (Moss and Griffin, 2012). In 2010, more than 20 000 cases were reported in 
South Africa, which shows the ease with which measles virus can re-enter communities and 
cause large outbreaks if population immunity is not sustained (Moss and Griffin, 2012). In 
addition, an outbreak of pertussis was reported between 2008 and 2009 in 18 children, with 12 
children being 6 months of age and had incomplete immunization. Of the 12 children younger 
than 6 months of age, five were HIV-infected and younger than 10 weeks, however, no deaths 
were reported (Hallbauer et al., 2011). Recently an outbreak of diphtheria was reported, which 
involved 14 cases of individuals aged 4-40 years of age and 4 deaths which occurred among 
children who had not been fully vaccinated (NICD, 2015). 
 
2.8.2 History of childhood immunization 
The WHO recommends immunization against a number of serious infectious diseases, including 
diphtheria (WHO, 2006a), tetanus (WHO, 2006b), pertussis (WHO, 2005), HepB (WHO, 2009a), 
invasive Hib disease (WHO, 2013b), and measles (WHO, 2009b) for all children, as well as 
pneumococcal disease, yellow fever, and rotavirus disease for children in some areas as part of 
their EPI. The EPI was established in 1974 with the main objective of expanding immunization 
services beyond smallpox and with an emphasis on improving vaccine coverage in children from 
developing countries (Galazka, 1993). The EPI at the time included vaccines against tuberculosis 
(BCG), polio, diphtheria, tetanus, pertussis and measles (Galazka, 1993). Since their introduction 
more than 3 million lives have been saved each year, which approximates to 10 000 lives a day 
and also protects millions from illness and permanent disability as well as averting 6 million 
deaths globally (Kane and Lasher, 2002, Ehreth, 2003). Recently there has been a drastic increase 
in the implementation of new and under-utilized vaccines providing additional prevention of 
premature deaths and disabilities (WHO, 2010c). These include vaccines against HepB, Hib, S. 
pneumoniae (pneumococcus), rotavirus, and rubella (WHO, 2010c). 
Pre-exposure immunization of children with several antigens is the main aim of any successful 
immunization programme (Andre et al., 2008). Specific vaccines have also been utilized to 
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protect those at risk of infection such as pregnant women, cancer patients and 
immunocompromised individuals (Succi and Farhat, 2006). However, breakthrough infections 
have been observed in immunized individuals that may have resulted from primary vaccine 
failure; in such cases the disease is milder than in unvaccinated individuals (Schmitt et al., 1996, 
Vazquez et al., 2004, Ruiz-Palacios et al., 2006, Preziosi and Halloran, 2003). This observation 
has been confirmed on many occasions, for example in Germany  people vaccinated with 
acellular pertussis developed whooping cough, but  had a significantly shorter duration of chronic 
cough than unvaccinated controls (Schmitt et al., 1996), this was also observed for rotavirus and 
varicella infections (Ruiz-Palacios et al., 2006, Vazquez et al., 2004).  
 
2.8.3 South African EPI (EPI-SA) 
The South African EPI programme was established in 1995, and initially included BCG vaccine, 
oral polio vaccine, and DTwP and measles vaccines. HepB vaccine (1995) and HibCV (1999) 
were subsequently introduced (Baker, 2010). The success of the EPI programme in South Africa 
included near elimination of neonatal tetanus by 2002 and the declaration of South Africa being 
polio-free by 2006. More recently, the EPI vaccine repertoire has been expanded with the 
inclusion of pneumococcal polysaccharide protein conjugate vaccine (PCV) and rotavirus 
vaccine in 2009; as well as a change from wP and oral polio vaccine (OPV) to acellular pertussis 
(aP) and inactivated polio vaccines (IPV) since 2009 (Table 2.4). In addition, a booster dose of 
HibCV, as part of the  pentavalent DTaP-HibCV-IPV vaccine used in the primary series of 
vaccination was also introduced into the immunization programme in 2009 (Baker, 2010). The 
EPI-SA schedule is represented in Table 2.4. 
 
Table 2.4: Vaccination schedule for South Africa for the years 2005 and 2013  
Age of child EPI schedule for 2005 EPI schedule for 2013 
At birth OPV (0)  
BCG 
OPV (0) 
BCG 
6-weeks OPV (1)  
DTwP/Hib (1)  
HepB (1)  
OPV (1) 
DTaP-IPV/Hib (1) 
RV (1) 
HepB (1) 
PCV (1) 
10-weeks OPV (2) 
DTwP/Hib (2) 
HepB (2) 
DTaP-IPV/Hib (2) 
HepB (2) 
14-weeks OPV (3) 
DTP/Hib (3) 
HepB (3) 
DTaP-IPV/Hib (3) 
HepB (3) 
PCV (2) 
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 RV (2) 
9-months MV (1) MV (1) 
PCV (3) 
18-months OPV (4) 
DTP (4) 
MV (2) 
DTaP-IPV/Hib (4) 
MV (2) 
Footnote: (0) : Birth dose, which doesn‘t count as part of primary series; (1) : First dose in a series; (2) : Second 
dose in a series; (3) : Third dose in a series; (4) : Fourth dose (booster); BCG : Bacille Calmette-Guérin 
(tuberculosis vaccine); DTaP-IPV/Hib (pentavalent) : Diphtheria, tetanus, acellular pertussis/inactivated polio 
vaccine and Haemophilus influenzae type b vaccine; DTwP/Hib: Diphtheria, tetanus, whole cell pertussis and 
Haemophilus influenzae type b vaccine combined; EPI : Expanded Programme of Immunisation; HepB : 
Hepatitis B vaccine; MV : Measles vaccine; OPV : Oral polio vaccine; PCV : Pneumococcal conjugated vaccine; 
RV : Rotavirus vaccine 
 
Since the introduction of the EPI programme, as well as additional vaccines becoming available 
worldwide, there has been a major impact on the burden of vaccine-preventable diseases in South 
Africa; which could be contributing to the decline in under-5 mortality in South Africa (WHO, 
2013a).   
 
2.8.4 Immunology of vaccines  
Since the success of the smallpox vaccine that was discovered by Edward Jenner in 1796, there 
have been dramatic reductions in disease incidence as a result of vaccination (Glezen, 2003). 
These include reduction in disease from viruses including polio virus, hepatitis B virus, measles, 
mumps and rubella viruses. In addition, control of bacterial infections including that from 
pertussis, tetanus, diphtheria and many more (Andre, 2003, Walker and Burton, 2008).  For these 
vaccines and many others, protection has been achieved by mimicking infection with the 
pathogen and thereby establishing immunologic memory that can rapidly respond should an 
actual infection occur (Walker and Burton, 2008). A perfect example of mimicry is in the use of 
live-attenuated vaccines such as the measles vaccine, which infects the host without causing 
severe illness and elicits a strong and long-lasting immune response (Walker and Burton, 2008). 
A second example is inactivated vaccines such as inactivated-polio virus vaccine and whole cell 
pertussis which functions in a similar manner as the live-attenuated vaccine but does not replicate 
within the host. A third approach utilizes exposure of the immune system to recombinant viral 
proteins alone or toxoids, as in the case of the hepatitis B vaccine and diphtheria and tetanus 
toxoids (Walker and Burton, 2008). 
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To be effective and confer long-lasting immunity, a vaccine should be capable of eliciting the 
following: a) activation of APCs to initiate antigen processing and producing interleukins; b) 
activation of both B- and T-lymphocytes to give a high yield of memory cells; c) generation of 
Th and CTLs to several epitopes, to overcome the variation in the immune response in the 
population due to MHC polymorphism and d) persistence of antigen, probably on follicular 
dendritic cells in lymphoid tissue, where memory B-lymphocytes are recruited to form antibody 
secreting cells that will continue to produce antibody. Live-attenuated vaccines fulfil these 
criteria excellently (Siegrist, 2008). Subunit vaccines induce poor immune responses and several 
doses with adjuvant are required to get an adequate response. The two main functions of an 
adjuvant antigen are to keep the antigen at or near the injection site and to activate APCs to 
achieve effective antigen processing and interleukin production (Janeway et al., 2001d). The 
main outcome of each vaccination strategy is to induce an immunologic response that will 
prevent infection or failing that, minimize the severity of illness. 
 
i) Immunology of viral vaccines 
The mainstay of protection using vaccines targeting viruses is through the induction of 
neutralizing antibodies (Warrington et al., 2011). Pre-existing serum or mucosal antibody 
induced by an earlier infection or through vaccination can bind to free virus particles, prevent 
viral entry to host T-lymphocytes, resulting in neutralization of the pathogen, and thereby prevent 
establishment of infection (Walker and Burton, 2008). In the case were host T-lymphocytes 
become infected; antibodies can bind to such cells, trigger their elimination via host effector 
mechanisms, and perhaps contribute to abortion of infection. This type of immunity is known as 
‗sterilizing immunity‘ (Walker and Burton, 2008, Warrington et al., 2011).  
Sterilizing immunity has been demonstrated in many animal models where antibodies were 
administered intravenously or mucosally. However, for human vaccines, antibodies are unlikely 
to provide sterilizing immunity and instead limit the initial burst of virus replication so that it can 
then be contained by the on-going immune response without substantial disease symptoms 
(Walker and Burton, 2008). The second line of defence is the cellular immune response, 
particularly CTLs. Vaccination with TD antigens generates a population of memory T-
lymphocytes that can rapidly expand in the first days after infection (Walker and Burton, 2008). 
These expanding CTLs kill virus infected cells by recognizing foreign viral proteins that bind to 
developing MHC-1 molecules and are displayed on the surface, providing a signal that the cell 
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should be destroyed. Lysis of a virus infected cell before the assembly of mature progeny virions 
leads to elimination of the virus, which undergoes rapid degradation in the extracellular milieu in 
the absence of the protective outer envelope. CTLs also release antiviral cytokines which may act 
to limit the impact of progeny virions already produced (Walker and Burton, 2008). 
 
Many live-attenuated vaccines elicit both neutralizing antibody and CTL responses, the 
combination of which is likely necessary for rapid elimination of the virus or successful 
immunologic containment, preventing the development of disease (Walker and Burton, 2008). 
CTL can also be induced by killed and recombinant vaccines through cross-priming when these 
vaccine antigens are taken up by professional antigen presenting cells (e.g. dendritic cells) 
(Walker and Burton, 2008).  
 
In summary, protection against  viral infections are mediated by neutralizing antibodies and 
cytotoxic T-lymphocytes, therefore  both these arms of immune response need to be correctly 
balanced, (i.e. they need the correct type of cells being activated, according to tissue type and 
type of pathogen for an effective elimination of the pathogen and control) thus resulting in 
clearance of the infection and prevention of severe disease, as well as immunological memory 
against that pathogen (Kalinski et al., 2001).  
 
ii) Immunology of bacterial vaccines 
The acquired immune response may exert its effects either independently of certain innate 
defence mechanisms for example neutralization of bacterial exotoxin by antitoxic antibodies. 
Alternatively, they may function in concert with other components of the host immune system, 
for example when antibodies opsonize infectious particles or when antibodies interact with the 
complement pathway and an infectious microorganism resulting in lysis of the microorganism 
(Benjamin, 1996a).  
 
Antitoxic immunity is predominantly associated with IgG, although IgA many also neutralize 
exotoxins such as diphtheria toxin (Benjamin, 1996a). Exotoxins bind firmly to their target 
tissue; they generally cannot be displayed by the subsequent administration of antitoxin. In those 
diseases mediated by exotoxins (diphtheria and tetanus) prompt administration of antitoxin is 
necessary to prevent attachment of additional exotoxin and the damage caused by the exotoxin 
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(Benjamin, 1996a). The presence of antitoxic activity in IgG means that an adequately 
immunized mother can transmit antitoxin to her fetus and thus confer protection to the neonate 
(Benjamin, 1996a). Antibacterial immune responses include lysis of bacterial cells via antibody 
and complement, opsonization and phagocytosis with elimination of phagocytosed bacteria by 
the liver, spleen and other components of the reticuloendothelial system.  
 
Opsonozation and phagocytosis of gram-positive bacteria involves the action of IgG and IgM 
alone or with C3b, which promotes phagocytosis of bacteria by polymophonuclear cells. The 
alternative complement pathway may be non-specifically triggered by the lipopolysaccharide 
endotoxin found in the cell wall of gram-negative bacteria, or by the polysaccharide of gram-
positive and gram-negative bacteria acting on C3. This alternative complement pathway results in 
the formation of chemotactic molecules C3a and C5a and the opsonin C3b. in addition to this, the 
activation of the alternative complement pathway may lead to immune adherence and 
bacteriolytic action of C5-C9. The classical lytic complement pathway operates in conjunction 
with IgM against gram-negative bacteria. Cell mediated immunity is active against certain 
bacteria characterized by their intracellular habitat e.g. Mycobacterium tuberculosis (Benjamin, 
1996a).    
 
2.8.5 Early life vaccine antibody responses 
Vaccine induced  protection relies on the production of sufficient  concentration of antigen 
specific antibodies to allow neutralization of pathogen at mucosal or immediately after pathogen 
invasion (Siegrist, 2001). Vaccines that have been shown to be successful examples of antibody 
mediated protection at preventing both colonization and invasive disease include polysaccharide-
protein conjugate Haemophilus influenzae type b and Streptococcus pneumoniae vaccines 
(Mulholland et al., 1997). In contrast, vaccine induced antibodies against many viral pathogens 
(Measles, Hepatitis B, polio and influenza, etc.) are unable to fully prevent viral infection, such 
that viral clearance  and hence clinical disease prevention rely on both antibody-mediated-
neutralization and cell mediated direct (toxicity) and indirect (cytokine release) effects (Siegrist, 
2001).  All childhood vaccines developed to date (with the exception of BCG) require more than 
one dose in order to provide adequate protection from disease when administered before 6 
months of age (Siegrist, 2001, Plotkin, 2010). This can be noted by the persistent risk of pertussis 
or Hib in partly vaccinated children. This slow development of vaccine mediated protection in 
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children is directly correlated with the progressive maturation of their immune system, as well as 
that multiple antigen exposure through vaccination is required for inducing  high-avidity 
antibody(Siegrist, 2001).  
 
Immune responses to vaccination are complex and require the integration of several components 
of the immune system that include both B- and T-lymphocytes, which are still undergoing 
development in the first year of life (Siegrist, 2001, Pensieroso et al., 2009, Butler et al., 2009, 
Jaspan et al., 2006).  HIV-infection has been shown to cause detrimental effects on these 
components of the immune system in a time dependant manner (Pensieroso et al., 2009). 
Pensieroso and others have, however, proposed that initiation of ART in the first year of life 
allows the normal development of an intact T-lymphocyte repertoire (Zanchetta et al., 2008, 
Violari et al., 2008, Romiti et al., 2001, Palma et al., 2008, Pensieroso et al., 2009), as well as the 
B-lymphocyte compartment and limit the deterioration of antigen specific pools of memory B-
lymphocytes that could occur in the absence of ART (Pensieroso et al., 2009). Although 
quantitative measures are frequently performed to evaluate immune recovery (example: assays of 
CD4+ T-cell number and Ig concentrations), these measures do not fully evaluate functional 
recovery (Pensieroso et al., 2009). Understanding the degree of functional immune recovery after 
ART initiation may be important in guiding vaccine administration. 
 
2.8.6 Correlates of protection 
Correlates of protection in vaccine-induced immunity is important not only for research purposes, 
but for linking immunity with protection. These factors provide insight into the reliability of 
vaccine production and protection at the community level (Plotkin, 2010). According to Plotkin a 
correlate is ―an immune response that is responsible for a statistically interrelated protection‖ 
(Plotkin, 2010). Defining protection is the first step in determining correlates of protection. The 
mechanism by which protection is achieved by vaccination may vary by the type of immune 
response required against the pathogen. In addition, the ideal way of evaluating correlates of 
protection involve the assessment of longitudinal studies with the end outcome being those that 
get the disease (Plotkin, 2010).   
Most vaccines induce antibodies of which correlates of protection may relate to functionality and 
specific concentrations. In addition, immune memory is also  a critical measure of  correlates of 
protection (Plotkin, 2010). 
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2.9 SELECTED VACCINES OF THE EPI 
2.9.1 Vaccination in HIV-infected children 
In 2010, 50% of the close to 8 million deaths in children <5 years were due to infectious diseases 
(WHO, 2013a), of which approximately half were vaccine-preventable  (WHO, 2013a). National 
immunization programmes  represent major milestones in preventative medicine and public 
health (Levine, 2011, Clemens et al., 2010), contributing to a reduction in under 5 mortality from 
12 million deaths in 1990 to 7.6 million in 2010 (WHO, 2013a).  Nevertheless, an estimated 3 
million children under 5 years died in 2010, due to vaccine preventable diseases (Clemens et al., 
2010).  
 
The majority of available vaccines have been developed through approaches where the efficacy 
has been studied in relatively healthy populations. The diminished level of protective immune 
response in immunocompromised people remains problematic. In addition, there are data to 
suggest that immunization coverage may be less in HIV-exposed children (Healy et al., 2013). A 
survey of over 2000 children between the ages of 12 and 23 months in South Africa found that 
maternal HIV status was a risk factor for decreased immunization coverage for several childhood 
immunizations (Ndirangu et al., 2009).  
 
Even in those that are relatively healthy, immunization schedules are being updated continuously 
in accordance with scientific knowledge, epidemiology and advances in vaccine design (Menson 
et al., 2012) and this is also country specific (Geretti and Doyle, 2010). There are uncertainties 
with regards to the correct vaccination schedule among HIV-infected children (Geretti and Doyle, 
2010). The status of selected single mandatory and recommended vaccines for HIV-infected 
children in relation to ART strategies prior to and post ART initiation compared with vaccination 
outcomes of healthy children, will be reviewed below.  
 
2.9.2 Non-replicating vaccines 
Non-replicating vaccines have been reportedly found to be safe in HIV-infected children, 
although antibody responses may be suboptimal especially in those with immunosuppression 
(Moss et al., 2003). The WHO has recommended that all HIV-infected children be immunized 
with inactivated vaccines including diphtheria, tetanus, pertussis, HibCV and hepatitis B vaccine. 
Immune response among HIV-infected vaccinees already on ART varies depending on the 
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vaccine administered (Sutcliffe and Moss, 2010), sero-protective responses range from 40-65% 
for DT (Zaccarelli-Filho et al., 2007), 38-65% for TT (Ching et al., 2007, Rigaud et al., 2008, 
Farquhar et al., 2009, Zaccarelli-Filho et al., 2007) and 1-100% for hepatitis B (Fernandes et al., 
2008, Siriaksorn et al., 2006, Abzug et al., 2009, Zaccarelli-Filho et al., 2007).   
 
2.9.2.1 Diphtheria toxoid vaccine 
Infection with Corynebacterium diphtheriae causes symptoms of diphtheria. The pathogenic 
nature of C. diphtheriae is caused by an exotoxin, the gene for which is located in a prophage 
(Efstratiou et al., 2000). The toxin is a 62 kilodalton polypeptide composed of two fragments (A 
and B) of different functionality (Demirci, 2011). The toxin binds to receptors on the target cell 
via fragment B and is absorbed into the cell. Once inside the cell, fragment A blocks the 
synthesis of proteins irreversibly (WHO, 2006a). Two syndromes may occur from C. diphtheriae 
infection: the first is local infection and second is primary systemic toxicity. Diphtheria vaccines 
are based on diphtheria toxoid that induces protective antitoxin. Diphtheria toxoid is part of a 
triple component vaccine DTP and has been part of the WHO EPI since 1974. During 1980-2000 
the total number of reported diphtheria cases has decreased by >90% (WHO, 2006a). Following 
primary immunization the average duration of protection afforded by the diphtheria vaccine is 
said to be 10 years, however, boosting of immunity is required either by exposure to wild-type 
strains or by booster vaccination at early school age (WHO, 2006a).  
 
In the era before HIV-infection, responses to the diphtheria-toxoid vaccine were 100% (WHO, 
2006a), while only 18-76% of HIV-infected persons develop protective antibody concentrations  
(Borkowsky et al., 1987, Borkowsky et al., 1992, Ryder, 1993, Zaccarelli-Filho et al., 2007); 
Table 2.5. HIV-infected persons develop lower geometric mean concentrations than HIV-
uninfected persons after primary vaccination. Furthermore, there is greater waning of antibody 
concentration over time (Tejiokem et al., 2007). Between 18-71% (Table 2.5) of HIV-infected 
children not on ART, who developed protective levels of antibodies post primary vaccination, 
retained these levels 6-36 months after vaccination (Borkowsky et al., 1987, Tejiokem et al., 
2007). There is limited information on the immunogenicity of the diphtheria-toxoid vaccine in 
sub-Saharan Africa (Table 2.5) and especially in countries with a high prevalence of HIV-
infection (Tejiokem et al., 2007, Ryder, 1993). Additionally, studies have not systemically 
evaluated the effect of timing of ART on the primary and memory immune response in HIV-
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infected children (Essajee et al., 1999, Zaccarelli-Filho et al., 2007). To date, only two studies 
have studied immune response to DT in HEU children in comparison with HIV-unexposed 
children. In both studies no differences in sero-protective threshold (>0.1 IU/ml) was observed 
between HEU and HIV-unexposed children (Abramczuk et al., 2011, Ryder, 1993). From these 
studies, it can be seen that there is limited data on response to diphtheria-toxoid vaccine in the era 
of high HIV-prevalence as well as increased access to ART. None of the studies conducted thus 
far have evaluated the effects of ART on primary vaccine response, as well as anamnestic 
response to booster vaccination. Furthermore, there is a paucity of data with regards to response 
to diphtheria-toxoid in HEU children.    
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Table 2.5: Comparison of antibody response to diphtheria-toxoid epitope between HIV-infected, HEU and/or HIV-unexposed 
children 
Study 
setting and 
Reference 
Study 
design 
HIV-infected 
N (Age at study 
entry) 
HEU 
children 
N (Age 
at study 
entry) 
HIV-
unexpose
d 
children 
N (Age 
at study 
entry) 
Vaccination 
schedule and 
timing of 
blood sample 
Number 
on 
ART 
Initiatio
n of 
ART 
prior to 
vaccinati
on and 
duration 
on ART 
CD4+ at 
study 
entry 
Main findings HIV-infected only# 
or (HIV-infected vs. HIV-
unexposed)†  
or  
(HIV-infected vs. HEU)††  
or  
(HEU vs. HIV-unexposed)††† 
Summary 
HIV-infected only 
1987 
USA 
(Borkowsk
y et al., 
1987) 
NS 
17 (11-90 
months) 
ND ND 
DTP: 3 doses 
 
Bloods: NS 
ND ND ND 
>0.02 U/ml; N/n (%): 3/17 (18%)# 
 
CMI, N/n (%):8/17 (47%) 
Sub-optimal response seen 
after primary vaccination. 
8/17 had cell mediated 
response,  of which they 5 
had no evidence of 
antibody response to DT 
1999 
USA 
(Essajee et 
al., 1999) 
Cohort 25 (8.9 years) ND ND 
Previously 
vaccinated† 
n=15:  3 
doses 
followed by 
booster doses 
at 4-6 years 
and  12 years 
 
Re-
vaccination‡ 
n=6: 1 dose 
Bloods: NS† 
and 1-2 
months‡ 
 
25 
ART was 
initiated 
post 
vaccinati
on in the 
previousl
y 
vaccinate
d 
children 
and were 
on ART 
for 18.8 
months 
prior to 
blood 
sampling. 
 
ART 
initiated 
16 
months 
prior to 
booster 
dose in 6 
children 
who were 
re-
vaccinate
d. 
2% 
 
LPA SI>3: 0% †# 
 
LPA SI>3 N/n (%): 0/6 (0%)#‡ 
 
Sub-optimal response to 
vaccination, with ART not 
improving immunological 
memory responses to 
additional doses of DT 
vaccine. 
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HIV-infected vs. HIV-unexposed 
1993 
Zaire 
(Ryder, 
1993) 
Non-
randomi
zed 
prospecti
ve 
cohort 
48 (NS) 202 (NS) 440 (NS) 
DTP at 6, 10, 
14 weeks 
 
Bloods: 9 
months 
ND ND ND 
<0.01, IU/ml, N/n (%): 
14/48 (29.7%) vs. 19/440 (4.3%), 
p<0.001*† 
 
14/48 (29.7) vs. 3/202 (1.5%), 
p<0.001*†† 
 
≥0.01-0.09 IU/ml, N/n (%): 
29/48 (60.4%) vs. 260/440 (59%), 
p=1.00*† 
 
29/48 (60.4%) vs. 114/202 (56%), 
p=0.63*†† 
 
≥0.1 IU/ml, N/n (%): 
5/48 (10%) vs. 161/440 (37%), 
p<0.001†; 
5/48 (10%) vs. 85/202 (42%), 
p<0.001†† 
 
GMT, IU/ml: 0.018 vs. 0.070 and 
0.018 vs. 0.080 p<0.05 significant 
difference between HIV-infected 
vs. HIV-unexposed and HEU 
Difference between HIV-
infected vs. HEU and HIV-
unexposed for DT ≥0.1 
IU/ml and GMT. 
2007 
Brazil 
(Zaccarelli-
Filho et al., 
2007) 
Observat
ional 
Good VLR: 9 
(11 years) 
 
Partial VLR: 13 
(7.4 years) 
 
 
Poor VLR: 14 
(9.4 years) 
 
ND 
20 (11 
years) 
DTP: 2, 4, 6 
months 
Booster 15 
months 
 
Booster 15 4-
6 years 
 
Bloods: NS 
41 
Good 
VLR: 
initiated 
prior to 
2nd 
booster 
dose at 
5.8 years 
of age 
 
Partial 
VLR: 
initiated 
prior to 
2nd 
booster 
dose at 
3.7 years 
of age 
 
Poor 
VLR: 
Initiated 
post 2nd 
booster 
dose at 
7.3 years 
Good 
VLR: 
33% 
 
Partial 
VLR: 
26% 
 
Poor 
VLR: 
37% 
>0.1 IU/ml: 
Good VLR: 65% vs. Partial VLR: 
61% vs. Poor VLR: 40%, p=0.239 
 
Mean antibody levels IU/ml,  (95% 
CI): 
Good VLR: 0.26 (0.005-20.8) vs. 
Partial VLR: 0.156 (0.001-15.1) vs. 
Poor VLR: 0.36 (0.001-22.3), 
p=0.172 
 
Weak response between 
levels of viral control 
compared to the HIV-
unexposed control group. 
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of age 
HIV-infected vs. HEU 
1992 
USA 
(Borkowsk
y et al., 
1992) 
Prospect
ive 
33 
(<4 years) 
53 
(<4 
years) 
ND 
DTP: primary 
series 2, 4, 6 
months 
 
Booster 18 
months 
 
Bloods: 2 and 
6 months 
ND ND ND 
>0.02 U/ml, N/n (%): 21/24 (88%) 
vs. 10/10 (100%), p=0.54*††√ 
 
>0.02 U/ml, N/n (%): 7/13 (54%) 
vs. 8/8 (100%), p=0.048*††√√ 
 
 
No differences between 
humoral responses in HIV-
infected vs. HEU after 
primary doses. Attrition in 
the 2nd year of life resulted 
in differences being 
observed in HIV-infected 
vs. HEU. 
2007 
Cameroon 
and Central 
Africa 
(Tejiokem 
et al., 2007) 
Cross 
sectional 
51 
(25 months) 
78 
(25 
months) 
ND 
DTwP: 6, 10, 
14 weeks 
18 months 
booster 
 
Bloods: 17 
months 
(range: 3.9 to 
31 months) 
33 
No ART 
was 
initiated 
prior to 
primary 
or 
booster 
dose. 
 
ART was 
initiated 
6 months 
before 
blood 
sampling. 
<15 to 
>25% 
>0.1 IU/ml, N/n(%)√: 22/44 (50%) 
vs. 51/66 (77%), p=0.003 
 
>0.1 IU/ml, N/n(%)√√: 5/7 (71%) vs. 
12/11 (92%), p=0.29 
 
GMC IU/ml, (95% CI): 245 (166-
361) vs. 312 (246-396), p=0.13 
 
Proportion of children with 
CD4+<25% had low DT titers (OR: 
4.1; 95% CI: 1.7-10.1, p=0.002) 
Significantly reduced titers 
in HIV-infected vs. HEU 
HEU vs. HIV-unexposed 
1993 
Zaire 
(Ryder, 
1993) 
Non-
randomi
zed 
prospecti
ve 
cohort 
ND 202 (NS) 440 (NS) 
DTP at 6, 10, 
14 weeks 
 
Bloods: 9 
months 
ND ND ND 
<0.01, IU/ml N/n (%): 3/202 (1.5%) 
vs. 19/440 (4.3%), p=0.10*††† 
 
>0.01 IU/ml N/n (%): 114/202 
(56%) vs. 260/440 (59%), 
p=0.55*††† 
 
>0.1 IU/ml: 85/202 (42%) vs. 
161/440 (37%), p=0.19*††† 
 
GMT, IU/ml: 0.080 vs. 0.070, 
p=NS 
No difference in sero-
protective antibody titers 
≥0.01 and ≥0.1 IU/ml as 
well as GMT  between 
HEU vs. HIV-unexposed 
2011 
Brazil 
(Abramczu
k et al., 
2011) 
NS ND 
19 
(7.7 
months) 
112 
(7.5 
months) 
DTP-Hib at 2, 
4, 6 months 
 
Bloods: 16 
weeks 
ND ND ND 
>0.1 IU/ml N/n(%): 18/19 (95%) 
vs. 110/112 (98%), p=0.38*√††† 
 
GMT, IU/ml (95% CI): 0.526 
(0.289-0.967) vs. 0.559 (0.465-
0.67), p=0.81 
No difference between 
sero-protective titers and 
GMT for  HEU vs. HIV-
unexposed 
Footnote: HEU: HIV-exposed, uninfected; N: total number of participants; ART: antiretroviral therapy; ND: not done; LPA= lymphoproliferative assay; SI= 
stimulation indices; NS= not stated; 
†
 previously vaccinated in early childhood; 
‡
 re-vaccination: children who received all primary and booster doses in early 
childhood, and received a full series of vaccination in older age; 
√
 response after primary vaccination; 
√√
 response to booster vaccination; IU/ml: international 
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units per milliliter; IQR: interquartal range; VLR: viral load responders; GMT/C: geometric meant titer/concentration; *Calculated from data given in paper, using Fischer‘ 
exact test; DTP: diphtheria, tetanus, pertussis vaccine;  DTwP: diphtheria, tetanus, whole cell pertussis vaccine; Hib: Haemophilus influenzae type b; CI; confidence 
interval.  
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2.9.2.2 Tetanus toxoid vaccine 
Neonatal tetanus is a potentially fatal infection that is caused by Clostridium tetani. Maternal and 
neonatal tetanus, is the most common form of tetanus in developing countries, and was 
responsible for approximately 5% of global neonatal deaths in 2000 (WHO, 2004, Vandelaer et 
al., 2003). A significant reduction in maternal and neonatal associated infection has been reported 
following the introduction of tetanus vaccine in pregnant women  (WHO, 2006b). In 2004 an 
estimated 290 000 individuals had died as a result of tetanus infection this included 257 000 cases 
of neonatal tetanus (WHO, 2004). The World Health Assembly called for the elimination of 
neonatal tetanus, with elimination being defined as less than 1 case per 1000 live births at district 
level (WHO, 2006b). 2005 was the target date for the global elimination of neonatal tetanus by 
all member states of WHO, United Nations Children‘s Fund (UNICEF) and the United Nations 
Population Fund (UNFPA) (Esen et al., 2007). So far 104 developing countries had achieved this 
goal by 2000 (WHO, 2004).  Exceptional progress has been made in the 15 years since the 
implementation of the neonatal tetanus elimination programme, worldwide mortality from 
neonatal tetanus was estimated at 180 000 in 2002, which represents a 78% reduction since the 
late 80s (WHO, 2006b). In developed countries, maternal and neonatal tetanus are exceedingly 
rare (Pascual et al., 2003, Rushdy et al., 2003), however, deaths due to neonatal tetanus continue 
to  be reported in low-income countries from South Asia and Africa (WHO, 2006b).  
 
Tetanus-toxoid is a commonly included as part of the DTP combination vaccines. It is prepared 
by formaldehyde treatment of cell free tetanus toxin, which is adsorbed to an adjuvant (WHO, 
2006b). It is given as a 3 dose primary series, in addition to which it is recommended that 
children receive a booster dose before school entry (3-5 years) and at 13-18 years of age (WHO, 
2004).  Tetanus-toxoid antigen is one of the most effective, safe, stable and inexpensive vaccines 
to be developed, and can be safely given during pregnancy and to immunosuppressed individuals 
(Balmer et al., 2007). The duration of protection is dependent on dose and on the age at which it 
is administered (Balmer et al., 2007). Antibody responses to the first dose develop slowly and 
consist of mainly non-neutralizing IgM and a small amount of IgG, this response is insufficient to 
provide protection. After the second dose, approximately 90% of people develop protective 
antibody levels, which however declines to <80% within a year. A third dose induces  sero-
protective titers in 98% of recipients, which remains high for several years (Balmer et al., 2007). 
The long-term protection has been observed after receiving 5-6 doses, and lasts for 20-25 years if 
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the primary vaccination series was administered during infancy, and booster doses are given 
during late childhood and adolescence (Simonsen et al., 1987, de Melker et al., 1999, 
Matouskova et al., 2005).  
 
Children infected with HIV generally mount a protective response to tetanus toxoid; Table 2.6. 
Low levels of antibody titers against tetanus in HIV-infected individuals have been previously 
reported, and found to be more common amongst those with CD4+ cell counts less than 
300cell/µl  (Dieye et al., 2001, Rosenblatt et al., 2005, Lederman et al., 2003, Talesnik et al., 
1998, Bonetti et al., 2004). In a study conducted in Brazil on maternal tetanus IgG transplacental 
transfer, it was observed that HIV-infected mothers transferred fewer antibodies than HIV-
uninfected mothers (Rosenblatt et al., 2005), however, this  was not evident in  Zambia (de 
Moraes-Pinto et al., 1996). Persistence of these tetanus antibodies in HIV-infected children has 
been shown to be short lived as compared to HIV-uninfected control of similar age (Rosenblatt et 
al., 2005). They also showed that HIV-infected children with relatively well-preserved immune 
function who initiated ART had partial reconstitution, and  responded well to re-vaccination 
(Rosenblatt et al., 2005).  
 
The majority of studies conducted in HEU children, have indicated similar responses to primary 
TT vaccination (3 dose schedule) when compared to HIV-unexposed children; Table 2.6 
(Abramczuk et al., 2011, Reikie et al., 2013, Jones et al., 2011, Garcia-Knight et al., 2015, 
Hesseling et al., 2016), except for one from Brazil in which  GMTs where lower in HEU than 
HIV-unexposed children (Abramczuk et al., 2011). Furthermore, there is only a single study 
which  evaluated booster response to TT at 18-months of age (received a 3 dose primary 
vaccination series 6, 10 and 14 weeks), which reported higher GMCs in HEU compared to  HIV-
unexposed children (Reikie et al., 2013).  
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Table 2.6: Comparison of vaccination response to tetanus-toxoid epitope between HIV-infected children and HEU and/or HIV-
unexposed children 
Study 
setting 
And 
Reference 
Study 
design 
HIV-infected 
N (Age at 
study entry) 
HEU 
children 
N (Age at 
study entry) 
HIV-
unexposed 
children 
N (Age at 
study 
entry) 
Vaccination 
schedule 
and timing 
of blood 
sample 
Number 
on 
ART 
Initiation of 
ART prior 
to 
vaccination 
and 
duration on 
ART 
CD4+ at 
study 
entry 
Main findings 
HIV-infected 
children only# or  
(HIV-infected vs. 
HIV-unexposed)†  
or  
(HIV-infected vs. 
HEU)††  
or  
(HEU vs. HIV-
unexposed)††† 
Summary 
HIV_infected only 
1987 
USA 
(Borkowsk
y et al., 
1987) 
NS 
17 (11-90 
months) 
ND ND 
DTP: 3 doses 
 
Bloods: NS 
ND ND ND 
>0.001 U/ml; N/n (%): 
9/15 (60%)#√ 
 
CMI, N/n (%):8/13 
(62%)#√ 
Sub-optimal response seen 
after primary vaccination. 
1999 
USA 
(Essajee et 
al., 1999) 
 
Cohort 25 (8.9 years) ND ND 
Previously 
vaccinated† 
n=15:  3 
doses 
followed by 
booster 
doses at 4-6 
years and  12 
years 
 
Re-
vaccination‡ 
n=6: 1 dose 
Bloods: NS† 
and 1-2 
months‡ 
 
25 
ART 
initiated 
prior to 
booster dose 
in 6 children 
who were 
re-
vaccinated 
2% 
LPA SI>3: 0% †# 
 
LPA SI>3 N/n (%): 
3/6 (50%)‡ ; 1/6 
(16.6%) had an 
additional booster 6 
weeks post re-
vaccination 
 
Sub-optimal response to 
vaccination even after re-
vaccination and being on 
ART for more 16 months 
prior to booster dose. 
2005 
USA 
(Rosenblatt 
et al., 2005) 
Randomi
zed 
clinical 
trial 
37 (6.1 years) ND ND 
DTaP 
booster at 
either 16 or 
36 weeks 
 
Bloods: 4, 8, 
18, 32 weeks 
37 
ART 
initiated at 
16 weeks or 
36 weeks 
prior to 
booster dose 
ND 
>1:243#√√ 
74% vs. 67% vs. 53% 
vs. 38% at 4, 8, 18 and 
32 weeks after 
vaccination 
Increase in tetanus titers 
after vaccination, with an 
increase of 27-fold over 
the baseline values at 
weeks 4 and 8. The effect 
on tetanus titers faded to a 
9-fold and 3-fold increase 
over baseline values at 
weeks 18 and 32, 
respectively. 
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2007 
USA 
(Ching et 
al., 2007) 
Prospect
ive 
15 (12 years) ND ND 
Booster TT 
 
Bloods: 6 
years post 
primary, 2.3 
months post 
booster 
15 
No ART 
initiated 
post 
primary, but 
initiated 
ART at 
booster and 
on ART for 
2 years prior 
to blood 
sampling. 
35% 
>0.15IU/ml: 
Pre-booster:: 38%√ 
 
92% after booster√√ 
HIV-infected children had 
modest responses to TT 
post booster vaccination 
2008 
USA 
(Rigaud et 
al., 2008) 
 
Randomi
zed 
compara
tive 
response 
Group 1: 22 
(13 years) 
Group 2: 24 
(12 years) 
ND ND 
Group1: 
DTaP, Td or 
DT at 8, 16, 
24 weeks of 
the study 
 
Group 2: 32, 
40, 48 weeks 
in the study 
 
Bloods: 12, 
28, 36, 52, 
76, 100 
weeks 
46 
Initiated 
ART prior 
to re-
vaccination 
in both 
groups. 
Duration on 
ART was 
not stated 
7% in 
both 
groups 
>0.1IU/ml 
N/n (%): 
Group 1: 18/18(100% 
vs. Group 2: 
11/20(55%), p=0.001# 
 
Weeks 28 median titre 
(IQR) IU/ml: Group 1: 
3.63 (1.99-6.19) vs. 
0.11 (0.06-0.47), 
p<0.001# 
Significant differences 
were seen between 
children receiving 
vaccination and not 
receiving vaccination 
2009 
Kenya 
(Farquhar 
et al., 2009) 
Prospect
ive 
90 (4.9 years) ND ND 
Re-
vaccination‡ 
 
Bloods: 4 
weeks 
90 
No ART 
post primary 
 
ART given 
8 months 
prior to 
booster 
dose. 
6.3 >0.01IU/ml 75%#‡ 
Sero-conversion was 
associated with older age 
(p=0.03). 
. 
2009 
Italy 
(Pensieroso 
et al., 2009) 
 
Cross 
sectional 
70 
(Early 
treatment: 6.8 
years: 
Late control: 
13.7 years 
Late failure: 
15.8 years 
Treatment 
naïve: 11.8 
years) 
ND ND 
Vaccination 
NS 
 
Bloods: 
Early 
control: 5.3 
years 
Late control: 
7.4 years 
Late failure: 
9.7 years 
Treatment 
naïve: 5.0 
years 
64 
ART 
initiated in 
early and 
late 
controller 
and late 
failure. 
Duration on 
ART was 
stated. 
Early 
treatment
: 35% 
Late 
control: 
33% 
Late 
failure: 
22% 
Treatmen
t naïve: 
25% 
 
Early control: 92% 
Late control: 38% 
Late failure: 25% 
Treatment naïve: 
100% 
Antibodies were higher in 
the early-treated compared 
with the late-treated 
patients (p= 0.02). The late 
control group and for the 
late failure group p= 0.05.  
Significant difference was 
also found between the late 
failure and the treatment 
naive group (p= 0.01). 
HIV-inefected vs. HIV-unexposed 
1993 
Zaire 
(Ryder, 
Non-
randomi
zed 
48 (NS) 202 (NS) 440 (NS) 
DTP at 6, 10, 
14 weeks 
 
ND ND ND 
≥0.01IU/ml, N/n (%): 
46/48 (96%) vs. 
418/440 (94%), 
No difference between 
percentage with sero-
protective antibody titers in 
50 
 
1993) prospecti
ve 
cohort 
Bloods: 9 
months 
p=1.00*†√ 
 
46/48 (96%) vs. 
190/202 (94%), 
p=1.00*††√ 
 
 
GMT, IU/ml: 9.1 vs. 
9.1† √ and 9.1 vs. 7.6††√ 
p>0.05 no significant 
difference between 
HIV-infected vs. HIV-
unexposed and HEU 
HIV-infected vs. HEU and 
HIV-unexposed 
2007 
Brazil 
(Zaccarelli-
Filho et al., 
2007) 
Observat
ional 
Good VLR: 9 
(11 years) 
 
 
 
 
 
Partial VLR: 
13 (7.4 years) 
 
 
 
 
 
Poor VLR: 14 
(9.4 years) 
 
ND 
20 (11 
years) 
Previously 
vaccinated: 
DTP: 2, 4, 6 
months 
 
Booster 15 
months and 
4-6 years 
 
 
Bloods: NS 
41 
Good VLR: 
initiated 
prior to 2nd 
booster dose 
at 5.8 years 
of age 
 
Partial 
VLR: 
initiated 
prior to 2nd 
booster dose 
at 3.7 years 
of age 
 
Poor VLR: 
Initiated 
post 2nd 
booster dose 
at 7.3 years 
of age 
 
 
Good 
VLR: 
33% 
 
Partial 
VLR: 
26% 
 
Poor 
VLR: 
37% 
>0.1 IU/ml: 
Good VLR: 71% vs. 
Partial VLR: 77% vs. 
Poor VLR: 73%, 
p=0.851#√√ 
 
Mean antibody levels 
IU/ml,  (95% CI): 
Good VLR: 0.26 
(0.005-20.8) vs. Partial 
VLR: 0.156 (0.001-
15.1) vs. Poor VLR: 
0.36 (0.001-22.3), 
p=0.823#√√ 
 
Weak response between 
levels of viral control 
compared to the HIV-
unexposed control group. 
2009 
Germany 
(Ghosh et 
al., 2009) 
Cross 
sectional 
48 (9.36 
years) 
ND 
62 (6.03 
years) 
DTP at 2, 3, 
4 and 11-14  
months 
 
Booster at 5-
6 years 
 
Bloods: 7 
years 
 
 
9 
No ART 
was initiated 
prior to 
either 
primary or 
booster 
doses. ART 
was initiated 
>12 months 
prior to 
blood 
sampling. 
68.9% 
SI: before initiation of 
ART 36 months after 
primary vaccination 
mean (SD), EU/ml: 
0.67 (0.9) 
84 months after 
booster mean (SD):3.3 
(1.8) 
All children had specific 
immunity to TT at an 
average of 7 years post 
vaccination. Three children 
had spontaneous 
reconstitution of tetanus 
antibody 
HIV-infecetd vs. HEU 
1992 
Italy 
NS 
20 (18-24 
months) 
52 (8-24 
months 
ND 
2 or 3 doses 
 
ND ND ND 
>0.1 IU/ml, N/n %; 
(95% CI): 
Symptomatic HIV could 
be considered one of the 
51 
 
(Barbi et 
al., 1992) 
Bloods: 9 
months for 
HIV-infected 
 
4 months for 
HEU 
13/17 (76.5%) vs. 
39/41(95.1%), 
p=0.055*†† 
 
GMT, antitoxin 
titer≥1:1024: 1:1737 
vs. 1:5884, p<0.05†† 
causes of short persistence 
of antibody. 
2007 
Cameroon 
and Central 
Africa 
(Tejiokem 
et al., 2007) 
Cross 
sectional 
51 
(25 months) 
78 
(25 months) 
ND 
DTwP: 6, 10, 
14 weeks 
 
Booster at 18 
months 
 
Bloods: 17 
months 
(range: 3.9 to 
31 months) 
33 
No initiation 
of ART 
prior to 
either 
primary or 
booster 
dose. ART 
was initiated 
6 months 
prior to 
blood 
sampling. 
<15 to 
>25% 
>0.1 IU/ml, N/n(%)√††: 
36/44 (82%) vs. 64/66 
(97%), p=0.01 
 
>0.1 IU/ml, 
N/n(%)√√††: 7/7 
(100%) vs. 12/112 
(100%), p=NE 
 
GMC IU/ml, (95% 
CI): 289 (228-367) vs. 
491(396-609), p=0.001 
 
Proportion of children 
with CD4+<25% had 
low DT titres (OR: 
7.3; 95% CI: 1.3-39.9, 
p=0.02) 
Significantly reduced titres 
in HIV-infected vs. HEU 
children 
Post primary vaccination 
 
Similar proportion 
protected post booster 
vaccination 
 
GMC was lower in HIV-
infected than HEU 
1992 
USA 
(Borkowsk
y et al., 
1992) 
Prospect
ive 
33 
(<4 years) 
53 
(<4 years) 
ND 
DTP: 
primary 
series 2, 4, 6 
months 
 
Booster 18 
months 
 
Bloods: 2 
and 6 months 
ND ND ND 
>0.01 U/ml, N/n (%): 
24/24 (100%) vs. 
10/10 (100%), 
p=NE††√ 
 
>0.01 U/ml, N/n (%): 
10/13 (77%) vs. 8/8 
(100%), p=NE††√√ 
 
 
No differences between 
humoral responses in HIV-
infected vs. HEU after 
primary and booster doses. 
HEU vs. HIV-unexposed 
2010 
Uganda 
(Elliott et 
al., 2010) 
NS ND ±129 (NS) ±1304 (NS) 
DTwP-
HepB-Hib at 
6, 10, 14 
weeks 
 
Bloods: NS 
ND ND ND 
Reduced IFN-γ, IL-5 
and IL-13 responses to 
tetanus toxin in HEU 
children††† 
Reduced response but not 
significant between HEU 
vs. HIV-unexposed 
2011 
Brazil 
(Abramczu
k et al., 
2011) 
NS ND 
19 
(7.7 months) 
112 
(7.5 
months) 
DTP-Hib at 
2, 4, 6 
months 
 
Bloods: 16 
weeks 
ND ND ND 
>0.1 IU/ml N/n(%): 
19/19 (100%) vs. 
108/112 (98%), 
p=NE√††† 
 
GMT, IU/ml (95% 
CI): 1.520 (1.247-
1.851) vs. 2.712 
(2.258-3.258), 
No difference between 
proportion protected in 
HEU vs. HIV-unexposed 
 
 
 
 
HEU had reduced GMT to 
HIV-unexposed 
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p=0.013√††† 
2011 
South 
Africa 
(Jones et 
al., 2011) 
Prospect
ive 
cohort 
ND 
38 (<4 
months) 
55 (<4 
months) 
DTwP-Hib 
at 6, 10, 14 
weeks 
 
Bloods: 16 
weeks 
ND ND ND 
No difference after 3 
doses, median 
concentration in 
infants not completed 
all 3 doses, mg/L 
(IQR): 1.86 (0.51-
2.21) vs. 0.50 (0.10-
0.93), p=0.01√††† 
 
Fold increase (IQR): 
14.0 (3.26-116.2) vs. 
12 (2.8-136.35), 
p=0.54√††† 
Similar results between 
HEU and HIV-unexposed 
2013 
South 
Africa 
(Reikie et 
al., 2013) 
Prospect
ive 
cohort 
ND 
27 (3 
months) 
28 (3 
months) 
DTwP-Hib 
at 6, 10, 14 
weeks 
 
Booster at 18 
months 
 
Bloods: 3, 6, 
12, 18, 24 
months 
ND ND ND 
No differences post-
primary DTP, but 
higher post-booster 
DTP in HEU infants, 
p<0.05 
No differences in 
proportion protected††† 
Similarities between HEU 
and HIV-unexposed post 
primary vaccination; and 
HEU had significantly 
higher titres post-booster 
dose 
2015 
Kenya 
(Garcia-
Knight et 
al., 2015) 
Cross 
sectional 
ND 
8 (3 months) 
 
26 (12 
months) 
8 (3 
months) 
 
17 (12 
months) 
DTwP-
HepB-Hib at 
6, 10, 14 
weeks 
 
Bloods: 3, 12 
months 
ND ND ND 
No difference in 
response to TT antigen 
at 3 months††† 
 
At 12 months, lowered 
CD4+ IL-2 response 
and dual IL-2 TNF-α 
response to TT 
antigens in HEU 
children 
Similar response post 
primary vaccination in 
HEU vs. HIV-unexposed 
 
Reduced responses at 12 
months post primary 
vaccination 
2016 
South 
Africa 
(Hesseling 
et al., 2016) 
NS ND 118 (NS) 60 (NS) 
DTwP-Hib 
at 6, 10, 14 
weeks 
 
 
Bloods: 14, 
24, 52 weeks 
ND ND ND 
GMCs and proportions 
protected similar 
between HEU and 
HIV-uninfected 
children††† 
Similar between HEU and 
HIV-unexposed 
Footnote: HEU: HIV-exposed, uninfected; N: total number of participants; ART: antiretroviral therapy; ND: not done; LPA= lymphoproliferative assay; SI= 
stimulation indices; NS= not stated; 
†
 previously vaccinated in early childhood; 
‡
 re-vaccination: children who received all primary and booster doses in early 
childhood, and received a full series of vaccination in older age; 
√
 response after primary vaccination; 
√√
 response to booster vaccination; IU/ml: international 
units per milliliter; IQR: interquartal range; VLR: viral load responders; GMT/C: geometric meant titer/concentration; *Calculated from data given in paper, using Fischer‘s 
exact test;  NE: not evaluable; SD: standard deviation; DTP: diphtheria, tetanus, pertussis vaccine;  DTwP: diphtheria, tetanus, whole cell pertussis vaccine; Early control= 
children who started on combined ART in the first year of life; Late control= children who were started on  combined ART after the first year of life and in 
whom viral suppression was achieved; Late failure= children who started on combined ART after the first year of life and in whom viral suppression was not 
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achieved. DT: diphtheria toxoid; TT= tetanus toxoid; DTaP= diphtheria, tetanus, and acellular pertussis vaccine; Td= tetanus and diphtheria vaccine; Hib: 
Haemophilus influenzae type b; HepB: hepatitis B vaccine; CI; confidence interval; EU: ELISA Units.  
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2.9.2.3 Pertussis vaccine 
Bordetella pertussis is a gram-negative pleomorphic bacillus which is the causative agent of 
pertussis or ―whooping cough‖. It is a severe, potentially life-threatening infection of the lower 
respiratory tract (Watanabe et al., 2006, Healy et al., 2004). Bordetella species has been shown to 
alter their phenotypes depending on the surrounding environment, and may show differing 
expression of virulence factors (WHO, 2010d). These factors are PT, FHA, pertactin (PRN), 
fimbriae (FIM) type 2 and type 3, adenylate cyclase toxin (ACT), tracheal cytotoxin (TCT), 
lipooligosaccharide and B. pertussis endotoxin (WHO, 2010d, Mills, 2001). There full spectrum 
of pertussis pathogenesis is not fully understood, however, FHA, PRN and FIM assist with 
attachment to the target cell, while PT, TCT and ACT play a role in the destruction of the host 
epithelial lining and evasion of the hosts‘ immune defences (WHO, 2010d).  
 
B. pertussis is transmitted from infected to susceptible persons through droplets. During the 
primary stages of pertussis (catarrhal phase), the infection is highly contagious, which lasts for 
one to two weeks (WHO, 2010d, Galazka and Robertson, 1996). Individuals in this stage, exhibit 
mild symptoms of upper respiratory infection with rhinorrhoea, conjunctivitis, lacrimation, mild 
cough, and low grade fever (Galazka and Robertson, 1996). The paroxysmal phase, which 
follows usually lasts for two to four weeks, however, can persist for as long as 20 weeks. This 
phase is characterized by a repetitive series of paroxysmal coughs during a single expiration, 
followed by a sudden massive inspiratory effort that produces a ―whoop‖ as air is inhaled 
forcefully against a narrow glottis (Galazka and Robertson, 1996). The coughing becomes so 
severe that patients cannot sleep or eat, and may lead to vomiting resulting in weight loss and 
malnutrition, especially in children with borderline nutritional status (Galazka and Robertson, 
1996). The convalescent phase is the final phase of the disease, when the paroxysmal symptoms 
gradually decrease in frequency and severity. Following natural infection, antibodies to PT (the 
only B. pertussis antigen) are found in 80-85% of patients. Neither type nor concentration of 
antibodies is correlated with immunity and thus far no protective correlate of protection has been 
identified for cell mediated immunity (Plotkin, 2010, WHO, 2010d). Natural infection does not 
confer long-term protection against pertussis (Konig, 2010).  
Before the vaccine era, B. pertussis infection was responsible for substantial morbidity and 
mortality in childhood (WHO, 2010d, Healy et al., 2004).  Following the scale up of vaccination 
during the 1950s and 1960s there was a dramatic decrease (>90%) in the incidence of pertussis in 
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developed countries. The pertussis vaccine (combined with diphtheria toxoid and tetanus toxoid) 
has been part of WHOs‘ EPI since 1974. As of 2008, the WHO estimated that worldwide, 16 
million cases of pertussis had occurred of which 95% occurred in developing countries and with 
approximately 687 000 deaths being averted as a result of vaccination (WHO, 2010d). Majority 
of clinically recognized pertussis cases occur in children between the ages of one and five years, 
with severe disease and death being observed in the first weeks and months of life (Archer et al., 
2011). In South Africa, the incidence of pertussis has been increasing ever since improved 
surveillance was introduced. With 287 cases being reported in 2011, of which 67% (192/287) 
were children under three months of age, and 22% of these children were under 6 weeks of age 
(Archer et al., 2011).    
 
After natural infection with B. pertussis, relatively long-lived immunity results against 
subsequent infection.  Two types of vaccines against B. pertussis, the killed wP  vaccine, which 
protects against disease (Mills, 2001), however, the reactogenicity of this vaccine and its 
association with mild to severe neurological complications (Donnelly et al., 2001, Geier and 
Geier, 2004) have been major influences in the development of new generation aP vaccines. aP 
vaccines may include 2-5 of the following antigens PT, FHA, PRN and FIM 2 & 3 (WHO, 
2010d). Efficacy trials under controlled conditions during the 1990s have shown that aP vaccines 
have a considerably better safety profile than wP vaccines, and have been introduced into most 
EPIs of developed countries (Olin et al., 1997, Gustafsson et al., 1996, Greco et al., 1996, 
Trollofors et al., 1995). However, due to the cost and ease of local production wP vaccines are 
still widely used in developing countries (Mills, 2001). 
 
Pertussis vaccination has dramatically decreased the incidence of whooping cough, but the 
organism still continues to circulate in the human population (Watanabe et al., 2006). Severe 
pertussis infection occurs in children under the age of five years and in children who have not 
been adequately vaccinated (Watanabe et al., 2006). Contrasting results are available on the 
presence of maternal antibodies on immune response to vaccines. Response to acellular pertussis 
vaccine in children with and without maternal antibodies was evident in 81.1% vs. 71.9% of 
children, respectively, indicating  that maternal antibodies had no effects on immune response to 
vaccine (Saffar et al., 2007). However some studies that were similar to the latter have shown 
that vaccination with wP in the presence of maternal antibodies reduce the immune response, 
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possibly due to neutralization of vaccine antigen by maternal antibodies (Siegrist and Lambert, 
1998, Englund et al., 1995).  
 
Therefore, the schedule at which the wP vaccine is administered might influence the immune 
response  and persistence of antibody elicited by wP (Silfverdal et al., 2007). Silfverdal and 
colleagues reported that givingthree wP vaccine doses within or less than 5-months of age 
resulted in the vaccine being less effective in protection against clinical pertussis infection in 
childhood as compared with a schedule with a longer interval between doses (over 10 months 
between second and third dose) (Silfverdal et al., 2007). These studies show that the wP vaccine 
is highly effective at protecting against whooping cough in later in life.  
 
Since the emergence of HIV, re-emergence of B. pertussis has been observed resulting in 
significant increases in acute and prolonged respiratory infection in children and adults with 
HIV-infection (Colebunders et al., 1994, Nordman et al., 1992, Doebbeling et al., 1990). The 
extent at which HIV-infected children are protected (by preventing the incidence of whooping 
cough) by pertussis-containing vaccines during early childhood has previously been determined 
(Abzug et al., 2007, Tejiokem et al., 2007, Tovo et al., 2000). In studies conducted prior to the 
wide spread use of ART, immunogenicity of the primary whole cell pertussis vaccine was found 
to be decreased in HIV-infected children (30.0%-75.0%) than HIV-uninfected children after 
booster dose (Tejiokem et al., 2007, Abzug et al., 2007). These results were correlated with 
CD4+ T-lymphocyte counts and comparable to HIV-exposed uninfected children (75.0%); Table 
2.7. There is however no direct evidence that HIV-infected children have higher vaccine failure 
rates than their healthy counterparts. de Martino et al (1997), reported that HIV-infected children 
who sero-converted to the acellular pertussis vaccine, had lower GMTs to PT when compared to 
HIV-uninfected children (30% vs. 55.1%, respectively) (de Martino et al., 1997).  
 
In contrast responses to pertussis vaccine, particularly PT and FHA epitopes, indicate that aP 
vaccination induced  higher antibody levels post primary vaccination in HEU compared to HIV-
unexposed children (Reikie et al., 2013, Jones et al., 2011, Hesseling et al., 2016), which was 
however similar following the  booster dose of vaccine (Reikie et al., 2013, Hesseling et al., 
2016). 
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There is limited or no data available on the immune response to whole cell pertussis especially in 
sub-Saharan Africa (summarized in Table 2.7). Studies suggest that ART is associated with 
improved responses to re-vaccination with a variety of vaccine antigens, however, the response 
of HIV-infected children who are on ART at the time of the primary series of  pertussis vaccine 
has not been fully described (Melvin and Mohan, 2003, Sutcliffe and Moss, 2010). Furthermore, 
response to primary immunization with pertussis vaccine in HIV-infected children initiated on 
early ART has not been described. 
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Table 2.7: Comparison of vaccination response to pertussis epitopes between HIV-infected children and HEU and/or HIV-
unexposed children 
Study 
setting 
and 
Reference 
Study design HIV-infected 
N (Age at 
study entry) 
HEU 
children 
N (Age at 
study 
entry) 
HIV-
unexposed 
children 
N (Age at 
study 
entry) 
Vaccination 
schedule and 
timing of 
blood sample 
Number 
on 
ART 
Initiation of 
ART prior 
to 
vaccination 
and 
duration on 
ART 
CD4+ at 
study 
entry 
Main findings 
HIV-infected# 
(HIV-infected 
vs. HIV-
unexposed)†  
or  
(HIV-infected 
vs. HEU)††  
or  
(HEU vs. HIV-
unexposed)††† 
Summary 
HIV-infected only 
1997 
Italy 
(de Martino 
et al., 1997) 
Cohort 
12 (6-107 
months) 
ND ND 
3 dose 
schedule at 8 
week intervals 
 
Bloods: 0, 2, 
4, 6, 8 months 
ND ND ND 
GMC EU/ml 
(95% CI)√: 
0 weeks: 
PT: 3.01 (0-7.9) 
vs. 2.1 (1.4-3.2)† 
FHA: 6.6 (2.2-
10.9) vs. 7.6(4.9-
11.9)† 
2 months 
PT: 7.24 (0-
15.04) vs. 27.6 
(17.2-44.6)† 
FHA: 12.02 (7.9-
10.1) vs. 82.4 
(49.5-137.4)† 
 
4 months 
PT: 13.8 (3.5-
23.8) vs. 133.8 
(79.4-225.5)† 
FHA: 19.9 (13.7-
26.15) vs. 611.3 
(439.2-1088)† 
 
6 months 
PT: 29.5 (18.01-
41) vs. 106.5 
(37.8-304.4)† 
FHA: 25.7 (19.9-
31.4) vs. 759.7 
(439.2-1088)† 
Antibody titre fold-rise 
correlated with pre-
immunization 
CD4+ cell counts. 
Significant titres were 
still detectable 4 months 
after the third dose. 
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8 months 
PT: 11.7 (2.7-
20.7) vs. ND 
FHA:19.00 
(13.6-24.21) vs. 
ND 
 
2007 
USA 
(Abzug et 
al., 2007) 
Cohort 
92 (9.3 years) 
4 strata 
Group1: 2 (8.9 
years) 
Group 2: 33 (10 
years) 
Group 3: 28 
(9.3 years) 
Group 4: 29 
(5.6 years) 
ND ND 
Booster DTaP 
at study entry 
 
Bloods: 0, 8, 
24, 72 weeks 
post booster 
vaccination 
92 
No ART was 
initiated prior 
to primary 
vaccination. 
 
ART was 
initiated > 3 
months prior 
to booster 
dose in 
Group 1 and 
>6 months 
for Group 2-
4 
Group 1: 
16% 
Group 2: 
27% 
Group 3: 
33% 
Group 4: 
39% 
Pre-booster 
antibody levels 
were low: GMC 
EU/ml, (95% CI) 
PT#√: 4.8 (3.7-
6.5)  & FHA: 4.1 
92.9-5.8) 
 
Post-booster 
GMCs rose#√√: 
PT: 22.3 (15.9-
31.2) 
FHA: 77.0 (51.0-
116.2) 
 
 
Antibody levels fell 24 
weeks after vaccination 
but remained higher 
than pre-booster levels. 
Predictors of response 
were pre-booster 
antibody levels, lower 
HIV-RNA level, and 
higher CD4+% at entry. 
 
.HIV-infected children 
may be deficient in 
immunologic memory 
from previous DTP 
containing vaccination 
and/or that immune 
reconstitution with ART 
may be incomplete for 
pertussis antigens. 
HIV-infected vs. HEU 
2007 
Cameroon 
and Central 
Africa 
(Tejiokem et 
al., 2007) 
Cross 
sectional 
51 
(25 months) 
78 
(25 
months) 
ND 
DTwP: 6, 10, 
14 weeks 
 
Booster at 18 
months 
 
Bloods: 17 
months 
(range: 3.9 to 
31 months) 
33 
No ART 
prior to 
primary or 
booster dose. 
ART was 
initiated 6 
months prior 
to blood 
sampling. 
<15 to 
>25% 
Seropositive after 
primary 
vaccination√ N/n 
(%): 10/43 (23) 
vs. 34/66 (51.5), 
p=0.003†† 
 
Seropositive after 
booster 
vaccination N/n 
(%)√√: 5/7 (71.4) 
vs. 9/12 (75), 
p=0.63†† 
 
GMT, (95% CI): 
52.8 (41.4-67.3) 
vs.62.8 (52.2-
75.6), p=0.28 
 
Proportion of 
children with 
CD4+<25% had 
low wP titers 
Significantly reduced 
titres in HIV-infected 
vs. HEU children 
Post primary 
vaccination 
 
Similar proportion 
protected post booster 
vaccination 
 
GMC were similar in 
HIV-infected and HEU 
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(OR: 4.9; 95% 
CI: 1.8-13.4, 
p=0.002) 
HEU vs. HIV-unexposed 
2011 
South Africa 
(Jones et al., 
2011) 
Prospective 
cohort 
ND 
38 (<4 
months) 
55 (<4 
months) 
DTwP-Hib at 
6, 10, 14 
weeks 
 
Bloods: 16 
weeks 
ND ND ND 
PT & FHA 
median, FDA 
U/mL (IQR): 
270.1 (84.4-
355.0) vs. 91.7 
(27.9-168.4), p 
=0.006†√ 
 
Fold increase 
(IQR): 9.51 
(IQR, 2.80-
24.25) vs. 2.16 
(IQR, 0.41-6.84), 
p = 0.002†√ 
HEU had increased 
antibody against 
pertussis than HIV-
unexposed 
2013 
South Africa 
(Reikie et 
al., 2013) 
Prospective 
cohort 
ND 
27 (3 
months) 
28 (3 
months) 
DTwP-Hib at 
6, 10, 14 
weeks 
 
Booster at 18 
months 
 
Bloods: 3, 6, 
12, 18, 24 
months 
ND ND ND 
PT & FHA 
higher 
concentrations 
post primary 
vaccinations (6 
&12 months age, 
p=<0.001), no 
difference at 24 
months, post 
booster. 
 
Higher 
proportion of 
seropositive 
HEU infants at 6 
months, 
P<0.001* 
HEU had significantly 
higher titres post-
primary vaccination; 
And similarities 
between HEU and HIV-
unexposed post booster 
dose. 
2013 
South Africa 
(Hesseling et 
al., 2016) 
NS ND 118 (NS) 60 (NS) 
DTwP-Hib at 
6, 10, 14 
weeks 
 
 
Bloods: 14, 
24, 52 weeks 
ND ND ND 
PT & FHA 
higher at week 
24 (p=0.003)√†††, 
similar at weeks 
14 and 52 
Higher 
proportion of 
seropositive 
HEU infants at 
week 24 (OR: 
1.80; 95% CI: 
1.19-2.72, 
p=0.007) 
HEU had higher titres 
post-primary 
vaccination; but was 
similar at weeks 14 and 
52 
Footnote: HEU: HIV-exposed, uninfected; N: total number of participants; ART: antiretroviral therapy; ND: not done; NS= not stated; 
√
 response after primary 
vaccination; 
√√
 response to booster vaccination; IU/ml: international units per milliliter; GMT/C: geometric meant titer/concentration; DTaP: diphtheria, tetanus, acellular 
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pertussis vaccine;  DTwP: diphtheria, tetanus, whole cell pertussis vaccine; Hib: Haemophilus influenzae type b; HepB: hepatitis B vaccine; CI; confidence interval; 
EU: ELISA Units; IQR: interquartal range.  
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2.9.2.4 Hepatitis B vaccine 
Of the 400 million people worldwide who have chronic hepatitis B, a disproportionate number 
(46 million) of those are infected with HIV (Mahoney, 1999, UNAIDS, 2007, Thio, 2003). 
Hepatitis B virus (HBV) is not classified as an opportunistic infection in HIV-infected persons, 
but due to the common modes of transmission, co-infections occur frequently (up to 10%) 
(Phung et al., 2014). In Africa, where hepatitis B endogenous antigen (HBeAg) positivity is low, 
most childhood exposure to HBV is a result of horizontal transmission rather than vertical 
transmission (Kiire, 1996). Thus the most practical approach in controlling early childhood 
transmission of HBV in Africa, while children are still protected by maternal antibodies (Ayoola, 
1988), and before they are exposed to exogenous sources of HBV (Kiire, 1996), is through 
vaccination programmes of neonates and infants (Burnett et al., 2005). Only a few studies of 
long-term effects of the hepatitis B vaccine in childhood have been published in Africa 
(Coursaget et al., 1990, Whittle et al., 1995). In The Gambia and Senegal, the HepB vaccine has 
been reported to elicit protective antibodies against Hepatitis B surface antigen (HBsAg)  in 85-
90% of the vaccinated children (Coursaget et al., 1990, Fortuin, 1993). The Gambia is one of the 
first African countries to introduce HepB vaccine into its public immunization programme, with 
other southern African countries following thereafter. Long-term follow up studies in The 
Gambia and Senegal indicated that between 51-76% of vaccinated children had sero-protective 
HepB antibody titers 10 years following vaccination (Coursaget et al., 1990, Whittle et al., 1995). 
Evidence of eradication of HBV carrier state in The Gambia in children under 5 year age  has 
already been achieved (Whittle et al., 1995). In South Africa, one study described a decline in 
prevalence of HBsAg in the Eastern Cape from 10.1% in unvaccinated children to 0% in 
vaccinated children (Schoub, 2002). In another study by Tsebe et al (2001), none of the 598  
children tested were positive for HBsAg, even though some (n=6) were born to HBsAg positive 
mothers (Tsebe et al., 2001). Overall, 93% had sero-protective antibody levels at 23.3 months of 
age, which was similar to that  observed in two other studies, with no breakthrough infections or 
chronic carriage of HBsAg (Aspinall and Kocks, 1998, Tshatsinde et al., 1996). These studies 
were conducted in relatively healthy HIV-uninfected children. In three other studies conducted in 
South Africa to determine chronic carriage in HIV-infected children, the prevalence of  chronic 
HBV infection was  1.2-2.1% (Simani et al., 2009, Beghin et al., 2016, Amponsah-Dacosta et al., 
2014). 
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Approximately 30% of HIV-infected patients not on ART are non-responsive to primary hepatitis 
B vaccination compared to  2.5% in immunocompetent individuals, with sero-protective 
responses occurring in 20-70% of HIV-infected children and adults (Bruguera et al., 1992, 
Zuccotti et al., 1994, Rey et al., 2000); Table 2.8. This lower immunogenicity of HepB vaccine  
seems to correlate more with lower CD4+ counts than with the mode of HIV acquisition (Thio, 
2003). In such cases, re-vaccination is recommended at double the dose (Wasmuth and 
Rockstroth, 2004), however, Rey et al (2000) demonstrated that three additional doses of HepB 
separated by 1 month each increased the response rate in HIV/HBV co-infected adults to 90%. 
Nevertheless, this declined to only 59% having persistence of sero-protective titers one-year later 
(Rey et al., 2000). HIV-positive individuals, who had a primary response to HepB vaccine, are 
likely to lose their immunity over time (Bruguera et al., 1992). HIV-infected children and adults 
who respond to the HepB vaccine have a more rapid decline in antibody titer than uninfected 
persons, as was observed in a study by Scolfaro et al (1996), in which only 42% of children who 
responded to the primary three dose series had protective antibody 13-18 months post 
immunization (Scolfaro et al., 1996). Long-term follow up studies of HIV-negative children and 
adults, however, suggest that loss of antibody to HepB over time does not mean loss of immunity 
(Mahoney and Kane, 1999). Whether this phenomenon of retained memory response applies to 
HIV-positive persons is unknown (Moss et al., 2003).    
 
HIV-1-infected children may be unprotected from HBV in spite of receiving the full three-dose 
immunization series, due to a less robust initial immunologic response and waning of HepB 
antibody titers (Simani et al., 2009, Pippi et al., 2008, Abzug et al., 2009, Beghin et al., 2016); 
Table 2.8). Immune reconstitution after treatment with cART does not restore HepB immunity in 
the majority of children, and the response to re-vaccination is variable. In several small cohorts, 
1–40% of HIV-infected children with a history of receiving their primary HepB vaccine series 
had protective HepB antibody levels (>10 IU/ml) detected when measured after initiation of 
treatment with cART (Aurpibul et al., 2012, Abzug et al., 2009, Fernandes et al., 2008, Pessoa et 
al., 2010, Siriaksorn et al., 2006, Lao-araya et al., 2007); Table 2.8. In a study conducted by the 
International Maternal Pediatric Adolescent AIDS Clinical Trials group, only 24% of 204 HIV-
infected cART-treated children (median age: 9-years) with a history of previous immunization 
with three doses of HepB vaccine had protective HepB antibody levels prior to receiving a 
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booster vaccine. Forty five percent of the children became seropositive 8 weeks after a booster 
vaccine (Abzug et al., 2009). Vaccine response was greatest in those children with higher CD4+ 
counts and undetectable viral loads. Lao-araya et al. reported on 64 HIV-infected children 
(median age: 10 years) on cART for a median of 31 months with a previous history of routine 
infant HepB immunization. Eighty-seven percent had no measurable HepB antibody prior to re-
vaccination. The response rate to a repeat HBV immunization series was 17% after the first 
vaccine, 82.5% after the second and 92% after the third (Lao-araya et al., 2011). After 3 years, 
71% of these children maintained protective HBsAg antibody levels, suggesting that HIV-
infected children will benefit from a repeat HBV vaccine series after initiation of cART (Abzug 
et al., 2009). In study conducted in Thailand adolescents, low overall sero-protection was 
detected in HIV-infected adolescents on ART (18%), however after re-vaccination of 75 
adolescents and stratification according to time of ART, they found that 93% of those on ART 
prior to re-vaccination and only 6% had anti-HepB titers ≥10 mIU/ml (Aurpibul et al., 2012).  
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Table 2.8: Comparison of vaccination response to antibody to HepB epitopes between HIV-infected children and HEU and/or HIV-
unexposed children 
Reference 
and 
Country 
Study 
design 
Vaccination 
Schedule 
And timing of 
blood sample 
Study 
Population 
(n) 
Age at 
study 
entry 
CD4+ status 
at study 
entry 
Number 
taking 
ART 
Initiation of ART 
prior to vaccination 
and duration on ART 
Main findings HIV-
infected# (HIV-
infected vs. HIV-
unexposed)† 
or 
(HIV-infected vs. 
HEU)†† 
or 
(HEU vs. HIV-
unexposed)††† 
Summary 
HIV-infected only 
2006 
Thailand 
(Siriaksorn et 
al., 2006) 
 
Cross 
sectional 
Previously 
vaccinated†: 
HepB at 0, 2 
and 6 months 
 
Bloods: NS 
HIV-
infected 
(75) 
9.6 years 5% 75 
No ART initiated prior 
to primary vaccination. 
ART was initiated 2 
years prior to blood 
sampling. 
N/n (%); ≥10 mIU/ml 
(%): 1/69 (1)†# 
Despite being immunized with 
3 doses of HepB in early 
childhood and showing signs 
of immune recovery as a result 
of c ART. Most 
most HIV-infected children are 
still susceptible to HBV 
infection 
2007 
Thailand 
(Lao-araya et 
al., 2007) 
 
Cohort 
Re-
vaccination‡ 
HepB: 0, 2, 6 
months 
 
Bloods:2 
months after 
1st dose; 4 
months after 
second dose 
and 1 month 
after 3rd dose 
HIV-
infected: 
(63) 
10.1 years 27.2% 63 
ART initiated 31 
months prior to re-
vaccination. 
≥10 mIU/ml‡#: 2 
months after 1st dose: 
17% 
 
4 months after 2nd 
dose: 83% 
 
1 month after 3rd dose: 
92% 
 
 
Viral load below detection 
limit at the time of re-
vaccination was associated 
with successful vaccine 
response. 
2008 
Tanzania 
(Pippi et al., 
2008) 
 
Cohort 
Re-
vaccination‡: 
HepB: 0, 1 
and 6 months 
 
Bloods: 5 
months 
HIV-
infected: 
(84) 
4.7years 40.4% 47 
ART initiated 69 
weeks before re-
vaccination. 
Sero-conversion rate 
was 59.5%; 
Sero-conversion was 
found in 70.8% of 
ART-treated and 
44.4% of treatment 
naıve children. 
≥10 mIU/ml: 71%†‡ 
Sero-conversion rate was 
higher in individuals in 
CDC category 1 than in CDC 
Categories 2 and 3. ART use 
and absolute CD4+ cell counts 
were 
independently associated with 
probability of sero-conversion 
and with higher antibody titer 
2009 
Country NS 
NS 
Re-
vaccination‡: 
HIV-
infected: 
9.1 years 34% 204 
No ART was initiated 
prior to re-vaccination 
% ≥10 mIU/ml#‡: 8 
weeks: 46% 
Decreased sero-protection in 
HIV-infected children with 
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(Abzug et 
al., 2009) 
 
HepB: NS 
 
Bloods: 8, 48, 
96 weeks 
 
4.6 years post 
booster dose 
(204) vaccination. ART was 
initiated > 6 months 
prior to booster dose 
48 weeks: 38% 
96 weeks: 38% 
4.6 years: 25% 
decreased responses to booster 
dose despite being on cART 
for more than 6 months. 
2011 
Thailand 
(Lao-araya et 
al., 2011) 
 
Cohort 
Re-
vaccinated‡:  
HepB: 0, 2 
and 6 months 
 
Bloods: 1 
month and 3 
years 
HIV-
infected: 
(69) 
12.9 years 5.4% 69 
ART was initiated 
prior to re-vaccination 
and duration was 5 
years 
% ≥10 mIU/ml:  1 
month: 95%‡ 
3 years: 71.0%‡ 
Improved sero-protection in 
cART treated children; and 
recommend giving a 3-dose 
HBV vaccination to HIV-
infected children with immune 
recovery while receiving 
cART. 
2012 
Thailand 
(Aurpibul et 
al., 2012) 
 
Cross-
sectional 
Previously 
vaccinated†: 
HepB: NS 
 
Bloods: 4.3 
years 
HIV-
infected: 
(521) 
14.8 years 685 cells/µL 521 
ART-initiated post 
vaccination, but 
duration on ART was 
not stated. 
% ≥10 mIU/ml: 
18%#† 
HIV-infected children showed 
low level of sero-protective 
antibody. 
HIV-infected vs. HIV-unexposed 
2007 
Brazil 
(Zaccarelli-
Filho et al., 
2007) 
 
Observationa
l 
Previously 
vaccinated: 
HepB at 2, 4 
and 6 months 
 
Bloods: NS. 
 
 
 
Good VLR: 
(9) 
Partial 
VLR (13) 
Poor VLR 
(14) 
HIV-
unexposed 
(25) 
Good 
VLR: 10.9 
years 
Partial 
VLR: 7.4 
years 
Poor 
VLR: 9.4 
years 
HIV-
unexposed
: 10.6 
years 
Good VLR: 
33.0% 
Partial VLR: 
26.4% 
Poor VLR: 
21.6% 
41 
Good VLR: ART 
initiated post primary 
vaccination at 5.8 
years of age. 
 
Partial VLR: ART 
initiated post primary 
vaccination at 3.7 
years of age 
 
Poor VLR: ART 
initiated post primary 
vaccination at 7.3 
years of age 
N/n; (%) ≥10 IU/ml√: 
Good VLR: 9/9 (100) 
vs. 
Partial VLR: 13/13 
(100) vs. 
Poor VLR: 13/14 
(93); p=NE# 
No difference in sero-
protective levels in children 
with good or partial or poor 
viral load controllers 
2008 
Brazil 
(Fernandes et 
al., 2008) 
 
Cohort 
Previously 
vaccinated†:  
HepB: 3, 4 
and 5 months 
 
Bloods: 68 
months for 
HIV-infected 
 
64 months for 
HIV-
unexposed 
HIV-
infected: 
(58) 
 
HIV-
unexposed: 
(116) 
7 years 831 cells/μl 53 
No ART was initiated 
prior to primary 
vaccination. ART was 
initiated prior to blood 
sampling for 27 
months. 
N/n (%); ≥10 
mIU/ml†:  14/58 
(24.1) vs. 101/116 
(87.1); p<0.001*† 
Difference between sero-
protective rate between HIV-
infected and HIV-unexposed 
children. 
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2009 
South Africa 
(Simani et 
al., 2009) 
 
Cross-
sectional 
HepB: 6, 10 
and 14 weeks 
 
Bloods: from 
4 weeks 
HIV-
infected: 
(73) 
 
HIV-
unexposed: 
(230) 
HIV-
infected: 
8.7 
months 
 
HIV-
unexposed
: 11.9 
months 
ND ND 
No ART was initiated 
prior to primary 
vaccination. No ART 
was initiated on blood 
sampling. 
≥10 mIU/ml N/n 
(%):57/73 (78%) vs. 
197/230 (86%), 
p=0.125√† 
 
GMT IU/ml: 
289.2 vs. 370.6 
There were no differences in 
sero-protective titers between 
HIV-infected and HIV-
unexposed children. However 
hospitalized HIV-infected 
children had lower responses 
to vaccine than children 
attending routine 
immunization clinic. 
2016 
South Africa 
(Beghin et 
al., 2016) 
 
Retrospectiv
e 
Previously 
vaccinated†: 
HepB at 6, 10 
and 14 weeks 
 
Bloods: NS 
HIV-
infected 
(183) 
 
HIV-
unexposed 
(108) 
HIV-
infected: 
9.1 years 
HIV-
unexposed
: 9.0 years 
ND ND ND 
N/n (%) ≥10 
mIU/ml†:  
28/183(15.1) vs. 
66/108(61.1); 
p<0.001*† 
HIV-infected children have 
reduced response to previous 
vaccination. 
HIV-infected vs. HEU 
1992 
Italy 
(Zuin et al., 
1992) 
 
 
Prospective 
HepB: 3 doses 
 
Bloods: 2-4 
months 
HIV-
infected: 
(18) 
 
HEU: (33) 
<24 
months 
ND ND ND 
N/n (%); ≥10 
mIU/ml√: 
414/18 (77.8) vs.32/33 
(97.0); p=0.046*†† 
Sero-protection was 
significantly higher in HIV-
unexposed than in HEU 
children post primary 
vaccination. 
1994 
Italy 
(Zuccotti et 
al., 1994) 
 
Longitudinal 
HepB: 0,1 and 
6 months 
 
Booster at  3-4 
months after 
last dose 
 
Blood: NS 
HIV-
infected (5) 
 
HEU (13) 
NS ND ND ND 
N/n (%); ≥10 
mIU/ml√: 1/5 (20%) 
vs. 13/13 (100); 
p=NE†† 
 
Response of HIV-infected 
children to the hepatitis 
B vaccine is poor, even when 
an adult dose of the vaccine 
is administered at birth. A 
rapid fall in levels of 
antibody to hepatitis B virus 
is observed when a response 
is present. It is likely that 
immunologic damage is 
already present at birth. 
HEU vs. HIV-uninfected 
2011 
Brazil 
(Abramczuk 
et al., 2011) 
NS 
HepB: 0, 1 
and 6 months 
 
Bloods: 1 
month 
HEU: (45) 
HIV-
unexposed: 
(112) 
HEU: 7.7 
months 
HIV-
unexposed
: 7.5 
months 
ND ND ND 
N/n (%); 
≥10mIU/ml√: 13/45 
(28.9) vs.  65/112 
(58.0); p=0.001*††† 
Significant differences in sero-
protective rates between HEU 
and HIV-unexposed children, 
decreased response in HEU 
was associated with exposure 
to ART for the prevention of 
mother to child transmission of 
HIV. 
2013 
South Africa 
(Reikie et al., 
2013) 
 
Prospective 
cohort 
HepB: 6, 10, 
14 weeks 
 
Bloods: 3, 6, 
12, 18, 24 
months 
HEU: (27) 
 
HIV-
unexposed: 
(28) 
3 months ND ND ND 
N/n (%); ≥10 
mIU/ml√: 
20/27 (75%) vs. 
21/28 (75%), 
p>0.99*††† 
No significant differences 
were observed in response to 
primary vaccination. 
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Footnote: HEU: HIV-exposed uninfected; ND: Not done;  N: total number of participants; ART: antiretroviral therapy; ND: not done ; NS= not stated; mIU= milli 
international unit; HepB= hepatitis B virus vaccine; 
†
 previously vaccinated in early childhood; 
‡
 re-vaccination: children who received all primary and booster doses 
in early childhood, and received a full series of vaccination in older age; 
√
 response after primary vaccination; 
√√
 response to booster vaccination; *Calculated 
from data given in paper, using Fischer‘s exact test;  NE: not evaluable; VLR: viral load responders. 
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2.9.2.5 Haemophilus influenzae type b disease and Hib conjugated vaccine use in HIV-
infected children. 
Haemophilus influenzae type b, is a gram-negative coccobacillus which is encapsulated 
(Mangtani et al., 2010). In the 1930s it was discovered that some strains of H. influenzae 
possessed a polysaccharide capsule with 6 capsular serotypes (a-f) (Pittman, 1931). Invasive 
isolates from patients where predominantly type b (Hib) organisms which possess a PRP capsule 
(Kelly et al., 2004). Hib is said to be an important cause of bacterial infections, in unvaccinated 
individuals, which include meningitis, septicaemia, epiglottitis, and cellulitis, pneumonia and 
septic arthritis (Watt et al., 2009, Mangtani et al., 2010). However, Hib has also been shown to be 
a commensal of the nasopharynx in 3-11% of unvaccinated children (Adegbola et al., 1998, 
Takala et al., 1991), and only a minority of those exposed or who are carriers of the organism 
suffer invasive disease (Kelly et al., 2004). At the end of 2007, the World Health Organization 
estimated that Hib disease caused 8.1 million episodes of serious illness and 371, 000 childhood 
deaths yearly, of which 8100 were in HIV-infected children (WHO, 2013b, Watt et al., 2009).  
 
Of the 2.5 million HIV-infected children under the age of 15 years, in the absence of  
antiretroviral therapy, one in three HIV-infected children would die before the age of one year 
from serious bacterial diseases, including Hib (Newell et al., 2004). Even though scale up of 
ART in many high HIV prevalence countries has increased, less than 30% of children requiring 
this have access to it (UNICEF, 2010). The use of cotrimoxizole prophylaxis in HIV-infected 
children has been instrumental in reducing hospitalization by 23% and childhood mortality by 
43%, however, the prolonged use of this prophylaxis has some limitations (Mulenga et al., 2007). 
Therefore, immunization with vaccines such as HibCV remains an important  approach in 
reducing the risk of bacterial infections in HIV-infected children (Mangtani et al., 2010).   
 
The type b polysaccharide capsule is instrumental in invasive disease and thus is an attractive 
antigen to use as part of a vaccine, as invasive disease is almost exclusively restricted to type b 
organisms and PRP antibodies are important in natural immunity (Kelly et al., 2004). However, 
early observations with Hib demonstrated the limitations of plain polysaccharide as a vaccine 
antigen. When administered in children less than two years of age, purified PRP induces sub-
optimal responses and does not provide sufficient protection against invasive disease (Parke et 
al., 1977, Peltola et al., 1977, Smith et al., 1973). With regards to immune memory post 
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vaccination, antibody levels wane quickly and follow up immunization shows no evidence of 
immunological priming in any age group (Kayhty et al., 1984). Polysaccharides, although 
recognized by B-lymphocyte receptors, cannot be presented to T-lymphocytes in conjunction 
with major histocompatibility complex class II molecules. B-lymphocytes therefore lack the 
ability to directly recruit cognate T-cell help when stimulated with polysaccharide. The lack of 
specific T-cell interaction in the immune response limits the immunogenicity of PRP, and the 
development of memory B-lymphocytes with class-switched antibody and subsequent avidity 
maturation cannot occur (Kelly et al., 2004). It is still unclear whether the poor antibody 
responses in the first 2 years of life are caused by infrequent Hib carriage at this age or 
immunological immaturity. The same vaccine administered later in childhood results in increased 
antibody responses (Peltola et al., 1977, Kayhty et al., 1984, Weinberg et al., 1987). There is 
some evidence for specific inhibitory mechanisms that act in infancy to delay the development of 
TI response (Rijkers et al., 1998). Protein conjugation has provided a solution for the lack of 
interaction between B-lymphocytes and T-lymphocytes when using purified polysaccharide as a 
vaccine during early childhood (Kelly et al., 2004).  
 
H. influenzae type b is an important cause of invasive bacterial infections amongst children 
especially those with HIV-infection, in whom the infection rate is increased 6 to 8 fold when 
compared to HIV uninfected children (Madhi et al., 2000, Madhi et al., 2002). Despite this 
increased disease burden and the widespread use of HibCV in much of the developed world, 
there is limited data regarding the immunogenicity and efficacy of the vaccine amongst HIV-
infected children (Peltola, 2000).  In the absence of immunosupression or CD4+ ≤25%, 37-86% 
of HIV-infected children develop protective antibody responses to HibCV, but the geometric 
mean titers are significantly lower than in HIV uninfected children (Madhi et al., 2002, Peters 
and Sood, 1997, Rustein et al., 1996, Jeena, 2008). Furthermore, they found that waning of 
memory response by 15 months of age (Jeena, 2008). In addition, the bactericidal activity and 
avidity of anti-PRP was investigated by Madhi and colleagues (2005), they concluded that a 
lower percentage of HIV-infected children not on ART (51.5%) had protective antibody levels 
when compared to HIV-uninfected children (95.3%). Furthermore, a lower percentage of HIV-
infected children had serum bactericidal antibody activity (76.1%) than in HIV-uninfected 
children (97.1%). The antibody concentration required for 50% bactericidal activity  in HIV-
infected children was much higher compared to HIV-uninfected children, and the risk of vaccine 
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failure was  greater (Madhi et al., 2005). This observation has led to the recommendation of   
booster doses to be administered after 2 years of age in HIV-infected children (Mangtani et al., 
2010). 
 
A study conducted in Uganda and the USA reported higher vaccine responses to PRP epitope in 
HEU (75µg/ml) and HIV-unexposed children (3.3µg/ml; p=0.002) 48 weeks post primary 
vaccination (Gaensbaier et al., 2014). Furthermore, studies conducted in South Africa found 
similar results to the study in Uganda and the USA (Jones et al., 2011, Hesseling et al., 2016) 
although this as not observed by Reikie et al  either  post primary and post booster vaccination 
(Reikie et al., 2013).   
 
2.9.3 Live-attenuated vaccines 
Although live-attenuated vaccines may cause serious complications in  immunosuppressed 
individuals (WHO, 2010b), HIV-infected children without signs of immunosuppression can be  
safely immunized with live-attenuated vaccines (Sutcliffe and Moss, 2010, Melvin and Mohan, 
2003), except for BCG (Hesseling et al., 2006).In some developing countries with high HIV 
prevalence, the advantage of routine administration of live vaccines i.e. OPV and measles 
vaccines far outweigh the theoretical risks of complications from these vaccines (Halsey, 2002). 
Additionally, vaccination at birth or early in life often results in an adequate immune response as 
it precedes HIV-induced immunosuppression. Therefore, the WHO and many countries 
recommend routine immunization of HIV-infected children with these vaccines (Sutcliffe and 
Moss, 2010). 
 
2.9.3.1 Measles vaccine 
The measles virus belongs to the Paramyxoviridae family, which include other human pathogens 
such as mumps virus, and parainfluenza virus (WHO, 2009b). Measles is a single-stranded RNA 
virus with a diameter of 90-140 nm, and has a pleomorphic structure and a coating which is 
derived from the cell membrane (WHO, 2009b). The measles virus genome encodes for 8 
proteins, which include two major proteins shown to be major role players in life long immunity 
following infection, they are the haemogglutinin (H) and fusion (F) proteins (de Swart et al., 
2005). Sequencing of the measles genome has revealed 23 different genotypes which have been 
used in tracking transmission (Rota et al., 2009). 
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In the pre-vaccine era, measles virus was highly infectious and resulted in >90% of individuals 
being infected by 10 years of age (WHO, 2009b). Humans are the only known reservoir of 
measles and transmission is through aerosolized respiratory droplets and close contact with 
infected fluid. The typical incubation period is 10-14 days following exposure to measles virus, 
and individuals may be contagious from approximately 4 days before eruption of the rash until 4 
days after eruption (WHO, 2009b). Near the end of the incubation period, individuals develop 
prodromal symptoms of high fever, cough, coryza and conjunctivitis (WHO, 2009b). Severity 
and case fatality of measles is increased in children <5 years of age, overcrowded living 
conditions, malnutrition (especially vitamin A deficiency), and immunosuppression (such as 
advanced HIV-infection). 
 
The case fatality in developing countries has been shown to be 5-10% among young children 
(Helfand et al., 2007). On a global scale, mortality due to measles in children under five years of 
age has shown trends of reduction from 544 200 to 145 700 per year between 2000 and 2013 
(United Nations, 2015). This reduced mortality is a result of substantial increases in measles 
vaccination coverage through routine health services as well as mass immunization campaigns.  
 
The measles vaccine is composed of a live-attenuated measles virus (Edmonston-Zagreb strain) 
(Arpadi et al., 1996). In four of six WHO regions, substantial progress has been made in measles 
prevention and control, transmission no longer occurs indigenously and importation does not 
result in sustained spread of the virus (Muller et al., 2007). The key reason for this success was 
95% vaccination coverage through a two dose vaccination regimen (Andre et al., 2008). 
Increasing vaccination levels in Africa, where the coverage average was 67% in 2004, is essential 
for eradication of measles disease (Andre et al., 2008). Between 2001 and 2005, >360 million 
children in sub-Saharan Africa had been vaccinated against measles, on the African continent 
126 000 deaths had been reported during the same time period compared to the previous 506 000 
(Katz, 2007). 
 
In sub-Saharan Africa, where a substantial number of measles-related deaths still occur, a major 
obstacle in the control of measles is the HIV epidemic (Muller et al., 2007). HIV-infection may 
modify the clinical manifestations of measles, thus disrupting surveillance efforts,  and HIV-
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infection may prolong the infectious period of measles (Helfand et al., 2005). Furthermore, HIV-
infection may result in high rates of primary and secondary vaccine failure after vaccination, thus 
decreasing vaccine efficacy. Measles vaccine has been recommended for children, adolescents 
and young adults with known HIV-infection (Kaplan et al., 1992). In developing countries, the 
case-fatality rate attributable to measles has been between 5-10% for HIV-infected children 
(Wolfson et al., 2009, WHO, 2009b). It has been observed that 25-77% of HIV-infected children 
sero-convert to the initial dose of the vaccine (Brunell et al., 1995, Arpadi et al., 1996); (Table 
2.9), in contrast 95% of HIV uninfected children sero-convert to the measles vaccine (Moss et al., 
2003). The potential impact of HIV-infection on maternal antibody transfer in children born to 
HIV-infected mothers is unclear, but the risk of exposure to measles is reduced in early childhood 
in regions where measles has been successfully controlled in older children (Moss et al., 1999, 
Gans et al., 1998). Clinical experience with measles demonstrated that a critical maturation of the 
immune system occurs between 6- and 12-months, as a result of high vaccine failures observed in 
children less than 12-months. This vaccine failure was attributed to the persistence of maternal 
antibodies in mothers who had been exposed to wild-type measles virus (Gans et al., 1998). 
Recently most children are now born to mothers who have vaccine induced immunity to measles 
and can be expected to lose maternal antibodies by 9-12-months of age instead of 12-15-months 
(Leuridan, 2010). This might be further accelerated in children born to HIV-infected mothers due 
to waning of immunity in the mothers. Scott et al. reported that HIV-exposed infants had low 
levels of protective maternal antibodies by 6-months of age, compared to 9-12-months in children 
born to HIV-uninfected women (Scott et al., 2007). As a consequence of this decrease in 
maternal antibodies, there is also an increase in the pool of susceptible children to wild type 
measles virus infection, which could result in high morbidity and mortality (Scott et al., 2007). 
 
Because the measles vaccine consists of a live-attenuated virus, it has been found that HIV-
infected people, who did not respond to the primary and secondary doses of the vaccine, shed the 
vaccine virus for a longer period than HIV negative persons (Permar et al., 2001). 
 
Table 2.9: Immunogenicity of measles virus vaccine in children with HIV prior to use of ART 
in HIV-infected children 
Country and 
Reference 
Number  
studied 
Age group Response to primary vaccination 
Response to repeat 
vaccination 
USA 
1989 
(Krasinski and 
Borkowsky, 1989) 
8 11-41 months 25% - 
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Zaire 
1989 
(Oxtoby et al., 
1989) 
37 9 months 
36% of symptomatic CD4+ >25%; 77% of 
asymptomatic CD4+<25% 
- 
USA 
1992 
(Palumbo et al., 
1992) 
35 12-194 months 37% 0% 
USA 
1993 
(Brena et al., 
1993) 
2 unknown - 50% 
USA 
1994 
(Frenkel et al., 
1994) 
10 22-121 months - 20% 
USA 
1994 
(Rudy et al., 1994) 
25 6-12 months 69.20% 50% 
USA 
1995 
(Brunell et al., 
1995) 
11 72-120 months - 36% 
USA 
1996 
(Arpadi et al., 
1996) 
7 31-120 months - 14% 
Uganda 
1999 
(Waibale et al., 
1999 
50 
15 months- 3.5 
years 
- 19% 
Thailand 
2000 
(Thaithumyanon, 
2000) 
16 9 months 57% - 
Cameroon and 
Central Africa 
2007 
(Tejiokem et al., 
2007) 
129 18.1-35.6 months 
16.0% for HIV-infected 
62.3% in HIV-exposed uninfected children 
results correlated with CD4+ cell count 
- 
Zambia 
2007 
(Moss et al., 2007) 
 
50 2-27 months 88% 55% 
 
Improved immunization of children against measles has reduced measles-associated mortality 
globally over the past decade (Wolfson et al., 2007, WHO, 2009b). Sporadic measles-outbreaks 
persist in many settings, disproportionately involving children too young to be vaccinated 
(Machaira and Papaevangelou, 2012). Twenty-four percent of cases in a recent measles-outbreak 
in South Africa were aged less than  9-months (Diseases, 2010). A greater proportion of measles 
associated hospitalization occurs in children aged less than 9-months among HIV-infected (33%) 
compared to HIV-uninfected African children (23%) (Moss et al., 2002).  Factors contributing to 
the sporadic outbreaks of measles include vaccine-coverage below the 95% threshold required to 
interrupt wild-type virus circulation in communities, pockets of susceptible individuals who 
remain unimmunized or have sub-optimal immune-responses to vaccine and reduced 
transplacental measles-antibody transfer to fetuses as maternal immunity is now mainly vaccine-
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induced (Machaira and Papaevangelou, 2012, Leuridan et al., 2010, WHO, 2009b). Furthermore, 
maternal HIV-infection has been associated with lower measles-antibody titers (Farquhar et al., 
2005), impaired transplacental antibody transfer to the fetus and more rapid decay of maternal-
derived antibodies in HIV-infected children (Caceres et al., 2000, Farquhar et al., 2005, Kruczek, 
2010, Scott et al., 2005). A recent meta-analysis identified a limited number of studies (n=1) 
evaluating the immunogenicity of measles-vaccine following primary vaccination in 
predominantly antiretroviral treatment (ART)-naïve HIV-infected children (Scott et al., 2011). 
The meta-analysis reported that 59% (95% confidence intervals [95%CI], 46-71%) of HIV-
infected children were sero-positive after receiving standard-titer measles vaccine at 6, 9 or 12 
months of age without any differences by age of vaccination. Fewer HIV-infected children (40%) 
remained protected compared to HIV-exposed, uninfected children 12 months post-vaccination 
(Scott et al., 2011). A higher proportion of older HIV-infected children (78-89%) developed sero-
protective titers when vaccinated post immune-reconstitution following ART initiation (Aurpibul 
et al., 2007, Aurpibul et al., 2006); Table 2.10. Despite sub-optimal immune responses and higher 
rates of vaccine failure in HIV-infected children, this was not considered a major hurdle in 
measles control and elimination because of the high mortality rate in the absence of ART 
(Helfand et al., 2005). Improved survival of HIV-infected children on ART may, however, 
paradoxically impair measles control because of sub-optimal immune responses to vaccine (Scott 
et al., 2008). In another study, 57% of HIV-infected children and 99% in HEU children, however, 
when the HIV-infected children were stratified according to ART status and number of measles 
doses received, 85% of HIV-infected children on sustained combined ART and receiving more 
than 2 doses of measles vaccine had sero-protective measles antibody titers (Siberry et al., 2015). 
None of the studies were undertaken in the context of early-initiation of ART in HIV-infected 
children; Table 2.10.
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Table 2.10: Studies reporting immune response to measles virus vaccination in children born to HIV-infected mothers 
Reference and 
country 
Study 
design 
Vaccination 
Schedule and 
blood sample 
collection 
HIV-status 
(n) 
Age at 
study entry 
Number taking 
ART 
Initiation of 
ART prior to 
vaccination 
CD4+ status at 
study entry 
Main findings 
HIV-infected 
children only# 
or  (HIV-
infected vs. 
HIV-
unexposed)† 
or 
(HIV-infected 
vs. HEU)†† 
or 
(HEU vs. HIV-
unexposed)††† 
Summary 
HIV-infected only 
2001 
USA 
(Berkelhamer 
et al., 2001) 
 
NS 
Re-vaccination‡: 
MMR: Between 
11 and 40 months 
 
Bloods: 1-4 
months post 
vaccination 
HIV-
infected: 
cART (14) 
 
no cART 
(14) 
2.2-11 years 14 
ART initiated >4 
months prior to 
re-vaccination in 
the cART group. 
No cART was 
initiated in the 
no cART group. 
10-45% 
N/n (%); >0.7 
ELFA: 9/14 
(64.3) vs. 3/14 
(21.4); p=0.027#‡ 
cART 
improves 
response to 
additional 
measles 
vaccination. 
2006 
Amsterdam 
(Bekker et al., 
2006) 
 
Prospective 
cohort 
Previously 
vaccinated†: 
MMR: NS 
 
Bloods: 48 weeks 
HIV-infected 
(59) 
4.3 years 59 
ART initiated 
post vaccination 
and duration on 
ART was 205 
weeks post 
vaccination. 
NS 
% ≥9.0 AU/ml†#: 
HIV-infected: 
43% 
Despite 
immune 
reconstitution, 
antibodies 
against MMR 
disappear 
over time in up 
to 40% of 
children with 
HIV- infection 
2006 
Thailand 
(Aurpibul et al., 
2006) 
 
Cross-
sectional 
Previously 
vaccinated†: 
MMR: NS 
 
Bloods: 79.6 
months 
HIV-infected 
(93) 
9.7 years 93 
Children were on 
ART for 24 
months prior to 
booster dose of 
MMR. 
>15% 
N/n (%); 
>320mIU/ml†: 
39/93 (41.9) 
 
Mean antibody 
level (SD): 1389 
(4147) 
Low 
prevalence of 
measles 
protective 
antibody in 
HIV-infected 
children with 
immune 
recovery after 
HAART, 
despite routine 
immunization 
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during 
childhood. Re-
vaccination 
may be 
indicated. 
2007 
Thailand 
(Aurpibul et al., 
2007) 
 
Cross-
sectional 
Re-vaccination‡: 
MMR: NS 
 
Bloods: 4 and 24 
weeks 
HIV-infected 
(51) 
10.2 years 51 
Children were on 
ART for 127 
weeks prior to 
re-vaccination 
≥15% 
4 weeks: N/n 
(%); >320 
mIU/ml#‡ : 46/51 
(90) 
 
Mean antibody 
level (SD); 
mIU/ml: 3166 
(2659) 
 
24 weeks: N/n 
(%); >320 
mIU/ml#‡: 39/49 
(80) 
 
Mean antibody 
level (SD); 
mIU/ml: 1952 
(1949) 
 
 
Children re-
vaccinated 
after immune 
recovery after 
cART respond 
well to MMR. 
2009 
Italy 
(Pensieroso et 
al., 2009) 
 
Cross-
sectional 
Re-vaccination‡: 
MMR: Booster 
 
Bloods: Early 
control: 4.2 years 
Late control: 4.7 
years 
Late failure: 3.7 
years 
Treatment naïve: 
6.1 
HIV-infected 
(70) 
 
Early 
treatment: 
6.8 years: 
Late control: 
13.7 years 
Late failure: 
15.8 years 
Treatment 
naïve: 11.8 
years 
 
64 
ART initiated in 
in early and late 
controller and 
late failure prior 
to booster dose. 
Duration on 
ART was not 
stated 
Early treatment: 
35% Late 
control: 33% 
Late failure: 
22% 
Treatment naïve: 
25% 
 
Early control: 
mean 4.2 years; 
82% protected 
Late control: 
mean 4.7 years; 
39% protected. 
Late failure: 
mean 3.7 years; 
40% protected. 
Treatment naïve: 
33%√ 
Late-treated 
HIV-1 
controllers and 
Late failures 
lose protective 
antibody titers 
against 
measles 
vaccine. 
2009 
Kenya 
(Farquhar et al., 
2009) 
 
Prospective 
Re-vaccination‡: 
MMR:  booster 
dose 
 
Bloods: 4 weeks 
HIV-infected 
(90) 
4.9 years 90 
No ART post 
primary 
 
ART given 8 
months prior to 
booster dose. 
Median 6.3% 
Among 62 
children 
completing 6 
months on 
cART:  17/43 
(40%) without 
protective 
measles IgG 
sero-converted; 
10/19 (53%) 
who were 
positive prior to 
ART lost 
After 6 months 
of cART, more 
than half of 
previously 
immunized 
children still 
lacked measles 
antibody. 
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antibodies (p= 
0.3). Children 
who lost 
responses had 
significantly 
lower measles 
antibody 
concentrations 
than those who 
remained 
measles 
IgG positive 
during follow-up 
(7.1 vs. 20.3 
mg/mL; p= 
0.003). 
2016 
India 
(Seth et al., 
2016) 
 
Prospective 
Re-vaccination‡: 
MMR: NS 
 
Bloods: 8-12 
weeks 
HIV-
infected: 
(66) 
5-18 years 66 
ART initiated >6 
months prior to 
re-vaccination. 
>15% 
 
Pre-vaccination: 
N/n (%): 16/66 
(24.2)# 
 
Post-
vaccination#‡: 
N/n (%) 62/66 
(93.3) 
 
Immune 
reconstitution 
post cART 
resulted in 
adequate 
responses to 
additional dose 
of measles. 
HIV-infected vs. HIV-unexposed 
2007 
Brazil 
(Zaccarelli-
Filho et al., 
2007) 
 
Observationa
l 
MMR: 
9 and 15 months 
 
Bloods: NS 
HIV-
infected: 
Good VLR: 
(9) 
Partial VLR: 
(13) 
Poor VLR: 
(14) 
Good VLR: 
11 years 
Partial VLR: 
7.4 years 
Poor VLR: 
9.4 years 
Controls: 
10.6 years 
41 
Good VLR: 
initiated prior to 
2nd booster dose 
at 5.8 years of 
age 
 
Partial VLR: 
initiated prior to 
2nd booster dose 
at 3.7 years of 
age 
 
Poor VLR: 
Initiated post 2nd 
booster dose at 
7.3 years of age 
 
Good VLR: 
33.0% 
Partial VLR: 
26.4% 
Poor VLR: 
21.6% 
N/n (%) >0.12 
IU/ml#:  Good 
VLR: 4/9 (43) 
vs. 
Partial VLR: 
6/13 (44) vs. 
Poor VLR: 6/14 
(45); p=0.99* 
 
 
Good VLR: 
0.10 (0.06–
0.33) vs. Partial 
VLR: 0.09 
(0.02–0.22) vs. 
Poor VLR: 0.09 
(0.01–0.55); 
p>0.99 
Mean measles, 
plasma 
antibody levels 
were similarly 
low for all 
three groups of 
HIV-infected 
children. No 
differences 
were observed 
when assessing 
the percentage 
of children 
with protective 
antibody levels 
2007 
Zambia 
Prospective 
cohort 
MV: 9 months 
 
HIV-infected 
(50) 
HIV-
infected: 9.0 
ND 
No ART was 
initiated prior to 
ND 
6 months: N/n 
(% );  >120 
Despite good 
primary 
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(Moss, 2007) 
 
Bloods: 6 after 
vaccination 
 
HIV-
unexposed 
(98) 
 
HEU (211) 
months 
 
HIV-
unexposed: 
9.1 months 
 
HEU: 9.1 
months 
vaccination mIU/ml√: 44/50 
(88) vs. 92/98 
(94) vs. 198/211 
(94); p=0.3 
 
GMC (95% CI) 
mIU/ml: 504 
(349-727) vs. 
484 (399-588) 
vs. 555 (486-
634) 
 
 
antibody 
responses to 
measles 
vaccine, there 
was rapid 
waning of 
antibody. 
HIV-infected vs. HEU 
2007 
Cameroon and 
central Africa 
(Tejiokem et 
al., 2007) 
 
Cross 
sectional 
MMR at 18 
months 
 
Bloods: 12.8 
months 
HIV-infected 
(51) 
 
HEU (78) 
18-36 
months 
33 
No initiation of 
ART prior to 
either primary or 
booster dose. 
ART was 
initiated 6 
months prior to 
blood sampling 
<15 to >25% 
N/n (%); >335 
mIU/ml√√: 8/50 
(16.0) vs. 48/77 
(62.3); p<0.001†† 
 
GMC (95% CI); 
mIU/ml: 1091.5 
(576.1-2067.8) 
vs. 943.2 (782.7-
1136.6); 
p=0.56†† 
 
 
Antibody 
concentration 
after a single 
dose of the 
measles 
vaccine was 
substantially 
lower than 
expected, 
particularly 
low in HIV-
infected 
children with 
low CD4+ T-
lymphocyte 
counts. 
2015 
USA 
(Siberry et al., 
2015) 
 
Prospective 
cohort 
MMR: Previously 
vaccinated† 
 
Bloods: 9.2 years 
after primary 
vaccination 
HIV-infected 
(428) 
 
HEU (221) 
13.9 years 347 
No ART was 
initiated prior to 
vaccination; in 
those on ART 
duration was not 
stated. 
34% 
N/n (%); 
mIU/ml†: HIV-
infected: 57%† 
HEU: 99%†† 
High 
percentage of 
HIV-infected 
children lack 
serologic 
evidence of 
immunity to 
measles 
vaccine, 
despite full 
immunization 
and current 
cART. 
HEU vs. HIV-unexposed 
2013 
South Africa 
(Reikie et al., 
2013) 
 
Prospective 
cohort 
MV: 9 and 18 
months 
Bloods:12, 18, 24 
months 
 
HEU (27) 
 
HIV-
unexposed 
(28) 
3 months ND ND ND 
No differences 
post primary or 
booster measles 
vaccine between 
HEU and HIV-
unexposed 
children 
Similar rates of 
sero-protection 
were observed 
between HEU 
and HIV-
unexposed 
children. 
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Footnote: HEU: HIV-exposed, uninfected; ND: not done; Early control= children who started on HAART in the first year of life; Late control= children who 
were started on HAART after the first year of life and in whom viral suppression was achieved; Late failure= children who started on HAART after the first 
year of life and in whom viral suppression was not achieved. EIA= enzyme immunoassay; IU= international units; 
†
 previously vaccinated in early childhood; 
‡
 
re-vaccination: children who received all primary and booster doses in early childhood, and received a full series of vaccination in older age; 
√
 response after 
primary vaccination; 
√√
 response to booster vaccination; mIU= milli international unit; MMR= measles, mumps, and rubella; MV: measles vaccine; ELFA: 
enzyme linked fluorescent immunoassay; AU= arbitrary unit; VLR: viral load responder in children receiving ART. 
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2.10 ASSESSMENT OF ANTIBODY RESPONSE TO VACCINES  
ELISA has been seen for decades as the most widely used assay for vaccine antibody serology, 
which is both specific and sensitive, and is ideal for testing many samples against a single analyte 
(Edwards et al., 1995, Lal et al., 2005, Farquhar et al., 2009, Maede et al., 1995) However, 
evaluation of IgG responses following routine immunization, entails measurement of multiple 
analytes, and screening by ELISA has become time consuming, costly and requires large sample 
volumes (Pickering et al., 2002a). Studies have demonstrated the ability of ELISA to accurately 
determine vaccine responses (Fu et al., 2010), however, with increased number of combined 
antigens (Fletcher et al., 2004) the use of ELISA has become increasingly unsuitable for purposes 
of studying immunogenicity and efficacy of vaccines in large numbers of samples (Pickering et 
al., 2002a). Therefore new methods which can rapidly and reliably determine specific IgG levels 
are required. Microsphere-based flow cytometric assays allow the simultaneous measurement of 
many analytes from a single sample (Ling et al., 2007). Studies have shown the ability to 
effectively multiplex a range of biological analytes such as cytokines (de Jager et al., 2003), 
bacterial pathogen nucleic acid (Dunbar et al., 2003) as well as antigen and antibodies to specific 
pathogens (van Gageldonk et al., 2008, Pickering et al., 2002a, Pickering et al., 2002b). 
Multiplexing allows high sample throughput and use of very small sample volumes, whilst still 
retaining the advantages of a conventional ELISA (Fu et al., 2010).  Microsphere-based 
technology permits transfer of the simple ELISA format into a bead format in which the 
fluorescent bead is used as the solid support for the target antigen (Lal et al., 2005). Since ELISA 
kits are expensive, and are only available in a monoplex layout, we developed a multiplex 
method for the simultaneous detection of antibodies to five antigens, DT, TT, PT, FHA and 
HBsAg. This assay uses Luminex multiple analyte profiling technology (Luminex, Austin, TX), 
which is a flow cytometric system that allows a single sample to be tested simultaneously for 
several different analytes (Pickering et al., 2002b).  
 
The Luminex platform has several advantages when compared to the conventional ELISA: the 
ability to  multiplex, high sensitivity and specificity, has higher throughput, has a greater 
dynamic range on smaller sample volume and reduced time and less labour intensive (van 
Gageldonk et al., 2008). With all these advantages in mind, we aimed to determine whether the 
Luminex system was comparable to ELISA assays for measuring select vaccine responses.  
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2.11. CHAPTER SUMMARY  
The WHO has recommended that all HIV-infected children should receive routine childhood 
vaccination, with the exception of BCG and measles vaccine in severely immunosuppressed 
children. HIV-infection impairs humoral and cell mediated immune functions early in  childhood 
(Resino et al., 2004, Letvin and Walker, 2003). Immune dysfunction in HIV-infected individuals 
include loss of T-lymphocytic proliferative responses and hyper-activation of T-lymphocytes 
leading to accelerated apoptosis (Letvin and Walker, 2003, Palumbo et al., 1992, Borkowsky et 
al., 1992),  decline in B-lymphocyte number and function (Lane et al., 1983, Shearer et al., 2000), 
and impaired priming for immunological memory and/or loss of anamnestic responses 
(Pensieroso et al., 2009, al-Attar et al., 1995). Early initiation of combination ART in HIV-
infected children prior to immunological or clinical deterioration is associated with improved 
survival (Violari et al., 2008). Control of HIV replication limits and reverses immunosuppression 
in HIV-infected individuals (Resino et al., 2004, Valdez, 2002, Melvin and Mohan, 2003), 
improving immune responses to vaccines (Simani et al., 2013, Madhi et al., 2010, Obaro et al., 
2004).    
 
Due to effective ART regimens for preventing mother-to-child HIV-transmission, the majority 
(>97%) of children born to HIV-infected women are HIV-uninfected (Chuachoowong et al., 
2000, Connor et al., 1994, Kind, 1998, Simonds et al., 1998). HEU children may, however, have 
increased risk of morbidity and mortality than children born to HIV-uninfected mothers (i.e. 
HIV-unexposed) (Newell et al., 2004, Koyanagi et al., 2011). This may be due to perturbations of 
the immune systems of HEU children due to in-utero HIV virion particle exposure and/or ART-
exposure (Hygino et al., 2008, Faye et al., 2007, Bunders et al., 2005, Clerici et al., 2000, Gesner 
et al., 1994, Neilsen et al., 2001), affecting lymphocyte differentiation and function (Hygino et 
al., 2008, Faye et al., 2007, Feiterna-Sperling et al., 2007, Borges-Almeida et al., 2011, Bunders 
et al., 2005, Clerici et al., 2000). There are conflicting data on vaccine-related immune responses 
of HEU compared to HIV-unexposed children. These include variable responses to BCG vaccine 
(Van Rie et al., 2006, Mahomed et al., 2006), tetanus-toxoid, pertussis, HibCV, HBV and PCV 
(Jones et al., 2011, Abramczuk et al., 2011, Madhi et al., 2010). Differences in immune responses 
to some vaccines in HEU compared to HIV-unexposed children is attributed to lower maternal-
derived  vaccine-epitope specific antibody in HEU children, possibly reducing interference in 
immune responses to the homotypic vaccines (Jones et al., 2011, Abramczuk et al., 2011).  
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Memory induced by vaccination is crucial to long-term protection, particularly for diseases with 
long incubation periods such as hepatitis B (Plotkin, 2010). The establishment of long-term 
serologic memory is dependent on the generation and maintenance of antigen-specific memory 
CD4+ T-lymphocytes and memory B-lymphocytes (Cagigi et al., 2012). These lymphocytes are 
capable of re-circulating between the peripheral circulation and the lymphoid tissues, upon 
antigen encounter through vaccination or natural infection, B-lymphocytes in the presence of 
cognate help from CD4+
 
T-lymphocytes, are able to differentiate into plasma cells with the 
production of high-affinity antibodies in the periphery (Cagigi et al., 2012).   
 
HIV-infection is associated with aberrations in all major lymphocyte populations, including B-
lymphocytes which are the cornerstone of humoral immune responses (Letvin and Walker, 2003, 
Shearer et al., 2000, Pensieroso et al., 2009, Gona et al., 2006, Palma et al., 2008, Moir and 
Fauci, 2009, Moir et al., 2004, Titanji et al., 2005, Titanji et al., 2006). In HIV-infected 
individuals T-lymphocyte and B-lymphocyte dysfunction may result in lower rates of sero-
conversion post-vaccination, quicker decline of antibody levels, and impaired generation or 
accelerated loss of antigen-specific memory B-lymphocytes (Ghosh et al., 2009, Moir and Fauci, 
2008). Extensive progress has been made in improving the lives of children born to HIV-infected 
mothers, through access to ART (Miller and Rathore, 2012). Successful HIV viral suppression 
through ART treatment has been shown to restore CD4+ T-lymphocytes and to normalize the 
percentage of B-lymphocytes when therapy is available during primary infection (Faye et al., 
2004, Moir et al., 2008). Regarding the impact of ART on the immune responses to vaccines in 
vertically HIV-infected children, available data  has shown that initiation of ART as early as 
possible induced better immune responses compared to when ART was deferred until there was 
immunological or clinical deterioration (Cagigi et al., 2012, Pensieroso et al., 2009, Madhi et al., 
2010). Early initiation of ART has been associated with relatively normal development of the T-
lymphocyte lineage, and with preservation of high numbers of functional memory B-lymphocytes 
in HIV-infected individuals (Palma et al., 2008, Pensieroso et al., 2009, Zanchetta et al., 2008, 
Romiti et al., 2001). In some studies, however, despite B-lymphocyte function being improved 
following ART initiation, memory responses remained low at least over a year after viral control 
was attained (Iwajomo et al., 2015, Moir et al., 2008, Moir et al., 2010, Lederman et al., 1998, 
Soriano-Sarabia et al., 2005, Bekker et al., 2006).   
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Therefore, the data shows that the problem with children born from HIV-infected mothers 
(infected or uninfected) is that they are at an increased risk of severe, recurrent, or unusual 
infections by vaccine preventable infectious agents. Even though routine immunization 
programmes have been the most practical and safe approach in controlling childhood infections 
in HIV-infected children, their responses are sub-optimal, and results in HIV-infected children on 
ART and those who are HEU are conflicting. In the absence of ART, progressive 
immunodeficiency and disease is an inevitable consequence. A review of studies conducted in 
HIV-infected children indicates a paucity of studies that evaluate the effects of ART on the 
immune response to childhood vaccines, especially in sub-Saharan Africa. A large number of 
studies have shown the effects of HIV-infection or risk of being born to an HIV-infected mother 
on the immune response to vaccines, however, a limited number have assessed the effects of 
HIV-infection and ART on the immune response to vaccines prior to and post vaccination. Of the 
limited number of studies conducted on the effects of HIV and ART, these effects were assessed 
in either HIV-infected adolescents and/or adults; including evaluation of the effects of ART after 
primary or re-vaccination.  
  
85 
 
CHAPTER 3:  STUDY OBJECTIVES 
The primary objectives of this study were to:  
(i) Design a microbead multiplex assay on the Bio-Plex 200 instrument that can 
qualitatively and quantitatively detect antibody responses to diphtheria-toxoid (DT) 
vaccine, tetanus-toxoid (TT) vaccine, whole cell pertussis (wP) vaccine (DTwP 
vaccine), and recombinant hepatitis B vaccine (HepB). To compare Luminex and 
ELISA assays for the detection and quantification of antibodies to DT vaccine, TT 
vaccine, wP vaccine and HepB vaccine. Validate the Luminex method for the 
evaluation of immunological responses to DT vaccine, TT vaccine, wP vaccine and 
HepB vaccine (Results in Chapter 5).   
 
(ii) Evaluate sero-conversion and sero-protection rates after primary series against 
combined DT, TT, wP vaccine, as well as HepB in HIV-infected children that are 
receiving versus those not receiving ART and compare this to HIV-unexposed children 
(Results in Chapter 6). 
 
(iii) Evaluate sero-conversion and sero-protection rates after primary series against 
combined DT, TT, wP vaccine, as well as HepB vaccine in HEU children following 
the primary series of vaccines and compare this to HIV-unexposed children (Results in 
Chapter 6). 
 
(iv) Evaluate sero-conversion and sero-protection rates after a booster-dose against 
combined DT, TT, and wP vaccine, in HIV-infected children that are receiving versus 
those not receiving ART and compare this to HIV-unexposed children. In addition 
persistence of HepB vaccine antibodies was compared between the same children 
(Results in Chapter 7). 
 
(v) Evaluate sero-conversion and sero-protection rates after a booster-dose against 
combined DT, TT, and wP vaccine, in HEU children and compare this to HIV-
unexposed children. In addition persistence of HepB vaccine antibodies was compared 
between the same children (Results in Chapter 7). 
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(vi) Evaluate sero-conversion and sero-protection rates to a primary dose and following a 
booster dose of measles vaccine in HIV-infected children that with a CD4+ percentage 
≥25 randomized to either early or deferred initiation of ART compared to HIV-
unexposed children (Results in Chapter 8). 
 
(vii) Evaluate sero-conversion and sero-protection rates to a primary dose and following a 
booster-dose of measles vaccine in HEU children compared to HIV-unexposed 
children (Results in Chapter 8). 
 
The secondary objectives of this study were to:  
(viii) Determine effects of ART on responses rate to HepB and DTwP vaccines by 
comparing ART-Def children and ART-Immed children and HIV-infected children 
with CD4+ <25% receiving early ART (CD4+<25%), pre-vaccination and post-
primary vaccination (Results in Chapter 6). 
 
(ix) Determine effects of ART on response to DTwP vaccine by comparing ART-Def 
children and ART-Immed children, pre-booster, post-booster (Results in Chapter 7). 
 
(x) Determine effects of ART on persistence of antibody to HepB and DTwP vaccine by 
comparing ART-Def children and ART-Immed children at 15-18 months and 24 
months of age (Results in Chapter 7). 
 
(xi) Determine effects of antiretroviral therapy on responses rate to measles vaccine by 
comparing ART-Def children with ART-Immed and CD4+<25% children, pre-
vaccination and post-vaccination (Results in Chapter 8). 
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CHAPTER 4: METHODS  
4.1 Ethical clearance and approval  
Permission to conduct the study was sought and obtained from the Human Research Ethics 
Committee (HREC), at the University of the Witwatersrand (M080966) and the faculty of Health 
Sciences Higher Degrees Committee. This study was performed retrospectively on samples that 
were obtained as part of Comprehensive International Programme for Research on AIDS in 
South Africa (CIPRA-SA Project 4) HREC: 040704. All participants were given a unique study 
identification (ID) number at the beginning of the study. All laboratory specimens, evaluation 
forms, reports and other records were identified only by the study ID number to maintain subject 
confidentiality. All records were stored in a secure place, and all computer entry and networking 
programmes were carried out with coded numbers only. 
 
4.2 Study design and site 
This was a retrospective analysis of a prospective cohort on the immunogenicity of vaccines 
within the EPI-SA in HIV-infected, HEU and HIV-unexposed, uninfected children (HIV-
unexposed) as the control group. These children were predominantly from the public sector either 
born or receiving care at the Chris Hani-Baragwanath Hospital in Johannesburg, and at 
Tygerberg Hospital in Stellenbosch, South Africa. HIV-uninfected children were recruited from 
the maternity wards of the respective study sites by a trained health worker in HIV counselling. 
The mothers must have tested HIV negative based on their participation in the PMCT programme 
that was conducted at each study site. HEU children were recruited from a cohort of children 
originally identified to participate in the ―Children with HIV Early Antiretroviral (CHER)‖ study, 
but the child tested HIV negative at 4 weeks of age by polymerase chain reaction (PCR). HIV-
exposed infected children were identified to be HIV-infected within the CHER study and had to 
have a baseline CD4+ T-lymphocyte count available. These children were randomized to either 
early or delayed antiretroviral treatment groups, detailed information on the groups of children 
are discussed in section 4.3. The vaccination schedule was based on the WHO and South African 
Department of Health guidelines, however, at 64-76 weeks of age children from all groups were 
either randomized, in equal proportions, to either receive a PncCV or HibCV booster dose of the 
vaccines by means of stratified permuted block randomization. Quantitative antibody responses 
to DTwP-HibCV, HepB and live-attenuated measles virus vaccines among HIV-uninfected 
(exposed and non-exposed) and HIV-infected children stratified by ART status were measured. 
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4.3 Description of study population 
The study was conducted on archived serum samples from 578 children in whom the effect of 
HIV exposure and timing of ART initiation was evaluated on the quantitative and qualitative 
antibody responses to PncCV as the primary objective (Madhi et al., 2010). Five groups of 
children, aged at 6-12-weeks, were enrolled from April 2005 to June 2006. This included HIV-
unexposed children born to HIV-uninfected mothers; and HEU children born to HIV-infected 
mothers; Figure 4.1. In addition, peri-natally HIV-infected children with a CD4+ T-lymphocyte 
percentage ≥25% at enrolment were randomized to initiate ART when clinically and/or 
immunologically indicated (ART-Def) as per then WHO recommendations, or immediately upon 
enrolment (ART-Immed) (Violari et al., 2008). ART-Immed children were subsequently 
randomized to either interrupt ART at 12- (ART-12m) or 24-months of age (ART-24m) if 
immunologically stable and virologically suppressed, with ART being re-initiated if clinically 
and/or immunologically indicate; Figure 4.1. Furthermore, a convenience sample of HIV-infected 
children with CD4+<25% initiated on ART at enrolment (CD4+<24%) were included. HIV-
infected children were co-enrolled from the CHER Study as described (Violari et al., 2008).  
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Figure 4.1: Flow diagram of all recruited study participants. N=total number recruited, however, there may have been missing 
samples at later visits. 
Maternal HIV-
infection status 
Mother is infected 
Mother is 
uninfected 
HIV-exposed, 
uninfected child 
(HEU), N=125 
HIV-unexposed, 
uninfected child 
(HIV-unexposed); 
N=124 
HIV-infected 
child 
Continued 
treatment till 24 
months 
(ART/24m); 
N=87 
Interrupted ART at 
12 months of age 
(ART/12m.); N=85 
HIV-infected 
receiving delayed 
ART (ART-Def); 
N=105 
HIV-infected 
receiving early ART 
(CD4+<25%); N=14 
HIV-infected receiving 
early ART (ART-
Immed); N=210 
CDC disease 
category 1 and 
CD4+≥25% 
CDC disease 
category 2 or 3 
and CD4+<25% 
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 4.3.1 Inclusion criteria 
Recruited children had to be between the age of four and ten weeks and have a birth weight of at 
least 2000 grams. The parent or legal guardian of the child had to have indicated that they would 
stay in the study area for the study duration. Documentation of the mothers HIV status at 24 weeks 
gestation had to be available, and breastfeeding was permitted. Inclusion criteria for HIV-infected 
children were that the child had to be co-enrolled in the CHER study, HIV status had to have been 
confirmed by a positive DNA or RNA PCR at birth and a second one at four to ten weeks of age. 
Children born to HIV-infected mothers were allowed into the study if they were ART naïve except 
for receipt of ART within the PMCT programme. Allowed medications were antipyretics for 
auxiliary temperatures ≥38°C after vaccination. HIV-infected children were allowed to receive 
ART as part of the study as well as trimethroprim-sulfamethoxazole prophylaxis as per the South 
African guidelines ((NDoHSA), 2004). 
 
 4.3.2 Exclusion criteria 
Children were excluded from the study if they had received any blood products, any vaccine with 
the exception of BCG and OPV, prior to study entry. Children, who had received 
immunosuppressant agents for more than 2 weeks and were unable to tolerate oral medication, were 
excluded from the study. Presence of any major congenital anomalies that were life threatening. 
Children with acute, moderate to severe intercurrent illness or fever ≥38°C within 72 hours before 
vaccination that resulted in hospitalization, were excluded from the study. The presence of Grade 2 
allergic reaction and any Grade 3 clinical toxicity; the presence of any Grade 3 or 4 clinical or 
laboratory toxicity; were excluded from the study. Parent or guardian unable or unwilling to attend 
scheduled study visits. The use of ART other than the regimens described within the study, 
systemic cytotoxic chemotherapy and interleukin or other immune modulators. Insufficient sample 
volume or children with more than two visits not attended. 
 
4.4 Antiretroviral therapy administered 
At Chris-Hani Baragwanath Hospital, mothers who were identified as HIV-infected received a 
single dose of nevirapine at the time of delivery; this was also give to their child at the time of 
delivery to prevent mother-to-child transmission. While at Tygerberg Hospital the regimen 
consisted of zidovudine given to the HIV-infected mother from 34 weeks gestation and to the 
neonates for seven days and a single-dose nevirapine to both at the time of delivery. ART received 
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during the study was as follows: first-line antiretroviral was zidovudine at a dose of 240mg per 
square meter of body-surface area twice daily; lamivudine at a dose of 4mg per kilogram of body 
weight twice daily and lipinavir (300mg)-ritonivar (75mg) given twice daily up-to 6 months of age 
and thereafter at 230mg and 57.5mg respectively. The second-line regimen consisted of didanosine, 
abacavir and nevaripine (Violari et al., 2008). 
 
4.5 Study vaccine regimens, administration and duration 
Study subjects had five immunization visits were they received routinely administered childhood 
vaccines, as recommended in the EPI-SA, which included combined DTwP-HibCV, HepB and live-
attenuated measles virus vaccine. PncCV was administered along with study vaccines and 
immunological responses were measured within the CIPRA-SA project 4 study. Table 4.1 below, 
illustrates the timing and administration of EPI vaccines being studied (in bold). DTwP-HibCV 
(CombAct-Hib®, Aventis, France) and HepB (Heberbiovac HB®; HerberBiotec S.A., Cuba) 
vaccines were administered intramuscularly into the right or left anterolateral external aspect of the 
upper thigh, respectively following the standard three dose schedule of 6, 10, 14 weeks of age (with 
a 4 to 6 week interval between doses) and a booster dose of DTwP at 67.8 weeks of age. Children 
were randomized at 67.8 weeks of age to either receive HibCV or PncCV booster dose, as part of 
the CIPRA-SA project 4. Live-attenuated measles vaccine (Schwarz strain, Rouvax®; Aventis, 
France) was administered intramuscularly into the right anterolateral external aspect of the upper 
thigh following a two dose schedule at 39.5 weeks and 67.8 weeks of age.   
 
Table 4.1: EPI vaccine regimen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Footnote: aDTwP-HibCV was administered as a combination vaccine, CombAct-Hib® (diphtheria toxoid+ tetanus toxoid + whole 
cell pertussis+ HibCV); bChildren were randomized to either receive a booster dose of HibCV or PnCV; cThe hepatitis B vaccine 
was administered as a monovalent vaccine, Heberbiovac HB®; dMeasles vaccine (Rouvax®) was administered as a monovalent 
vaccine. 
 
Immunization Dose 1 Dose 2 Dose 3 1
o 
Measles 2° 
Measles
 
Age in Weeks 6-8 10-12 14-16 38-40 66-68 
DTwP-HibCV (CombAct-Hib®)
a
 X X X  X
b 
Trivalent oral polio vaccine (OPV) 
(POLIORAL-trivalEnt®) 
X X X   
HepB  
(Heberbiovac HB®)
c 
X X X   
PncCV (Prevnar®) X X X  X 
Measles vaccine (Rouvax®)
d    X X 
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4.6 Specimen collection 
Clotted blood samples were collected immediately prior to the first DTwP-HibCV/HepB doses 
(Time-point 1), one-month following the third dose (Time-point 2), prior to first live-attenuated 
measles vaccine dose (Time-point 3), prior to booster-doses of DTwP-HibCV or PnCV and live-
attenuated measles vaccine (Time-point 4), two-weeks following booster doses (Time-point 5) and 
at two years of age (Time-point 6); at the Respiratory and Meningeal Pathogens Research Unit 
(RMPRU) and Tygerberg Hospital; Table 4.2. Serum was archived at -70°C until processed at the 
RMPRU, Johannesburg, South Africa.  
 
Table 4.2: Specimen collection schedule 
Time-point 1
a 
  2
b 
3
c 
4
d 
5
e 
6
f 
Age in weeks 6-8 10-12 14-16 18-20 38-40 66-68 67-70 109-
112 
Serum for 
DTwP-HibCV 
and  
HepB antibodies 
X   X X X X X 
Serum for  
measles 
antibodies 
X   X  X X X 
Footnote: a1= Enrollment time-point and first dose of DTwP-HibCV and hepatitis B vaccines as well as pre-vaccination for 
measles vaccine; b2= immunogenicity visit which was four weeks post third dose of vaccines; c3=first dose of measles vaccination 
and 28 weeks post third dose of vaccination against DTwP-HibCV and Hepatitis b vaccine; d4= Booster-dose of DTwP and 
monovalent HibCV as well as second measles vaccine dose, no hepatitis b vaccine booster was given; e5=two weeks post-booster 
doses of study vaccines; f 6= two year follow-up visit. 
 
4.7 MEASUREMENT OF QUANTITATIVE AND FUNCTIONAL ANTIBODY 
RESPONSES 
Archived serum samples were used to measure the quantitative immune response (total IgG 
antibodies) to study vaccine antigens (DT, TT, HepB); response to whole cell pertussis vaccine was 
measured using PT and FHA as surrogate markers for B. pertussis, these antigens have been shown 
to be good representatives of the whole cell response (Plotkin, 2010). Immune responses were 
measured at study Time-points 1, 2, 3, 4, 5 and 6 (Table 4.2), with an in-house multiplex 
fluorescent microbead immunoassay. Anti-PRP for HibCV was detected by standard in-house 
ELISA (Time-points 1-6) and a bactericidal assay to measure antibody functionality at study time-
point 2. Immune response to live-attenuated measles vaccine (IgG antibodies) were measured at 
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time-points 1, 2, 4, 5 and 6, with a commercially available enzyme immunoassay and tested 
according to the manufacturers‘ instructions.  All assays were conducted at RMPRU. The assays 
used are briefly described in sections 4.7.1 to 4.11.  However, a detailed description on the 
preparation of reagents and detailed standards of operations (SOPs) are presented in Appendix 5.  
 
4.7.1 Quantification of antibodies to DT, TT, PT, FHA and HepB using commercially 
available assays as gold standard assays for comparison with the Luminex assay 
 4.7.1.1 Material  
Diphtheria toxoid (Batch: D52-2; Staten Serum Institute, Copenhagen, Denmark) from 
Corynebacterium diphtheriae and tetanus toxoid (Batch: T177-1; Staten Serum Institute, 
Copenhagen, Denmark) from Clostridium tetani. Pertussis toxin (Batch: 181209A1; List Biological 
Laboratories, INC, USA) and Filamentous haemaglutinin (Batch: 17040B1; List Biological 
Laboratories, INC, USA). Hepatitis B surface antigen (Engerix B B59, Batch: AHBVBPA 097; 
Glasko-Smith Klien, Belgium). R-phycoerythryn (R-PE) conjugated goat anti-human IgG (gamma-
chain specific) (Jackson ImmunoResearch Laboratories Inc., Westgrove, Pa). Carboxylated 
microsphere beads (Bio-Rad Laboratories, Hercules, CA). N-hydroxy-sulphosuccinimide, Sulpho-
NHS (Cat # 56485; Sigma-Aldrich, Germany). 1-ethyl-3 (3-dimethylamino-propyl) carbodiimide-
HCl, EDC, (Cat # 77149; Thermo Scientific, Rockford IL, USA). 96 well round bottom plates 
Costar (Cat # 9017; Costar USA).  AcroPrep multi-well filter-plates, 1.2 μm (Pall Corporation, 
USA). Anti-diphtheria toxoid IgG enzyme immunoassay MK014 (Lot # 260929; The Binding Site 
Ltd, U.K.) and VaccZyme 
TM 
Anti-tetanus toxoid IgG enzyme immunoassay MK010 (Lot # 
265507; The Binding Site Ltd, U.K.). SERION ELISA classic Bordetella pertussis IgG ESR120G 
(Lot # SKY.CX; Institut Virion/Serion GmbH, Germany). ImmunoLISA 
TM 
HBsAb (Lot # 
40261000; Organics Ltd. Part of the Inverness Medical Innovations Group, Israel). 
 
4.7.1.2 Measurement of antibody to DT by quantitative ELISA 
Quantification of DT IgG antibodies was achieved by the use of Diphtheria toxoid IgG EIA 
(Binding site Ltd, UK), and tested according to the manufacturers‘ instructions. Briefly, 96 well 
microtiter plates were supplied pre-adsorbed with purified DT antigen derived from C. diphtheria. 
The reference sera (National Institute of Biological Standards and Control (NIBSC London, UK) 
diphtheria antitoxin reference preparation 00/496), controls and diluted unknown samples (1:100) 
were added in duplicate to each well and antibodies recognizing the DT antigen were bound during 
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the first incubation. Optical densities were determined at 450 nm on a microplate reader 
(Labsystems Multiskan RC; USA). DT-specific IgG antibody levels (IU/ml) were calculated from 
the log/linear scale of the plotted reference sera graph with a range of 0.004-3 IU/ml. Assays with 
concentrations between 0.1 and 0.2 IU/ml were considered as low positives and 0.6 and 1.0 IUml 
were considered as high positives. Samples for which the concentration was below the detection 
limit (0.004 IU/ml) were assigned a concentration of half the detection limit of the assay (i.e. 0.002 
IU/ml) when calculating GMC.  
 
4.7.1.3 Measurement of antibody to TT by quantitative ELISA 
Quantitative TT IgG antibodies were measured with VaccZyme™ Anti-Tetanus Toxoid IgG EIA 
(Binding site Ltd, UK), and tested according to the manufacturers‘ instructions. Briefly, 96 well 
microtiter plates were pre-coated with purified TT antigen derived from the toxin of C. tetani. The 
reference sera (NIBSC tetanus antitoxin reference preparation 76/589), controls and diluted 
unknown samples (1:100) were added in duplicate to each well and antibodies recognizing the TT 
antigen were bound during the first incubation. Optical densities were determined at 450 nm on a 
microplate reader (Labsystems Multiskan RC; USA). TT-specific IgG antibody levels (IU/ml) were 
calculated from the log/linear scale of the plotted reference sera graph with a range of 0.01-7 IU/ml. 
Assays with concentrations between 0.15 and 0.35 IU/ml were considered as low positives and 1.05 
and 1.75 IUml were considered as high positives. Samples for which the concentration was below 
the detection limit (0.009 IU/ml) were assigned a concentration of half the detection limit of the 
assay (i.e. 0.005 mIU/ml) when calculating GMC. 
 
4.7.1.4 Measurement of antibody to PT and FHA by quantitative ELISA 
Measurement of IgG antibodies against PT and FHA was untaken with the Serion ELISA (Institut 
Virion Serion GmbH, Germany) and tested according to the manufacturers‘ instructions. Briefly, 96 
well microtiter plates were adsorbed with PT and FHA from B. pertussis and this constituted the 
solid phase. Reference serum (human sera in PBS with protein) and unknown samples (1:100) and 
controls were added to the wells in duplicate and any antibodies specific to the antigens present 
were bound to the solid phase. The optical density was read at 405 nm on a microplate reader 
(Labsystems Multiskan RC; USA). The mean optical density value of the standard serum should 
have been within the validity range (OD 0.48-1.63), which was given on the lot specific quality 
control certificate (Lot number: SKY.CX) of the kit (after subtraction of the substrate blank). 
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Concentration of samples was calculated using the SERION evaluate-Software, which operates by 
inputting the 4-parameters and the reference value of the standard serum and antibody activity were 
calculated online. The following criteria were used to interpret the results, IgG>30 FDA-U/ml were 
considered as positive; <20 FDA-U/ml was negative and 20 to 30 FDA-U/ml was indeterminate. 
 
4.7.1.5 Measurement of antibody to HepB by quantitative ELISA 
The quantification of HepB antibodies was done by the use of ImmunoLISA™ HBs Ab EIA 
(Organics Ltd Inverness Medical Innovations Group, Israel), according to the manufactures‘ 
instructions. The 96 well microtiter plates were pre-coated with highly purified heat inactivated 
HBsAg from subtypes ―ad‖ and ―ay‖. Reference sera (NIBSC WHO anti-HBsAg 1st reference 
preparation 1977, lot 17-2-77), controls and unknown samples (undiluted) were added in duplicate 
to each of the pre-coated wells and incubated to allow antigen antibody interaction. Optical density 
was measured at 450nm with a microplate reader (Labsystems Multiskan RC; USA). The amount of 
antibody was quantitated by means of a standard curve calibrated against the WHO reference 
preparation. A positive sample was interpreted as a sample with HepB antibody concentration ≥10 
mIU/ml. Samples for which the concentration was below the detection limit (10 mIU/ml) were 
assigned a concentration of half the detection limit of the assay (i.e. 5 mIU/ml) when calculating 
GMC.  
 
4.7.1.6 Quantitative measurement of antibodies against DTwP and HepB vaccines using Luminex assay 
Luminex microspheres are colour-coded microbeads of approximately 50nm in size and are 
available in 100 distinct colour sets. Each bead set was coated with a different antigen, specific to a 
particular bioassay (which will be detailed in section Quantitative antibody assay for the 
measurement of DT, TT, PT, FHA and HepB antibody responses below). By combining multiple 
bead sets in a single reaction, the capture and detection of antibodies against multiple antigens can 
be made simultaneously from a single sample. Bound antibody is detected by the addition of rabbit 
anti-human IgG antibody which has been conjugated to R-phycoerythrin (R-PE), a fluorescent 
protein.  The beads are read on a dual-laser flow-based detection instrument, such as the Luminex 
200™ or Bio-Plex 200™ analyzer. One laser classifies the bead colour and determines the analyte 
that is being detected. The second laser determines the magnitude of the PE-derived signal, which is 
in direct proportion to the amount of the bound analyte.  
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i) Coupling of DT, TT, PT, FHA and HBsAg antigens to carboxylated microspheres 
The first step to this assay was the coupling of purified DT, TT, PT, FHA and HBsAg to activated 
microspheres, and this was achieved by using a two step carbodiimide reaction (Staros et al., 1986, 
van Gageldonk et al., 2008). Briefly, the protein antigens were linked to the microspheres by an 
EDC/Sulpho-NHS reaction, in which the COOH groups of the microspheres was dehydrated with 
EDC, and in the presence of NHS, modifies the COOH to form an amine-reactive ester (Staros et 
al., 1986). The NHS-ester-containing molecule can then be reacted spontaneously with a primary 
amine-containing molecule e.g. amino group found on the N-terminal of the protein and certain 
amino acids. While the carboxyl-containing molecule can be made to react directly with the amine-
containing molecule by the addition of EDC, the reaction is much more efficient with Sulpho-NHS 
present because a stable intermediate is created and incubated in the dark at room temperature 
(Staros et al., 1986). The final bead ratio for each antigen was 25µg/6.25x10
6
 for DT and TT 
antigens;
 
5µg/6.25x10
6 
for PT and FHA; and 14µg/6.25x10
6 
for HepB. 
 
ii) Reference, controls and serum samples  
An in-house standard sera consisted of pooled adult sera, which was calibrated against the 
International standards (NIBSC code 00/496 (diphtheria antitoxin), 76/589 (tetanus antitoxin), 
07/164 (anti-Hepatitis B surface antigen immunoglobulin) and 06/140 (Pertussis antiserum (human) 
1
st
 International Standard) and used as an in-house reference sera for determining concentrations of 
natural and vaccine induced antibodies to all study antigens. The in-house positive control was 
derived from pooled human plasma (Hebagam® IM, National Bioproduct Institute, Pinetown South 
Africa), each unit was individually tested and found negative for HBsAg, anti-HCV and anti-HIV-
1/-2. The negative control was assay buffer. For assay validation and optimization purposes (first 
phase of the study), unknown samples were collected from 25 HIV-uninfected children who were 
participants of the ―Durability study‖ (HREC number: 031013) which include children between 4 – 
7 years of age (described in detail in section 4.8). (. For the second phase of the study (determining 
passive and vaccine induced immune responses to DT, TT, PT, FHA and HBsAg), serum samples 
were collected as described in section 4.6.  
 
iii) Multiplex immunoassay (MIA) for quantitation of DT, TT, PT, FHA and HepB specific antibodies 
This was the second phase of the study; we assessed serum samples described in section 4.6. A 
standard curve was prepared from seven 4-fold dilutions (1:50 to 1: 204800) of the reference serum 
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in phosphate buffered saline with 10% Foetal Bovine Serum (PBS-F). Controls and unknown sera 
were diluted in PBS-F at 1:100. Unknown serum samples that were above the detection limit of the 
assay were further diluted until they were within the dynamic range of the assay. Reference, 
controls and unknown sera, were mixed with the coupled microsphere beads in a 96-well AcroPrep 
multi-well filter-plates 1.2 µm (5000 microspheres/region/well) and incubated for one hour at room 
temperature with shaking. Microspheres were collected by vacuum filtration and washed with PBS-
T. R-phycoerythrin-conjugated anti-human IgG was added across all wells and incubated for 30 
min, in a shaker, at room temperature. Following incubation, the plates were washed and the beads 
were re-suspended in PBS-T buffer and transferred into a 96-well round-bottom plate, and read 
with a Luminex platform Bio-Plex 200 instrument (Bio-Rad, Hercules CA, USA) for quantification 
of IgG antibodies. Antibody concentrations in either IU/ml for DT, -TT, -PT and -FHA and mIU/ml 
for HepB were determined relative to the standard curve, with a five parameter logistic log model 
with the BioPlex software (van Gageldonk et al., 2008, Pickering et al., 2002a).  
 
4.8 VALIDATION OF LUMINEX ASSAY 
4.8.1 Calibration curve and its fitting algorithm 
The dose response curve expressed in terms of response y (fluorescent intensity (FIs) on a linear 
scale) versus the dose x (IU on a log scale) commonly display a pronounced sigmoidal shape. The 
five parameter logistic function fits these data with a high degree of accuracy (van Gageldonk et al., 
2008, Cambron et al., 2009, Plikaytis et al., 1991). An unweighted five-parameter logistic function 
was used to fit the standard curve for all multiplex reference sera. In order to estimate the accuracy 
of the standard curves, R
2
, the percentage of the relative error (RE) and percentage recovery 
(percentage backfit dose error) were determined for each standard point. The backfit dose is the 
recalculated concentration of each standard obtained by extrapolating its response (FIs) through the 
fitted curve. The RE of each standard point is as follows: %RE = [(recalculated value – assigned 
value)/assigned value] x 100%. To evaluate the overall quality of the fitting of the standard curve, 
standard curves collected during the development phase of the assay were assessed for R
2 
and RE.  
 
4.8.2 Comparison of Luminex assay with ELISA  
The Luminex assay was compared to a monoplex ELISAs for quantification of IgG antibodies 
against DT, TT, PT, FHA and HepB. The same reference sera, controls and sera (n=25) were used 
for comparison of antibodies to all five antigens. Twenty five serum samples from children aged 
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between 4-7 years were tested with both assay systems. Samples that fell outside of the upper 
detection limit for the assays were repeated at a higher dilution. Serum antibody concentrations to 
the protein antigens were determined by both methods and were subjected to linear regression 
analysis and the correlation coefficients were also calculated and designated R
2
.  
 
4.8.3 Competitive inhibition studies of Luminex assay 
To determine the specificity of the Luminex method and reported as percent change in 
concentration in response to the addition of individual antigens to the serum, inhibition studies were 
performed as described previously (van Gageldonk et al., 2008, Pickering et al., 2002a) with slight 
modifications. A serum with known high concentrations of IgG antibodies directed against all five 
antigens was diluted 1:1000 times. Four aliquots of each serum dilution were prepared. Each aliquot 
was incubated with an equal volume of one of the five purified antigens in a concentration of 30 
μg/ml for DT, TT, PT, FHA and 14µ g/ml for HepB for 1 hour at room temperature or overnight at 
4°C. A 1:1000 dilution of the serum was used as a control (non-absorbed). Homologous and 
heterologous inhibition of the antibody concentration compared to the control was calculated as a 
percentage inhibition. 
 
4.8.4 Sensitivity of Luminex and ELISA serum IgG  
The lower limit of quantitation (LLOQ) for the Luminex assay was determined from the recorded 
blank values from independent runs (n=16) for each antigen. This value was given as the equivalent 
antibody concentration of the reference at the point where the fluorescence intensity was equal to 
the blank plus three standard deviations. For the ELISAs the manufacturers‘ results were reported 
as indicated in the package insert of the kit.  
 
4.8.5 Assay Reproducibility 
The reproducibility of the assay was determined by calculation of inter and intra assay variation. 
Intra-assay variation within a plate was determined by testing an independent duplicate of different 
samples. For each analyte the coefficient of variation (%CV) for each duplicate result per sample 
was calculated and averaged. Intra-assay variation (plate to plate variation) was done by testing a 
serum panel in dependent dilutions between different plates on the same day. The % CV between 
each of these results for each analyte was calculated and averaged. Inter-assay variation (variation 
from assay to assay) was assessed by testing a serum panel in two separate assay runs. The %CV 
between each of these results for each analyte was calculated and averaged. The reproducibility of 
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the results generated from separate batches of conjugated microsphere beads was determined with 
considerable time intervals. A serum panel was tested with different batches of conjugated 
microsphere beads. The results obtained with the different batches were compared by calculating 
the correlation of coefficient (R). 
 
4.9. MEASUREMENT OF HAEMOPHILUS INFLUENZAE TYPE B ANTI-PRP 
ANTIBODIES WITH AN IN-HOUSE ELISA 
4.9.1 Principle of the Method  
PRP antibodies were measured with a standardized in-house enzyme immunoassay (Kurikka et al., 
1995). Briefly, Hib antigen (HboHA; Wyeth Vaccines distributor NIBSC, UK) at a final 
concentration of 1 mg/ml was pre-coated onto 96 well microtiter plates, which act as the solid 
phase. Hib specific antibodies in the reference serum (anti-H.influenzae type b capsular 
polysaccharide serum, lot 1983 (NIBSC)), sample, and low and high control sera were bound to the 
antigens on the surface of the well, all were added in duplicate. The antibody-antigen complex was 
detected by adding anti-human IgG (γ-chain specific) alkaline phosphatase antibody (Sigma, USA) 
conjugate. Substrate (4-Nitrophenyl phosphate disodium salt hexahydrate (Sigma, USA)) was 
added to the antigen-antibody conjugate complex and measured colometrically at 405 nm. Sero-
protective antibody titre was defined as ≥0.15 µg/ml, samples for which the OD value was <0.1 
were arbitrarily assigned a titre of half the detection limit of the assay (i.e.0.06 µg/ml) to provide an 
unbiased calculation of GMTs.  
 
4.10 MEASUREMENT OF SERUM BACTERICIDAL ACTIVITY SPECIFIC FOR 
HAEMOPHILUS INFLUENZAE TYPE B 
4.10.1 Principle of Assay 
This assay differs from the quantitative ELISA that was performed for H. influenzae type b, in that 
it measures the functional binding of PRP antibodies to viable bacteria (H. influenzae Type b, strain 
GB3292), and their ability to illicit bacterial killing in the presence of complement. This protocol 
was based on the original method by Schlesinger et al (1992) and later modified by Romero-Steiner 
et al (2001). In this assay, serum samples are serially diluted in a microtiter plate and a known 
concentration of live bacteria are added to each well. An active source of complement is added to 
induce killing of opsonized bacteria. After incubating for an hour; the number of viable bacteria in 
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each well was determined by plating out each serum dilution onto agar plates. Functional killing 
titers were expressed as the reciprocal of the dilution at which the serum was able to illicit 50% 
bacterial killing. For statistical purposes, samples that were found to be below the detection limits 
were given an arbitrary value of half the detection limit. 
 
4.11 MEASUREMENT OF MEASLES VIRUS ANTIBODY TITRES 
4.11.1Principle of assay 
Measurement of quantitative levels of measles-specific IgG antibody titres for all serum specimens 
were determined by the Enzygnost (Dade Behring, Marburg, Germany) anti-masern-virus/IgG 
enzyme immunoassay (sensitivity =99·6%; specificity =100%), as described previously 
(Ovsyannikova et al, 2004). Briefly, serum samples were added in duplicate to a microtitre plate, 
which contained two parallel wells coated with a test whole measles virus antigen or control antigen 
derived from non-infected cells. Optical densities were determined at 450 nm and corrected at 650 
nm on a microplate reader (Labsystems Multiskan RC; USA). The difference in mean absorbance 
between the viral test antigen and the control antigen for each sample was calculated and multiplied 
by a correction factor (determined by dividing a kit specific nominal value by the mean of the 
reference standard) to give the corrected change in absorbance (ΔA). Measles-specific IgG antibody 
levels (mIU/ml) were calculated from the antilog of the following formula: log10=α*∆Aβ (where α 
and β are lot-dependent constants). Assays with titers <150 mIU/ml were considered as negative 
(equivalent to <0.1 optical density [OD]), 150–329 mIU/ml as equivocal (equivalent to 0.1-0.2 OD) 
and ≥330 mIU/ml as sero-protective (equivalent to >0.2 OD) per manufacturers criteria. For this 
study, sero-positivity was defined as antibody titers ≥150 mIU/ml. Samples for which the OD value 
was <0.1 were assigned a titer of half the detection limit of the assay (i.e. 75 mIU/ml) when 
calculating GMT. The coefficient of variation for this assay in our laboratory was 8.9%. 
 
4.12 Statistical analysis of antibody kinetics 
Statistical analyses were performed using GraphPad Prism 5a (GraphPad Software Inc, La Jolla, 
CA, USA), R (R Foundation for Statistical Computing, Vienna, Austria) and STATA statistical 
package (STATA Corporation, College Station, TX, USA). The thresholds for correlates of sero-
protection were defined as antibody concentrations greater or equal to 0.01 IU/ml and 0.1 IU/ml for 
DT, 0.1 IU/ml for TT, 10 mIU/ml for HepB, ≥0.15 µg/ml for PRP (i.e. Hib epitope) and 230 
mIU/ml for measles (Plotkin, 2010). Surrogate of immune response to pertussis was defined as ≥4-
101 
 
fold increase in antibody concentration from pre- to post-vaccination for PT and FHA (Plotkin, 
2010). Alternate antibody threshold levels evaluated included ≥100 mIU/ml for HepB and ≥1.0 
µg/ml for PRP, which may be a predictor for long-term protection (Plotkin, 2010). Pre- and post-
vaccination GMCs/GMTs and proportions with sero-protective levels or surrogates of antibody 
responses were compared using analysis of covariance or multivariate logistic regression 
considering gender, age, race (black African or mixed ancestry), CD4+ T-lymphocyte percentage, 
study center, birth weight, mother-to-child HIV-prevention antiretroviral regimen and pre-
vaccination antibody concentrations.  Pre- and post-booster vaccination GMCs/GMTs and 
proportions with sero-protective levels or surrogates of antibody responses were compared using 
analysis of covariance or multivariate logistic regression considering gender, age, race (black 
African or mixed ancestry), CD4+ T-lymphocyte percentage, study center, and post-primary 
vaccination antibody concentrations. Additional factors that may be associated with response to 
vaccination included breastfeeding, exposure to PMTCT and time since vaccination were evaluated 
by linear regression. 
 
To minimize additional confounders, the analysis was limited to children who received all three 
vaccine doses and for who blood for immunogenicity assays were collected within protocol-
specified window periods. A paired t-test was used in the comparison of pre- and post-vaccination 
CD4+ percentages. Any missing data for children in all the groups was excluded from all 
comparison analysis. For all the tests, a two-sided p-value of ≤0.05 was considered statistically 
significant.  
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CHAPTER 5 RESULTS: VALIDATION AND OPTIMIZATION OF LUMINEX ASSAY 
5.1 Results  
5.1.1 Calibration curve and its fitting algorithm 
The results for calibration curve and its fitting algorithms represented by  Figure 5.1 and Table 5.1 
which summarize R
2
, %RE and % recovery results. R
2
 was ≥0.99 for the study reference tested for 
all antibodies with %RE being less than 20% for the seven-step dilution series, which indicates high 
variability at the lower end of the plot. FHA showed high variability and decreased fit. Current 
literature and guidelines recommend an absolute value of RE of ≤20% and an r2 of >0.99 (Braggio 
et al, 1996; US FDA, 2001), which was observed for all the tested antibodies. Percentage recovery 
was set to be between 80 to 130%, from the data in Table 5.1 our reference sera performed very 
well with this regard.  
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Figure 5.1: Fitting algorithm of standard curves for observed versus expected concentration in a 
seven step 4-fold dilution of the reference sera.  
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Table 5.1: Data on percentage recovery and relative error for each standard point  
Antigen  Dilution  
Expected 
concentration (IU/ml) 
Mean obs. Conc. 
(IU/ml) CV (%) %Recovery % RE 
DT 
50 0.016 0.016 0.86 100.82 0.82 
200 0.004 0.004 2.84 98.06 -1.94 
800 0.001 0.001 8.50 103.83 3.83 
3200 0.00025 0.000268 11.90 107.17 7.17 
12800 0.00006 0.000065 10.99 107.50 7.50 
51200 0.00002 0.000022 23.26 110.00 10.00 
204800 0 0.000000  0  100 0  
TT 
50 0.184 0.193 17.74 104.65 4.65 
200 0.046 0.049 28.13 107.20 7.20 
800 0.0115 0.0111 15.68 96.37 -3.63 
3200 0.00288 0.00295 6.34 102.38 2.38 
12800 0.00072 0.00072 7.79 99.47 -0.53 
51200 0.00018 0.00019 12.89 105.56 5.56 
204800 0.00004 4.23077E-05 19.67 105.77 5.77 
PT 
50 6.7 6.7 2.21 100.63 2.21 
200 1.68 1.66 4.08 99.05 4.08 
800 0.42 0.42 6.52 100.98 6.52 
3200 0.10 0.11 13.56 105.44 13.56 
12800 0.03 0.03 12.57 102.33 12.57 
51200 0.01 0.01 18.21 95.73 18.21 
204800 0.002 0.002 27.47 93.84 27.47 
FHA 
50 2.6 2.6374 1.55 101.44 1.44 
200 0.65 0.6291 3.48 96.78 -3.22 
800 0.1625 0.1767 15.81 108.72 8.72 
3200 0.04063 0.0689 54.55 169.59 69.59 
12800 0.01016 0.0145 52.47 142.83 42.83 
105 
 
51200 0.00254 0.0288 226.08 1133.13 1033.13 
204800 0.00063 0.0331 191.17 5254.95 5154.95 
HepB 
50 2 1.975 12.80 98.77 -1.23 
200 0.5 0.500 5.71 100.06 0.06 
800 0.125 0.121 7.00 96.86 -3.14 
3200 0.03125 0.0328 5.08 105.06 5.06 
12800 0.00781 0.0077 6.97 98.44 -1.56 
51200 0.00195 0.0020 12.75 103.79 3.79 
204800 0.00049 0.00047 25.18 94.98 -5.02 
Footnote: DT: diphtheria-toxoid; TT: tetanus-toxoid; PT: pertussis toxin; FHA: filamentous haemaglutanin; HepB: hepatitis B; %RE: 
percentage relative error. 
 
5.2 Comparison of Luminex assay with ELISA  
Twenty five serum samples were assessed for antibody concentrations to the study protein antigens 
using both methods and were subjected to linear regression analysis and the correlation coefficients 
were determined as shown in Figure 5.2. The correlation coefficients for DT, TT, PT, FHA and 
HepB were 0.90, 0.93, 0.97, 0.89 and 0.72 respectively.  
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Figure 5.2: Comparison of the IgG concentrations against DT, TT, PT, FHA and HepB 
determined by Luminex assay and monoplex ELISA. Sera from 25 patients were quantitated by 
both Luminex and ELISA methods. Antibody concentrations for all five protein antigens were 
reported in either IU/ml (DT, TT, PT and FHA) or mIU/ml (HepB). 
 
The results were further analysed by determining frequencies of agreement with respect to a cut-off 
of the sero-protective concentration for each antigen; Table 5.2. There was <8% non agreement 
observed for DT, TT, and HepB between ELISA and Luminex.    
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Table 5.2: Frequency table of agreement between the Luminex assay and ELISA (antibody 
concentration classified as above or below sero-protective titers for DT (≥0.1IU/ml), TT 
(≥0.1IU/ml) and HepB (≥10mIU/ml). While PT was classified by antibody concentration 
≥20IU/ml and FHA was classified by antibody concentration ≥2IU/ml). 
Antibody Luminex and 
ELISA ≥ sero-
protection 
Luminex and ELISA 
<sero-protection 
Luminex ≤sero-
protection and 
ELISA >sero-
protection 
Luminex >sero-
protection and 
ELISA ≤sero-
protection 
DT 23 (92%) 0 (0%) 0 (0%) 2 (8%) 
TT 18 (72%) 5 (20%) 2 (8%) 0 (0%) 
PT 20 (80%) 5 (20%) 0 (0%) 0 (0%) 
FHA 25 (100%) 0 (0%) 0 (0%) 0 (0%) 
HepB 9 (36%) 14 (56%) 0 (0%) 2 (8%) 
Footnote: DT: diphtheria-toxoid; TT: tetanus-toxoid; PT: pertussis toxin; FHA: filamentous haemaglutanin; HepB: hepatitis B; 
ELISA: enzyme immunoassay. 
 
We then studied the difference between ELISA and Luminex methods for the detection of 
antibodies; Figure 4.3. A difference of 0.022 [95% CI: -0.40-0.44] for antibody to DT; TT was 0.09 
[95% CI: -0.67-0.84]; PT was -4.32 [95% CI: -39.93-31.29]; FHA was 4.44 [95% CI: -89.23-98.10] 
and HepB was 10.31 [95% CI: -57.70-78.31] between ELISA and Luminex methods by Bland-
Altman regression test.  
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Figure 5.3: Difference between Luminex assay and ELISA using the Bland-Altman plot. The 
closer the difference is to zero the more alike the methods are; DT: diphtheria-toxoid; TT: 
tetanus-toxoid; PT: pertussis toxin; FHA: filamentous haemaglutanin; HepB: hepatitis B 
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5.3 Competitive inhibition studies of Luminex assay 
The addition of  homologous antigen to the serum at saturated concentrations of 30 μg/ml for DT, 
TT , PT, FHA and 14 µg/ml for HepB, resulted in inhibition of >90% of signal compared to the 
control sample for all tested antigens with the Luminex assay; Figure 5.4.  
 
 
Figure 5.4: Specificity assay: Percentage inhibition on addition to homologous antigen inhibitor. 
DT=93%, TT= 99%, PT=91%, FHA=85% and HepB= 91% for homologous inhibition per 
antigen. 
 
Non-heterologous antigen was added to the samples, inhibition was <15% for all other antigens 
except HepB and FHA which resulted in 16.88% non-homologous inhibition; Figure 5.4.  
 
5.4 Sensitivity of Luminex and ELISA serum IgG  
For the ELISAs the manufacturer results were reported as indicated in the package insert of the kit. 
The calculated LLOQ and the fold difference between assays are shown in Table 5.3.  The 
Multiplex assays were 4-, 9-fold more sensitive than ELISA for DT and TT respectively. While a 
decreased sensitivity of 0.25-fold was observed for PT, FHA and HepB. No upper limit of detection 
was determined since all samples above the measurable range were re-diluted to fall within the 
measurable range of the standard curve of the reference serum.  
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Table 5.3: Lower limit of quantitation of antigen specific IgG antibodies against DT, TT, PT, 
FHA and HepB antigens determined by ELISA and Multiplex methods, and the –fold difference 
in sensitivity of Multiplex over ELISA. 
Antigen ELISA 
(
*
LLOQ) 
Multiplex  
(
*
LLOQ) 
**
Fold difference 
between assays 
DT 0.004 IU/ml 0.001 IU/ml 4 
TT 0.0093 IU/ml 0.001IU/ml 9 
HepB 2.5 mIU/ml 10.00 mIU/ml 0.25 
PT 
†
5 FDA-U 19.823 IU/ml 0.25 
FHA 1.657 IU/ml 3 
Footnote: *LLOQ: lower limit of quantification. **Fold difference between assays was calculated as ELISA LLOQ/ Multiplex 
LLOQ, † PT and FHA in the ELISA were coated together in a single well on the plate therefore the results could not be differentiated 
for each antigen. 
 
5.5 Linearity and range of assay 
Each antigen was conjugated to an individual microsphere bead region. To assess the conjugation 
and to determine the range of fluorescence generated each microsphere bead region (monoplex) and 
all five microsphere bead regions (pentaplex) were assayed with seven 4-fold dilutions of the 
reference serum. The MFI generated from the pentaplex assay were similar for all five microsphere 
bead sets and demonstrated linearity over the seven 4-fold dilution range; Figure 5.5.  
 
 
 
Figure 5.5: MFI generated from the pentaplex assay with in-house standard reference sera 
titration. 
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The possibility of interference between the different microsphere bead regions was determined by 
comparing the MFIs generated from the monoplex assay with those obtained with the pentaplex 
assay. The pentaplex was performed by combining all microsphere bead regions. Figure 5.6 shows 
the MFIs obtained from all microsphere bead regions run individually and in a pentaplex assay. 
MFIs generated by the pentaplex were comparable to that generated by the monoplex, for all 
combinations of microsphere bead regions. 
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Figure 5.6: Comparison of MFI generated from monoplex and pentaplex assays for (A) DT, (B) 
TT, (C) PT, (D) FHA and (E) HepB. 
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5.6 Multiplex assay reproducibility 
The mean percentage CV obtained from duplicates of 5 samples within a plate ranged from 7.7% 
for DT to 22.7% for TT (Table 5.4), indicating the variation within a plate was acceptable. Inter-
assay variation was determined by comparison of antibody concentrations obtained from 5 samples 
run in three separate assays. The mean percentage CV was similar to that obtained for intra-assay 
variation.  
 
Table 5.4: Intra- and inter assay variation. 
Intra-assay variation (Within Assay) 
 DT TT HepB PT 
Day 1 2.10 17.91 405.97 1355.24 
 2.20 23.02 464.87 1254.92 
 2.60 18.98 551.80 1507.75 
 2.50 21.59 537.69 1514.39 
 2.41 22.53 502.16 1421.25 
Day 2 2.36 33.18 661.78 1053.97 
 2.85 27.28 490.65 1052.52 
 2.52 37.40 635.01 1071.26 
 2.59 25.34 576.72 1249.58 
 2.59 36.97 849.83 1340.41 
Day 3 2.67 26.59 513.33 1385.15 
 2.57 23.59 540.32 1361.66 
 2.68 25.74 519.92 1432.53 
 2.61 25.13 602.70 1246.27 
 2.38 22.19 516.48 1455.76 
Mean 2.51 25.83 557.95 1313.51 
SD 0.19 5.86 103.37 155.89 
CV % 7.69 22.67 18.53 11.87 
Inter-assay variation (Between assays) 
 DT TT HepB PT 
Day 1 mean 2.36 20.81 492.50 1410.71 
Day 2 mean 2.58 32.03 642.80 1153.55 
Day 3 mean 2.58 24.65 538.55 1376.27 
Mean 2.51 25.83 557.95 1313.51 
SD 0.13 5.71 77.01 139.60 
CV % 5.13 22.09 13.80 10.63 
 
5.7 Concluding comments 
We describe for the first time the determination of anti-HBs with a multiplex platform. We also 
show that a single reference serum can be used to verify all the test antibodies. Commercially 
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available antigens with high purity were utilized to ensure antigen availability for future testing. 
The major advantage of this multiplex assay was the need for small sample volumes (5µl) 
compared to ELISAs which ranged from 10µl to 100µl of sample. In addition, reduction of assaying 
time with the multiplex assay, that required 2.5 hours to test 38 samples for all five vaccine antigens 
simultaneously; instead of the 10.5 hours required for ELISAs. Studies have demonstrated the 
ability of ELISAs to accurately determine vaccine responses (Fu et al., 2010), but with advances in 
the vaccinology fields of new vaccines with increased number of combined antigens the use of 
ELISA has become increasingly unsuitable (Pickering et al., 2002a). The optimal bead conjugation 
concentration and procedure was found to be similar to those reported for elsewhere.(van 
Gageldonk et al., 2008)  MFIs generated from all five conjugated microsphere bead regions showed 
linearity over a seven step 4-fold reference serum dilution range, the consequence of this increase in 
range was the resultant increase in accuracy, a reduction in the number of sample dilutions required 
and the ability to detect much lower antibody levels. MFI comparisons between monoplex and 
pentaplex assays allowed for determination of interference between the microsphere bead regions. 
Multiplexing did not affect specificity and sensitivity of the assay when compared to monoplexing. 
The multiplex assay was found to be reproducible, with minimal variability inter- and intra assay, 
and correlated well with commercially available ELISAs.  
  
115 
 
CHAPTER 6 RESULTS: EFFECT OF HIV-1 EXPOSURE AND ANTIRETROVIRAL 
TREATMENT STRATEGIES IN HIV-INFECTED CHILDREN ON IMMUNOGENICITY 
OF VACCINES DURING INFANCY 
 In this chapter, results on the effects  of HIV exposure in HIV-uninfected and timing of ART 
initiation in HIV-infected children on the kinetics of antibodies to epitopes of diphtheria-toxoid, 
tetanus-toxoid, whole cell pertussis(i.e. DTwP-HibCV) and monovalent HBV prior to and one-
month following the primary three-dose series of vaccines were evaluated (The published paper is 
attached in Appendix 2). In addition, independent factors that may be associated with response to 
vaccination will be presented.  
 
6.1 Results 
6.1.1 Study population and demographic information  
Briefly, four groups of children aged 6-12 weeks were enrolled at two South African Centers (Chris 
Hani-Baragwanath Hospital in Soweto, Johannesburg and Tygerberg Children‘s Hospital, 
Stellenbosch) from April 2005 to June 2006. HIV-unexposed children born to HIV-uninfected 
mothers (confirmed by a non-reactive HIV ELISA at enrolment); and HEU children in whom HIV-
PCR was non-reactive at enrolment. HIV-infected children participating in the ―Children with HIV 
Early Antiretroviral (CHER)‖ study were co-enrolled (Violari et al., 2008).  The latter were aged 
less than 12 weeks with CD4+ % ≥25% and randomized to deferred ART until immunological 
and/or clinically indicated (ART-Def) or immediately started on ART upon confirmation of their 
HIV-infection status (ART-Immed). Additionally, a convenience sample of HIV-infected children 
from CHER with CD4+T-lymphocyte <25% (CD4+<25%) was recruited. The first-line ART 
regimen in CHER included zidovudine, lamivudine and lopinavir-ritonavir. Following an interim 
analysis of the CHER study in which HIV disease progression to AIDS or death was greater in 
ART-Def compared to ART-Immed children, the Data Safety and Monitoring Board recommended 
halting recruitment to the ART-Def group and that all children in this group be evaluated whether 
they required ART to be initiated (Violari et al., 2008). Participants were scheduled to receive three 
doses of combined DTwP-HibCV (CombAct-Hib®, Sanofi Pastuer, France) and monovalent 
recombinant HBV (HerberBiotec S.A., Cuba)  at approximately 6, 10 and 14  weeks of age with a 
4-6 week interval between doses. Both, DTwP-HibCV and HBV were administered at separate sites 
in the left arm, PCV (Prevnar-7®; Wyeth Vaccines and Pediatrics, Philadelphia, US) in the right 
arm and trivalent oral polio vaccine (POLIORAL-trivalEnt®, Novartis Vaccines and Diagnostics, 
Srl, Italy) orally. Values for unknown test sera were generated from a standard curve of MFI against 
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expected IgG concentration for the in-house reference sera and converted to either IU/ml or 
mIU/ml. The LLOQ were 0.001 IU/ml for antibody to diphtheria-toxoid and tetanus-toxoid, 20 
IU/ml for antibody to pertussis toxoid, 2 IU/ml for FHA and 10 mIU/ml for HepB. These values 
were regarded as sero-positive thresholds. Samples with a concentration below the LLOQ were 
assigned a concentration of half the LLOQ when calculating GMC. The thresholds for correlates of 
sero-protection were defined as antibody concentrations greater or equal to 0.01IU/ml and 0.1 
IU/ml for DT, 0.1 IU/ml for TT, 10 mIU/ml for HepB (Plotkin, 2010). Surrogate of immune 
response to pertussis was defined as ≥4-fold increase in antibody concentration from pre- to post-
vaccination for PT and FHA.(Plotkin, 2010) Alternate antibody threshold level evaluated was 
≥100mIU/ml for HepB, which may be a predictor for long-term protection (Plotkin, 2010). 
 
 Samples from 493 (85.3%) of 578 children in the parent-study (CIPRA-4) were available as shown 
in Table 6.1. The main reasons for unavailability of samples post-vaccination were the high 
mortality rate in ART-Def children as reported (Violari et al., 2008) and time-points undertaken 
beyond the protocol-defined window-period; Figure 6.1. The mean age at pre-vaccination (±SD) 
was 7.3 (SD 1.3) weeks and 19.5 (SD 1.3) weeks at post-vaccination being similar between groups; 
Table 1. Forty six percent were male and 90.7% were of black-African descent; Table 1. All 
children in the ART-Immed and CD4+<25% groups were initiated on ART within four days prior 
to the first DTwP-HibCV/HBV dose. Thirteen (16.9%) ART-Def children were initiated on ART at 
a median of 40 days following the first vaccine-doses (Madhi et al., 2010). The mean CD4+-
lymphocyte percentages were 35.1% in ART-Immed, 37.5% in ART-Def and 22.0% in CD4+<25% 
group pre-vaccination; and 40.7% (p<0.001), 30.1% (p<0.001) and 27.5% (p=0.06) one-month post 
third-dose in the respective groups; Table 6.1. 
 
 
 
 
117 
 
 
Table 6.1: Demographic and baseline features of participants included in the analysis evaluating the immunogenicity of a three doses primary 
series of diphtheria toxoid-tetanus toxoid- whole cell pertussis and Haemophilus influenzae type-b conjugate vaccine and hepatitis B vaccine. 
Variable            Total HIV-
unexposed
a 
HEU
b 
ART-Immed
c 
ART-Def
d 
CD4+<25%
e 
Total subjects enrolled 
 578 124 125  210 105 14 
Number included in analysis             493 114 120 172  77 10 
Male sex (%)           227 (46.1)   61 (53.5)  65 (54.2)   68 (39.5) 29 (37.7)   4  (40.0) 
Total Race: Black African (%)           447 (90.7)   86 (75.4) 112 (93.3)  164 (95.3) 76 (98.7)   9  (90.0) 
                 Mixed ancestry (%)             46  ( 9.3)   28 (24.6)      8 ( 6.7)     8  ( 4.7)   1 ( 1.3)   1  (10.0) 
Mean age (Standard deviation; SD) at time of vaccine administration in weeks  
Dose-1 (SD)
f
                7.3 (1.3)   6.7 (1.3)     7.4 (1.0)  7.5 (1.2)    7.3 (1.2)  8.6 (1.6) 
          Dose-2            11.4 (1.3) 11.1 (1.2) 11.4 (1.1) 11.5 (1.4)   11.4 (1.4) 12.7 (1.8) 
          Dose-3            15.4 (1.3) 15.2 (1.3) 15.5 (1.2) 15.5 (1.4)   15.4 (1.3) 16.6 (1.7) 
Post dose-3 (SD) 
g
             19.5 (1.3)    19.2 (1.2)    19.5 (1.0) 19.6 (1.3)    19.6 (1.5) 20.6  (1.6) 
9 months of age (SD)           39.3 (1.1)    38.8 (0.8)   39.2 (0.8) 39.4 (1.1)    39.9 (1.2) 40.5 (1.3) 
Pre-vaccination median HIV-1 Viral 
load copies/ml (range) 
 
 
 
 
 
Not done 
>750000 (394500 to 
>750000) 
>750000 (448000 to 
>750000) 
>750000 (>750000 to 
>750000) 
Pre-vaccination median CD4+ 
lymphocyte Count (IQR)
h
 
2070 
(1572 to 2070) 
2083 
(1654 to 2083) 
1568 
(1194 to 1568) 
Pre-vaccination mean CD4+
 
lymphocyte % (SD) 
35.1 (8.3) 37.5(9.2) 22(6.0) 
One-month post dose-3 median 
CD4+ lymphocyte count at (IQR)
i 
 
2230 (1713 to 2230) 1872 (1112 to 1872) 1827 
(990 to 1827) 
One-month post dose-3 mean CD4+ 
% (SD)
i
 
40.7 (9.4) 30.1 (9.0) 27.49(8.7) 
Six-months post dose-3 median 
CD4+ lymphocyte count at (IQR) 
 2201 (1604 to 2751) 1587 (1202 to 
2253.5) 
1772.5 (1284 to 1981) 
Six-months post dose-3 mean CD4+ 
% (SD) 
 40.0 (9.3) 31.4 (7.9) 32.4 (6.1) 
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Footnote: aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers. bHEU: HIV-uninfected children born to HIV-infected mothers. cART-Immed: HIV-infected children with 
CD4+ ≥25% at enrolment randomized to initiate antiretroviral treatment (ART) immediately. dART-Def: HIV-infected children with CD4+ ≥25% at enrolment randomized to deferred anti-
retroviral treatment (ART). eCD4+<25%: HIV-infected children with CD4+ cell count <25% started on ART at enrolment.  fBlood draw was undertaken just prior to and on the same day of 
DTwP-HibCV and hepatitis B vaccination where applicable (Time-point 1). gIncluded subjects who received all three doses within protocol-defined window periods and available 
immunogenicity data within 3-6 weeks after 3rd dose of diphtheria toxoid- tetanus toxoid- whole cell pertussis- Haemophilus influenzae type b conjugate vaccine (DTwP-HibCV) and hepatitis B 
(Time-point 2). hIQR: interquartile range. iInvolve 171, 77 and 10 observations in ART-Immed, ART-Def and CD4+<25% children, respectively. j13 (16.8%) of 77 ART-Def children had been 
initiated on ART at the time of the immunogenicity analysis.
Median days (range) to ART 
initiation relative to 1
st
 vaccine 
 0 (-4 to 0) 40 (7.0 to 71.0)
j
 0 days 
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Total study cohort; N = 564 
 
 
  
     
HIV-infected, early anti-retroviral 
treatment (ART-Immed)a 
N = 210 
 
 HIV-infected, delayed ART 
(ART-Def)b  
N = 105 
 
 HIV-exposed, HIV 
uninfected (HEU-)  
N = 125 
 
 HIV-unexposed,  
N = 124 
 
     
Excluded from ATPc analysis (N 
= 38; 18.1%): 
i .  Voluntary 
withdrawal = 1  
ii. Vaccines not given within 
window-period = 26 
iii. Died before ATP visit = 5 
iv. Post vaccination antibody not 
within window period = 1 
v. Did not receive all vaccines = 2  
vi. Unable/unwilling to adhere to 
protocol = 1 
vii. Loss to follow-up = 1 
viii. Other = 1 
 
 
 
 
Excluded from ATP analysis 
(N = 28; 26.7%): 
i .  Voluntary 
withdrawal = 1 
ii. Vaccines not given 
within window-period = 12 
iii. Died before ATP visit = 11 
iv. Post vaccination antibody 
not within window period = 1 
v. Did not receive all vaccines = 3 
 
 Excluded from ATP 
analysis 
(N = 5; 4.0%): 
i. Vacancies not given 
within window-period = 3 
ii. Unable/unwilling to 
adhere to protocol = 2 
 
 Excluded from ATP 
analysis 
(N = 10; 8.8%): 
i. Voluntary withdrawal = 
2  
ii. Vaccines not given 
within window-period = 6  
iii. Unable/unwilling to 
adhere to protocol= 2 
 
      
 
Included in ATP analysis; N 
= 172 (80.9%) 
 
  
Included in ATP analysis; N 
= 77 (73.3%) 
 
  
Included in ATP analysis; N 
= 120 (95.2%) 
 
  
Included in ATP analysis; N 
= 114 (91.2%) 
  
Figure 6.1: Stratification of study population and reasons for children being excluded from analysis.  
a
ART-Immed: HIV-infected children with CD4+%≥25% who were initiated on treatment upon immediately upon enrolment. 
b
ART-Def: HIV-infected 
children with CD4+%≥25% who were initiated on treatment when clinically and/or immunologically indicated. 
c
According to protocol, i.e. received all 
vaccines within window-period and also pre-vaccination and post-vaccination blood available per defined  window-period.  
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Note.  In  addition, a  convenience  sample  of  10  HIV-infected children  who had  CD4+ cell  count <25% at enrolment were also included as a fifth 
descriptive group. 
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6.1.2 Antibody responses in HIV-unexposed compared to HIV-infected children  
Compared to HIV-unexposed, ART-Immed and ART-Def children had lower antibody GMCs 
to TT (p<0.001 for both), HepB (p=0.01 for ART-Immed; p=0.002 for ART-Def) and PT 
(p<0.001 for both); Table 6.2. The proportion of children with antibodies above the sero-
protective threshold were generally similar between HIV-unexposed and the HIV-infected 
groups, except for HepB which was lower in ART-Def (39.5% vs. 49.6% in HIV-unexposed, 
p=0.03); Table 6.2.    
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Table 6.2: Antibody concentrations and proportion of children with sero-protective antibody levels prior to first dose of diphtheria toxoid- 
tetanus toxoid- whole cell pertussis- Haemophilus influenzae type b conjugate vaccine (DTPw-HibCV) and Hepatitis-B vaccines 
Footnote: aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected mothers. cp-value comparing HEU to HIV-
unexposed children; dART-Immed: HIV-infected children with CD4+ ≥25% at enrolment randomized to initiate antiretroviral treatment (ART) immediately; ep-value comparing ART-Immed 
with HIV-unexposed children; fp-value comparing ART-Immed with HEU children; gART-Def: HIV-infected children with CD4+ ≥25% at enrolment randomized to deferred ART; hp-value 
comparing ART-Def with HIV-unexposed children; ip-value comparing ART-Def with HEU children; jp-value comparing ART-Def with ART-Immed children; kCD4+<25%: HIV-infected 
children with CD4+ cell count <25% started on ART at enrolment; lGMC (95% CI): geometric mean concentration with 95% confidence interval in parenthesis; mn: Total number of samples 
available for calculating percent response. nTT=Tetanus-toxoid. oDT=diphtheria-toxoid. pHepB= antibody to Hepatitis B. rFHA=Filamentous haemagglutanin. sPT= pertussis toxin. 
Antibo
dy 
Measure HIV-
unexposed
a                         
 
n=114
 
HEU
b
                     
n=120 
p-value
c
 
ART-Immed
d
                             
n=172
 
p-
value
e 
p-
value
f 
ART-Def
g
                           
n=77 
p-
value
h
 
p-
value
i 
p-
value
j 
CD4+<25
%
k 
n=10 
TT
n GMC (95% 
CI)
l 
0.421  
(0.309-0.573) 
0.219  
(0.181-0.265) 
0.001 0.086  
(0.071-0.105) 
<0.001 <0.001 0.074  
(0.054-0.103) 
<0.001 <0.001 0.34 0.100  
(0.065-
0.155) 
 ≥0.01IU/ml  
N/n
m
 (%; 
95%CI) 
110/113  
(97.4; 
92.5-99.1) 
 
117/118 
(99.2;  
95.4-100) 
0.07 
 
164/168  
(97.6;  
94.0-99.1) 
0.12 
 
0.41 
 
72/76 
(94.8;  
87.5-97.9) 
0.48 
 
0.15 
 
0.45 
 
10  
(100; 
72.3-100) 
DT
o GMC (95% 
CI) 
0.078  
(0.069-0.088) 
0.136  
(0.115-0.161) 
<0.001 0.085  
(0.074-0.097) 
0.26 <0.001 0.076  
(0.064-0.089) 
0.08 <0.001 0.54 0.127  
(0.088-
0.184) 
 ≥0.1 IU/ml 
N/n (%; 
95%CI) 
33/113  
(29.2;               
21.6-38.2) 
72/118  
(61.0; 
52.0-69.3) 
<0.001 67/168  
(39.9;  
32.8-47.4) 
0.86 
 
<0.001 26 /76 
(34.2;  
24.5-45.4) 
0.45 
 
<0.001 0.76 8  
(80.0;  
49.0-94.3) 
HepB
p GMC 
(95% CI)  
 
7.74  
(5.25-11.42) 
29.77  
(21.05-42.11) 
<0.001 5.81  
(4.12-8.17) 
0.01 <0.001 4.26  
(2.70-6.73) 
0.002 <0.001 0.38 396.98  
(152.6-
1032.9) 
 ≥10 mIU/ml 
N/n (%; 
95%CI) 
56/113  
(49.6;  
41.0-59.0) 
95/118 
(80.5;  
72.5-86.7) 
<0.001 77/168  
(45.8;  
38.9-53.4) 
0.11 
 
<0.001 30/76 
(39.5;  
29.3-50.7) 
0.03 
 
<0.001 0.47 10  
(100;  
72.3-100) 
FHA
q GMC IU/ml 
(95% CI) 
20.09  
(17.91-22.55)   
35.08  
(29.65-41.50) 
<0.001 22.88  
(20.30-25.79) 
0.52 <0.001 20.83  
(17.99-24.12) 
0.23 <0.001 0.63 30.17  
(21.39-
42.54) 
PT
r GMC IU/ml 
(95% CI) 
40.65  
(33.83-48.84) 
31.70  
(27.67-36.30) 
0.06 17.67  
(15.57-20.04) 
<0.001 <0.001 16.29  
(13.63-19.46) 
<0.001 <0.001 0.53 26.76  
(16.56-
43.26) 
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Compared to HIV-unexposed, lower post-vaccination GMCs were observed in the ART-
Immed and ART-Def groups for TT (p<0.001 for both) and HepB (p<0.001 for both); Table 
6.3. Also, lower GMCs were observed in ART-Immed children to DT (p=0.001) and FHA 
(p<0.001), as well as for PT in ART-Def children (p<0.001) compared to HIV-unexposed 
children, Table 6.3.  
 
In HIV-unexposed, despite higher post-vaccination antibody GMCs to some epitopes, the 
proportion with sero-protective levels of antibody were similar for TT (82.7% to 100%), DT 
at ≥0.01IU/ml (100%) and HepB (>84%) compared to ART-Immed and ART-Def children; 
Table 6.3. Also, a similar proportion in each group had antibody above ≥100mIU/ml for 
HepB (>84%) and DT ≥0.1IU/ml (76.9% to 100%); Table 6.3. Sero-conversion rates 
associated with pertussis vaccination, however, were higher in HIV-unexposed (38.2%) for 
FHA compared to ART-Immed children (20.6%, p=0.008), and lower for PT in HIV-
unexposed (39.1%) compared to ART-Def (51.4%, p=0.02) children, Table 6.3. 
 
Antibody to HepB was lower in ART-Def (601.99 mIU/ml) compared to HIV-unexposed 
(1571.17 mIU/ml; p<0.001); Table 6.4. Similar proportions between HIV-unexposed and 
HIV-infected children were observed for all study vaccine epitopes 4 months post 
vaccination. 
 
124 
 
Table 6.3: Antibody concentrations and proportion of children with sero-protective antibody levels following primary series of three doses of 
diphtheria toxoid- tetanus toxoid- whole cell pertussis- Haemophilus influenzae type b conjugate vaccine and hepatitis B vaccines.  
Antibody Measure 
HIV-
unexposed
a 
n= 114
 
HEU
b
                     
n= 120 
p-
value
c
 
ART-Immed
d
                             
n= 169
 
p-
value
e 
p-
value
f 
ART-Def
g
                           
n= 75 
p-
value
h
 
p-
valuei 
p-
value
j 
 
CD4+<2
5%
k 
n=9 
TT
o
 GMC  
(95% CI)
l
 
0.952  
(0.849-
1.068) 
0.762  
(0.679-
0.854) 
0.11 0.405 
(0.343-0.478) 
<0.001 <0.001 0.323  
(0.228-
0.457) 
<0.001 <0.001 0.24 0.470  
(0.128-
1.722) 
≥0.1 IU/ml N/nm 
(%; 95%CI) 
111/111                   
(100;  
96.7-100 
 
116/118                 
(98.3;  
94.0-99.5) 
 
NE
n
 156 
(92.3;  
87.3-95.5) 
NE 0.41 62  
(82.7;  
72.6-89.6) 
NE 0.02 0.03 8  
(88.9;  
56.5-
98.0) 
DT
p
 GMC  (95% CI) 0.272 
(0.250-
0.296) 
0.372  
(0.333-
0.415) 
0.14 0.200  
(0.173-0.231) 
0.001 <0.001 0.233  
(0.194-
0.281) 
0.25 0.03 0.10 0.172  
(0.060-
0.492) 
≥0.01 IU/ml N/n 
(%; 95%CI) 
111/111            
(100;                    
96.7-100) 
 
118/118                
(100;                  
96.9-100) 
 
NE 169 
(100; 
97.8-100) 
NE NE 75  
(100;  
95.2-100) 
NE NE NE 8  
(88.9;  
56.5-
98.0) 
≥0.1 IU/ml N/n 
(%; 95%CI) 
111/111               
(100;                      
96.7-100)  
 
117/118               
(99.2;              
95.4-100) 
 
NE 130  
(76.9; 70.0-
82.6) 
NE <0.001 60  
(80.0;  
69.6-87.5) 
NE 0.001 0.65 8  
(88.9;  
56.5-
98.0) 
HepB
q
 GMC (95% CI) 2521.03  
(2249.84-
2824.92) 
2019.28 
(1740.28-
2343.00) 
0.04 924.87 
(778.28-
1099.07) 
<0.001 <0.001 536.60  
(372.97-
772.02) 
<0.001 <0.001 0.02 6545.81  
(1256.29-
34106.64
) 
≥10 mIU/ml N/n 
(%; 95%CI) 
111/111                 
(100;                 
117/118                  
(99.2;              
NE 167  
(98.8;  
NE 0.67 
 
73  
(97.3;  
NE 0.540 
 
0.52 
 
9 
(100.0;  
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Footnote: a HIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected mothers; c p-value comparing HEU with HIV-
unexposed children; dART-Immed: HIV-infected children with CD4+ ≥25% at enrolment randomized to initiate ART immediately;  e p-value comparing ART-Immed with HIV-unexposed 
children; f p-value comparing ART-Immed with HEU children; g ART-Def : HIV- infected children with CD4+ ≥25% at enrolment randomized to deferred ART; h p-value comparing ART-Def 
with HIV-unexposed children; i p-value comparing ART-Def with HEU children; j p-value comparing ART-Def to ART-Immed children; kCD4+<25%: HIV-infected children with CD4+ cell 
count <25% started on ART at enrolment ; lGMC (95% CI): geometric mean concentration with 95% confidence interval in parenthesis; mn: Total number of samples available for calculating 
percent response; nNE: not evaluable p-value is not calculable through logistic regression due to group having 100%. oTT=Tetanus toxoid. pDT=diphtheria toxoid. qHepB= Hepatitis B surface 
antigen. rFHA=Filamentous haemagglutanin. sPT= pertussis toxoid.  
96.7-100)  
 
95.4-100)  
 
95.8-99.7) 90.8-99.3) 70.1-
100.0) 
≥100 mIU/ml 
N/n (%; 95%CI) 
111/111                 
(100;                 
96.7-100)  
 
117/118               
(99.2;         
95.4-100) 
 
NE 164  
(97.0;  
93.3-98.7) 
NE 
 
0.47 
 
63  
(84.0;  
74.1-90.6) 
NE <0.001 
 
0.02 
 
8  
(88.9;  
56.5-
98.0) 
FHA
r
 GMC (95% CI) 61.24  
(53.65-
69.91) 
72.23  
(62.59-
83.36) 
0.54 40.48  
(34.09-48.08) 
<0.001 <0.001 51.05  
(40.39-
64.51) 
0.23 0.14 0.02 39.26  
(14.39-
107.06) 
4-fold increase 
N/n (%; 95%CI) 
42/110 
(38.2;               
29.7-47.5) 
 
25/116 
(21.6;                 
15.1-29.9)  
 
0.53 34/165  
(20.6;  
15.1-27.4) 
0.008 
 
0.060 
 
19/74 (25.7; 
17.1-36.7) 
0.13 
 
0.37 
 
0.52 
 
1  
(11.1;  
2.0-43.5) 
PT
s
 GMC (95% CI) 134.34  
(111.97-
161.17) 
261.30  
(221.56-
308.18) 
<0.001 138.11  
(114.47-
166.64) 
0.44 <0.001 72.55 
(52.81-
99.66) 
<0.001 <0.001 0.06 76.05  
(20.38-
283.78) 
4-fold increase  
N/n (%; 95%CI) 
43/110  
(39.1;            
30.5-48.4) 
89/116  
(76.7;              
68.3-83.5) 
<0.001 117/165    
(70.9;               
63.6-77.3) 
0.56 <0.001 38/74          
(51.4; 
40.2—62.4) 
0.02 
 
<0.001 0.14 5  
(55.6;  
26.7-
81.1) 
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Table 6.4: Antibody concentrations and proportion of children with sero-protective antibody levels six months following primary 
series of three doses of diphtheria toxoid- tetanus toxoid- whole cell pertussis- Haemophilus influenzae type b conjugate vaccine and 
hepatitis B vaccines (9-months of age).  
Antibody Measure 
HIV-
unexposed
a 
n= 106
 
HEU
b
                     
n= 112 
p-
value
c
 
ART-
Immed
d
                             
n= 163
 
p-
value
e 
p-
value
f 
ART-Def
g
                           
n= 59 
p-
value
h
 
p-
valuei 
p-
valu
e
j 
 
CD4+<2
5%
k 
n=8 
TT
p GMC  
(95% CI)
l 
0.251 
(0.216-
0.293) 
0.228 
(0.194-
0.268) 
0.58 0.148 (0.123-
0.179) 
0.66 0.23 0.158 
(0.108-
0.230) 
0.37 0.41 0.59 0.223 
(0.124-
0.399) 
 Fold-
change
m 
-1.9 (1.7-
2.2) 
-1.8 (1.5-
2.2) 
0.59 -2.0 (1.7-2.4) 0.94 0.50 -1.5 (1.0-
2.1) 
0.11 0.31 0.38 -4.5 (0.7-
26.5) 
 ≥0.1 IU/ml 
N/n
n
 (%; 
95%CI) 
103/103 
(100; 96.4-
100) 
110/111 
(99.1; 95.1-
99.8) 
NE
o 
144/146 
(98.6; 95.1-
99.6) 
NE 0.72 52/52 (100; 
93.1-100) 
NE NE NE 8/8 (100; 
67.6-
100) 
DT
q GMC  (95% 
CI) 
0.097 
(0.084-
0.112) 
0.073 
(0.053-
0.099) 
0.58 0.095 (0.084-
0.107) 
0.66 0.23 0.118 
(0.094-
0.147) 
0.37 0.41 0.59 0.101 
(0.077-
0.133) 
 Fold-change -3.5 (3.1-
4.0) 
-1.2 (0.8-
1.9) 
<0.001 -3.8 (3.2-4.5) 0.90 <0.001 -3.3 (2.5-
4.2) 
0.69 <0.001 0.48 -7.1 (1.5-
34.3) 
 ≥0.01 IU/ml 
N/n (%; 
95%CI) 
103/103 
(100; 96.4-
100) 
102/111 
(91.9; 85.3-
95.7) 
NE 146/146 
(100; 97.4-
100) 
NE NE 52/52 (100; 
93.1-100) 
NE NE NE 8/8 (100; 
67.6-
100) 
 ≥0.1 IU/ml  
N/n (%; 
95%CI) 
103/103 
(100;96.4-
100) 
101/111 
(91.0; 84.2-
95.0) 
NE 146/146 
(100;97.4-
100) 
NE NE 52/52 (100; 
93.1-100) 
NE NE NE 8/8 (100; 
67.6-
100) 
HepB
r GMC (95% 
CI) 
1571.17 
(1302.0-
1896.0) 
1422.49 
(1087.14-
1861.28) 
0.09 1099.36 
(955.89-
1264.30) 
0.83 0.84 601.99 
(430.88-
841.04) 
<0.001 0.03 0.00
1 
10941 
(5829.67
-
20533.85
) 
 Fold-change -1.2 (1.0-
1.4) 
-0.7 (0.5-
1.0) 
0.007 -1.3 (1.0-1.5) 0.60 0.001 -1.1 (.8-
1.5) 
0.97 0.04 0.31 -2.2 (0.3-
18.2) 
 ≥10 mIU/ml 
N/n (%; 
95%CI) 
103/103 
(100; 96.4-
100) 
111/111 
(100; 96.7-
100) 
NE 146/146 
(100; 97.4-
100) 
NE NE 52/52 (100; 
93.1-100) 
NE NE NE 8/8 (100; 
67.6-
100) 
 ≥100 
mIU/ml N/n 
(%; 95%CI) 
103/103 
(100; 96.4-
100) 
104/111 
(93.7; 87.6-
96.9) 
NE 144/146 
(98.6; 95.1-
99.6) 
NE 0.05 47/52 
(90.4; 79.4-
95.8) 
NE 0.74 0.05 8/8 (100; 
67.6-
100) 
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Footnote: a HIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected mothers; c p-value comparing HEU 
with HIV-unexposed children; dART-Immed: HIV-infected children with CD4+ ≥25% at enrolment randomized to initiate ART immediately;  e p-value comparing ART-Immed 
with HIV-unexposed children; f p-value comparing ART-Immed with HEU children; g ART-Def : HIV- infected children with CD4+ ≥25% at enrolment randomized to deferred 
ART; h p-value comparing ART-Def with HIV-unexposed children; i p-value comparing ART-Def with HEU children; j p-value comparing ART-Def to ART-Immed children; 
kCD4+<25%: HIV-infected children with CD4+ cell count <25% started on ART at enrolment ; lGMC (95% CI): geometric mean concentration with 95% confidence interval in 
parenthesis; m Fold-change: Fold-change in GMC between post-vaccination and 9 months of age; nn: Total number of samples available for calculating percent response; oNE: 
evaluable. p-value is not calculable through logistic regression due to group having 100%. pTT=Tetanus toxoid. qDT=diphtheria toxoid. rHepB= Hepatitis B surface antigen. 
sFHA=Filamentous haemagglutanin. tPT= pertussis toxoid.  
 
FHA
s GMC (95% 
CI) 
41.26 
(35.23-
48.31) 
45.23 
(38.88-
52.62) 
0.04 31.02 (27.41-
35.12) 
0.55 0.03 33.49 
(27.22-
41.20) 
0.01 0.07 0.78 31.48 
(14.56-
68.05) 
 Fold-change -3.1 (2.4-
4.1) 
-3.2 (2.6-
4.0) 
0.55 -5.6 (4.6-6.8) 0.002 <0.001 -4.7 (3.4-
6.5) 
0.09 0.01 0.31 -7.6 (1.6-
35.2) 
PT
t GMC (95% 
CI) 
55.16 
(46.81-
65.01) 
78.85 
(67.17-
92.55) 
0.37 59.56 (50.34-
70.47) 
0.41 0.81 51.97 
(38.20-
70.71) 
0.70 0.77 0.80 46.48 
(16.56-
130.44) 
 Fold-change -1.8 (1.5-
2.2) 
-1.4 (1.2-
1.7) 
0.04 -1.9 (1.5-2.3) 0.79 0.05 -2.1 (1.4-
3.0) 
0.54 0.02 0.95 -3.8 (0.7-
19.8) 
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6.1.3 Antibody responses in HIV-unexposed compared to HEU children 
Prior to vaccination, HEU only had lower antibody GMCs to TT (p=0.001) than HIV-unexposed 
children; but higher GMCs for DT, HepB and FHA (p<0.001 for all); Table 6.2. HEU were also 
more likely than HIV-unexposed children to have sero-protective DT (61.0% vs. 29.2%, 
p<0.001) and HepB (80.5% vs. 49.6%, p<0.001) antibody concentrations at pre-vaccination; 
Table 6.2.   
 
Antibody GMCs were similar post-vaccination between HIV-unexposed and HEU for TT, DT 
and FHA. Antibody GMCs in HIV-unexposed were, however, slightly higher for HepB (2521.0 
vs. 2019.3 mIU/ml; p=0.041) and lower for PT (134.3 vs. 261.3 IU/ml, p<0.001) than in HEU; 
Table 6.3.A high proportion (>99%) of HEU and HIV-unexposed children developed sero-
protective levels to TT, DT and HepB post-vaccination, which did not differ by group. Similarly, 
>99% of HIV-unexposed and HEU children had antibody levels ≥100mIU/ml to HepB post-
vaccination. The proportion of HIV-unexposed compared to HEU children with sero-conversion 
(i.e. ≥4 fold increase between pre-vaccination and post-vaccination) to pertussis antigens was 
similar for FHA (38.2% vs. 21.6%; p=0.53), however, against PT this proportion was lower in 
HIV-unexposed children (39.1% vs. 76.7%; p>0.001); Table 6.3.  
 
Similar GMCS were observed between HIV-unexposed and HEU, for TT, DT, HepB and PT; 
Table 6.4. Antibody to FHA was slightly higher in HEU (45.23 IU/ml) than in HIV-unexposed 
(41.26 IU/ml; p=0.04). Over 90% of study children had antibody levels above the protective 
threshold for all study epitope; Table 6.4. 
 
6.1.4 Antibody responses in HEU compared to HIV-infected children  
Pre-vaccination antibody GMCs were lower in ART-Immed and ART-Def children than HEU 
children for all epitopes (p<0.001 for all comparisons); Table 6.2. HEU children were also more 
likely to have sero-protective antibody concentrations against DT (61.0%) and HepB (80.5%) 
compared to ART-Immed (39.9%, and 45.8%, respectively) and ART-Def (34.2%, and 39.5%, 
respectively); p<0.001 for all comparisons, Table 6.2. 
Post-vaccination antibody GMCs were higher in HEU than ART-Immed or ART-Def children to 
TT, DT, HepB and PT; Table 6.3. The proportion of children with sero-protective antibody levels 
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were similar in HEU and ART-Immed children, although the latter were less likely to have 
antibody threshold ≥0.1IU/ml for DT (99.2% vs. 76.9%; p<0.001). In contrast, lower proportions 
of ART-Immed children had sero-protective antibody levels post-vaccination compared to HEU 
children to TT (82.7% vs. 98.3%; p=0.02), DT at the ≥0.1IU/ml threshold (80.0% vs. 99.2%; 
p=0.001), HepB at ≥100mIU/ml threshold (84.0% vs. 99.2%; p=0.02) and were also less likely to 
demonstrate sero-conversion to PT (51.4% vs. 76.7%; p<0.001); Table 6.3.  
 
Significant differences were observed when comparing HEU and ART-Def children for the HepB 
epitope (1422 vs. 601.99 mIU/ml; p=0.03 respectively); Table 6.4. However, the proportion of 
children with sero-protective thresholds for the vaccine epitopes was similar between HEU and 
HIV-infected children. 
 
6.1.5 Antibody responses in antiretroviral treatment-Immed compared to antiretroviral 
treatment-Def. children 
There were no differences between ART-Immed and ART-Def groups prior to vaccination in 
either GMCs or the proportion of children with sero-protective antibody levels for any vaccine 
epitope; Table 6.2. 
 
Post-immunization immune GMCs against most epitopes were similar, but higher in ART-Immed 
for HepB (p=0.017) and lower for FHA (p=0.02) than ART-Def children; Table 6.3. A similar 
proportion of ART-Immed and ART-Def children developed antibody concentrations above the 
sero-protective threshold for most vaccines, except for more ART-Immed children with TT 
antibody ≥0.1 IU/ml (92.3% vs. 82.7%; p=0.03) and HepB antibody ≥100 mIU/ml (97.0% vs. 
84.0%; p=0.02); Table 6.3. The proportion of CD4+<25% group with sero-protective levels of 
antibody and/or with sero-conversion to PT and FHA was similar to ART-Immed children. 
 
No significant differences were observed in the persistence of vaccine induced antibodies six 
months post primary vaccination, when comparing ART-Immed to ART-Def children; Table 6.4. 
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6.2 Correlation of pre-vaccination response with post-vaccination response in study 
participants  
There was correlation between pre- and post-vaccination antibody levels for TT (r=-0.35; 
p<0.001) and PT (r=0.18; p<0.001) in HIV-unexposed children. Children born to HIV-infected 
mothers showed correlation for FHA between pre- and post primary vaccination antibody 
concentrations, except for CD4+<25%; Table 6.5. In addition to this, ART-Immed children had 
correlation for DT (r=0.49; p<0.001) and HepB (r=0.45; p<0.001) epitopes; Table 6.5. No 
correlation was observed for post vaccination antibody level and CD4+ percent; Table 6.6. 
 
Table 6.5: Correlation of pre-vaccination (Time-point 1) and post-vaccination (Time-point 2) 
antibody levels. 
Group (N) TT DT PT FHA HepB 
 r
*  
(95% 
CI) 
p-
value 
r  
(95% 
CI) 
p-
value 
r  
(95% 
CI) 
p-
value 
r  
(95% 
CI) 
p-
value 
r  
(95% 
CI) 
p-
value 
HIV-
unexposed 
(104) 
-0.35  
(-0.51 
to -
0.17) 
<0.001 0.18  
(-0.02 
to 
0.37) 
0.06 -0.49 (-
0.63 to 
-0.33) 
<0.001 -0.0003 
(-0.20 
to 0.20) 
1.00 0.0003 
(-0.20 
to 
0.20) 
1.00 
HEU  
(110) 
-0.25  
(-0.43 
to -
0.06) 
0.01 0.30 
(0.11 
to 
0.46) 
0.002 -0.15 (-
0.34 to 
0.04) 
0.11 0.27 
(0.08 to 
0.44) 
0.004 -0.09 
(-0.27 
to 
0.11) 
0.37 
ART-Def 
(60) 
-0.22 
 (-0.46 
to 
0.04) 
0.08 0.66 
(0.48 
to 
0.78) 
<0.001 0.03 (-
0.23 to 
0.29) 
0.83 0.63 
(0.45 to 
0.77) 
<0.001 0.24 (-
0.02 to 
0.47) 
0.06 
ART-
Immed 
(147) 
0.04  
(-0.13 
to 
0.20) 
0.66 0.49 
(0.36 
to 
0.61) 
<0.001 0.004 
(-0.16 
to 
0.17) 
0.96 0.53 
(0.40 to 
0.64) 
<0.001 0.45 
(0.28 
to 
0.55) 
<0.001 
CD4+<25% 
(8) 
-0.04 
 (-0.73 
to 
0.68) 
0.92 -0.18  
(-0.78 
to 
0.06) 
0.68 -0.23 (-
0.81 to 
0.56) 
0.58 0.19 (-
0.59 to 
0.79) 
0.65 -0.36 
(-0.85 
to 
0.47) 
0.39 
Footnote: TT: tetanus-toxoid; DT: diphtheria-toxoid; PT: pertussis toxin; FHA: filamentous haemolglutanin; HepB: hepatitis B 
vaccine; r*= Spearman's correlation coefficient; HIV-unexposed: HIV-unexposed uninfected; HEU: HIV-exposed uninfected; 
ART-Def: HIV-infected on deferred ART; ART-Immed: HIV-infected on immediate ART; CD4+<25%: HIV-infected on 
immediate ART with CD4+= % <25%. 
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Table 6.6: Correlation of CD4+% with response to primary vaccination (Time-point 2) 
Group (N) TT DT PT FHA HepB 
 r
*  
(95% 
CI) 
p-
value 
r  
(95% 
CI)  
p-
value 
r  
(95% 
CI) 
p-
value 
r  
(95% 
CI) 
p-
value 
r  
(95% 
CI) 
p-value 
ART-Def 
(60) 
-0.08  
(-0.33 
to 0.19) 
0.56 -0.13  
(-0.38 
to 
0.14) 
0.32 0.18  
(-0.09 
to 
0.42) 
0.18 -0.11  
(-0.36 
to 
0.16) 
0.42 0.13  
(-0.14 
to 
0.38) 
0.32 
ART-
Immed 
(150) 
-0.01  
(-0.17 
to 0.16) 
0.92 -0.02  
(-0.19 
to 
0.14) 
0.80 0.15  
(-0.02 
to 
0.31) 
0.07 -0.04  
(-0.21 
to 
0.12) 
0.59 -0.02  
(-0.19 
to 
0.14) 
0.76 
CD4+<25
% (8) 
0.13  
(-0.63 
to 0.76) 
0.76 0.18  
(-0.60 
to 
0.79) 
0.66 0.56  
(-0.24 
to 
0.91) 
0.15 -0.01  
(-0.71 
to 
0.70) 
0.97 -0.13  
(-0.76 
to 
0.63) 
0.76 
 Footnote: TT: tetanus-toxoid; DT: diphtheria-toxoid; PT: pertussis toxin; FHA: filamentous haemolglutanin; HepB: hepatitis B 
vaccine; r*= Spearman‘s correlation coefficient; ART-Def: HIV-infected on deferred ART; ART-Immed: HIV-infected on 
immediate ART; CD4+<25%: HIV-infected on immediate ART with CD4+ % <25%. 
 
6.3 Factors associated with response to vaccination at following primary vaccination for all 
study children 
In multiple linear regression model for factors associated with magnitude of specific antibody 
response to vaccination, breastfeeding, study center, baseline antibody titer and combined 
AZT/NVP for the prevention of mother to child transmission in HIV-exposed children, birth 
weight and CD4+% were found to be associated with response and were also found to be vaccine 
epitope specific; Table 6.7. 
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Table 6.7: Independent variables and their association to response to primary vaccination at Time-point 2 for DTwP and HepB 
vaccines 
 TT DT PT FHA HepB 
Independent 
variables 
b SE P b SE P b SE P b SE P b SE P 
Gender -0.08 0.09 0.42 -0.08 0.09 0.42 -0.08 0.12 0.52 -0.13 0.08 0.08 -0.18 0.11 0.09 
Age 0.003 0.04 0.94 0.003 0.04 0.94 0.05 0.05 0.34 -0.02 0.03 0.56 -0.01 0.04 0.86 
Birth-weight 0.0002 0.0001 0.12 0.002 0.0001 0.12 0.0001 0.0001 0.55 0.0001 0.0001 0.16 0.0002 0.0001 0.04 
Race 0.27 0.18 0.13 0.27 0.18 0.13 0.01 0.23 0.96 -0.21 0.15 0.16 -0.29 0.20 0.16 
Breastfeeding 0.35 0.11 0.002 0.35 0.11 0.002 -0.04 0.14 0.76 0.16 0.09 0.07 0.59 0.12 <0.001 
Study center -1.19 0.11 0.002 -1.19 0.12 0.002 0.08 0.15 0.60 -0.86 0.09 <0.001 -0.42 0.13 0.001 
Time since 
last dose 
-0.16 0.12 0.17 -0.16 0.12 0.17 -0.14 0.16 0.37 0.06 0.10 0.55 -0.02 0.14 0.91 
Time-point 1 
antibody 
0.15 0.04 <0.001 0.15 0.04 <0.001 -0.003 0.07 0.97 0.42 0.51 <0.001 0.15 0.02 <0.001 
R
2   0.25   0.25   0.006   0.36   0.18 
Born to HIV-
infected 
mother 
TT DT PT FHA HepB 
Independent 
variables 
b SE P b SE P b SE P b SE P b SE P 
NVP -0.24 0.16 0.14 -0.24 0.16 0.14 -0.17 0.20 0.41 -0.24 0.15 0.12 -0.15 0.20 0.46 
AZT 0.33 0.41 0.43 0.33 0.42 0.43 0.63 0.52 0.23 0.13 0.39 0.75 -0.28 0.51 0.59 
Combined 
AZT/NVP 
0.77 0.17 <0.001 0.77 0.17 <0.001 -0.13 0.21 0.55 0.73 0.16 <0.001 0.27 0.21 0.20 
CD4+% 0.002 0.01 0.80 0.002 0.01 0.80 0.03 0.01 <0.001 -0.01 0.01 0.18 0.01 0.01 0.19 
R
2   0.16   0.16   0.10   0.17   0.02 
Footnote: b: unstandardized coefficient; SE: standard error; P: p-value. Independent variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 
male); Race (0 coloured, 1 Black); study center (0 Stellenbosch, 1 Soweto); Breastfeeding (0 not breastfed, 1 breastfed). TT: tetanus-toxoid; DT: diphtheria-toxoid; PT: pertussis 
toxin; FHA: filamentous haemoglutinin; HepB: hepatitis B; MV: measles virus vaccine; NVP: Neverapine; AZT: Zidovudine.   
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6.4 Factors associated with immune response to three dose schedules of DTwP and HepB 
vaccines stratified by maternal HIV status 
Being born to an HIV-infected mother had a negative association with antibody levels for TT 
(b=-0.59; SE, 0.19; p=0.002), DT (b=-0.59; SE, 0.19; p=0.002) and HepB (b=-0.53; SE, 0.21; 
p=0.01). Children from Soweto were less likely to have antibody to TT, DT, FHA and HepB; 
Table 6.8. Pre-vaccination antibody levels had a positive association with presence of post 
vaccination antibody levels for TT (b=0.13; SE, 0.04; p<0.001), DT (b=0.13; SE, 0.04; p<0.001), 
FHA (b=0.42; SE, 0.05; p<0.001) and HepB (b=0.15; SE, 0.02; p<0.001); Table 6.8.  
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Table 6.8: Independent variables and their association to response to primary vaccination at Time-point 2 for DTwP and HepB 
vaccines by maternal exposure to HIV in their children 
All children TT DT PT FHA HepB 
Independent 
variables 
b SE P b SE P b SE P b SE P b SE P 
Gender -0.09 0.09 0.34 -0.09 0.09 0.34 -0.07 0.12 0.54 -0.13 0.08 0.08 -0.20 0.11 0.06 
Age 0.02 0.04 0.69 0.02 0.04 0.69 0.05 0.05 0.36 -0.02 0.03 0.59 0.005 0.04 0.92 
Birth-weight 0.0001 0.0001 0.25 0.0001 0.0001 0.25 0.0001 0.0001 0.53 0.0001 0.0001 0.18 0.0001 0.0001 0.11 
Race 0.33 0.18 0.06 0.33 0.18 0.06 0.002 0.23 0.99 -0.20 0.15 0.18 -0.22 0.21 0.29 
Breastfeeding -0.05 0.17 0.75 -0.05 0.17 0.75 0.01 0.22 0.96 0.13 0.14 0.37 0.22 0.19 0.25 
Study center -1.15 0.12 <0.001 -1.15 0.12 <0.001 0.08 0.15 0.60 -0.86 0.09 <0.001 -0.41 0.13 0.002 
Time since 
last dose 
-0.16 0.12 0.18 -0.16 0.12 0.18 -0.14 0.16 0.37 0.06 0.10 0.55 -0.02 0.14 0.90 
Time-point 1 
antibody 
0.13 0.04 <0.001 0.13 0.04 <0.001 0.001 0.07 0.98 0.42 0.05 <0.001 0.15 0.02 <0.001 
HIV status -0.59 0.19 0.002 -0.59 0.19 0.002 0.08 0.25 0.75 -0.04 0.16 0.77 -0.53 0.21 0.01 
R
2   0.26   0.26   0.01   0.36   0.20 
Footnote: b: unstandardized coefficient; SE: standard error; P: p-value. Independent variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 
male); Race (0 coloured, 1 Black); study center (0 Stellenbosch, 1 Soweto); Breastfeeding (0 not breastfed, 1 breastfed); Status (0 unexposed, 1 HIV-exposed). TT: tetanus-toxoid; 
DT: diphtheria-toxoid; PT: pertussis toxin; FHA: filamentous haemoglutinin; HepB: hepatitis B; MV: measles virus vaccine; NVP: Neverapine; AZT: Zidovudine.   
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6.5 Factors associated with immune response to three dose schedules of DTwP and HepB 
vaccines, as well as after booster dose of DTwP in children born to HIV-infected 
woman 
HIV-infection was associated with less robust immune response to primary vaccination for all 
vaccine epitopes, Table 6.9. In addition to this, children from Stellenbosch were more likely 
to have antibody to TT (b=-1.26; SE, 0.40; p=0.002), DT (b=-1.26; SE, 0.40; p=0.002), FHA 
(b=-0.67; SE, 0.34; p=0.05) and HepB (b=-1.04; SE, 0.47; p=0.03), Table 6.9. Interestingly 
female gender was associated with less robust immune response to HepB vaccination (b=-
0.32; SE, 0.13; p=0.02), this was not seen for any of the other vaccine epitopes; Table 6.9. 
PMTCT did not have an effect on response to primary vaccination, for all children who were 
exposed to either AZT/NVP or a combination of both for a mean of 8 days (±5.7). 
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Table 6.9: Independent variables and their association to response to primary vaccination at Time-point 2 for DTwP and HepB vaccines in 
HEU and HIV-infected children 
 TT DT PT FHA HepB 
Independent 
variables 
b SE P b SE P b SE P b SE P b SE P 
Gender -0.20 0.11 0.07 -0.20 0.11 0.07 -0.24 0.14 0.09 -0.15 0.09 0.12 -0.32 0.13 0.02 
Age -0.001 0.04 0.98 -0.001 0.04 0.98 0.03 0.05 0.63 -0.02 0.04 0.58 -0.0 0.05 0.82 
Birth-weight 0.00002 0.0001 0.87 0.00002 0.0001 0.87 
-
0.00003 
0.0001 0.82 0.00005 0.0001 0.66 0.0002 0.0001 0.27 
Race 0.29 0.26 0.26 0.29 0.26 0.26 0.0004 0.32 0.99 0.09 0.21 0.68 -0.08 0.30 0.78 
Breastfeeding -0.01 0.18 0.95 -0.01 0.18 0.95 0.04 0.23 0.85 0.16 0.15 0.30 0.26 0.22 0.24 
Study center -1.26 0.40 0.002 -1.26 0.40 0.002 -0.16 0.50 0.74 -0.67 0.34 0.05 -1.04 0.47 0.03 
Time since last 
dose 
-0.04 0.14 0.75 -0.04 0.14 0.75 -0.08 0.17 0.63 0.09 0.12 0.43 0.06 0.16 0.71 
Time-point 1 
antibody 
0.09 0.05 0.07 0.09 0.05 0.07 0.004 0.09 0.38 0.40 0.06 <0.001 0.14 0.03 <0.001 
NVP -0.21 0.15 0.17 -0.21 0.15 0.17 -0.17 0.20 0.38 -0.24 0.13 0.06 -0.10 0.18 0.59 
AZT 0.45 0.44 0.31 0.45 0.44 0.31 0.98 0.55 0.08 0.36 0.37 0.32 0.04 0.52 0.93 
Combined 
AZT/NVP 
-0.27 0.41 0.51 -0.27 0.41 0.51 -0.26 0.52 0.61 0.04 0.34 0.92 -0.68 0.48 0.16 
HIV status -0.70 0.13 <0.001 -0.70 0.13 <0.001 -0.96 0.16 <0.001 -0.48 0.10 <0.001 -0.64 0.15 <0.001 
R
2   0.29   0.29   0.13   0.39   0.21 
Footnote: b: unstandardized coefficient; SE: standard error; P: p-value. Independent variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 male); Race 
(0 coloured, 1 Black); study center (0 Stellenbosch, 1 Soweto); Breastfeeding (0 not breastfed, 1 breastfed); Status (0 unexposed, 1 HIV-exposed). TT: tetanus-toxoid; DT: diphtheria-toxoid; PT: 
pertussis toxin; FHA: filamentous haemoglutinin; HepB: hepatitis B; MV: measles virus vaccine; NVP: Neverapine; AZT: Zidovudine.   
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6.6 Factors associated with immune response to three dose schedules of DTwP and HepB 
vaccines, in HIV-infected children stratified by ART status 
Initiation of ART in the first year of life was associated with a more robust response to HepB 
only (b=0.68; SE, 0.18; p<0.001). The inverse was seen with FHA for ART-Immed children 
(b=-0.27; SE, 0.13; p=0.03); Table 6.10. Being from Stellenbosch was associated with more 
robust immune response to all vaccine epitopes, except PT which showed there is no 
association between which region the children received vaccination; Table 6.10. CD4+ 
percent was only associated with immune response to the PT epitope (b=0.03; SE, 0.01; 
p=0.003). Pre-vaccination antibody concentration was associated with FHA (b=0.53; SE, 
0.09; p<0.001) and HepB (b=0.15; SE, 0.04; p<0.001) epitopes only. 
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Table 6.10: Independent variables and their association to response to primary vaccination at Time-point 2 for DTwP and HepB vaccines in 
ART-Def and ART-Immed children 
 TT DT PT FHA HepB 
Independent 
variables 
b SE P b SE P b SE P b SE P b SE P 
Gender -0.23 0.16 0.14 -0.23 0.16 0.14 -0.01 0.19 0.95 -0.14 0.12 0.26 -0.32 0.17 0.06 
Age -0.05 0.06 0.42 -0.05 0.06 0.42 -0.04 0.07 0.62 -0.08 0.05 0.11 -0.10 0.07 0.14 
Birth-weight 0.0001 0.002 0.68 0.0001 0.002 0.68 
-
0.00004 
0.0002 0.86 0.0001 0.0001 0.28 0.0002 0.0002 0.19 
Race 0.43 0.38 0.27 0.43 0.38 0.27 0.18 0.46 0.70 0.01 0.29 0.98 0.06 0.42 0.88 
Breastfeeding 0.02 0.25 0.93 0.02 0.25 0.93 0.23 0.29 0.43 0.10 0.19 0.60 0.43 0.27 0.12 
Study center -1.51 0.19 <0.001 -1.51 0.19 <0.001 -0.39 0.23 0.08 -1.16 0.14 <0.001 -0.76 0.20 <0.001 
Time since last 
dose 
-0.07 0.19 0.72 -0.07 0.19 0.72 -0.06 0.22 0.79 0.09 0.14 0.52 0.10 0.20 0.59 
Time-point 1 
antibody 
0.10 0.06 0.11 0.10 0.06 0.11 -0.03 0.12 0.78 0.53 0.09 <0.001 0.15 0.04 <0.001 
CD4+% 0.002 0.01 0.80 0.002 0.01 0.80 0.03 0.01 0.003 
-
0.0003 
0.01 0.96 -0.004 0.01 0.68 
ART status 0.22 0.16 0.19 0.22 0.16 0.19 0.35 0.20 0.07 -0.27 0.13 0.03 0.68 0.18 <0.001 
R
2   0.28   0.28   0.10   0.47    
Footnote: b: unstandardized coefficient; SE: standard error; P: p-value. Independent variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 male); Race 
(0 coloured, 1 Black); study center (0 Stellenbosch, 1 Soweto); Breastfeeding (0 not breastfed, 1 breastfed); ART status (0 ART-Def, 1 ART-Immed). TT: tetanus-toxoid; DT: diphtheria-toxoid; 
PT: pertussis toxin; FHA: filamentous haemoglutinin; HepB: hepatitis B.   
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6.7 Sensitivity Analysis 
Because of the imbalance of race in the population among the different groups, a sensitivity 
analysis was performed restricting the analysis to black African participants. P-values were 
similar to those when including mixed race participants suggesting that any differences can be 
attributed to HIV exposure and not race (data not shown).     
 
6.8 Concluding comments 
HEU children were not at increased susceptibility to most of the studied vaccine-preventable 
diseases by 6-weeks of age, suggesting similar acquisition of antibody from their mothers in our 
study. Furthermore, the immune responses in HEU were similar to HIV-unexposed children post-
vaccination. Although HIV-infected children had lower GMCs post-vaccination, including to TT 
and HepB irrespective of timing of ART initiation, the proportion with sero-protective antibody 
concentrations post-vaccination were similar and timing of ART initiation generally did not 
affect immune responses between HIV-infected groups. The results indicate that vaccination of 
HEU and HIV-infected children initiated on early-ART with DTwP/HBV would provide similar 
immunity to the targeted vaccine-preventable disease compared with HIV-unexposed children. 
Short-term persistence of vaccine induced antibodies 4 months post vaccination, showed that 
over 90% of children maintained sero-protective antibody concentrations. However, persistence 
of sero-protective antibody concentrations (>4 months) and anamnestic responses to the studied 
vaccines among HEU and HIV-infected children initiated on early-ART needs to be investigated. 
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CHAPTER 7 RESULTS: ANTIBODY PERSISTENCE AND BOOSTER RESPONSE TO 
DIPHTHERIA-TETANUS-PERTUSSIS AND HEPATITIS B VACCINATION AMONG 
HIV-UNINFECTED AND HIV-INFECTED CHILDREN INITIATED ON EARLY 
ANTIRETROVIRAL THERAPY 
Anamnestic immune response induced by vaccination is crucial for long-term protection against 
disease (Plotkin, 2010). HIV-infection is associated with aberrations in all major lymphocyte 
populations, including B-lymphocytes which are the cornerstone of humoral immune 
responses.(Letvin and Walker, 2003, Shearer et al., 2000, Pensieroso et al., 2009, Gona et al., 
2006, Palma et al., 2008, Moir and Fauci, 2009, Moir et al., 2004, Titanji et al., 2005, Titanji et 
al., 2006) In HIV-infected individuals T-lymphocyte and B-lymphocyte dysfunction may result 
in lower rates of sero-conversion post-vaccination, quicker waning  of antibody levels, and 
impaired generation or accelerated loss of antigen-specific memory B-lymphocytes.(Ghosh et al., 
2009, Moir and Fauci, 2008) This might be mitigated through advances made in the antiretroviral 
therapy (ART) of HIV-infected children.(Miller and Rathore, 2012)  Early initiation of ART has 
been associated with relatively normal development of the T-lymphocyte lineage, and with 
preservation of high numbers of functional memory B-lymphocytes in HIV-infected 
individuals.(Palma et al., 2008, Pensieroso et al., 2009, Zanchetta et al., 2008, Romiti et al., 
2001) In some studies, however, despite B-lymphocyte function being improved following ART 
initiation, memory responses remained low at least over a year after viral control was 
attained.(Iwajomo et al., 2015, Moir et al., 2008, Moir et al., 2010, Lederman et al., 1998, 
Soriano-Sarabia et al., 2005, Bekker et al., 2006) We and others have previously reported that 
early initiation of ART induced better immune responses to vaccines compared to when ART 
was deferred until there was immunological or clinical deterioration (Simani et al., 2014, Cagigi 
et al., 2012, Pensieroso et al., 2009, Madhi et al., 2010).  
 
Furthermore, immunological aberrations have also been reported in HIV-uninfected children 
born to HIV-infected women. This could be due to in-utero HIV virion particle exposure and/or 
ART-exposure (Hygino et al., 2008, Faye et al., 2007, Bunders et al., 2005, Clerici et al., 2000, 
Gesner et al., 1994, Neilsen et al., 2001), affecting lymphocyte differentiation and function 
(Hygino et al., 2008, Faye et al., 2007, Feiterna-Sperling et al., 2007, Borges-Almeida et al., 
2011, Bunders et al., 2005, Clerici et al., 2000), which might affect immune responses to 
vaccines, including anamnestic responses and persistence of antibody responses.  
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In this chapter, results on antibody persistence and responses to a booster dose of with or without 
H. influenzae type-b conjugate vaccine (DTwP-HibCV) in HIV-unexposed, HEU  and HIV-
infected children with CD4+ ≥25% previously randomized to initiate ART within 4-10 weeks of 
age (ART-Immed) or when clinically or immunologically indicated per then World Health 
Organization criteria (ART-Def). We also compared the persistence of antibody to HepB vaccine 
up to 24-months of age (The published paper is under review).  
 
7.1 Results 
7.1.1 Study population and demographic information 
This study was conducted on archived serum samples from children in whom the effects of HIV-
exposure and timing of ART initiation on immune responses to 7-valent pneumococcal conjugate 
vaccine (PCV7) had been evaluated (Madhi et al., 2010). Briefly children aged 6-12 weeks were 
enrolled in Soweto (Gauteng) and Stellenbosch (Western Cape) in South Africa from April 2005 
to June 2006. Participants included HIV-infected children with CD4+ T-lymphocyte cells ≥25% 
randomized to initiate ART immediately (ART-Immed); or when clinically (CDC Stage C or 
investigator-selected severe Stage B) and/or immunologically indicated as per then WHO 
recommendations for ART treatment (ART-Def). All HIV-infected children were co-enrolled in 
the Children with HIV Early Antiretroviral (CHER) study, in which the first line ART regimen 
used was zidovudine, lamivudine and lopinavir/ritonavir (Violari et al., 2008). Children in the 
ART-Immed group were randomized to interrupt ART if clinically and immunologically stable at 
either 12- (ART/12m) or 24-months (ART/24m) of age (Simani et al., 2013, Violari et al., 2008). 
Furthermore, children born to HIV-infected mothers who tested negative for HIV (HEU) or born 
to HIV-uninfected mothers (HIV-unexposed) were also enrolled. Details of verification of the 
HIV-infection status of the children and mothers have been described, including repeat testing of 
the HEU to confirm their HIV-uninfected status (Violari et al., 2008).  
 
Participants within each group were randomized to receive either a booster-dose of HibCV or 
PCV7 (Prevnar®, Wyeth Vaccines, NJ, USA) at 15-18-months of age. The immune responses to 
the booster dose of PCV7 and HibCV will be reported separately. Those children randomized to 
receive HibCV, received a DTwP-HibCV (CombAct-Hib
®, Sanofi Pasteur, Marcy L‘Etoile, 
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France) dose, whereas the others received DTwP (Sanofi Pasteur, Marcy L‘Etoile, France) at 15-
18-months of age. No booster vaccine was scheduled for HBV.  
 
Antibodies to DT, TT, HepB, PT and FHA were measured by an in-house Luminex-multiplex 
immunoassay as previously described (Simani et al., 2014). Antibody persistence and booster 
response were described for established putative thresholds of sero-protective levels for 
diphtheria (≥0.1IU/ml), tetanus (≥0.1IU/ml) and HepB (≥10mIU/ml) (Plotkin, 2010). Immune 
responses to pertussis vaccine were evaluated by measuring sero-conversion rates (≥4-fold 
increase from pre-booster compared to post-booster antibody concentration) for PT and FHA. 
Other predefined antibody thresholds were ≥0.01IU/ml and ≥1.0IU/ml (threshold correlated with 
long-term protection) for tetanus and diphtheria and ≥100mIU/ml for HepB (Madhi et al., 
2013b). 
 
Of the 483 children who completed the primary series vaccination (Simani et al., 2014), 465 
(96.3%) returned for booster-vaccination at 15-18 months of age; Table 1. The reasons for 
exclusion from analyses at the different study-visits are summarized in Figure 1. The mean age 
(±standard deviation) at the 3 study-visits was 15.1 months (±0.5) at the time of booster, 15.4 
months (±0.6) at the post-booster visit and 24.9 months (±0.7) at last study-visit. Forty-seven 
percent of children were male and 90% of black-African descent; Table 1. All children in the 
ART-Def group were initiated on ART at 6.4 months (±3.9) of age. In the early ART group, 81 
children interrupted treatment at 12 months of age (ART/12m) and 90 continued on ART until 
their second birthday (ART/24m) (Simani et al., 2013).  The mean CD4+ cell percentages were 
similar between the ART-Immed compared to the ART-Def groups pre-booster (31.1% vs. 
32.3%, respectively) and at 24 months of age (34.3% vs. 36.3%, respectively); Table 1.  
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Table 7.1: Demographic and baseline information of participants who had received three doses of diphtheria toxoid-tetanus toxoid-
whole cell pertussis-Haemophilus influenzae type b conjugate vaccine and hepatitis B vaccines and where available for follow-up. 
Variable Total 
HIV-
unexposed
a HEU
b 
ART-Immed
c 
ART-Def
d 
Number vaccinated  465 110 115 171 69 
Male, n (%) 218 (46.9) 59 (53.6) 63 (54.8) 71 (41.5) 25 (36.2) 
Black race, n (%) 420 (90.3) 81 (73.6) 108 (93.9) 163(95.3) 68 (98.6) 
Coloured race, n (%) 45 (9.7) 29 (26.4) 7 (6.1) 8(4.7) 1 (1.5) 
Soweto study center, n (%) 312 (67.1) 71 (64.6) 80 (69.6) 116 (67.8) 45 (65.2) 
Stellenbosch study center, n (%) 153 (32.9) 39 (35.5) 35 (30.4) 55 (32.2) 24 (34.8) 
Mean time in months between last dose 
in primary series and  booster dose (±SD) 
12.0 (0.6) 11.9 (0.4) 11.8 (0.6) 12.0 (0.4) 12.2 (0.8) 
Mean age in months (±SD)      
Pre-booster
e
 15.1 (0.5) 14.9 (0.4) 14.9 (0.6) 15.2 (0.4)
* 
15.4 (0.6)
†√ 
Post-booster
f 
15.4 (0.6) 15.2 (0.4)
 †† 
 15.4 (0.6)
 **  
 15.4 (0.5)
+ 
15.6 (0.7)
√√ 
24 months 24.9 (0.7) 24.8(0.5)
++ 
24.9 (0.6) 24.9 (0.7) 24.7 (0.9)
° 
Age in months at ART initiation [±SD]    0  6.4 (3.9) 
Booster median CD4+ T-lymphocyte 
count (IQR)
g 
 
1592 (1138 to 2166); 
n=171 
1611 (1357 to 2272);  
n=69 
Booster mean CD4+ T-lymphocyte % 
(±SD) 
31.1 (8.7); n=171 
32.3 (7.1);  
n=69 
24 months of age median CD4+ T-
lymphocyte count (IQR) 
1404 (982 to 1765); 
n=107 
1826 (1272 to 
20921828);  
n=43 
24 months of age mean CD4+ T-
lymphocyte % (±SD) 
34.3 (7.5); n=107 
36.3 (7.1);  
n=43 
Footnote: aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected mothers; cART-Immed: HIV-infected 
children with CD4+% ≥25% at enrolment who were initiated on antiretroviral therapy (ART) at enrolment; dART-Def: HIV-infected children with CD4+ ≥25% at enrolment 
randomized to deferred ART; eBlood draw was undertaken just prior to and on the same day of DTP booster vaccination. fChildren who received booster dose within protocol-
defined window periods and available immunogenicity data within 2-4 weeks after booster. gIQR: interquartile range.  
 *p-value<0.001 when comparing HIV-unexposed and HEU to ART-Immed; †p-value<0.001 when comparing HIV-unexposed and HEU to ART-Def; √ p-value=0.048 when 
comparing ART-Immed to ART-Def; **p-value=0.001 when comparing HIV-unexposed to HEU; ††p-value<0.001 when comparing ART-Immed and ART-Def to HIV-unexposed; 
√√p-value=0.03 when comparing HEU to ART-Def; +p-value=0.02 when comparing ART-Immed to ART-Def; ++p-value=0.03 when comparing HEU to HIV-unexposed; °p-
value=0.03 when comparing HEU to ART-Def 
  
144 
 
 
 
 
 
    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
     Figure 7.1: Reasons for exclusion from analyses at the different study time-points. 
Number of children who received booster dose and 
available for follow-up visits according to study group 
ART-Immed
a 
N=171 
ART-Def
b
 
N=69 
HEU
c
 
N=115 
HIV-unexposed
d
 
N=110 
Pre-booster time-point: 15.5-months of age
e 
Included in booster ATP 
N=146 
  Unavailable sample=22 
  Miss visit=3 
Included in booster ATP 
N=61 
  Unavailable sample=8 
Included in booster ATP 
N=114 
 Unavailable sample=1 
 
Included in booster ATP 
N=107 
 Unavailable sample=2 
 Other=1 
Post-booster time-point: 15.9-months of age
 
Included in post-booster ATP 
N=135 
  Unavailable sample=19 
  Miss visit=5 
  Other=10 
  Withdrawal=2 
Included in post-booster ATP 
N=52 
  Unavailable sample=7             
Miss visit=1 
  Withdrew=1 
  Other=10 
Included in post-booster 
ATP N=103 
  Miss visit=3 
  Other=8 
  Withdrawal=1 
Included in post-booster 
ATP N=100 
 Unavailable sample=2 
 Miss visit=1 
 Other=7 
24 months of age time-point: 24.9-months of age
 
Included in 24 months of 
age ATP N=122 
  Unavailable sample=21 
  Miss visit=11 
   Loss to follow up=7 
  Withdrawal=3 
  Deceased=1 
  Other=6 
 
Included in 24 months of 
age ATP N=50 
  Unavailable sample=8 
  Miss visit=4 
  Loss to follow up=1 
  Other=6 
Included in 24 months of 
age ATP N=97 
  Unavailable sample=2 
  Miss visit=7 
  Other=4 
  Withdrawal=2 
  Lost to follow up=3 
 
Included in 24 months of 
age ATP N=97 
Unavailable sample=2 
  Miss visit=8 
  Withdrawal=1  
  Other=2 
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aART-Immed: HIV-infected children with CD4+% ≥25% at enrolment who were initiated on antiretroviral therapy (ART) at enrolment; bART-Def: HIV-infected 
children with CD4+ ≥25% at enrolment randomized to deferred ART; cHEU: HIV-uninfected children born to HIV-infected mothers; dHIV-unexposed: HIV-uninfected 
children born to HIV-uninfected mothers; ePre-booster: 15.5 months of age, all children received a booster dose of DTP and no booster dose of hepatitis-B vaccine was 
administered.  
Explanatory notes: ATP: analysis time-point; Unavailable sample: sample unavailable for further testing; Lost to follow-up: due to relocation or the children stopped the 
study without reason; Withdrew: parent or guardian withdrew informed consent; Missed visit: children missed a schedule visit; Other: Unable/unwilling to adhere to 
study protocol; number of participants who left the study (excluded, missed visit, lost to follow-up, withdrawals, deceased) are represented as cumulative pre- and post-
vaccination. 
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7.1.2 Pre- and post-booster antibody kinetics to tetanus-toxoid  
Prior to the booster dose, TT IgG antibody GMC were lower among the ART-Immed group (0.08 
IU/ml; p<0.001) and similarly so in the ART-Def group (0.11 IU/ml; p=0.09) compared to HIV-
unexposed children (0.13 IU/ml); Table 7.2. Nevertheless, ≥99% of children in all groups had 
antibody levels ≥0.01IU/ml to TT pre-booster dose; Table 7.2. Compared to HIV-unexposed 
children (79%), the ART-Immed (49%; p<0.001) and ART-Def (43%; p<0.001) were, however, 
less likely to have TT antibody levels ≥0.1IU/ml.  
 
Following the booster dose of TT, IgG GMC were lower among the ART-Immed (6.6 IU/ml; 
p<0.001) and ART-Def groups (4.4 IU/ml; p<0.001) compared to HIV-unexposed children (17.9 
IU/ml). Furthermore, the ART-Def group had lower TT GMC post-booster compared to the 
ART-Immed group (p=0.01); Table 7.2. Also, the fold-increase in GMC were lower in the ART-
Def group (39.8) compared to either the HIV-unexposed (135.6; p<0.001) or the ART-Immed 
group (87.9; p=0.001). There was an association with reduced antibody response to booster dose 
of TT in children born to HIV-infected mothers (unstandardized coefficient [b] =-0.59; SE, 0.11; 
p<0.001) and older age (b=-0.21; SE, 0.08; p=0.01); however, there was a positive association 
between time lapsed pre- and post-booster, which was associated with a more robust response 
(b=0.39; SE, 0.06; p<0.001); Table 7.3. 
 
One hundred percent of HIV-infected and HIV-unexposed children, however, had antibody levels 
≥0.1IU/ml to TT post-boost. The majority of children in each group also had antibody 
concentrations ≥1.0IU/ml, although this too was lower in the ART-Def group (85%) than HIV-
unexposed (100%; p<0.001) and ART-Immed groups (96%; p=0.01).  
 
At 24 months of age, the TT antibody GMC were lower among the ART-Immed (0.79 IU/ml; 
p<0.001) and ART-Def groups (0.23 IU/ml; p<0.001) compared to HIV-unexposed children (1.7 
IU/ml); Table 7.2. There was greater fold decline in TT antibody between the post-booster visit 
and at 24 months of age in the ART-Def group (-21.3) when compared to HIV-unexposed (-10.1; 
P<0.001) and ART-Immed (-9.7; p=0.002) groups; Table 7.2. Although ≥96% of children in all 
groups retained TT antibody levels ≥0.01IU/ml, the percentage of ART-Def children (72%) with 
TT antibody levels ≥0.1IU/ml was lower than HIV-unexposed children (100%; p<0.001) or the 
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ART-Immed group (100%; p<0.001). Furthermore, TT antibody levels ≥1.0 IU/ml were less 
prevalent in the ART-Immed (36%; p<0.001) and ART-Def groups (14%; p<0.001), compared to 
HIV-unexposed children (76%); Table 7.2.  
 
Comparing the HEU to HIV-unexposed children, in general the TT antibody kinetics were 
similar pre-boost and in response to a booster dose of vaccine. The TT IgG GMC were, however, 
lower in HEU at 24 months of age (1.7 vs. 1.3 IU/ml; p=0.01), as were the percentage of HEU 
children with TT IgG ≥1.0 IU/ml (66% vs. 76%; p=0.05).  However, no differences were 
observed in the fold decrease of antibody between the post-boost and 24 month of age time-point 
between these two groups; Table 7.2. 
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Table 7.2: Percentage of children with sero-protective antibody levels and geometric mean concentrations to Tetanus-toxoid at pre-
booster, post-booster and at 24 months of age  
Threshold Time-point 
HIV-
unexposed
a 
N=107 
HEU
b  
N=114 
p-value
c ART-Immed
d
 
N=146 
p-value
e ART-Def
f
 
N=61 
p-value
g
 p-value
h 
GMC 
Pre-Booster 
0.13  
(0.12-0.15) 
0.13  
(0.12-0.15) 
0.47 
0.08  
(0.07-0.09) 
<0.001 
0.11  
(0.08-0.15) 
0.09 0.07 
Post-
booster 
17.9 
(15.8-20.4) 
15.4 
(13.3-17.9) 
0.72 
6.6  
(5.7-7.6) 
<0.001 
4.4 
(3.2-6.1) 
<0.001 0.01 
Fold-
change
i
 
135.6  
(114.1-161.0) 
116.6 
(97.5-139.3) 
0.72 
87.9  
(71.7-107.7) 
0.12 
39.8  
(23.0-68.8) 
<0.001 0.001 
24 months 
1.7  
(1.5-1.9) 
1.3 
(1.1-1.5) 
0.01 
0.79  
(0.69-0.90) 
<0.001 
0.23  
(0.15-0.35) 
<0.001 <0.001 
Fold-
change
j
 
-10.1 (8.7-
11.8) 
-11.9 (9.8-
14.5) 
0.08 -9.7 (8.0-11.7) 0.74 
-21.3 (13.8-
32.7) 
<0.001 0.002 
≥0.01  
Pre-
booster: 
n/N; % 
(95% CI) 
107/107; 100  
(97-100) 
114/114; 100  
(97-100) 
NE
k 145/146; 99  
(96-100) 
0.39 
61/61; 100  
(94-100) 
NE 0.52 
Post-
booster: 
n/N; % 
(95% CI) 
100/100; 100  
(96 -100) 
103/103; 100  
(96-100) 
NE 
135/135; 100  
(97-100) 
NE 
52/52; 100  
(93-100) 
NE NE 
24 months: 
n/N; % 
(95% CI) 
97/97; 100  
(96-100) 
97/97; 100 
(96-100) 
NE 
122/122; 100  
(97-100) 
NE 
48/50; 96  
(87-99) 
0.05 0.03 
≥0.1  
Pre-
booster: 
n/N; % 
(95% CI) 
85/107; 79  
(71-86) 
90/114; 79  
(71-85) 
0.63 
72/146; 49  
(41-57) 
<0.001 
26/61; 43  
(31-55) 
<0.001 0.38 
Post-
booster: 
n/N; % 
(95% CI) 
100/100; 100  
(96-100) 
103/103; 100  
(96-100) 
NE 
135/135; 100  
(97-100) 
NE 
52/52; 100  
(93-100) 
NE NE 
24 months: 
n/N; % 
(95% CI) 
97/97; 100  
(96-100) 
95/97; 98  
(93-99) 
0.16 
122/122; 100  
(97-100) 
NE 
36/50; 72  
(58-83) 
<0.001 <0.001 
≥1  
Pre-
booster: 
n/N; % 
0/107; 0 
1/114; 0.9  
(0.2-5) 
0.33 
1/146; 0.7  
(0.1-4) 
0.39 
1/61; 2  
(0.3-9) 
0.18 0.47 
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(95% CI) 
Post-
booster: 
n/N; % 
(95% CI) 
100/100; 100  
(96-100) 
103/103; 100  
(96-100) 
NE 
130/135; 96 
(92-98) 
0.05 
44/52; 85  
(73-92) 
<0.001 0.01 
24 months: 
n/N; % 
(95% CI) 
74/97; 76  
(67-84) 
64/97; 66  
(56-75) 
0.05 
44/122; 36  
(28-45) 
<0.001 
7/50; 14  
(7-26) 
<0.001 0.01 
Footnote: Percentage of participants with concentration above threshold (95% confidence interval) and geometric mean concentration (95% confidence interval); Units for 
geometric mean concentration (GMC) are IU/ml. aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected 
mothers; c p-value: HIV-unexposed vs. HEU; dART-Immed: HIV-infected children with CD4+ ≥25% at enrolment who were initiated on ART at enrolment; ep-value: HIV-
unexposed vs. ART-Immed; fART-Def: HIV-infected children with CD4+ ≥25% at enrolment randomized to deferred ART; gp-value: HIV-unexposed vs. ART-Def; hp-value: 
ART-Immed vs. ART-Def; iFold-change: Fold-change in GMC between pre-booster and post-booster; jFold-change: Fold-change in GMC between post-booster and 24 months of 
age; kNE: not evaluable;.  
 
Explanatory notes:  
Percentage participants: p-values were either calculated by logistic regression and adjusted for age, gender, race, study center, pre-booster antibody concentration (for post-booster 
and 24 months time-point) and CD4+ cell percentage in HIV-infected children; or by Pearson‘s chi-square test for values in italics. 
 
Geometric mean concentration: All p-values were calculated by linear regression and adjusted for age, gender, race, study center, pre-booster antibody concentration (for post-
booster and 24 months time-point) and CD4+ cell percentage in HIV-infected children. 
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Table 7.3: Independent variables and their association with response to booster vaccination for 
DTwP-HibCV and DTwP vaccines by HIV status 
 TT DT PT FHA 
Independent 
variables 
b SE P b SE P b SE P b SE P 
Gender 0.11 0.09 0.22 0.09 0.06 0.16 -0.04 0.10 0.69 
-
0.003 
0.08 0.97 
Age -0.21 0.08 0.01 
-
0.15 
0.06 0.01 -0.25 0.09 0.005 -0.09 0.07 0.23 
Race -0.40 0.17 0.02 
-
0.40 
0.12 0.001 -0.49 0.18 0.008 -0.49 0.15 0.001 
Study center 0.09 0.12 0.44 0.01 0.08 0.95 0.57 0.12 <0.001 -0.04 0.10 0.67 
Time since 
vaccination 
0.39 0.06 <0.001 0.26 0.04 <0.001 0.48 0.07 <0.001 0.34 0.06 <0.001 
Time-point 4 
antibody 
0.03 0.06 0.62 
-
0.07 
0.03 0.03 0.05 0.07 0.49 
-
0.005 
0.05 0.93 
HIV status -0.59 0.11 <0.001 0.01 0.08 0.92 -0.26 0.12 0.03 0.27 0.10 0.005 
R
2   0.23   0.16   0.22   0.14 
Footnote: b: unstandardized coefficient; SE: standard error; P: p-value. Independent variables were entered simultaneously into 
the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 Black); study center (0 Stellenbosch, 1 Soweto); 
Status (0 unexposed, 1 HIV-exposed). TT: tetanus-toxoid; DT: diphtheria-toxoid; PT: pertussis toxin; FHA: filamentous 
haemoglutinin. 
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7.1.3 Pre- and post-booster antibody kinetics to diphtheria-toxoid  
Prior to receiving the booster dose of DT, IgG antibody GMCs were similar in HIV-unexposed 
children (0.08 IU/ml); compared to either the ART-Immed (0.10 IU/ml; p=0.22) or ART-Def  
(0.12 IU/ml; p=0.05) group; Table 7.4.  The percentage of children with pre-booster DT antibody 
≥0.1IU/ml was, however, higher among the ART-Immed (54%; p=0.001) and ART-Def groups 
(57%; p=0.02) compared to HIV-unexposed children (38%); Table 7.4.  
 
Post-booster of DT, the fold increase in IgG GMC was lower in ART-Def children (17.9) than 
HIV-unexposed (49.6; p=0.001) or ART-Immed group (30.4; p=0.001). Consequently, the IgG 
GMC post-booster were lower in the ART-Def (2.3 IU/ml) compared to HIV-unexposed (3.9 
IU/ml; p=.003) or ART-Immed children (3.0 IU/ml; p<.001). Younger age (b=-0.15; SE, 0.06; 
p=0.01), coloured race (b=-0.40; SE, 0.12; p=0.001) and low pre-booster antibody level (b=-0.07; 
SE, 0.03; p=0.03) were negatively associated with immune response to the DT booster, but not so 
for HIV-infection (b=0.01; SE, 0.08; p=0.92); Table 7.3. Furthermore, shorter time since last 
time-point was associated with a more robust immune response (b=0.26; SE, 0.04; p<0.001).  
 
One hundred percent of the HIV-infected and HIV-unexposed groups had antibody levels 
≥0.1IU/ml post-booster. Furthermore, ≥93% of children in each group had DT antibody levels 
≥1IU/ml, except for the ART-Def group (85%)  which was lower compared to HIV-unexposed 
children (99%; p=0.02); Table 7.4.  
 
At 24 months of age, compared to HIV-unexposed children (0.68 IU/ml), GMC were lower in 
ART-Immed (0.46) IU/ml; p<0.001) and ART-Def (0.20 IU/ml; p<0.001) groups; Table 7.4. 
Furthermore, antibody decay (fold-decline in GMC) was more pronounced in ART-Def group (-
11.4) compared to HIV-unexposed (-5.5; p=0.001) and ART-Immed children (-6.8; p=0.008). 
Nevertheless, 100% of HIV-infected and HIV-unexposed children maintained DT antibody levels 
≥0.01IU/ml, although a lower percentage of ART-Def children (80%) had DT antibody levels 
≥0.1IU/ml compared to HIV-unexposed (99%; p=0.02) or ART-Immed children (99.2%; 
p=0.004). Furthermore, a lower percentage of children in the ART-Immed (13%, p=0.001) and 
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ART-Def groups (2%; p=0.003) had DT antibody levels ≥1.0 IU/ml compared to HIV-unexposed 
children (32%).  
 
Comparing HEU to HIV-unexposed children, the pre-boost DT IgG GMC was similar (0.07 vs. 
0.08 IU/ml, respectively). Although HEU children were less likely to have DT IgG ≥0.01IU/ml 
(92% vs. 100%; p=0.003), a greater percentage had titres ≥0.1 IU/ml (54% vs. 38%; p=0.03).  
Post-boost, HEU children had a higher fold increase in DT GMC (68.4 vs. 49.6; p=0.004), with 
resultant higher GMCs as well (4.6 vs. 3.9 IU/ml, respectively; p=.002). There was, however, no 
difference in the percentage of children between these two groups for the different analysed DT 
IgG thresholds, including >97% having a threshold of ≥1.0 IU/ml. Similarly, the GMC at 24 
months of age and percentage with antibody threshold above the correlate of protection were 
similar between these two groups, however, antibody decay was greater in HEU (-7.7) compared 
to HIV-unexposed (-5.5) children, Table 7.4.    
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Table 7.4: Percentage of children with sero-protective antibody levels and geometric mean concentration to diphtheria-toxoid at pre-
booster, post-booster and at 24 months of age  
Threshol
d 
Time-point 
HIV-
unexposed
a 
N=107 
HEU
b  
N=114 
p-value
c ART-Immed
d 
N=146 
p-value
e ART-Def
f
  
N=61 
p-value
g
 p-value
h 
GMC 
Pre-Booster 
0.08  
(0.07-0.09) 
0.07  
(0.05-0.09) 
0.07 
0.10  
(0.09-0.11) 
0.22 
0.12  
(0.10-0.15) 
0.05 0.05 
Post-
booster 
3.9 
(3.5-4.3) 
4.6 
(4.1-5.2) 
0.002 
3.0  
(2.7-3.3) 
0.15 
2.3 
(1.8-3.0) 
0.003 0.04 
Fold-
change
i 
49.6 
(41.4-59.4) 
68.4 
(48.9-95.8) 
0.004 
30.4  
(25.7-36.0) 
0.08 
17.9  
(12.2-26.2) 
0.001 0.001 
24 months 
0.68  
(0.60-0.77) 
0.61  
(0.53-0.70) 
0.37 
0.46  
(0.41-0.52) 
<0.001 
0.20  
(0.15-0.27) 
<0.001 <0.001 
Fold-
change
j -5.5 (4.8-6.4) -7.7 (6.5-9.1) 0.004 -6.8 (5.8-8.0) 0.08 -11.4 (8.3-15.7) 0.001 0.008 
≥0.01  
Pre-booster: 
n/N; % 
(95% CI) 
107/107; 100  
(97-100) 
105/114; 92.  
(86-96) 
0.003 
146/146; 100  
(97-100) 
NE
k 61/61; 100  
(94-100) 
NE NE 
Post-
booster: 
n/N; % 
(95% CI) 
100/100; 100 
(96-100) 
103/103; 100  
(96-100) 
NE 
135/135; 100  
(97-100) 
NE 
52/52; 100  
(93-100) 
NE NE 
24 months: 
n/N; % 
(95% CI) 
97/97; 100  
(96-100) 
97/97; 100  
(96-100) 
NE 
122/122; 100  
(97-100) 
NE 
50/50; 100  
(93-100) 
NE NE 
≥0.1  
Pre-booster: 
n/N; % 
(95% CI) 
41/107; 38  
(30-48) 
61/114; 54  
(44-62) 
0.03 
79/146; 54  
(46-62) 
0.001 
35/61; 57  
(45-69) 
0.02 0.95 
Post-
booster: 
n/N; % 
(95% CI) 
100/100; 100  
(96-100) 
103/103; 100  
(96-100) 
NE 
135/135; 100  
(97-100) 
NE 
52/52; 100  
(93-100) 
NE NE 
24 months: 
n/N; % 
(95% CI) 
96/97; 99  
(94-100) 
95/97; 98  
(93-99) 
0.49 
121/122; 99  
(96-100) 
0.76 
40/50; 80  
(67-89) 
0.02 0.004 
≥1  
Pre-booster: 
n/N; % 
(95% CI) 
0/107; 0 0/114; 0 NE 0/146; 0  NE 0/61; 0 NE NE 
Post-
booster: 
n/N; % 
99/100; 99  
(95-100) 
100/103; 97.1  
(92-99) 
0.45 
125/135; 93  
(87-96) 
0.08 
44/52; 85  
(73-92) 
0.02 0.14 
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(95% CI) 
24 months: 
n/N; % 
(95% CI) 
31/97; 32  
(24-42) 
26/97; 27  
(19-36) 
0.40 
16/122; 13  
(8-20) 
0.001 
1/50; 2 
(0.3-1.0) 
0.003 0.03 
Footnote: Percentage of participants with concentration above threshold (95% confidence interval) and Geometric mean concentration (95% confidence interval); Units for 
geometric mean concentration (GMC) are IU/ml. aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected 
mothers; c p-value: HIV-unexposed vs. HEU; dART-Immed: HIV-infected children with CD4+ ≥25% at enrolment who were initiated on ART at enrolment; ep-value: HIV-
unexposed vs. ART-Immed; fART-Def: HIV-infected children with CD4+ ≥25% at enrolment randomized to deferred ART; gp-value: HIV-unexposed vs. ART-Def; hp-value: 
ART-Immed vs. ART-Def; iFold-change: Fold-change in GMC between pre-booster and post-booster; jFold-change: Fold-change in GMC between post-booster and 24 months of 
age; kNE: not evaluable.  
 
Explanatory notes:  
Percentage participants: p-values were either calculated by logistic regression and adjusted for age, gender, race, study center, pre-booster antibody concentration (for post-booster 
and 24 months time-points) and CD4+ cell percentage in HIV-infected children; or by Pearson‘s chi-square test for values in italics. 
 
Geometric mean concentration: All p-values were calculated by linear regression and adjusted for age, gender, race, study center, pre-booster antibody concentration (for post-
booster and 24 months time-points) and CD4+ cell percentage in HIV-infected children. 
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7.1.4 Pre- and post-booster antibody kinetics to pertussis antigens (PT and FHA) 
Comparing the HIV-unexposed to HIV-infected children,  prior to wP booster dose of vaccine,  
FHA IgG GMC were higher in the ART-Immed (34.0 IU/ml; p=0.001) group, and a similar trend 
observed for the ART-Def group (31.9 IU/ml; p=0.09), compared to HIV-unexposed children 
(24.6 IU/ml), Pertussis toxoid IgG antibody GMCs were, however, lower in both the ART-
Immed (31.8 IU/ml; p=0.004) and ART-Def groups (27.2 IU/ml; p=0.004) compared to HIV-
unexposed children (38.3 IU/ml) ; Table 7.5.  
 
Post-booster dose of wP, the fold change in GMC to FHA was similar between the HIV-infected 
and HIV-unexposed children; however, ART-Immed (30.1; p=0.01) and ART-Def groups (27.9; 
p=.04) had lower fold increase to PT than HIV-unexposed children (56.1). Also, whilst there was 
no difference in FHA antibody GMC between the HIV-infected and HIV-unexposed groups post-
booster, PT antibody GMC were lower in the ART-Immed (951.5 IU/ml; p<0.001) and ART-Def 
groups (767.6 IU/ml; p<0.001) compared to HIV-unexposed children (2168.8 IU/ml). There was 
a positive association between children enrolled at Chris Hani Baragwanath Hospital (b=0.57; 
SE, 0.12; p<0.001) and time since last time-point (b=0.48; SE, 0.07; p<0.001) and immune 
resulting to the booster wP dose. In contrast, Age (b=-0.25; SE, 0.09; p=0.005) and Race (-0.49; 
SE, 0.18; p=0.008) were negatively association with response to the booster dose; Table 7.3. 
There were, however, no difference in the sero-conversion rates between either HIV-infected 
groups compared to HIV-unexposed children for either FHA (>88%) or PT (≥90%); Table 7.5. 
 
At 24 months of age, the ART-Def group  showed greater waning of antibody, as evident by the 
fold decrease between the post-booster and 24 month antibody concentrations, for both FHA (-
3.6 fold) and PT (-12 fold) compared to HIV-unexposed (-2.6; p=0.04 and -7.7; p=0.01, 
respectively) or ART-Immed children (-2.1; p=0.03 and -4.0; p<0.001, respectively); Table 7.5. 
This was associated with the ART-Def group having lower GMC to both FHA and PT compared 
to HIV-unexposed and ART-Immed groups (p≤0.02 for all observations) at 24 months of age; 
Table 7.5. In contrast, there was no difference in the fold decline of FHA antibody concentrations 
between the ART-Immed and HIV-unexposed groups, for whom GMCs were similar at 24 
months of age; Table 4. HIV-unexposed group (-7.7; p=0.001) however had a greater decline in 
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PT GMC compared to ART-Immed children (-4.0; p=0.001) between the post-boost and 24 
months of age. 
  
Comparing the HEU to HIV-unexposed children, although the pre-booster FHA GMC was higher 
in HEU children (34.5 vs. 24.6 IU/ml; p=0.01), this did not differ for PT. The post-booster fold 
increase in GMC was also greater in HEU than HIV-unexposed children to both FHA (23.1 vs. 
18.7 fold; p=0.01) and PT (79.7 vs. 56.1 fold; p=0.001). This was associated with higher GMCs 
in HEU compared to HIV-unexposed children to both FHA (806.2 vs. 467.6 IU/ml; p<0.001) and 
PT (3138.2 vs. 2168.8 IU/ml; p<0.001). There was, however, no difference in sero-conversion 
rates for either FHA or PT between these two groups. Although HEU showed a greater fold 
decrease in GMC between the post-booster and 24 month of age visits compared to HIV-
unexposed group for FHA (-5.8 vs. -2.6; p<0.001) and similarly so PT (-9.6 vs. -7.7; p=0.06), 
there were no difference in GMCs between the two groups at 24 months of age, Table 7.5. 
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Table 7.5: Geometric mean concentration at pre-booster, post-booster and at 24-months of age for pertussis antigens and percentage of 
children who achieved a 4-fold increase in antibody levels  
Antibody 
Threshold Time-
point 
HIV-unexposed
a
 
N=107 
HEU
b
  
N=114 
p-
value
c 
ART-Immed
d 
N=146 
p-value
e ART-Def
f  
N=61 
p-value
g
 
p-
value
h 
FHA
 
GMC 
 
Pre-
booster 
24.6 
(20.9-28.9) 
34.5 
(30.1-39.6) 
0.01 
34.0  
(30.3-38.1) 
0.001 
31.9 
(26.9-38.0) 
0.09 0.23 
Post-
booster 
467.6 
(395.8-552.4) 
806.2 
(703.2-924.2) 
<0.001 
426.0  
(371.6-488.3) 
0.71 
402.2 
(324.9-497.9) 
0.78 0.50 
Fold-
change
i 
18.7 
(14.8-23.6) 
23.1 
(19.0-28.1) 
0.01 
13.0  
(10.8-15.8) 
0.22 
12.3 
(9.1-16.6) 
0.36 >0.99 
24 
months 
170.3 
(151.2-191.8) 
140.9 
(120.1-165.4) 
0.14 
198.4  
(169.7-232.0) 
0.26 
103.9 
(70.3-153.7) 
0.02 0.001 
Fold-
change
j -2.6 (2.1-3.2) -5.8 (4.8-7.0) <0.001 -2.1 (1.7-2.6) 0.40 -3.6 (2.3-5.6) 0.04 0.03 
≥4 fold 
increase
k
: 
n/N; % 
(95% CI) 
Post-
booster 
91/100; 91  
(84-95) 
100/103; 97  
(92-99) 
0.06 
116/131; 89  
(82-93) 
0.75 
45/50; 90  
(79-96) 
0.99 0.69 
PT
 
GMC 
Pre-
booster 
38.3 
(33.9-43.3) 
39.5 
(35.3-44.3) 
0.64 
31.8  
(28.7-35.2) 
0.004 
27.2  
(21.6-34.2) 
0.004 0.38 
Post-
booster 
2168.8 
(1856.7-2533.3) 
3138.2 
(2650.6-3715.5) 
<0.001 
951.5  
(802.7-1127.8) 
<0.001 
767.6 
(594.8-990.7) 
<0.001 0.19 
Fold-
change 
56.1  
(45.6-69.0) 
79.7  
(65.7-96.7) 
0.001 
30.1  
(24.6-36.8) 
0.01 
27.9 
(18.3-42.5) 
0.04 0.89 
24 
months 
268.4  
(228.3-315.5) 
348.6  
(288.6-421.2) 
0.09 
254.6  
(225.3-287.7) 
0.54 
67.2 
(47.9-94.3) 
<0.001 <0.001 
Fold-
change 
-7.7 (6.1-9.7) -9.6 (7.6-12.2) 0.06 -4.0 (3.3-4.9) 0.001 -12.0 (8.6-16.7) 0.01 <0.001 
≥4 fold 
increase: 
n/N; % 
(95% CI) 
Post-
booster 
99/100; 99  
(95-100) 
102/103; 99  
(95-100) 
0.88 
126/131; 96  
(91-98) 
0.31 
45/50; 90  
(79-96 
0.10 0.19 
Footnote: Percentage of participants who achieved a 4-fold increase in antibody levels from pre- to post-booster (95% confidence interval) and geometric mean concentration (95% 
confidence interval); Units for geometric mean concentration (GMC) are IU/ml. aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-
uninfected children born to HIV-infected mothers; c p value: HIV-unexposed vs. HEU; dART-Immed: HIV-infected children with CD4+ ≥25% at enrolment who were initiated on 
ART at enrolment; ep value: HIV-unexposed vs. ART-Immed; fART-Def: HIV-infected children with CD4+ ≥25% at enrolment randomized to deferred ART; gp value: HIV-
unexposed vs. ART-Def; hp value: ART-Immed vs. ART-Def; iFold-change: Fold-change in GMC between pre-booster and post-booster; jFold-change: Fold-change in GMC 
between post-booster and 24 months of age; k≥4 fold increase: sero-conversion rate,  children showing 4 fold  increase in antibody concentration from pre-booster to post-booster 
dose. Explanatory notes:≥4 fold increase: p-values were calculated by logistic regression and adjusted for age, gender, race, study center, pre-booster antibody concentration (for 
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post-booster time-point) and CD4+ cell percentage in HIV-infected children; Geometric mean concentration: All p-values were calculated by linear regression and adjusted for age, 
gender, race, study center, pre-booster antibody concentration (for post-booster and 24 months time-points) and CD4+ cell percentage in HIV-infected children. 
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7.1.5 Persistence and antibody kinetics to hepatitis B 
No booster dose of HepB vaccine was scheduled in this study; hence we only measured 
persistence of antibody to HepB post-primary vaccination. At approximately 15 months of age, 
100% of children retained HepB sero-protective antibody levels ≥10mIU/ml and 94% to 100% 
had levels ≥100mIU/ml; Table 7.6. HepB GMC were, however, significantly lower in ART-
Immed (769.4 mIU/ml; p=0.001) and ART-Def groups (700.2 mIU/ml; p=0.002) compared to 
HIV-unexposed children (1198.5 mIU/ml); and similarly so in HEU children (880.1 mIU/ml; 
p=0.02); Table 7.6. All groups showed a decrease in HepB GMC antibody between the  post 
primary series GMC at 5 months of age compared to 15 months of age, except for the ART-Def 
group in whom there was a 0.8-fold increase, which was significant compared to HIV-unexposed 
group (-2.1; p<0.001). Also, the fold decrease in GMC was lower in the ART-Immed group (-1.2; 
p<0.001) than in HIV-unexposed children.   
 
At 24 months of age, the HepB antibody GMCs were lower in the ART-Immed (242.0 mIU/ml, 
p=0.001) and ART-Def (54.8 mIU/ml; p<0.001) groups compared to HIV-unexposed children 
(396.1 mIU/ml). Also, ART-Def children were less likely to maintain HepB antibody levels 
≥10mIU/ml (72%) or ≥100mIU/ml (50%) compared to HIV-unexposed or ART-Immed groups 
(≥92% -100%; P<.001 for all comparisons); Table 7.6. The decay of antibody was also more 
evident in ART-Def children with -13.3 fold change from the 15 months compared to 24 months 
of age, which was significant compared to HIV-unexposed and ART-Immed groups (-3.0 fold 
change; p<0.001 for all comparisons); Table 7.6. 
 
Comparing the HIV-unexposed to HEU children, although there was no difference in fold 
decrease of GMC between 5 and 15 months of age, HEU had lower GMC (880.1 vs. 1198.5; 
p=0.02) and were less likely to have titres >100mIU/ml (94% vs. 100%; p=0.01). These 
differences were, however, no longer evident by 24 months of age; Table 7.6.  
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Table 7.6: Percentage of children with sero-protective antibody levels and geometric mean concentration to hepatitis B at 15-18 
months and 24 months of age  
Threshold Age 
HIV-unexposed
a 
N=107 
HEU
b  
N=114 
p-value
c ART-Immed
d
 
N=146 
p-value
e ART-Def
f  
N=61 
p-value
g
 p-value
h 
GMC 
5 months
i
 
2521.0  
(2249.8-2824.9) 
2019.3 
(1740.3-2343.0) 
0.04 
924.9 
(778.3-1099.1) 
<0.001 
536.6  
(373.0-772.0) 
<0.001 0.02 
15-18 
months 
1198.5 
(1033.9-1389.4) 
880.1 
(719.2-1077.0) 
0.02 
769.4  
(654.4-904.7) 
0.001 
700.2 
(587.3-834.7) 
0.002 0.55 
Fold-
change
j
 
-2.1 (1.8-2.5) -2.3 (1.8-3.0) 0.78 -1.2 (0.9-1.5) <0.001 0.8 (0.50-1.3) <0.001 0.13 
24 months 
396.1 
(332.5-471.8) 
311.9  
(264.8-367.4) 
0.11 
242.0  
(209.9-279.1) 
0.001 
54.8 
(32.2-93.0) 
<0.001 <0.001 
Fold-
change
j
 
-3.0 (2.5-3.7) -3.0 (2.3-4.0) 0.97 -3.0 (2.4-3.7) 0.94 -13.3 (7.6-23.2) <0.001 <0.001 
≥10  
15 -18 
months: 
n/N; % 
(95% CI) 
107/107; 100  
(97-100) 
114/144; 100  
(97-100) 
NE
k 146/146; 100  
(97-100) 
NE 
61/61; 100  
(94-100) 
NE NE 
24 months: 
n/N; % 
(95% CI) 
97/97; 100  
(96-100) 
97/97; 100  
(96-100) 
NE 
122/122; 100  
(97-100) 
NE 
36/50; 72.0  
(58-83) 
<0.001 <0.001 
≥100  
15-18 
months: 
n/N; % 
(95% CI) 
107/107; 100  
(97-100) 
107/114; 94  
(88-97) 
0.01 
142/146; 97  
(93-99) 
0.08 
61/61; 100  
(94-100) 
NE 0.19 
24 months: 
n/N; % 
(95% CI) 
93/97; 96  
(90-98) 
89/97; 92  
(85-96) 
0.17 
112/122; 92 
(86-96) 
0.28 
25/50; 50  
(37-63) 
<0.001 <0.001 
Footnote: Percentage of participants with concentration above threshold and geometric mean concentration (95% confidence interval); Units for geometric mean concentration 
(GMC) are mIU/ml. aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected mothers; cp-value: HIV-
unexposed vs. HEU; dART-Immed: HIV-infected children with CD4+ ≥25% at enrolment who were initiated on ART at enrolment; ep-value: HIV-unexposed vs. ART-Immed; 
fART-Def: HIV-infected children with CD4+ ≥25% at enrolment randomized to deferred ART; gp-value: HIV-unexposed vs. ART-Def; hp-value: ART-Immed vs. ART-Def; i5 
months: results of primary vaccination and seen in table 6.3; jFold-change: Fold-change in GMC between 5 months and 15-18 months of age; jFold-change: Fold-change in GMC 
between 15-18 months and 24 months of age;  kNE: not evaluable. Explanatory notes: Percentage participants: p-values were either calculated by logistic regression and adjusted for 
age, gender, race, study center, pre-booster antibody concentration (for 24 months of age time-point) and CD4+ cell percentage in HIV-infected children or by Pearson‘s chi-square 
test for values in italics; Geometric mean concentration: All p-values were calculated by linear regression and adjusted for age, gender, race, study center, pre-booster antibody 
concentration (for 24 months of age time-point) and CD4+ cell percentage in HIV-infected children. 
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7.2 Correlation of post-primary vaccination response with post-booster response in study 
participants.  
There was a correlation between antibody level at time-point 2 (after 3 doses of primary 
vaccination) and antibody levels at Time-point 5 (2-weeks post-booster vaccination) in HEU 
children for DT (r=0.23; p=0.02) epitope; Table 7.7. 
 
Table 7.7: Correlation of primary vaccination and post-booster antibody levels in study 
participants 
Group (N) TT DT PT FHA 
 r
* 
(95% 
CI) 
p-value r (95% 
CI) 
p-value r (95% 
CI) 
p-value r (95% 
CI) 
p-value 
HIV-
unexposed 
(100) 
-0.06 (-
0.26 to 
0.14) 
0.55 -0.01  
(-0.21 to 
0.19) 
0.93 -0.04 (-
0.24 to 
0.17) 
0.72 0.01 (-
0.19 to 
0.21) 
0.92 
HEU (103) 0.18 (-
0.02 to 
0.36) 
0.08 0.23 (0.04 
to 0.41) 
0.02 0.13 (-
0.07 to 
0.32) 
0.18 0.10 (-
0.10 to 
0.29) 
0.32 
ART-Def 
(50) 
-0.23 (-
0.49 to 
0.06) 
0.10 -0.20  
(-0.46 to 
0.10) 
0.17 -0.24 (-
0.49 to 
0.05) 
0.09 -0.09 (-
0.37 to 
0.20) 
0.52 
ART-
Immed 
(131) 
-0.12 (-
0.29 to 
0.06) 
0.19 -0.11  
(-0.28 to 
0.07) 
0.21 0.05 (-
0.12 to 
0.23) 
0.55 -0.12 (-
0.29 to 
0.06) 
0.17 
Footnote: TT: tetanus-toxoid; DT: diphtheria-toxoid; PT: pertussis toxin; FHA: filamentous haemoglutanin; r*: Spearman‘s 
correlation coefficient; CI: confidence interval; HIV-unexposed: HIV-exposed uninfected; HEU: HIV-exposed uninfected; 
ART-Def: HIV-infected on deferred ART; ART-Immed: HIV-infected on immediate ART. 
 
7.3 Factors associated with response to booster vaccine in all children irrespective of HIV 
status 
Factors associated with booster responses in study children included race which showed a 
negative association for all study epitopes, and time since last visit, showed a positive association 
with all vaccine epitopes; Table 7.8. Age was negatively associated with response to TT (b=-
0.30; SE, 0.08; p<0.001); DT (b=-0.14; SE, 0.06; =0.01) and PT (b=-0.29; SE, 0.08; p=0.001); 
Table 7.8. Hepatitis B was not included in this analysis as no booster dose was administered at 
this time point. 
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Table 7.8: Independent variables and their association to response to booster vaccination at Time-
point 5 for DTwP 
 TT DT PT FHA 
Independent 
variables 
b SE P b SE P b SE P b SE P 
Gender 0.14 0.09 0.14 0.09 0.06 0.16 -0.02 0.10 0.81 -0.02 0.08 0.81 
Age -0.30 0.08 <0.001 -0.14 0.06 0.01 -0.29 0.08 0.001 -0.04 0.07 0.57 
Race -0.72 0.17 <0.001 -0.39 0.12 0.001 -0.62 0.18 <0.001 -0.37 0.15 0.01 
Study center 0.20 0.12 0.09 0.005 0.08 0.95 0.59 0.11 <0.001 -0.06 0.10 0.52 
Time since 
last dose 
0.39 0.06 <0.001 0.26 0.04 <0.001 0.48 0.07 <0.001 0.34 0.06 <0.001 
Time-point 
4 antibody 
0.09 0.06 0.12 -0.07 0.03 0.03 0.07 0.07 0.34 0.01 0.05 0.80 
R
2   0.18      0.21   0.12 
Footnote: b: unstandardized coefficient; SE: standard error; P: p-value. Independent variables were entered simultaneously into 
the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 Black); study center (0 Stellenbosch, 1 Soweto). 
TT: tetanus-toxoid; DT: diphtheria-toxoid; PT: pertussis toxin; FHA: filamentous haemoglutinin.   
 
7.4 Factors associated with immune response to booster dose of DTwP in children born to 
HIV-infected woman 
Similar to primary vaccination, HIV-infection was associated with having decreased response to 
booster vaccination, Table 7.9. In addition to HIV-infection, time since last time-point was 
strongly associated with robust responses in HEU children for all vaccine epitopes. 
 
Table 7.9: Independent variables and their association to response to booster vaccination at 
Time-point 5 for DTwP vaccines in HEU and HIV-infected children 
 TT DT PT FHA 
Independent 
variables 
b SE P b SE P b SE P b SE P 
Gender 0.04 0.10 0.74 0.08 0.08 0.33 
-
0.14 
0.10 0.16 
-
0.10 
0.09 0.27 
Age 
-
0.14 
0.09 0.10 
-
0.12 
0.07 0.08 
-
0.17 
0.08 0.05 
-
0.04 
0.07 0.57 
Race 
-
0.17 
0.25 0.49 
-
0.22 
0.18 0.24 
-
0.07 
0.23 0.78 
-
0.10 
0.21 0.65 
Study center 0.22 0.13 0.10 0.21 0.09 0.03 0.78 0.11 <0.001 0.14 0.10 0.17 
Time since 
last time-
point 
0.17 0.08 0.02 0.14 0.06 0.01 0.21 0.07 0.004 0.20 0.06 0.002 
Time-point 4 
antibody 
-
0.02 
0.07 0.74 
-
0.04 
0.04 0.32 
-
0.02 
0.07 0.82 
-
0.01 
0.06 0.92 
HIV status 
-
0.85 
0.12 <0.001 
-
0.39 
0.09 <0.001 
-
1.12 
0.11 <0.001 
-
0.54 
0.10 <0.001 
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R
2   0.24   0.18   0.43   0.19 
Footnote: b: unstandardized coefficient; SE: standard error; P: p-value. Independent variables were entered simultaneously into 
the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 Black); study center (0 Stellenbosch, 1 Soweto); 
Status (0 exposed, uninfected, 1 HIV-infected). TT: tetanus-toxoid; DT: diphtheria-toxoid; PT: pertussis toxin; FHA: filamentous 
haemoglutinin.   
 
7.5 Factors associated with immune response to booster dose of DTwP in HIV-infected 
children stratified by ART status 
Initiation of ART within the first year of life was associated with optimal responses to TT 
(b=0.40; SE, 0.13; p=0.002, DT (b=0.22; SE, 0.10; p=0.02) and PT (b=0.25; SE, 0.11; p=0.03) 
vaccine epitopes; Table 7.10. Children from Soweto were more likely to respond to the booster 
dose of DTwP than children from Stellenbosch for TT, DT and PT epitopes.  
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Table 7.10: Independent variables and their association to response to booster vaccination at Time-point 5 for DTwP vaccines in 
ART-Def and ART-Immed children 
 TT DT PT FHA 
Independent 
variables 
b SE P b SE P b SE P b SE P 
Gender -0.04 0.13 0.74 0.03 0.10 0.78 -0.16 0.12 0.17 -0.05 0.11 0.63 
Age 0.04 0.11 0.75 0.05 0.08 0.55 -0.03 0.10 0.76 0.04 0.10 0.69 
Race -0.11 0.32 0.73 -0.04 0.24 0.86 0.22 0.28 0.42 0.09 0.27 0.74 
Study center 0.78 0.17 <0.001 0.46 0.13 <0.001 1.19 0.13 <0.001 0.35 0.14 0.01 
Time since last 
time-point 
0.03 0.08 0.76 0.06 0.06 0.32 0.09 0.07 0.21 0.16 0.07 0.03 
Time-point 4 
antibody 
0.04 0.08 0.66 -0.07 0.07 0.35 -0.06 0.08 0.43 -0.03 0.08 0.68 
CD4+%
* 0.01 0.01 0.52 -0.001 0.006 0.93 0.005 0.007 0.43 -0.002 0.007 0.78 
ART status 0.40 0.13 0.002 0.22 0.10 0.02 0.25 0.11 0.03 0.07 0.11 0.52 
R
2   0.18   0.16   0.39    
Footnote: b: unstandardized coefficient; SE: standard error; P: p-value. Independent variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 
male); Race (0 coloured, 1 Black); study center (0 Stellenbosch, 1 Soweto); ART status (0 ART-Def, 1 ART-Immed). TT: tetanus-toxoid; DT: diphtheria-toxoid; PT: pertussis 
toxin; FHA: filamentous haemoglutinin.  *= CD4+ percent used in analysis was from CD4+ percent results from Time-point 4 as no CD4+ percent was measured for Time-point 5. 
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7.6 Concluding comments 
Protecting children born to HIV-infected mothers against vaccine-preventable diseases is 
important now that ART has improved life expectancy and general well being of these children. 
The results show that duration of sero-protection is shorter in HIV-infected children, especially 
those not initiated on ART prior to receiving their primary series of vaccines, if subsequently 
initiated on ART and establishing normal CD4+ counts.  With the current guidelines a large 
proportion of these children would have lost sero-protective antibody levels before the proposed 
booster dose schedules for the study vaccines. Therefore, this study shows that children on 
deferred ART require boosting for all the studied vaccine epitopes and continued monitoring of 
tetanus, diphtheria, pertussis and hepatitis B specific antibodies concentrations can guide the need 
for further booster doses to these and other vaccines.  
  
166 
 
CHAPTER 8 RESULTS: EFFECT OF IN-UTERO HIV EXPOSURE AND 
ANTIRETROVIRAL TREATMENT STRATEGIES ON MEASLES SUSCEPTIBILITY 
AND IMMUNOGENICITY OF MEASLES-VACCINE 
The aim of this chapter was to 1) evaluate the effect of in-utero HIV-exposure and timing of ART 
initiation to measles susceptibility prior to vaccination; (2). Examine the association of HIV-
exposure and different ART strategies on the kinetics of measles antibody following the primary 
and booster doses of measles vaccine. 
 
8.1 Results 
8.1.1 Study population and demographic information 
Samples were available for 528 (91.3%) of 578 children enrolled into the study from the initial 
time-point. The number of samples available at each time-point in the various groups is detailed 
in Figure 8.1. Of the 176 ART-Immed children with samples available at the time of the booster-
dose, 87 had been assigned to discontinue ART at age 12-months (ART/12m) and 89 were 
scheduled to interrupt ART at age 24-months (ART/24m). Forty-eight percent (n=251) of children 
were male and 90.9% (n=480) black-African descent. The mean age of children at each study 
time-points, at the time of primary-measles vaccination and booster-dose was similar between 
groups, Table 8.1. In addition to other childhood vaccines administered as described in chapter 6 
and 7, children received the Schwarz-strain measles vaccine (Rouvax®; Aventis, France) at age 
38-42 weeks and a booster dose at age 64-76 weeks. Measles antibody titers were analysed twice 
pre-vaccination at study enrolment (Time-point 1: age 6-12 weeks) and approximately 20-weeks 
of age (Time-point 2). Furthermore, measles-antibody was measured prior to (Time-point 4) and 
two weeks after the booster-dose (Time-point 5), as well as at approximately 24 months of age 
(Time-point 6). No blood was planned a priori immediately prior to the first dose of measles-
vaccine or anytime soon thereafter. Samples were analysed for measles specific IgG antibodies 
with a commercial indirect ELISA kit (Enzygnost, Dade Behring, Marburg, Germany) and results 
calibrated against the international reference preparation of measles antibody. Antibody titer 
levels were calculated using the -method and presented in milli–International Units per millilitre 
(mIU/ml) per manufacturer recommendation. Assays with titers <150mIU/ml were considered as 
negative (equivalent to <0.1 optical density [OD]), 150–329mIU/ml as equivocal (equivalent to 
0.1-0.2 OD) and ≥330mIU/ml as sero-protective (equivalent to >0.2 OD) per manufacturers 
criteria. For this study, sero-positivity was defined as antibody titers ≥150mIU/ml. Samples for 
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which the OD value was <0.1 were assigned a titer of half the detection limit of the assay (i.e. 75 
mIU/ml) when calculating GMTs. Due to the limited number of subjects in CD4+<25%, 
statistical comparisons were not undertaken between this and other Groups. 
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Figure 8.1: Subject follow-up during the duration of the study. 
Footnote: aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected mothers; cART-Def: HIV-infected 
children on deferred ART; dART-Immed: HIV-infected children on immediate ART; eCD4+<25%: HIV-infected children with CD4+% <25% on immediate ART; fART/12m: 
HIV-infected children who interrupted ART at 12 months of age;  gART/24m: HIV-infected children who continued ART till 24 months of age. Insufficient sample: sample 
unavailable for further testing; LFTU: loss to follow-up due to relocation or the child stopped the study without reason; Withdrawal: parent or guardian withdrew informed 
consent; Missed visit: children missed a schedule visit; number of participants who left the study (LTFU, Withdrawals, and Deceased) are represented as cumulative at each 
visit. Number in parenthesis is percentages of total enrolled. 
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Table 8.1: Demographic information for study groups at separate study time-points 
Characteristics 
HIV-
unexposed
a
 
HEU
b
 
ART-Def
c 
 
ART-Immed
d 
 
CD4+<25%
e 
 
Total 
 
Time-point 1: Enrolment N=115 N=116 N=103 N=182 N=12 N=528 
  Mean age, weeks ± SD
 
6.9 ± 1.0
 
7.3 ± 1.0 7.3 ± 1.1 7.4 ± 1.3 8.4 ± 1.5 7.3 ± 1.2 
  Mean CD4+ cell % ± SD NA NA 36.5 ± 1.1 35.4 ± 0.6 22.0 ± 1.9 NA 
Median CD4+ x10
6 
cells/ml 
(IQR) 
NA NA 2303 (2090-
2516) 
2304 (2142-2468) 1617 (1208-
2027) 
NA 
Time-point 2: Pre measles 
vaccination 
N=114 N=112 N=70 N=180 N=7 N=483 
  Mean age, weeks ± SD 19.3 ± 1.7 19.5 ± 1.1 19.7 ± 1.7 19.7 ± 1.6 20.7 ± 1.5 19.6 ± 1.6 
  Mean CD4+ cell % ± SD NA NA 29.9 ± 1.0
f 
41.6 ± 0.7
f
 
 
31.5 ± 2.1 NA 
Median CD4+ x10
6 
cells/ml 
(IQR) 
NA NA 1805 (1586-
2025)
f
 
2346 (2202-2491)
f
 2065 (1412-
2718) 
NA 
1
st
 Measles vaccine N=115 N=116 N=75 N=182 N=10 497 
  Mean age, weeks ± SD 38.9 ± 1.0 39.4 ± 1.6 40.8 ± 3.9 39.8 ± 2.0 41.5 ± 2.9 39.7 ± 2.3 
  Mean CD4+
 
cell % ± SD NA NA 31.0 ± 0.9
f 
39.1 ± 0.6
f 
30.6 ± 2.7 NA 
 ART/12m
g
 ART/24m
h 
 
 Time-point 4: Booster N=112 N=116 N=69 N=87 N=89 N=8 N=481 
  Mean age, weeks ± SD 67.2 ± 5.0 67.1 ± 2.2 69.3 ± 7.7 68.0 ± 1.9 67.8 ± 2.1 67.9 ± 1.5  67.8 ± 4.4 
Median CD4+ x10
6 
cells/ml 
(IQR) 
NA NA 1823 (1657-
1987)
i
 
1364 (1212-
1517)
i
 
1770 (1597-
1942)
i
 
1434 (872-
1995) 
NA 
Time-point 5: Post-booster N=115 N=114 N=68 N=82 N=90 N=8 N=477 
  Mean age, weeks ± SD 69.3 ± 5.4) 69.4 ± 2.8 72.1 ± 6.8
i 
69.7 ± 2.2
i 
69.3 ± 2.2
i 
69.4 ± 1.5 70.2 ± 5.4 
  Mean CD4+
 
cell % ± SD NA NA 34.5 ± 0.9 27.8 ± 0.9 36.2 ± 0.9 29.4 ± 3.4 NA 
Time-point 6: 24 months of 
age 
N=115 N=114 N=68 N=82 N=90 N=8 N=477 
  Mean age, weeks ± SD 69.3 ± 5.4 69.4 ± 2.8 72.1 ± 6.8
i 
69.7 ± 2.2
i 
69.3 ± 2.2
i 
69.4 ± 1.5 70.2 ± 5.4 
Footnote: 
a
HIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers;
 b
HEU: HIV-uninfected children born to HIV-infected mothers ; 
c
ART-
Def: HIV-infected children on deferred ART; 
d
ART-Immed: HIV-infected children on immediate ART; 
e
CD4+<25%: HIV-infected children with CD4+% 
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<25% on immediate ART; 
fp≤0.001 comparing ART-Def vs. ART-Immed; gART/12m: HIV-infected children who interrupted ART at 12 months of age;  
h
ART/24m: HIV-infected children who continued ART till 24 months of age;
 ip≤0.001 comparing ART-Def vs. ART/12m to and ART?12m vs. ART/24m. N= 
total number of children with available sample; SD= standard deviation; NA= not available; IQR=interquatile range (25-75
th
 Centile). 
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The CD4+ lymphocyte percentage at enrolment and subsequent time-points in HIV-infected 
children is summarized in Table 8.1. At a mean age of 19.6 weeks, CD4+% were higher in ART-
Immed (41.6%) compared to ART-Def (29.9%; p<0.001) and CD4+<25% (31.5%; p=0.003) 
children; Table 8.1. Similarly, CD4+% remained higher at the time of the first vaccine-dose in 
ART-Immed (39.1%) compared to ART-Def (31.0%; p<0.001) and CD4+<25% (30.6%; p=0.01). 
ART/12m had lower CD4+% (27.8%) when measured two weeks post-booster dose compared to 
ART-Def (34.5%; p<0.001) and ART/24m (36.2%; p<0.001), Table 8.1. The median age of ART 
initiation in ART-Def was 25.0 (18.4-40.0) weeks, and 65.3% (49/75) in this group had been 
initiated on ART by the time they received the first measles-vaccine and 68 (98.6%) of the 
remaining 69 had been initiated on ART by the time of their booster dose of measles-vaccine. 
Also, 67 (77.0%) of 87 ART/12m children had been re-initiated on ART by the time of their 
booster vaccine-dose.  
 
8.1.2 Pre-vaccination measles antibody kinetics 
The proportion of HIV-unexposed children who were sero-positive (78.3%) or had sero-
protective titers (65.2%) was similar to HEU children, but higher than in ART-Def (56.3% and 
37.9%, respectively) and ART-Immed (59.3% and 41.8%); Table 2. Also, GMTs were higher in 
HIV-unexposed (963 mIU/ml) compared to ART-Def (657 mIU/ml, p=0.04; Table 8.2) at 
enrollment. By 19.6-weeks of age, the proportion of children with sero-positive and sero-
protective titers among HIV-unexposed had declined to 28.9% and 16.7%, respectively; both 
higher than in ART-Def (5.7% and 0%,) and ART-Immed (16.1% and 7.2%; ); Table 8.2. There 
was no difference in the fold-decrease of antibody titers in HIV-unexposed (0.49) compared to 
HEU (0.39, p=0.21), ART-Def (0.31, p=0.97) and ART-Immed (0.42, p=0.96) between 
enrollment and 19.6 weeks of age, Table 8.2. 
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Table 8.2: Geometric mean titers and proportion of children with sero-positive and sero-protective levels of measles antibody prior 
to measles vaccination 
Time-
point 
Measure 
HIV-
unexposed
a
 
HEU
b
 
p-value
c
 
 
ART-Def
d
 
ART-
Immed
e
 
CD4+<25%
f
 
p-value
g
 
 
p-value
h
 
 
p-
value
i
 
 
Time-point 
1 
(Mean 
age: 7.3- 
weeks ) 
 N=115 N=116  N=103 N=182 N=12    
GMT (95% CI)
j
 
963 
(759-1223) 
935 
(737-1186) 
0.86 
657 
(497-869) 
731 
(596-896) 
938 
(43-20623) 
0.04 0.08 0.54 
N (%) 
≥150mIU/mlk 
90 (78.3) 80 (69.0) 0.11 57 (55.3) 108 (59.3) 2 (16.7) 0.001 0.001 0.62 
N (%) 
≥330mIU/mll 
75 (65.2) 64 (55.2) 0.12 39 (37.9) 76 (41.8) 2 (16.7) 0.0002 <0.0001 0.52 
Time-point 
2 
(Mean age 
19.6-
weeks ) 
 N=114 N=112  N=70 N=180 N=7    
GMT (95% CI) 
461 
(332-639) 
369 
(287-476) 
0.28 
202 
(126-324) 
309 
(249-385) 
0 
(0) 
0.09 0.05 0.16 
N (%) 
≥150mIU/ml 
33 (28.9) 31 (27.7) 0.83 4 (5.7) 29 (16.1) 0 (0.0) <0.0001 0.01 0.01 
N (%) 
≥330mIU/ml 
19 (16.7) 16 (13.8) 0.62 0 (0.0) 13 (7.2) 0 (0.0) <0.0003 0.01 0.02 
 GMT fold change
m
 0.49 0.39 0.21 0.31 0.42 1.0 0.97 0.96 0.94 
Footnote: aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected mothers; cp-value: HIV-unexposed 
vs. HEU; dART-Def: HIV-infected children on deferred ART; eART-Immed: HIV-infected children on immediate ART; fCD4+<25%: HIV-infected children with CD4+% <25% 
on immediate ART; gp-value: HIV-unexposed vs. ART-Def; hp-value: HIV-unexposed vs. ART-Immed; ip-value: ART-Def vs. ART-Immed; jGMT (95% CI) = geometric mean 
titer with 95% confidence interval in parenthesis; k≥150mIU/ml= proportion sero-positive for measles antibody; l≥330mIU/ml= proportion with sero-protective titers; mFold 
change in GMT from time-point1 to time-point 2. 
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8.1.3 Kinetics of measles antibody post-primary and booster doses of measles vaccine 
The first measles-vaccine was administered at 39.7 (S.D. ± 2.3) weeks of age. Twenty-eight 
weeks thereafter (Time-point 4), the proportion of HIV-unexposed children with sero-positive 
(93.8%) or sero-protective titers (91.1%) was similar to other Groups, except for a lower 
proportion of ART/12m (79.3%; p<0.001) having sero-protective titers; Table 8.3. This occurred 
despite 77.0% (67 of 87) ART/12m children already having been re-initiated on ART at this 
stage. ART/12m were also less likely to have sero-protective titers compared to ART-Def 
(95.7%; p=0.003) and ART/24m (92.1%; p=0.02; Table 8.3); and also had lower GMTs 
compared to each of the other groups at Time-point 4; Table 8.3.  
 
The booster-dose was given at 67.8 (S.D. ± 4.4) weeks of age, after which the proportion of 
children with sero-protective titers was ≥90.2% and did not differ between Groups when 
evaluated 1.9 weeks (S.D. 0.1) later; Table 8.3. The GMTs post-booster were higher in HIV-
unexposed (3124 mIU/ml) compared to HEU (2532 mIU/ml, p=0.02) and ART/12m (1435 
mIU/ml, p<0.001); Table 8.3. GMTs in ART/12m also remained lower compared to ART-Def 
(3254 mIU/ml, p<0.001) and ART/24m (2740 mIU/ml, p=0.002) post-booster dose; Table 8.3. 
The proportion of CD4+<25% children with sero-protective titers was 100% post-primary and 
post-booster vaccine.   
 
Persistence of antibody was evaluated 41.4 (S.D. ± 0.3) weeks following the booster-dose, at 
approximately 111 weeks of age, HIV-unexposed were more likely to have sero-protective titers 
(94.3%) compared to HEU (79.6%; p=0.002) and ART/12m (80.3%; p=0.010), Table 8.3. 
Although 75.4% (46/61) of ART/12m children had been re-initiated on ART by this time-point, 
they remained less likely to have sero-protective titers compared to ART-Def (96.0%; p=0.013) 
and similarly to ART/24m (86.4%; p=0.360). At the same time-point, GMTs were higher in HIV-
unexposed (2248 mIU/ml) compared to HEU (1773 mIU/ml, p=0.004) and ART/12m (1156 
mIU/ml, p<0.001), Table 8.3. ART/12m also had lower GMTs compared to ART-Def (2577 
mIU/ml, p<0.001) and ART/24m (1924 mIU/ml, p=0.009).  
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Table 8.3: Measles-antibody titers following primary and booster-vaccine stratified by HIV-exposure and HIV-infection status 
Measure 
HIV-
unexposed
a
 
HEU
b
 
p-
value
c 
 
ART-
Def
d 
p-
value
e 
 
ART/12m
f
 
p-
value
g 
 
p-
value
h 
 
ART/24m
i
 
p-
value
j 
 
p-
value
k 
 
p-value
l 
 
CD4+<25%
m 
Time-point 4 N=112 N=116  N=69  N=87   N=89    N=8 
GMT (95% 
CI)
n
 
2212 
(1888-
2591) 
3009 
(2653-
3412) 
0.008 
2253 
(1782-
2847) 
0.89 
1044 
(849-
1283) 
<0.001 <0.001 
2224 
(1822-
2717) 
0.96 0.94 <0.001 
2566 
(1188-5542) 
N (%) 
≥150mIU/mlo 
105 
(93.8) 
111 
(95.7) 
0.512 
68 
(98.6) 
0.13 
80 
(91.9) 
0.62 0.06 
85 
(95.5) 
0.59 0.28 0.33 
8 
(100.0) 
N (%) 
≥330mIU/mlp 
102 
(91.1) 
110 
(94.8) 
0.267 
66 
(95.7) 
0.25 
69 
(79.3) 
<0.001 0.003 
82 
(92.1) 
0.12 0.37 0.02 
8 
(100.0) 
Time-point 5 N=115 N=114  N=68  N=82   N=90    N=8 
GMT (95% 
CI) 
3124 
(2763-
3533) 
2532 
(2134-
3005) 
0.015 
3254 
(2656-
3988) 
0.72 
1435 
(1185-
1740) 
<0.001 <0.001 
2740 
(2334-
3217) 
0.19 0.18 0.002 
2480 
(1175-5233) 
N (%) 
≥150mIU/ml 
112 
(97.4) 
110 
(96.5) 
0.692 
67 
(98.5) 
0.61 
79 
(96.3) 
0.67 0.41 
87 
(96.7) 
0.76 0.46 0.91 
8 
(100.0) 
N (%) 
≥330mIU/ml 
111 
(96.5) 
104 
(91.2) 
0.095 
66 
(97.1) 
0.84 
74 
(90.2) 
0.07 0.10 
87 
(96.7) 
0.96 0.89 0.09 
8 
(100.0) 
Fold-change
 q
  1.4 0.95 0.0003 1.44 0.70 1.37 0.97 0.76 1.23 0.07 0.25 0.14 0.96 
Time-point 6 N=106 N=103  N=50  N=61   N=66    N=4 
GMT (95% 
CI) 
2248 
(1888-
2676) 
1773 
(1459-
2157) 
0.004 
2577 
(2005-
3311) 
0.379 
1156 
(898-
1488) 
<0.001 <0.001 
1924 
(1448-
2557) 
0.33 0.14 0.01 
1230 
(253-5990) 
N (%) 
≥150mIU/ml 
105 
(99.1) 
93 
(90.3) 
0.005 
49 
(98.0) 
0.584 
57 
(93.4) 
0.04 0.25 
64 
(96.9) 
0.31 0.73 0.35 
4 
(100) 
N (%) 
≥330mIU/ml 
100 
(94.3) 
82 
(79.6) 
0.002 
48 
(96.0) 
0.079 
49 
(80.3) 
0.01 0.01 
57 
(86.4) 
0.07 0.01 0.36 
4 
(100) 
Fold-change
q
  0.72 0.70 0.81 0.79 0.482 0.80 0.64 0.85 0.70 0.29 0.84 0.67 0.50 
Footnote: aHIV-unexposed: HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-uninfected children born to HIV-infected mothers; cp-value: HIV-unexposed 
vs. HEU; dART-Def: HIV-infected children on deferred ART; ep-value: HIV-unexposed vs. ART-Def;  fART/12m: HIV-infected children who interrupted ART at 12 months of 
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age; gp-value: HIV-unexposed vs. ART/12m; hp-value: ART-Def vs. ART/12m; iART/24m: HIV-infected children who continued ART till 24 months of age; jp-value: HIV-
unexposed vs. ART/24m; kp-value: ART-Def vs. ART/24m; lp-value: ART/12m vs. ART/24m; mCD4+<25%: HIV-infected children with CD4+% <25% on immediate ART; 
nGMT (95% CI)= geometric mean titer with 95% confidence interval in parenthesis; o≥150mIU/ml= proportion sero-positive for measles antibody; p≥330mIU/ml= proportion 
with sero-protective titers; qFold change in GMT. 
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8.2 Correlation of post-primary vaccination response with post-booster response in study 
participants  
There was no correlation between pre-vaccination measles antibody titer with post-vaccination 
titers at time-point 4 in HIV-infected and HEU children; Table 8.4. However, post-booster dose 
HIV-infected children and not HEU children showed a correlation between pre-booster and post-
booster antibody titers; Table 8.4. There was no correlation between CD4+ percent and measles 
antibody titer in ART/12m (r=0.04; p=0.77), ART/24m (r=0.03; p=0.76) and CD4+<25% 
(r=0.13; p=0.76) children; Table 8.5.  
 
Table 8.4: correlation of pre- and post vaccination antibody titers for measles vaccine 
Group (N) Time-point 2 vs. Time-point 4 Group (N) Time-point 4 vs. Time-point 5 
 r
* 
(95% CI) 
p-value 
 r
 
(95% CI) 
p-value 
HIV-unexposed 
(104) 
-0.27 
(-0.45 to -0.08) 
0.005 
HIV-
unexposed (99) 
0.43 
(0.25 to 0.59) 
<0.001 
HEU (111) -0.06 
(-0.25 to 0.13) 
0.54 
HEU (101) 0.13 
(-0.07 to 0.32) 
0.19 
ART-Def (56) -0.005 
(-0.28 to 0.27) 
0.97 
ART-Def (45) 0.84 
(0.71 to 0.91) 
<0.001 
ART/12m (71) 0.10 
(-0.14 to 0.34) 
0.39 
ART/12m (66) 0.61 
(0.43 to 0.75) 
<0.001 
ART/24m (78) -0.29 
(-0.48 to -0.06) 
0.01 
ART/24m (72) 0.62 
(0.45 to 0.75) 
<0.001 
CD4+<25% (5) 0.16 
(-0.84 to 0.91) 
0.80 
CD4+<25% (8) 0.34 (-0.48 to 
0.84) 
0.41 
Footnote: r*= Spearman‘s‘ correlation coefficient; HIV-uninfected children born to HIV-uninfected mothers; bHEU: HIV-
uninfected children born to HIV-infected mothers; ART-Def: HIV-infected children on deferred ART; ART/12m: HIV-infected 
children who interrupted ART at 12 months of age; ART/24m: HIV-infected children who continued ART till 24 months of age; 
CD4+<25%: HIV-infected children with CD4+% <25% on immediate ART. 
 
Table 8.5: Correlation of CD4+ percent with response to primary vaccination (Time-point 4) 
Group (N) MV1 
 r
*
 (95% CI) p-value 
ART-Def (58) 0.37 (0.11 to 0.58) 0.005 
ART/12m (72) 0.04 (-0.20 to 0.27) 0.77 
ART/24m (78) 0.03 (-0.20 to 0.26) 0.76 
CD4+<25% (8) 0.13 (-0.63 to 0.76) 0.76 
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Footnote: r*= Spearman‘s‘ correlation coefficient; ART-Def: HIV-infected children on deferred ART; ART/12m: HIV-infected 
children who interrupted ART at 12 months of age; ART/24m: HIV-infected children who continued ART till 24 months of age; 
CD4+<25%: HIV-infected children with CD4+% <25% on immediate ART. 
 
8.3 Factors associated with response to the two doses of measles virus vaccine administered 
in the study 
Pre-vaccination antibody titers (Time-point 2) were associated with a response to primary 
(unstandardized coefficient [b] =-0.14; SE, 0.06; p=0.02) and booster dose (b=0.35; SE, 0.04; 
p<0.001) of the measles vaccine; Table 8.6.  
 
Table 8.6: Independent variables and their association to response to primary vaccination at 
Time-point 4 (post-primary) and Time-point 5 (post-booster) for measles virus vaccine. 
 MV1 MV2 
Independent 
variables 
b SE P b SE P 
Gender 0.13 0.12 0.26 0.04 0.10 0.66 
Age 0.02 0.05 0.76 -0.002 0.02 0.93 
Race -0.05 0.22 0.80 -0.02 0.18 0.91 
Study center -0.11 0.14 0.43 -0.18 0.12 0.12 
Time since last dose -0.06 0.06 0.29 -0.01 0.07 0.83 
Pre-vaccination  
antibody 
-0.14 0.06 0.02 0.35 0.04 <0.001 
R
2   0.03   0.17 
Footnote: b: unstandardized coefficient; SE: standard error; P: p-value. Independent variables were entered simultaneously into 
the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 Black); study center (0 Stellenbosch, 1 Soweto); 
Breastfeeding (0 not breastfed, 1 breastfed).  MV1: first dose of measles virus vaccine; MV2 booster dose of measles virus 
vaccine.  
  
8.4 Factors associated with immune response to live-attenuated measles virus vaccine in 
children stratified by maternal HIV status 
Maternal HIV-infection was not associated with response to the first measles virus vaccine dose 
(b=-0.002; SE, 0.25; p=0.99); Table 8.7. Pre-vaccination antibody titer had a negative association 
with response to measles virus vaccine response in all children (b=-0.13; SE, 0.06; p=0.02. None 
of the other factors were associated with response to vaccine in children according to maternal 
HIV status; Table 8.7. 
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Table 8.7: Independent variables and their association to response to the first dose of measles 
virus vaccine by maternal exposure to HIV in their children 
 MV1 
Independent variables b SE P 
Gender 0.14 0.12 0.25 
Age 0.005 0.05 0.92 
Birth-weight 0.00002 0.0001 0.89 
Race -0.08 0.23 0.72 
Breastfeeding -0.06 0.22 0.77 
Study center -0.12 0.15 0.43 
Time since last dose -0.05 0.06 0.42 
Pre-vaccination titer (Time-point 2) -0.13 0.06 0.02 
HIV status -0.002 0.25 0.99 
R
2   0.03 
Footnote: MV1: first dosed of measles virus vaccine.  b: unstandardized coefficient; SE: standard error; P: p-value. Independent 
variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 
Black); study center (0 Stellenbosch, 1 Soweto); Breastfeeding (0 not breastfed, 1 breastfed); HIV status (0 unexposed, 1 HIV-
exposed). NVP: Neverapine; AZT: Zidovudine.  
 
HIV-unexposed children were less likely to have a robust response to measles virus vaccine (b=-
0.48; SE, 0.12; p<0.001) post-booster, as well as children from Stellenbosch (b=-0.23; SE, 0.12; 
p=0.05). Pre-booster antibody titers were also found to be associated with a more robust response 
to measles vaccine in HIV-infected children (b=0.35; SE, 0.04; p<0.001); Table 8.8.  
 
Table 8.8: Independent variables and their association to response to booster vaccination at 
Time-point 5 for measles virus vaccines by maternal exposure to HIV in children 
 MV2 
Independent variables b SE P 
Gender 0.01 0.09 0.92 
Age 0.02 0.02 0.41 
Race 0.22 0.18 0.23 
Study center -0.23 0.12 0.05 
Time since vaccination -0.02 0.07 0.77 
Pre-booster antibody (Time-point 4) 0.35 0.04 <0.001 
HIV status -0.48 0.12 <0.001 
R
2   0.20 
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Footnote: MV2: Booster dose of measles virus vaccine.  b: unstandardized coefficient; SE: standard error; P: p-value. Independent 
variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 
Black); study center (0 Stellenbosch, 1 Soweto); Breastfeeding (0 not breastfed, 1 breastfed); HIV status (0 unexposed, 1 HIV-
exposed). NVP: Neverapine; AZT: Zidovudine.  
 
8.5 Factors associated with immune response to first dose of live-attenuated measles virus 
vaccine as well as after booster dose in children born to HIV-infected woman 
HIV-infection was associated with a reduced response to the first dose of measles vaccine (b=-
0.66; SE, 0.14; p<0.001) when comparing children born to HIV-infected mothers; Table 8.9. 
Exposure to NVP (b=-0.25; SE, 0.18; p=0.16), AZT (b=-0.92; SE, 0.49; p=0.06) or combination 
therapy (b=0.14; SE, 0.46; p=0.76) for PMTCT was not associated with a response to first 
measles virus vaccine response; Table 8.9.  
 
Table 8.9: Independent variables and their association to response to primary vaccination at 
Time-point 4 for measles virus vaccine in HEU and HIV-infected children 
 MV1 
Independent variables b SE P 
Gender 0.02 0.13 0.89 
Age 0.003 0.04 0.95 
Birth-weight -0.0002 0.001 0.18 
Race 0.26 0.31 0.39 
Breastfeeding 0.02 0.21 0.93 
Study center 0.18 0.21 0.93 
Time since last dose -0.16 0.17 0.34 
Pre-vaccination titer (Time-point 2) -0.09 0.07 0.19 
NVP -0.25 0.18 0.16 
AZT -0.92 0.49 0.06 
Combined AZT/NVP 0.14 0.46 0.76 
HIV status -0.66 0.14 <0.001 
R
2   0.10 
Footnote: MV1: first dosed of measles virus vaccine.   b: unstandardized coefficient; SE: standard error; P: p-value. Independent 
variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 
Black); study center (0 Stellenbosch, 1 Soweto); Breastfeeding (0 not breastfed, 1 breastfed); HIV status (0 exposed, 1 HIV-
infected). NVP: Neverapine; AZT: Zidovudine.   
 
Post-booster; HIV-infection (b=0.57; SE, 0.13; p<0.001) and pre-booster antibody titer (b=0.43; 
SE, 0.05; p<0.001) were associated with response to the booster dose of live-attenuated measles 
virus vaccine in children; Table 8.10.  
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Table 8.10: Independent variables and their association to response to booster vaccination at 
Time-point 5 for measles virus vaccine in HEU and HIV-infected children 
 MV2 
Independent variables b SE P 
Gender 0.06 0.11 0.57 
Age 0.01 0.03 0.62 
Race 0.04 0.26 0.88 
Study center -0.37 0.13 0.005 
Time since last vaccination 0.16 0.08 0.06 
Pre-booster antibody (Time-point 4) 0.43 0.05 <0.001 
HIV status 0.57 0.13 <0.001 
R
2   0.24 
Footnote: MV2: Booster dose of measles virus vaccine.  b: unstandardized coefficient; SE: standard error; P: p-value. Independent 
variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 
Black); study center (0 Stellenbosch, 1 Soweto); HIV status (0 exposed, 1 HIV-infected).   
 
8.6 Factors associated with immune response to the first dose of measles vaccine in HIV-
infected children stratified by ART status 
Post-primary vaccination CD4+ percent was associated with increased response to live-attenuated 
measles virus vaccine in ART-Immed children (b=0.03; SE, 0.01; p=0.01); Table 8.11. 
 
Table 8.11: Independent variables and their association to response to the first dose of measles 
virus vaccine in ART-Def and ART-Immed children 
 MV1 
Independent variables b SE P 
Gender 0.10 0.17 0.53 
Age -0.01 0.05 0.87 
Birth-weight -0.0002 0.0001 0.17 
Race 0.26 0.42 0.54 
Breastfeeding -0.09 0.25 0.71 
Study center -0.32 0.19 0.09 
Time since last dose -0.21 0.21 0.32 
Pre-vaccination titer (Time-point 2) -0.14 0.09 0.13 
CD4+% 0.03 0.01 0.01 
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ART status -0.17 0.17 0.34 
R
2    
Footnote: MV1: first dose of measles vaccine.  b: unstandardized coefficient; SE: standard error; P: p-value. Independent 
variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 
Black); study center (0 Stellenbosch, 1 Soweto); Breastfeeding (0 not breastfed, 1 breastfed); ART status (0 ART-Def, 1 ART-
Immed).  
 
Response to booster dose was associated with time since last vaccination (b=0.15; SE, 0.07; 
p=0.04) and pre-booster antibody titer (b=0.54; SE, 0.05; p<0.001) in ART-Immed children; 
Table 8.12. 
 
Table 8.12: Independent variables and their association to response to booster vaccination at 
Time-point 5 for measles virus vaccine in ART-Def and ART-Immed children 
All children MV2 
Independent variables b SE P 
Gender 0.02 0.11 0.88 
Age 0.04 0.03 0.16 
Race 0.13 0.27 0.63 
Study center -0.03 0.14 0.82 
Time since last vaccination 0.15 0.07 0.04 
Pre-booster antibody (Time-point 4) 0.54 0.05 <0.001 
CD4+% 0.005 0.007 0.44 
ART status -0.22 0.12 0.06 
R
2   0.45 
Footnote: MV2: Booster dose of measles virus vaccine.  b: unstandardized coefficient; SE: standard error; p: p-value. Independent 
variables were entered simultaneously into the model and were defined as: Gender (0 Female, 1 male); Race (0 coloured, 1 
Black); study center (0 Stellenbosch, 1 Soweto); ART status (0 ART-Def, 1 ART-Immed).  
 
8.7 Concluding comments 
These results indicate that persistence of maternal measles-antibody is not an impediment to 
measles-vaccination by 6-months of age,  possibly with the Edmonston-Zagreb vaccine-strain, 
irrespective of the child‘s HIV-infection status (Scott et al., 2011). Reasonably good responses 
have been observed in ART-naïve HIV-infected children when immunized with an Edmonston-
Zagreb vaccine-strain as early as 6 months, followed by a booster-dose at 12 months of age 
(Chandwani et al., 2011). Sustainability of protection and need for further doses of measles 
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vaccine in HIV-infected children in whom ART has been interrupted and in HEU remains to be 
explored, as does the issue of sustainability of protection in HIV-infected children who are 
maintained on ART.  
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CHAPTER 9: DISCUSSION 
9.1 Validation and optimization of Luminex assay 
In the first phase of the study, validation and optimization of a Luminex multiplex assay for the 
simultaneous determination of serum IgG antibodies against diphtheria-toxoid, tetanus-toxoid, B. 
pertussis and hepatitis B epitopes in a single serum sample was undertaken, in order to evaluate 
IgG levels following routine immunization. Studies have demonstrated the ability of ELISAs to 
accurately determine vaccine responses (Fu et al., 2010), but with advances in the vaccinology 
fields of new vaccines with increased number of combined epitopes, the use of ELISA has 
become increasingly unsuitable (Pickering et al., 2002a).  
 
The major advantage of this multiplex assay, particularly when using paediatric samples, was the 
need for small sample volumes (5µl) compared to ELISAs which ranged from 10µl to 100µl of 
sample. Multiplexing allows for considerable savings in terms of materials and labour compared 
to single plex ELISA. In addition the reduced assaying time with the multiplex assay, that 
required 2.5 hours to test 38 samples for all five vaccine antigens simultaneously; instead of the 
10.5 hours required by all the ELISAs for the five study epitopes. Furthermore, the Luminex 
assays are approximately 50-100 folds more sensitive than conventional ELISA. Studies have 
been published on the multiplexing of epitopes against TT, DT, PT and FHA as either duplex, 
tetraplex and pentaplexes (van Gageldonk et al., 2008) , but the current study describes for the 
first time the determination of antibody to HepB with a multiplex system. The HepB antigen has 
been a problem with multiplexing assays because of its highly hydrophobic nature, and requires 
special attention when coupling it to the microbead. Correlation of the HepB antigen between 
ELISA and Luminex was R
2 
=0.72, reason being that antibody levels were higher with ELISA 
than with Luminex multiplex assay. Despite the low R
2 
we still found over 90% agreement 
between the two assays as seen in results in Table 5.2 and Figure 5.3. Correlation quantifies the 
degree to which two variables are related. But a high correlation does not automatically imply 
that there is good agreement between the two methods (Giavarina, 2015). The correlation 
coefficient and regression technique are sometimes inadequate and can be misleading when 
assessing agreement, because they evaluate only the linear association of two sets of observations 
(Giavarina, 2015). The R
2
, named the coefficient of determination, only tells us the proportion of 
variance that the two variables have in common. This study also showed that a single reference 
serum can be used to test all the test antigens. To ensure antigen availability for future testing 
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commercially available antigens with high purity were utilized. The optimal bead conjugation 
concentration and procedure was found to be similar to those reported for elsewhere (van 
Gageldonk et al., 2008). MFIs generated from all five conjugated microsphere bead regions 
showed linearity over a seven step 4-fold reference serum dilution range, the consequence of this 
increase in range was the resultant increase in accuracy, a reduction in the number of sample 
dilutions required and the ability to detect much lower antibody levels (Lal et al., 2005). MFI 
comparisons between monoplex and pentaplex assays allowed for determination of interference 
between the microsphere bead regions. This was important as there was always a risk of cross-
reactivity within a multiplexed assay than with a monoplex (Lal et al., 2005). For this study 
multiplexing did not seem to affect the specificity and sensitivity of the assay when compared to 
monoplexing. Even though heterologous and homologous inhibition was slightly lower than that 
reported previously (>95%) (Lal et al., 2005, van Gageldonk et al., 2008) it was still above 90% 
for all epitopes tested. 
 
The multiplex assay was found to be reproducible, with minimal variability inter- and intra assay. 
Good correlation was obtained when comparing IgG concentrations generated from the multiplex 
and ELISA and this was true for all epitopes. The correlation was further tested using the sero-
protective cut-offs for all epitopes, which showed an 8% discrepancy for TT, DT and HepB 
vaccine epitopes. The limitation of this multiplex method with the chosen epitopes is the short 
half-life of the coupling reaction, which was found to be a maximum of two weeks post coupling. 
The short half-life was also observed in a study by van Gageldonk and colleagues, especially 
with coupling of B. pertussis epitopes (van Gageldonk et al., 2008). Therefore it cannot be stored 
for use at a later date as are the commercially available assay that can be bought well in advance 
of use. 
 
9.2 Effects of HIV and treatment of HIV on response to childhood vaccines 
In the second phase of the study, the effects of HIV exposure and timing of ART initiation in 
HIV-infected children on the kinetics of antibodies to five EPI vaccines pre- and post vaccination 
as well as response to booster dose vaccination for DTwP and measles. This is the first and most-
comprehensive study evaluating immune responses to routine vaccines in HIV-infected children 
receiving early ART, irrespective of CD4+ count/percent according to current WHO 
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recommendations (WHO, 2010a). As the introduction of ART to treat HIV-infected children is 
increasing, especially in developing countries, there is a longer life expectancy and reduction in 
the number of individuals progressing to HIV disease (Tejiokem et al., 2007). Studies evaluating 
the immunogenicity of booster DTP vaccination as well as the persistence of antibodies to the 
HepB vaccine in HIV-infected children who initiated early ART in accordance to WHO 
guidelines are relatively few, and the proportion of children in these studies are limited (WHO, 
2010a). 
 
9.2.1 Immune response to DTwP and HepB vaccines in HEU children 
Data in the current study on the relative immune responses to DTwP/HBV in HEU compared 
with HIV-unexposed children differed from other reports. In-utero HIV-exposure was not 
consistently associated with lower GMCs prior to immunization in HEU compared to HIV-
unexposed children as proposed by others (Montoya et al., 2007, Miyamoto et al., 2010, Jones et 
al., 2011, Abramczuk et al., 2011, Scott et al., 2007). Although lower GMCs to TT in HEU 
children pre-vaccination were identified, the converse was true for antibody GMCs to DT, HepB 
and FHA. This could be due to regional differences in maternal antibody concentrations to 
different vaccine-epitopes and variations in factors which may influence transplacental antibody 
transfer, including differences in maternal HIV-viral load, total IgG antibody concentrations and 
placental function sufficiency in different populations (Jones et al., 2011, Abramczuk et al., 2011, 
Montoya et al., 2007, Miyamoto et al., 2010, Scott et al., 2007). These factors may influence 
HEU children‘ susceptibility to vaccine-preventable diseases during early childhood and prior to 
vaccination, and close monitoring of the HEU group of children needs to take place.  
 
Comparing HEU and HIV-unexposed children, HEU had a trend toward lower pre-vaccination 
PT GMCs but higher post-vaccination levels, and conversely had higher pre-vaccination HepB 
antibody GMCs, but lower post-vaccination levels to HepB. This corroborates that higher 
epitope-specific antibody levels pre-vaccination may interfere with the immunogenicity to 
homotypic epitopes. The higher pre-immunization HepB antibody GMCs in HEU in our study 
has been attributed to higher hepatitis B virus infection prevalence in HIV-infected than HIV-
uninfected women (Reikie et al., 2013). However, we also observed higher antibody levels to 
HepB and other vaccine-epitope GMCs in HEU compared to both ART-Immed and ART-Def 
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children. Our study did not determine HIV-infection status at birth and since only 10% of HIV-
exposed children were breast-fed, it is likely that the majority of HIV-infection in children of our 
cohort occurred either in utero or the immediate peri-partum period. Therefore, differences in 
pre-vaccination GMCs to most epitopes between HEU and either ART-Immed or ART-Def 
children, suggests an association between factors related to acquiring maternal-derived vaccine-
related antibodies and the risk of the child being HIV-infected. Placental abnormalities can affect 
transplacental antibody transfer. For example, placentas from HIV-infected women from the 
Tygerberg site showed a higher percentage of villitis and infarcts than from HIV-uninfected 
controls, especially in women with CD4+ counts below 200 cells/µl (Vermaak et al., 2012). In-
utero HEU children have increased incidence of infectious diseases, hospitalization and death 
compared to HIV-unexposed (Koyanagi et al., 2011, Kuhn et al., 2005, McNally et al., 2007, 
Slogrove et al., 2013, Kourtis et al., 2013, Slogrove et al., 2016). The mechanisms accounting for 
this increased vulnerability are not clear but a number of factors have been suggested including 
socioeconomic factors, acquisition of different pathogens from the HIV-infected mothers and 
possible immunological impairment either due to ART or HIV-exposure during development 
(Abramczuk et al., 2011, Dauby et al., 2012).  
 
Another notable finding from this study, is that despite the heightened susceptibility to morbidity 
and mortality in HEU compared to HIV-unexposed children during early infancy (Simani et al., 
2014), the memory responses to vaccine epitopes were generally similar if not occasionally more 
robust (for DT, PT and FHA) compared to HIV-unexposed children. In this study a similar 
proportion of HEU and HIV-unexposed children maintained sero-protective levels to TT, DT and 
HepB and had comparable PT and FHA GMCs 12-months post-primary vaccination series. These 
results are similar to those observed in another South African study, where HEU children had 
similar antibody levels to HIV-unexposed at 12-months to TT, DT and HepB (Reikie et al., 
2013). Anamnestic responses were also similar between HEU and HIV-unexposed, although 
HEU had higher FHA and PT GMC compared to HIV-unexposed children, the clinical 
significance of which is unclear in the absence of correlates of protection against pertussis.  
These results suggest that HEU mount good memory responses to booster-dose of DTP. 
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9.2.2 Immune response to DTwP and HepB vaccines in HIV-infected children on ART or 
not on ART 
The findings show that early ART in HIV-infected children is associated with similar quantitative 
and qualitative immune responses to vaccines as in HIV-unexposed children. Although the 
immune response in children among whom ART was deferred was generally similar to the ART-
Immed group, the ART-Def children had lower proportion with HepB antibody ≥100 mIU/ml.   
 
Differences observed between ART-Immed and ART-Def children may have been masked by 
survivor bias in the ART-Def group especially in the post-vaccination comparison. It is plausible 
that vaccine immune responses were even poorer among ART-Def children who died compared 
to surviving children. A recent review on the association of ART on vaccine immune responses 
in HIV-infected children, included studies in older children re-vaccinated between 28-weeks and 
5.3-years after ART initiation (Sutcliffe and Moss, 2010). We report a higher proportion of 
children with sero-protective antibody concentrations than in previous studies, undertaken prior 
to early ART initiation in children becoming policy, where the proportion of HIV-infected 
children without severe immunosuppression developing sero-protective antibody levels varied 
between 37% and 86% with GMCs generally much lower than in HIV- uninfected children 
(Madhi et al., 2002, Peters and Sood, 1997, Rustein et al., 1996).  
 
Timing of when ART was initiated during early infancy and in relation to receipt of the primary 
series of childhood vaccines had an on-going effect on the immune responses to booster dose of 
some of those vaccines; and persistence of protection against disease in children. Notably, even 
though all the children in the ART-Def group in our study had been initiated on ART during their 
first year of life and had similar CD4+ counts compared to the ART-Immed group at the time of 
the booster dose of vaccines, in general they had a more attenuated booster response to most 
vaccine epitopes compared to HIV-unexposed children (for TT, DT and PT) as well as compared 
to ART-Immed children (for TT and DT). In contrast, memory responses and persistence of 
antibody responses were generally similar, or differences less marked than observed for the ART-
Def group, between HIV-infected children who had been initiated on ART prior to receiving their 
primary series of vaccines (ART-Immed), compared to HIV-unexposed children. Furthermore, 
interruption of ART at 12-months of age in the ART-Immed group did not negatively impact on 
their booster responses or persistence of antibodies to the evaluated vaccine epitopes. Also, our 
study noted greater reduction in the percentage of ART-Def children with HepB antibody titres 
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≥10IU/ml at two years of age compared to it being 100% in other groups, however, it remains 
unclear whether this is indicative for booster doses of HepB vaccine in these children as 
underlying memory responses might persist even in the absence of detectable HepB antibody 
(Mahoney and Kane, 1999). 
 
Studies evaluating the immunogenicity of booster DTP vaccination as well as the persistence of 
antibodies to the HepB vaccine in HIV-infected children who initiated early ART in accordance 
to WHO guidelines are relatively few, and the proportion of children in these studies have been 
limited (WHO, 2010a). The duration of sero-protection was shorter in ART-Def than in ART-
Immed and HIV-uninfected children, as assessed by quantitative antibody response to TT, DT, 
HepB and PT. In general in previous studies, a high percentage of HIV-infected children on ART 
(±90%) were able to maintain serologic response to TT for up to one year post-vaccination 
(Zaccarelli-Filho et al., 2007, Rigaud et al., 2008, Melvin and Mohan, 2003). A recent meta-
analysis found that approximately 75% of HIV-infected children would maintain an immune 
response of ≥0.1IU/ml to tetanus-toxoid vaccine 2 to 5-years post-vaccination (Kerneis et al., 
2014). It has also been shown that children after ART initiation (similar to our ART-Def group), 
have a reduced capacity to mount sero-protective responses to toxoid antigens, especially during 
the first year of ART(Rigaud et al., 2008). In a small study pre- and post-booster responses to 
tetanus in complete versus incomplete ART responders (by suppression of HIV viral load) 
resulted in modest humoral and cellular responses in both groups, with short antibody persistence 
and antibody concentrations decaying rapidly within one year (Rosenblatt et al., 2005). Our 
results show that, despite reconstitution of the CD4+ T-lymphocyte pool over the first year of 
ART in ART-Def group, additional booster doses might be necessary to maintain sero-protective 
immunity to TT, as evident by only 72% of the ART-Def group maintaining titers ≥0.1IU/ml at 
24 months of age compared to >98% in the other three groups. 
  
Diphtheria toxoid is a weaker antigen than TT, and its immunity decays more rapidly in healthy 
children (Menson et al., 2012). In our study, in addition to an inferior anamnestic response to DT 
in the ART-Def group, these children were less likely to maintain sero-protective titers of 
≥0.1IU/ml at 24 months of age (80%) than the other groups (>98%). Nevertheless, these 
responses to DT even in the ART-Def group was higher than previously reported in children on 
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ART, where only 40-65% of children with viral suppression achieved sero-protective antibody 
levels (Zaccarelli-Filho et al., 2007).  
 
Interpretation of immune responses to pertussis vaccination is challenging, as correlates of 
protection have not been established (Taranger et al., 2000, Mallet et al., 2004, Pichichero et al., 
2001, Cherry et al., 1998, Storsaeter et al., 1998, Plotkin, 2010). Nonetheless, immune responses 
to PT and FHA were high in our study-groups, with ≥4-fold increase from pre-booster to post-
booster vaccination observed for each pertussis antigen in >87% of all children. The high sero-
conversion rates seen in our HIV-infected children were similar to previous studies on booster 
responses to DTP in relatively healthy HIV-uninfected children (Lin et al., 2007). Although our 
HIV-infected children had a significant increase in antibody concentration to PT and FHA post-
booster, the GMCs were generally lower than in HIV-uninfected children especially for PT. A 
cohort study of children on stable ART from the USA who received acellular pertussis vaccine 
reported low  antibody responses to a booster-dose and shorter duration of protective immunity 
when compared to HIV-uninfected children, despite a minimum of four doses of acellular 
pertussis vaccine during their primary series (Abzug et al., 2007).  
 
In our study persistence of antibodies to HepB surface antigen 12 months post-primary 
vaccination were high in all HIV-infected groups. However, GMC in HIV-infected children were 
substantially decreased when compared to HIV-unexposed children. Sero-protective antibody 
levels at 25-months of age had decreased from 100% to 72% in ART-Def children for 
concentrations ≥10mIU/ml, with antibody levels ≥100mIU/ml only being found in 50% of these 
children. In contrast the ART-Immed group had similar antibody levels when compared to HIV-
uninfected children, with 92% of children still having sero-protective antibody levels 
≥100mIU/ml at 25-months of age. Previous studies on the persistence of antibodies following 
HepB vaccination in HIV-infected children and adults the follow-up times range from 12 to 115-
months post-primary vaccination (Cruciani et al., 2009, Abzug et al., 2009, Fernandes et al., 
2008, Lao-araya et al., 2011, Rey et al., 2000, Scolfaro et al., 1996, Siriaksorn et al., 2006, 
Cooper et al., 2008, Kaech et al., 2012, Pessoa et al., 2010, Powis et al., 2012). As expected, the 
percentage of participants with sero-protective antibody levels decrease over time after three 
doses of HepB vaccine, 71% of primary responders maintained sero-protective antibody levels 
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(10mIU/ml) at one year of age (Cruciani et al., 2009), 33%–61% at year 2 (Cruciani et al., 2009, 
Cooper et al., 2008), and 40% at year 5 (Cooper et al., 2008). Due to the high prevalence of 
chronic hepatitis B in HIV-infected individuals (Phung et al., 2014), it is suggested that HIV-
infected individuals which show signs of immunosuppression should be tested annually and re-
vaccinated if antibody to HepB falls below the sero-protective threshold of 10 mIU/ml (Sokal et 
al., 2013, Spearman et al., 2013). Furthermore studies have shown that the standard 
immunization schedule was sub-optimal in immunosuppressed children and repeated or increased 
doses of vaccine after immune recovery should be considered (Lao-araya et al., 2011, Sokal et 
al., 2013, Wilkins et al., 2013).  
 
9.2.3 Immune response to measles virus vaccine in HIV-infected and HEU children 
 High susceptibility to measles infection as early as seven-weeks of age in the majority of HIV-
infected children and in >83% of all groups by 20-weeks of age was found in this study. Also, 
interruption of ART in HIV-infected children (ART/12m) was associated with them being less 
likely to have sero-protective levels 28-weeks following the primary-dose of measles-vaccine and 
less likely to maintain sero-protective titers 9.5-months after the booster-dose. Furthermore, there 
was also waning of immunity in HEU children 9.5-months post-booster indicated by a lower 
proportion with sero-protective titers and lower GMTs compared to HIV-unexposed.  This 
despite, the proportion of HEU with sero-protective titers being similar compared to HIV-
unexposed children following the initial and immediately following the booster-dose.   
 
This high susceptibility to measles in children under six-months is corroborated by other African 
studies in HIV-infected (85-91%) and HEU children (Lepage et al., 1992, Scott et al., 2007), and 
more recently among healthy children in developed countries (Machaira and Papaevangelou, 
2012). In developed countries, the increased susceptibility to measles infection among young 
children has been attributed to decrease in passive-immunity acquired from transplacental 
maternal measles-antibody transfer, because of lower measles antibody levels in pregnant women 
who acquired immunity from vaccination rather than by natural infection (Leuridan and Van 
Damme, 2007). Additional factors which may contribute to the increased immunological-
susceptibility to measles infection in children born to HIV-infected mothers compared to HIV-
unexposed children, include lower measles antibody titers and impaired trans-placental transfer 
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of antibody in HIV-infected mothers (Kruczek, 2010). Also, there may be greater decay of 
antibody in HIV-infected children (de Moraes-Pinto et al., 1996). The observation that GMTs and 
proportion of children with sero-protective titers were similar between HIV-unexposed and HEU 
children suggests that factors other than solely maternal HIV-positivity contributed to increased 
susceptibility to measles at an earlier age in HIV-infected children. Possible reasons include that 
mothers‘ of peri-partum HIV-infected children had higher HIV viral-load, which has been 
associated with increased perinatal HIV transmission and inversely associated with efficiency of 
trans-placental transfer of measles antibody (Farquhar et al., 2005, Thea et al., 1997, Garcia et al., 
1999).  
 
The WHO has recommended that in settings of high HIV-prevalence, children should receive two 
doses of live-attenuated measles virus vaccine at 6- and 9-months of age (WHO, 2009b). This 
recommendation has, however, not been widely implemented: for example in South Africa the 
initial dose is still scheduled for 9-months of age. Reasons for this include the inherent low 
immunogenicity of measles vaccine in younger children, coupled with interference in the 
immune response by prevailing maternal derived measles antibody (John et al., 2004, Helfand et 
al., 2008, Gans et al., 2001). Based on our study, the low prevalence of maternal-derived 
antibody in young children (<30% at 20 weeks of age) supports immunization at 6-months of 
age. A recent report from Guinea-Bissau indicated that vaccination as early as 4.5-months of age 
using the Edmonston-Zagreb measles-vaccine strain induced sero-protective antibody levels in 
77% of children, as well as being associated with 94% efficacy against measles infection 
(Martins et al., 2008). 
 
A drawback that was found was that immune response following the first dose of live-attenuated 
measles virus vaccine was only evaluated eight months after vaccination, as earlier evaluation 
had not been planned a priori in the parent-study. Consequently, although we were unable to 
undertake a direct comparison of immune responses in the overall ART-Immed compared to 
other groups, ART/24m may be representative of the initial ART-Immed cohort at least until 24 
months of age. Persistence of antibody levels up until prior to the booster-dose was similar in 
HIV-unexposed compared to ART/24m, as well as the surviving children in ART-Def. This 
indicated that the timing of ART did not affect immune responses to live-attenuated measles 
virus vaccine in those HIV-infected children with CD4+>25% at Time-point 1. However, a 
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previous reported showed a higher early-childhood mortality rate in ART-Def compared to ART-
Immed children (Violari et al., 2008). Additionally, 100% of CD4+<25% children also had 
persistence of sero-protective titers eight months post-primary dose. The good immune responses 
in HIV-infected children on ART corroborate reports that initiation of ART in the first year of 
life allows the normal development of T- and B-lymphocyte immunity (Palma et al., 2008, 
Romiti et al., 2001, Pensieroso et al., 2009). 
 
Although the proportion of ART/12m with sero-protective titers two-weeks following the booster 
dose of vaccine was similar (>90%) to the other groups, their GMTs were lower compared to 
other groups immediately post-booster dose. Furthermore, greater waning of immunity was 
observed in ART/12m following the initial and after the booster-dose, despite them being 
carefully monitored for clinical and immunological disease progression following ART 
interruption at 12-months of age, resulting in ART being re-initiated in 77% of them at the time 
of the booster-dose. CD4+ cell counts and percentage were however lower in ART/12m 
compared to ART-Def and ART/24m immediately following the booster-dose. This indicated 
that interruption of ART in ART/12m resulted in waning of immunity, including possible decline 
in anamnestic responses to measles. This may be explained by the deterioration of antigen 
specific pools of memory B-lymphocytes in the absence of ART (Pensieroso et al., 2009).  The 
proportion of ART/12m who had sero-protective titers at approximately two-years of age was, 
however, higher compared to ART-naïve HIV-infected children who had been vaccinated at 6- 
and 9-months of age and assessed at 20-months of age (41%) as reported (Fowlkes et al., 2011). 
 
In exploring the effect of HIV-exposure on persistence of measles antibody following 
vaccination, we observed that GMTs were higher in HEU compared to HIV-unexposed children 
prior to the booster-dose. Lower pre-vaccination antibody levels in HEU children have been 
previously reported to be associated with more robust immune responses to some vaccines during 
early-childhood.(Jones et al., 2011) This was, however, unlikely to be the reason for the higher 
GMTs in HEU in our study as pre-vaccination measles antibody levels were similar to that of 
HIV-unexposed children. The clinical relevance of the higher GMTs in HEU is unclear as the 
proportion of children with sero-protective titers was similar between the two groups. The higher 
GMTs in HEU children prior to the booster-dose is also difficult to explain in the context of 
lower GMTs being observed two-weeks thereafter in this group compared to pre-booster levels, 
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as well as relative to HIV-unexposed children post-booster. Lower GMTs persisted in HEU 
compared to HIV-unexposed until 9.5-months post-booster, at which time HEU were also less 
likely to be sero-positive or have sero-protective titers. The underlying immune aberration which 
may cause waning of immunity in HEU, as well as the need for further booster doses of vaccine 
in these children remain to be explored.  
 
9.3 Limitations of the study 
This study had some limitations, which included only having a convenience sample of HIV-
infected children with CD4+ T-lymphocyte <25% at screening (i.e. CD4+<25%). Data from 
CHER showed that by 7-weeks of age, 20% of HIV-infected children already have severe CD4+ 
T-lymphocyte depletion (Violari et al., 2008). Nevertheless, the observations in this group were 
similar to those of HIV-infected children on ART (i.e. ART/24m), suggesting that CD4+ 
percentage categorization at enrolment did not have an effect of immune responses to all vaccine 
epitopes in children who had been initiated on ART upon confirmation of being HIV-infected. In 
addition, we were unable to distinguish in utero from intra-partum infection and placentas were 
not collected in our study. Also, despite having used whole cell pertussis vaccine, we elected to 
measure antibody to pertussis toxoid and FHA rather than using the whole-cell pertussis ELISA 
assay, as this was more practical for inclusion in the multiplex Luminex assay. The pertussis 
toxoid and FHA antibody responses, although providing a relative measure of immunogenicity of 
the whole cell pertussis vaccine between groups in our study, is not recommended as a measure 
of immunogenicity of whole cell pertussis vaccine. Furthermore, our study involved measuring 
measles antibody by ELISA as a surrogate of protection, which have been shown to miss low 
antibody level responses (Ratnam et al., 1995), rather than the plaque reduction neutralization 
assay which correlates more strongly with protection (Cohen, 2008). We may therefore have 
over-estimated the protection against measles infection, particularly among HIV-infected 
children in whom poorer IgG avidity may affect neutralizing activity which has, however, only 
been observed in the absence of ART (Nair et al., 2009). The problem that arises with multiple 
comparisons when using the standard alpha (α) of 0.05 to determine statistical significance is that 
hundreds of p-values are presented and just by chance 5% will be statistically significant (Sinclair 
et al., 2013). This may have accounted for the unexpected associations presented for response to 
vaccines especially study center. 
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9.4 Concluding comments 
The results show that HIV-infected children on early ART require primary and booster doses at 
the same schedule and timing as HIV-uninfected children for tetanus, hepatitis B, pertussis and 
live-attenuated measles virus vaccines. This implies that early ART allowed for the development 
of memory B- and memory T-lymphocyte compartments thus allowing for relatively normal 
responses to occur in HIV-infected children (Cotton et al., 2013, Cotugno et al., 2012). On the 
other hand children treated later than one year after diagnosis, show similar responses to vaccines 
as those seen in ART naïve persons (Sutcliffe and Moss, 2010). This suggests that the 
development and reconstitution of the B-lymphocyte compartments is altered in the deferred 
treatment group (Cotugno et al., 2012). ART-Def children will require earlier booster dose 
schedules of diphtheria, tetanus and pertussis vaccine (depends on the countries formulation) than 
the specified booster dose schedule at 5-years of age. ART has been shown to partially restore 
memory T-lymphocytes for vaccine antigens to which children had been primed with prior to 
initiating treatment (Pensieroso et al., 2009).  
 
In conclusion, the first phase has shown that the multiplex assay described here was found to be 
rapid, specific, sensitive and reproducible. This assay has the potential to become a viable 
alternative to ELISAs for all the stated epitopes and allows the simplification of surveillance and 
vaccine efficacy studies. The second phase shows that HEU children were not at increased 
susceptibility to most of the studied vaccine-preventable diseases by 6-weeks of age, suggesting 
similar acquisition of antibody from their mothers in our study. Furthermore, the immune 
responses in HEU were similar to HIV-unexposed children post-vaccination. Our study indicates 
that persistence of maternal measles-antibody no longer appears to be an impediment to measles-
vaccination by 6-months of age,  possibly with the Edmonston-Zagreb vaccine-strain, 
irrespective of the child‘s HIV-infection status (Scott et al., 2011). Although HIV-infected 
children had lower GMCs post-vaccination, including to TT and HepB irrespective of timing of 
ART initiation, the proportion with sero-protective antibody concentrations post-vaccination 
were similar and timing of ART initiation generally did not affect immune responses between 
HIV-infected groups. The results indicate that vaccination of HEU and HIV-infected children 
initiated on early-ART confers with DTwP/HBV would provide similar immunity to the targeted 
vaccine-preventable disease compared with HIV-unexposed children.  Post-booster vaccination, 
duration of sero-protection was shorter in HIV-infected children, especially those on deferred 
196 
 
ART treatment, for all vaccine epitopes. With the current guidelines a large proportion of these 
children would have lost sero-protective antibody levels before the proposed booster dose 
schedules for the study vaccines. Therefore, continued monitoring of tetanus, diphtheria, 
pertussis, hepatitis B and measles specific antibody concentrations can guide the need for earlier 
boosting or re-vaccination in HIV-exposed children (infected or uninfected).   
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APPENDIX 3: OTHER TRIALS REFERRED TO IN THE STUDY 
HREC reference number: 040703  
Abbreviated title: CIPRA 2  
Trial title: A randomized trial to evaluate strategies for providing antiretroviral therapy to infants 
shortly after primary infection in a resource poor setting.  
Date of initial approval: Ethics: 24 August 2004 MCC: 21 September 2004 
 
HREC reference number: 040704  
Abbreviated title: CIPRA 4  
Trial title: Evaluation of quantitative and qualitative antibody responses to Streptococcus 
pneumoniae and Haemophilus influenza type B conjugate vaccines amongst HIV-1-exposed-
infected children that are receiving vs. those not receiving antiretroviral therapy, as well as 
among HIV-1-exposed-uninfected children and HIV-1-unexposed-uninfected children.  
Date of initial approval: Ethics: 30 August 2004 MCC: 8 November 2004  
 
HREC reference number: 031013  
Abbreviated title: Durability study  
Trial title: Durability of antibody response and measurement of anamnesis responses to a 
nanovalent Pneumococcal Conjugate Vaccine among HIV-infected and uninfected children  
Date of initial approval: 08 December 2003 
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APPENDIX 4: METHODOLOGY SECTION 
5.1. STUDY VACCINE FORMULATION.  
The vaccines‘ antigen composition is summarized in the Table 5.1 below. Commercial batches of 
CombAct-Hib were manufactured by Sanofi Pasteur, France the vaccine was prepared at the time 
of injection by reconstituting freeze-dried PRP-T with DTwP suspension (0.5ml).   Heberbiovac 
HB was obtained commercially and was manufactured by HerberBiotec S.A., Cuba and came in 
0.5ml vials. Commercial Live-attenuated measles vaccine (Rouvax®) was manufactured by 
Aventis, France and was reconstituted with 0.5ml injection water prior to use.  
 
Table 5.1: Antigen composition of study vaccines 
Antigen CombAct-Hib
 
Heberbiovac HB
 
Rouvax
 
Purified DT ≥30IU - - 
Purified TT ≥60IU - - 
wPertussis  ≥4 IUa - - 
Purified recombinant 
HBsAg 
- 10µg - 
PRP-T 10µg - - 
Schwarz strain of live-
attenuated measles virus 
- - 1000 CCID50
b 
Footnote: CombAct-Hib, Heberbiovac HB and Rouvax administered as 0.5 mL doses. a A Bordetella pertussis inactivated 
suspension, potency measured by the Kendrick test (mice intracerebral challenge assay). b CCID50, 50% cell culture infective 
doses (viral infectious units). DT indicates diphtheria toxoid; TT, tetanus toxoid; wPertussis, whole cell pertussis; HBsAg, 
HeberBiotec S.A. recombinant hepatitis B surface antigen; PRP-T, Haemophilus influenzae type b polysaccharide conjugated to 
tetanus protein 
 
5.2 EQUIPMENT, CONSUMABLES, CHEMICALS AND REAGENTS UTILIZED IN 
THE STUDY. 
 
Table 5.2: List of equipment and consumables 
Bio-Plex components Manufacturer  Maintenance/servicing  
Array reader Bio-Rad Laboratories Hercules, CA Daily 
Plate reader Bio-Rad Laboratories Hercules, CA Daily 
HTF system Bio-Rad Laboratories Hercules, CA Annually 
PC with Bio-Plex manager 
software version 4.1.1 
Bio-Rad Laboratories, Hercules, CA NA 
Waste bottle Bio-Rad Laboratories Hercules, CA Daily 
Sheath fluid bottle Bio-Rad Laboratories Hercules, CA Daily 
Bio-Plex vacuum pump 
and plate holder 
Bio-Rad Laboratories Hercules, CA Weekly and monthly 
MCV Plate IV Bio-Rad Laboratories Hercules, CA NA 
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Other equipment Manufacturer  
Ultra low freezer (-70°C)  SS engineering, Fontainebleau NA 
Refrigerator (+2 to +8°C) Staycold, Parys South Africa Annually 
Freezer (-20°C) Defy, Benrose South Africa Annually 
Orbital mixer  Thermo mixer Mxi4t, Fine PCR, Korea 
 
Monthly 
Ice flaker Scotsman, Italy  
Micro-centrifuge  
 
Boeco, Boeckel and Co, Germany Monthly 
Vortex  Fine vortex, Fine PCR, Velp Scientifica s.r.l., Italy 
 
Annually 
Timer 
 
Bio-Rad Laboratories Hercules, CA NA 
Single channel pipettes: 5-
50µl, 20-200µl, 200-
1000µl, 1-10 ml  
Nichipet, Japan 6 months 
Multi-channel pipettes: 5-
50µl, 50-300µl 
Finnpipette, Thermoscientific,  6 months 
Automatic pipettes: 
BIOHIT electronic 1200 
single and multi-channel 
 
Sartorius BIOHIT, Helsinki, Finland 6 months 
pH meter and electrode  Jenway, England 
 
monthly 
Balance  Ohaus Corporation, USA 
 
monthly 
Microscope  
 
Leica Microsystems, Heerbrugg monthly 
hemocytometer slide  Merck, Darmstadt Germany NA 
+37°C incubator Scientific, South Africa Every 2 years 
+37°C incubator under 5% 
CO2  
Sanyo Electric Biomedical, Japan Every 2 years 
Waterbath Scientific South Africa Annually 
Autoclave Gemmy Industrial Corp, Taiwan Annually 
Microplate reader  Labsystems Multiskan RC, USA Annually 
Microplate washer Molecular Devices, CA USA Annually 
Liquid Nitrogen chamber Vacuum Cryogenic Technology, South Africa NA 
   
Consumables Manufacturer Storage 
Tips: 10, 100, 1000µl AEC Amersham RT 
Tips: 5ml, 10ml and 25ml LP Italiano Spa, Italy RT 
5ml tubes with lids AEC Amersham RT 
1.5ml Microcentrifuge 
tubes 
Whitehead Scientific RT 
Erlemeyer flasks Schott Duran, Germany RT 
Graduated cylinders: 
50ml, 100ml, 1000ml and 
2000ml 
Schott Duran, Germany RT 
50µl centrifuge tubes Corning RT 
1000 and 2000ml bottles Schott Duran, Germany RT 
Polypropylene cryovials 
(2ml) 
Thermoscientific Nalgene, USA  RT 
Stericup filter unit (500ml, 
0.22µm) 
Millipore, Massachusetts RT 
Culture flasks (160ml) Nunc, Denmark RT 
Aluminium foil Various RT 
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Gloves Medic-Dent™ Supermax, Malaysia RT 
Multi-well filter plates Pall Life Sciences, USA RT 
96 well round bottom 
plate 
Sterilin® Limited, UK RT 
96 well flat bottom plates 
with lids 
Nunc, Denmark RT 
 
Table 5.3: List of antigens, chemicals and reagents for Luminex assay 
Antigen and Beads Manufacturer Code/Batch Stock 
concentration 
Storage 
Carboxylated microspheres 
(beads) 
BioRad Laboratories, 
Hercule CA 
Several 12x10^6 
beads/ml 
+2 to +8°C 
Diphtheria toxoid (DT) Staten Serum 
Institute, Denmark 
D52-2 1911 Lf/ml +2 to +8°C as 
powder 
-70°C 
reconstituted 
Tetanus toxoid (TT) Staten Serum 
Institute, Denmark 
T177-1 774 Lf/ml +2 to +8°C as 
powder 
-70°C 
reconstituted 
Pertussis toxin (PT) List biological 
Laboratories, Inc., 
USA 
181209A1 50µg +2 to +8°C as 
powder 
-70°C 
reconstituted 
Filamentous 
Hemagglutanin (FHA) 
List biological 
Laboratories, Inc., 
USA 
17036AI 50µg +2 to +8°C as 
powder 
-70°C 
reconstituted 
Hepatitis B surface antigen 
(HBsAg) 
Donated by Glaxo-
Smith Kline 
biological SA, 
Belgium 
08-011 14.99mg +2 to +8°C 
Conjugate     
R-phycoerthyryn (R-PE)-
conjugated goat anti-
human IgG (-chain 
specific) 
 
 
Phosphate buffered saline 
1x (PBS), pH 7.2±0.2 
 
Jackson 
ImmunoResearch 
Laboratories Inc. 
Westgrove, PA USA 
 
 
RMPRU 
 
109-115-098 
 
 
 
 
 
 
1xPBS 
 
0.5mg/ml +2 to +8°C 
 
 
 
 
 
 
RT 
 
Activation buffer Manufacturer Code/Batch Storage 
1x PBS, pH6.1±0.2 
 
N-hydroxy-
sulphosuccinimide 
 
1-ethyl-3-(-3-
dimethylaminopropyl)-
carbodiimide 
hydrochloride 
RMPRU 
 
Pierce, Rockland IL 
 
Pierce, Rockland IL 
1xPBS-6.1 
 
sulfo-NHS 
 
 
EDC 
RT 
 
+2-+8°C 
 
 
+2-+8°C 
Washing Buffer    
1x PBS, pH 7.2±0.2 
 
RMPRU 
 
1xPBS 
 
RT 
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Tween 20 (T) 
 
 
Sodium Azide (N) 
Merck 
 
 
Sigma-Aldrich 
8.22184.0500 
 
 
S 2002-100G 
    
Microbead coating buffer     
1x PBS, pH 7.2±0.2 
 
Fetal Bovine Serum (F) 
(1% v/v) 
 
Sodium Azide (N) (0.05% 
w/v) 
RMPRU 
 
Adcock Ingram 
 
 
Sigma-Aldrich 
1xPBS 
 
10270 
 
 
S 2002-100G 
RT 
 
+2 to +8°C 
 
 
RT 
Assay buffer (1xPBS-FN)    
1x PBS, pH 7.2±0.2 
 
Fetal Bovine Serum (F) 
(10% v/v) 
 
Sodium Azide (N) (0.05% 
w/v) 
RMPRU 
 
Adcock Ingram 
 
 
Sigma-Aldrich 
1xPBS 
 
10270 
 
 
S 2002-100G 
RT 
 
+2 to +8°C 
 
 
RT 
Standards and controls    
In-house reference serum RMPRU Luminex ref -70°C 
Positive control 
(commercial pooled IgG-
Hebagam) 
Natal Bioproducts, 
South Africa 
PC/2004/01P50 +2-+8°C 
Negative control (1xPBS-
FN) 
RMPRU 1xPBS-FN +2-+8°C 
 
Table 5.4: List of chemicals and reagents for the Hib ELISA 
Antigen Manufacturer Code/Batch Storage 
HbOHA (Hib polysaccharide conjugated to 
serum protein) 
Wyeth vaccines, 
distributed by NIBSC 
lot 17 
#BAHBOHA) 
-20ºC 
Coating buffer– PBS+Sodium azide (PBS-N) RMPRU PBS-N  RT 
Dilution buffers    
1xPBS  RMPRU 1xPBS RT 
    
Fetal bovine serum (F 10% v/v)  Adcock-Ingram(Delta) 14-501-A1 -20ºC 
Washing reagents    
1xPBS  
Tween 20 (0.05% v/v) 
RMPRU  
Merck 
PBS-T RT 
Distilled Water  <0.2µS/cm RMPRU  RT 
Conjugate    
Goat Anti-human IgG Alkali Phosphatase Sigma  A-3188 +4-8°C 
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conjugate    
Substrate    
p-nitrophenol phosphate disodium salt 
Hexahydrate 1.4 mg /ml in Carbonate buffer  
or 
Fluka, Sigma #71768 +4-8°C 
p-nitrophenol phosphate disodium salt 
1mg /ml in Carbonate buffer 
Calbiochem, Merck #4876 +4-8°C 
Carbonate buffer, pH 9.8 RMPRU  +4-8°C 
Stopping solution    
2-M NaOH RMPRU  +22°C 
Reference and controls    
Reference serum (Human anti-H. influenzae 
type b) 
FDA, Bethesda Lot 1983 -20°C 
High control (Commercial pooled IgG -
Polygam) 
Natal Bioproducts  -20ºC 
Low control (In house pool) RMPRU  -20°C 
External Quality Control Sera    
QC plasma 1 (Human anti-Hib polysaccharide, 
0.43µg/ml) 
FDA, Bethesda 
 
lot 1986A -20°C 
QC plasma 2 (Human anti-Hib polysaccharide, 
0.22µg/ml) 
FDA, Bethesda 
 
lot  1986B -20°C 
QC plasma 3 (Human anti-Hib polysaccharide, 
0.11µg/ml) 
FDA, Bethesda 
 
lot 1986C -20°C 
QC plasma 4 (Human anti-Hib polysaccharide, 
0.65µg/ml) 
FDA, Bethesda 
 
lot 1986D -20°C 
QC plasma 5 (Human anti-Hib polysaccharide, 
4.00µg/ml) 
FDA, Bethesda 
 
lot 1987E -20°C 
 
Table 5.5: List of reagents and consumable for Hib bactericidal assay 
Reagents Manufacturer Storage 
H. influenza Type B, strain B3292 Donated by Sandra Romero-Steiner, 
CDC Atlanta 
-70°C 
Hank`s Balanced Salt Solution  
w/o Ca
2+
 and Mg
2+
 (HBSS
-
) 
Life Technologies   +2-+8°C 
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10% Gelatine stock solution RMPRU  +2-+8°C 
100 x Ca
2+
/Mg
2+
 stock solution 
 
RMPRU +2-+8°C 
Dilution buffer   
44.5ml HANKS + 0.5ml Ca
++ 
and 
Mg
+
+ 5ml 1% gelatin 
 
RMPRU +2-+8°C 
Baby Rabbit Complement  (BRC) 
 
Peel-Freez Biologicals  
 
-70°C 
Media   
Brain Heart Infusion (BHI) Broth 
 
Difco +2-+8°C 
Fildes Enrichment 
 
BBL™ +2-+8°C 
Chocolate Agar 
 
NHLS media +2-+8°C 
 
5.3. DETAILED STANDARDS OF OPERATION (SOP) FOR MEASUREMENT OF 
QUANTITATIVE AND FUNCTIONAL ANTIBODY RESPONSES. 
5.3.1. Measurement of DT antibodies by quantitative ELISA (Anti-diphtheria toxoid IgG enzyme 
immunoassay (MK014)) 
Principle of the assay: 
Microwells are pre-coated with diphtheria toxoid antigen. The calibrators, control and diluted 
samples are added to the wells and antibodies recognizing the diphtheria toxoid antigen bind 
during the first incubation. After washing the wells to remove unbound proteins, purified 
peroxidase labelled rabbit anti-human IgG conjugate is added. The conjugate binds to the 
captured human antibody and the excess unbound conjugate is removed by a further wash step. 
The bound conjugate is visualized with 3‘, 3‘, 5, 5‘ tetramethylbenzidine (TMB) substrate which 
gives a blue reaction product, the intensity of which is proportional to the concentration of 
antibody in the sample. Phosphoric acid is added to each well to stop the reaction. This produces 
a yellow end point colour, which is read at 450nm.  
Materials 
Components of anti-diphtheria toxoid IgG enzyme immunoassay (MK014) kit 
Materials supplied Composition 
QC certificate Indicates expected performance of the batch and is lot 
specific 
Diphtheria toxoid coated wells 12 break apart 8 well strips coated with diphtheria 
toxoid derived from Corynebacterium diphtheria.  
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Sample diluent 50ml buffer for sample dilution. Ready to use 
Wash buffer 50ml of 20-fold concentrated buffer for washing the 
wells. Add 50ml wash buffer to 950ml of distilled 
water (1 in 220 dilution) and store at room 
temperature. 
Diphtheria toxoid IgG calibrators 7 bottles each containing 1.2ml diluted human serum, 
with the following concentrations of anti-diphtheria 
toxoid antibody: 3, 1, 0.33, 0.111, 0.037, 0.012, 
0.004IU/ml. Ready to use 
Diphtheria toxoid IgG high control 1 bottle containing 1.2ml of diluted human serum 
containing anti-diphtheria toxoid. The expected value 
is given on the QC card. Ready to use 
Diphtheria toxoid IgG high control 1 bottle containing 1.2ml of diluted human serum 
containing anti-diphtheria toxoid. The expected value 
is given on the QC card. Ready to use 
Diphtheria toxoid IgG conjugate 1 bottle containing 12ml of purified peroxidase 
labelled antibody to human IgG. Ready to use 
TMB substrate 1 bottle containing 14ml TMB substrate. Ready to use 
Stop solution 1 bottle containing 14ml of 3M phosphoric acid. 
Ready to use 
Working phase 
One hundred microliters (μl) of calibrator (NIBSC diphtheria antitoxin reference preparation 
00/496, range: 0.004-3 IU/ml), controls (high control range; 0.6-1.0 IU/ml and low control range: 
0.1-0.2 IU/ml) and diluted sample (1:100 pre-dilution) was dispensed into appropriate antigen 
pre-coated wells (MK014) and incubated at room temperature for 30 minutes. After incubation 
the microwell plates were washed three times with 350μl of wash buffer (Working wash buffer 
was prepared by 1:20 dilution) per well, using an automated plate washer (EM-96PW-TECAN-1; 
Australia). After the final wash, the plates were inverted and tapped dry, before proceeding to the 
next step. One hundred microliters of purified peroxidase labelled rabbit anti-human IgG (γ chain 
specific) conjugate was dispensed into each well and incubated for 30 minutes at room 
temperature. The plates were washed as mentioned previously. After the wash step, 100μl of 
TMB substrate (para-nitrophenylphosphate, solvent free buffer and <0.1% sodium azide as 
preservative) was dispensed into each well, and incubated at room temperature in the dark for 30 
minutes. To stop the reaction 100μl of stop solution (3M phosphoric acid) was added to each 
microwell, this resulted in a colour change from blue to yellow. The reaction was read at 450 
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nanometers (nm) on a plate reader (Labsystems Multiskan RC; USA) within 30 minutes of 
stopping of the reaction. 
 
Interpretation of results 
In order to accept the assay as valid, the following criteria have to be met:  
a. Reader settings: In order to accurately measure low samples, the manufacturer advised not to 
subtract blank optical density (OD) readings from the results, in addition ODs should be read at 
450nm without the use of a reference filter.  
b. Quality control (QC): In order accept the assay as valid; all the following criteria must be met:  
1. Calibrators and controls should have been included in each run.  
2. The value obtained for each control should be in the range specified on the supplied QC 
Certificate, which were 0.1-0.2IU/ml for the low control and 0.6-1.0IU/ml for the high 
control.  
3. The curve shape should have been similar to the calibration curve, shown on the QC 
Certificate (Figure 5.1).  
 
If the above criteria are not met, the assay is invalid and the test should be repeated.  
 
 
 
Figure 5.1: Two examples of calibration curves from the QC Certificate supplied by the 
manufacturer.  
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c. Calculate mean optical densities: For each calibrator, control and sample the mean OD was 
calculated of the duplicate readings. The percentage coefficient of variation (%C.V.) for each 
duplicate OD should have been less than 15%.  
d. Plot calibration curve: The calibration curve was plotted automatically by use of GraphPad 
Prism 5a (GraphPad Software Inc, La Jolla, California) as follows: by plotting the anti-DT IgG 
antibody concentration on the log scale against the OD on the linear scale for each calibrator by 
choosing the curve fit that bets fits the data.  
e. Treatment of anomalous point: If any one point does not lie on the curve, it can be removed. If 
the absence of this point means that the curve has a shape dissimilar to that of the sample 
calibration curve, or more than one point appears to be anomalous, then the assay should be 
repeated.  
f. Calculation of the control values: The anti-DT concentration of the controls should be read 
directly from the calibration curve and the values should be within the given ranges of the QC 
Certificate. 
g. Calculation of antibody levels in diluted samples: The anti-DT concentration of the diluted 
samples was read directly from the calibration curve. The calibrator values were adjusted by a 
factor of 100 to account for the 1:100 dilution of the sample, therefore no further correction was 
required.  
 
5.3.2. Measurement of TT antibodies by quantitative ELISA (VaccZyme tm anti-tetanus 
toxoid IgG EIA (MK010)). 
Principle of the assay 
Microwells are pre-coated with tetanus toxoid antigen. The calibrators, control and diluted 
samples are added to the wells and antibodies recognizing the tetanus toxoid antigen bind during 
the first incubation. After washing the wells to remove unbound proteins, purified peroxidase 
labelled rabbit anti-human IgG conjugate is added. The conjugate binds to the captured human 
antibody and the excess unbound conjugate is removed by a further wash step. The bound 
conjugate is visualized with TMB substrate which gives a blue reaction product, the intensity of 
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which is proportional to the concentration of antibody in the sample. Phosphoric acid is added to 
each well to stop the reaction. This produces a yellow end point colour, which is read at 450nm.  
 
Materials 
Components of VaccZyme 
TM 
Anti-tetanus toxoid IgG EIA (MK010) kit. 
Materials supplied Composition 
QC certificate indicates expected performance of the batch and is lot 
specific 
Diphtheria toxoid coated wells 12 break apart 8 well strips coated with tetanus toxoid 
derived from Clostridium tetani.  
Sample diluent 50ml buffer for sample dilution. Ready to use 
Wash buffer 50ml of 20-fold concentrated buffer for washing the 
wells. Add 50ml wash buffer to 950ml of distilled 
water (1 in 220 dilution) and store at room 
temperature. 
Tetanus toxoid IgG calibrators 7 bottles each containing 1.2ml diluted human serum, 
with the following concentrations of anti-tetanus 
toxoid antibody: 7, 2.33, 0.78, 0.26, 0.09, 0.03, 
0.01IU/ml. Ready to use 
Tetanus toxoid IgG high control 1 bottle containing 1.2ml of diluted human serum 
containing anti-diphtheria toxoid. The expected value 
is given on the QC card. Ready to use 
Tetanus toxoid IgG high control 1 bottle containing 1.2ml of diluted human serum 
containing anti-diphtheria toxoid. The expected value 
is given on the QC card. Ready to use 
Tetanus toxoid IgG conjugate 1 bottle containing 12ml of purified peroxidase 
labelled antibody to human IgG. Ready to use 
TMB substrate 1 bottle containing 14ml TMB substrate. Ready to use 
Stop solution 1 bottle containing 14ml of 3M phosphoric acid. 
Ready to use 
 
Working phase 
One hundred microliters of calibrator (NIBSC tetanus antitoxin reference preparation 76/589; 
measurable range: 0.01-7 IU/ml), controls (High control (range: 1.05-1.75 IU/ml) and low control 
(range: 0.15-0.35 IU/ml) and diluted sample (pre-diluted 1:100) were dispensed into appropriate 
wells and incubated at room temperature for 30 minutes. After incubation the plates were washed 
three times with 350μl of wash buffer per well, using an automated plate washer (EM-96PW-
TECAN-1; Australia) to remove all unbound antibodies. After the final wash, plates were 
inverted and tapped dry, before proceeding to the next step. One hundred microliters purified 
peroxidase labelled rabbit anti-human IgG (γ chain specific) conjugate was dispensed into each 
well and incubated for 30 minutes at room temperature. The plates were washed as previously 
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described. After the wash step, 100μl of TMB substrate was dispensed into each well, and 
incubated at room temperature in the dark for 30 minutes. To stop the reaction 100μl of stop 
solution (3M phosphoric acid) was added to each well, this resulted in a colour change from blue 
to yellow. The reaction was read at 450nm with a plate reader (Labsystems Multiskan RC; USA) 
within 30 minutes of stopping the reaction. 
 
Interpretation of results 
In order to accept the assay as valid, the following criteria had to be met:  
a. Reader settings: In order to accurately measure low samples, the manufacturer advised not to 
subtract blank OD readings from the results, in addition ODs should be read at 450nm without 
the use of a reference filter.  
b. QC: In order accept the assay as valid; all the following criteria must have been met:  
1. Calibrators and controls must have been included in each run.  
2. The value obtained for each control should have been in the range specified on the supplied 
QC Certificate, which were 0.15-0.35 IU/ml for the low control and 1.05-1.75 IU/ml for the 
high control.  
3. The curve shape should have been similar to the calibration curve, shown on the QC 
Certificate (Figure 5.2).  
 
If the above criteria were not met, the assay was invalid and the test should have been repeated. 
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Figure 5.2: Two examples of the anti-TT calibration curves from the QC Certificate supplied by 
the manufacturer.  
 
c. Calculate mean optical densities: For each calibrator, control and sample the mean OD was 
calculated of the duplicate readings. The %C.V. for each duplicate OD should have been less 
than 15%.  
d. Plot calibration curve: The calibration curve was plotted automatically by use of GraphPad 
Prism 5a (GraphPad Software Inc, La Jolla, California) as follows: by plotting the anti-TT IgG 
antibody concentration on the log scale against the OD on the linear scale for each calibrator by 
choosing the curve fit that bets fits the data.  
e. Treatment of anomalous points: If any one point does not lie on the curve, it can be removed. If 
the absence of this point means that the curve has a shape dissimilar to that of the sample 
calibration curve, or more than one point appears to be anomalous, then the assay should be 
repeated.  
f. Calculation of the control values: The anti-TT concentration of the controls should be read 
directly from the calibration curve and the values should be within the given ranges of the QC 
Certificate. 
g. Calculation of antibody concentration in diluted samples: The anti-TT concentration of the 
diluted samples was read directly from the calibration curve. The calibrator values were adjusted 
by a factor of 100 to account for the 1:100 dilution of the sample, therefore no further correction 
was required. 
 
5.3.3. Measurement of PT and FHA antibodies by quantitative ELISA (SERION ELISA 
classic Bordetella pertussis IgG (ESR120G)). 
 Principle of the assay 
Microwells are pre-coated with pertussis toxin and filamentous hemagglutanin antigens, which 
constituted the solid phase. The standard serum, control and diluted samples are added to the 
wells and antibodies recognizing these antigens bind during the first incubation. After washing 
the wells to remove unbound proteins, purified alkaline phosphatase is added. The conjugate 
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binds to the captured human antibody and the excess unbound conjugate is removed by a further 
wash step. The bound conjugate is visualized with para–nitrophenylphosphate (pNPP) substrate 
which gives a yellow reaction product, the intensity of which is proportional to the concentration 
of antibody in the sample. Sodium hydroxide is added to each well to stop the reaction. This 
produces a yellow end point colour, which is read at 405nm with a reference wavelength between 
620nm and 690nm.  
 
Materials 
Components of SERION ELISA classic Bordetella pertussis IgG (ESR120G) kit. 
Material Composition 
Quality control certificate with standard curve and 
evaluation table 
quantification of antibodies in IU/ml or U/ml 
PT and FHA coated microtiter strips Break apart microtiter test strips with 8 antigen coated 
single wells (altogether 12 strips), the coating material 
is inactivated. 
Standard serum Human serum in phosphate buffer with protein; 
negative for anti-HIV, HBsAg, and anti-HCV 
antibodies; preservative <0.1% sodium azide; 
colouring aminaranth O. Ready to use 
Negative control serum Human serum in phosphate buffer with protein 
negative for anti-HIV, HBsAg, and anti-HCV 
antibodies; preservative <0.1% sodium azide; 
colouring Lissamin green V. Ready to use 
Anti-human IgG conjugate Anti-human IgG from goat (polyclonal), conjugated to 
alkaline phosphatase, stabilized with protein 
stabilization solution; preservatives: 0.01% 
methylisothiazole, 0.01%  
Bromnitrodioxide. Ready to use 
Washing solution concentrate Sodium chloride solution with Tween 20, 30nM Tris, 
preservative: <0.1% sodium azide.  
Dilution buffer  Phosphate buffer with protein and Tween 20, 
preservative: <0.1% sodium azide and 0.01g/L 
Bromophenol blue sodium salt. 
Stopping solution 1.2N sodium hydroxide 
Substrate para-nitrophenylphosphate, solvent free buffer, 
preservative: <0.1% sodiumazide 
 
Working phase 
Prior to running the test, patient samples were diluted as follows: 10μl patient sample in 1000μl 
dilution buffer (phosphate buffer with protein and Tween 20, <0.1% sodium azide and 0.01g/l 
bromophenol blue sodium salt as preservative) and mixed thoroughly to prepare a homogenous 
solution. One hundred microliters of duplicate pre-diluted sample, negative control (human 
271 
 
serum in phosphate buffer with protein and <0.1% sodium azide as preservative and Lissamin 
green V as colouring) and Standard serum (human serum in phosphate buffer with protein, <0.1% 
sodium azide as preservative and amaranth O as colouring) were dispensed into appropriate wells 
pre-coated with PT and FHA, and incubated for 60 minutes under humid conditions at 37°C. 
Wells were washed three times with 300μl of wash buffer (chloride solution with Tween-20, 
30mM Tris and <0.1% sodium azide as preservative) per well. After the wash step, 100μl of 
Anti-human IgG-conjugate (anti-human-IgG from goat (polyclonal), conjugated to alkaline 
phosphatase, stabilized with protein stabilization solution, 0.01% methylisothiazolone and 0.01% 
bromnitrodioxane as preservative) was added to all wells except for the substrate blank well, and 
incubated at 37°C for 30 minutes under humid conditions. Plates were washed three times as 
previously described. Followed by the addition of 100μl of substrate (para-nitrophenylphosphate, 
solvent free buffer and <0.1% sodium azide as preservative) into all the wells including the 
substrate blank well, and incubated at 37°C for 30 minutes under humid conditions. The reaction 
was stopped by the addition of 100μl of stopping solution (1.2N sodium hydroxide) and the 
plates were gently shaken. The plates were read at 405nm with a plate reader (Labsystems 
Multiskan RC; USA) against the substrate blank. 
 
 Interpretation of results  
Substrate blank must be OD <0.25. The mean OD value of the standard serum must be within the 
validity range (OD 0.48-1.63), which was given on the lot specific QC certificate (Lot number: 
SKY.CX) of the kit (after subtraction of the substrate blank). The percentage variation of OD was 
to be less than 20%. Antibody concentration in the samples was calculated using the SERION 
evaluate-Software, which operates by inputting the 4-parameters and the reference value of the 
standard serum, antibody activity were calculated online.  
 
5.3.4. Measurement of HBsAg antibodies by quantitative ELISA (IMMUNOLISA TM HBSAB, 
ORGANICS). 
Principle of the assay 
Microtiter plates are coated with a preparation of highly purified hepatitis B surface antigen 
(HBsAg) that in the first incubation with sample specifically captures anti-HBs antibodies to the 
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solid phase. After washing captured antibodies are detected by an HBsAg labelled with 
peroxidase that specifically binds the second available binding site of these antibodies. The 
enzyme specifically bound to wells, by acting on the substrate/chromogen mixture, generates an 
optical signal that is proportional to the amount of anti-HBs in the sample and can be detected by 
an ELISA reader. The amount of antibodies may be quantified by means of a standard curve 
calibrated against the WHO reference preparation. Samples are pre treated in the wells with a 
specimen diluent able to block interference present in vaccinated individuals. 
 
Materials 
Components of ImmunoLISA 
TM 
HBsAb, Organics kit. 
Materials Composition 
Microtiter plate 8x12 microwell strips coated with purified heat-
inactivated HBsAg of both subtypes (ad and ay) from 
human origin. 
Calibration curve Standard curves, derived from anti-HBs positive 
plasma titrated on WHO standard for anti-HBs 91
st
 
reference preparation 1977, lot 17-2-77), ranging: 
Cal1=0mIU/ml; Cal2=10mIU/ml; Cal3=50mIU/ml; 
Cal4=100mIU/ml; Cal5=250mIU/ml. Contains human 
serum proteins, 5% BSA, 10nM phosphate buffer 
(pH7.4±0.1), 0.09% sodium azide and 0.1% Kathon 
GC as preservative. 
Wash buffer concentrate 20x concentrated solution. Once diluted, the wash 
solution contains 10nM phosphate buffer (pH7.0±0.2), 
0.05% Tween 20 and 0.1% Kathon GC as 
preservative. 
Enzyme conjugate Contains inactivated purified HBsAg of both subtypes 
ad and ay, labelled with horse radish peroxidase 
(HRP), 5% BSA, 10nM Tris buffer (pH6.8±0.1), 
0.3mg/ml entamicine sulphate and 0.1% Kathon GC as 
preservatives. 
Chromogen/substrate Contains a 50nM citrate-phosphate buffered solution 
pH3.5-3.8, 4% dimethylsulphoxide, 0.03% tetra-
methyl-benzidine (TMB) and 0.02% hydrogen 
peroxide. 
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Stop solution Contains 0.03M sulphuric acid solution. 
Specimen diluent 10mM Tris buffered solution pH 7.4±0.1, 0.09% 
sodium azide as preservative. 
Control serum Contains fetal bovine serum proteins, human anti-
HBsAg antibodies at about 50±10% WHO mIU/ml. 
0.3mg/ml gentamicin sulphate and 0.1% Kathon GC 
as preservatives 
 
Working phase 
Test strips pre-coated with highly purified HBsAg from subtypes ad and ay of human origin and 
reagents were brought to room temperature. Fifty microliters of specimen diluent (10mM Tris 
buffered solution pH 7.4 ±0.1, 0.09% sodium azide) was dispensed into all wells except the blank 
wells. One hundred microliters of all calibrators (five standards that contains human serum 
proteins, 5% bovine serum albumin, 10mM PBS pH 7.4 ±0.1, 0.09% sodium azide and 0.1% 
Kathon GC as preservatives. With a measurable range of 0-250mIU/ml), controls (Positive 
control: Inactivated human Anti-HBs positive serum; Negative control: serum non-reactive for 
hepatitis B virus (HBV) markers in buffer; both controls had protein stabilizers and 0.003% 
Gentamycin and 0.01% Thimerosal as preservatives) and samples were dispensed into 
appropriate wells and incubated for 60 minutes at 37°C. After incubation the plates were washed 
four times with 350μl per well of wash buffer (10mM PBS pH 7.0 ±0.2, 0.05% Tween-20 and 
0.1% Kathon GC as preservative). One hundred microliters of enzyme conjugate (inactivated 
purified HBsAg of ad and ay, labelled with horse radish peroxidase, 5% BSA, 10mM Tris buffer 
pH 6.8 ±0.1, 0.3 mg/ml gentamicin sulphate and 0.1% Kathon GC)  was added to each well 
except for the blank wells and incubated for 60 minutes at 37°C. The plates were washed as 
described previously. One hundred microliters of chromogen/substrate mixture (50mM citrate-
phosphate buffered solution pH 3.5-3.8, 4% dimethylsulphoxide, 0.03%tetra-methyl-benzidine 
(TMB) and 0.02% hydrogen peroxidase (H2O2)) was dispensed into each well including the blank 
wells and incubated at room temperature for 20 minutes in the dark. After the final incubation 
100μl of stop solution (0.3M sulphuric acid) was added to each well and the reaction was read at 
450nm with a plate reader (Labsystems Multiskan RC; USA). 
 
Interpretation of results 
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In order to accept the test as valid the following criteria in the list below should be met. 
 
Quality checks for validity of test. 
Parameters Requirements 
Blank wells <0.100 OD at 450nm 
Calibrator 0 WHO mIU/ml <0.200 OD at 450nm after blanking 
Calibrator 10 WHO mIU/ml OD 450nm higher than the OD 450nm of the 
calibrator 0 mIU/ml + 0.100 
Calibrator 250 WHO mIU/ml >1.500 OD at 450nm 
Control Serum OD 450nm = OD 450nm Cal 50mIU/ml ± 10% 
Coefficient of variation <30% for the calibrator 0mIU/ml 
 
Samples with a concentration lower than 10mIU/ml were considered negative for anti-HBs. 
Samples with a concentration higher than 10mIU/ml were considered as positive for anti-HBs. 
 
5.3.5. LUMINEX® bead-based multiplex assay  
Principle of the assay 
Luminex colour-codes microbeads called microspheres into 100 distinct sets. Each bead set can 
be coated with an antigen, antibody or reagent specific to a particular bioassay, allowing the 
capture and detection of multiple analytes from a single sample. The principle of the assay is that 
colour-coded microspheres pre-coated with analyte specific antigen or capture antibody for the 
analyte of interest are added to the micro-filter plates. Sample to be tested is added to the 
microspheres, Biotinylated detection antibodies specific to the analyte of interest are added and 
form an antigen antibody sandwich. Followed by, the addition of phycoerythryn (PE)-conjugated 
streptavidin. The beads are read on a dual-laser flow-based detection instrument, such as the 
Luminex 200™ or Bio-plex 100™ analyzer. One laser classifies the bead and determines the 
analyte that is being detected. The second laser determines the magnitude of the PE-derived 
signal, which is in direct proportion to the amount of the bound analyte. 
 
Equipment and consumables 
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Listed in section B.2, under the subtitle: List of equipment and consumables. 
 
 Reagents 
Listed in section 5.2, under the subtitle: List of antigens, chemical and reagents for Luminex 
assay 
 
Reagent and antigen preparation 
a. DT and TT antigens were prepared by converting limit of flocculation (Lf) per ml to 
micrograms per ml, where 0.332Lf/ml is equivalent to 1µg/ml. Followed by diluting the antigens 
in 1xPBS (pH7.2) to a final coating concentration of 25µg/ml.    
b. PT and FHA were prepared by dissolving the lyophilized powder in 1 ml sterile distilled water 
and shaken till all the powder was dissolved, the stock concentration was 50µg/ml for each 
antigen. From this the antigens were diluted in 1xPBS to a final concentration of 5µg/ml. 
c. HBsAg was used straight from the stock solution without any further dilution, with a working 
concentration of 14.99 µg/ml of antigen in 1x PBS. 
d. Activation buffer was prepared with 1xPBS (pH 6.1) containing 5mg EDC and 5mg Sulfo-
NHS per ml.  
e. Washing buffer was prepared with 1x PBS (pH 7.2), 0.05% Tween 20 (v/v), and 0.05% sodium 
azide (w/v). 
f. Blocking buffer was prepared with 1x PBS (pH 7.2), 1% FBS (v/v) and 0.05% sodium azide 
(w/v).  
g. Assay buffer was prepared with 1x PBS (pH 7.2), 10% FBS (v/v) and 0.05% sodium azide 
(w/v). 
 
 Activation carboxylated microsphere beads and conjugation of Antigens to activated beads 
Coupling of DT, TT, PT, FHA and HBsAg to activated microspheres was achieved by using a 
two step carbodiimide reaction.  
276 
 
Activation of beads 
Five hundred microliters of vigorously vortexed carboxylated microspheres (12.5 x 10
6 
beads/ml) 
were measured into sterile 1.5ml microcentrifuge tubes; the microsphere solution was washed 
twice with wash buffer. The supernatant was removed after each washing step and discarded. 
Five hundred microliters of the activation buffered was added to the 1.5ml microcentrifuge tube 
containing the microspheres. The microsphere and activation buffer mixture was incubated at 
room temperature for 20 minutes under constant rotation in the orbital mixer at 25 revolutions per 
minute (rpm) to allow for activation of microspheres to occur. Activated microspheres were 
washed three times with 500µl of wash buffer followed by centrifugation at 12 000xg for 5 
minutes per wash. 
 
Conjugation of beads with antigen after bead activation 
Microsphere regions were carefully chosen as to avoid regions being directly adjacent to each 
other: Microsphere regions for this assay were regions 63, 36, 66, 14 and 20 for DT, TT, PT, 
FHA and HBsAg respectively.  
 
After the final wash step post-activation of beads, the supernatant was removed and discarded. 
Activated beads were re-suspended in 500l 1x PBS (pH 7.2) with an antigen to bead ratio of 
25g/6.25 x 106 for DT and TT, 5g/6.25 x 106 for PT and FHA and 14g/6.25 x 106 for HBsAg. 
This mixture was subsequently incubated for 18 hours at room temperature in the dark under 
constant rotation in the orbital mixer at 25 rpm. The beads were washed three times with 500µl 
wash buffer and supernatant discarded. The beads were then stored in 500l blocking buffer at 
4°C in the dark until used. 
 
 Bead counting 
This process was performed prior to storage of beads at 4°C as a means of quality control. Five 
microliters of the bead suspension was diluted in 45µl of blocking buffer and mixed gently by 
rocking microcentrifuge tube up and down for 10 seconds. Ten microliters of the bead solution 
was placed on a hemocytometer slide, and the number of beads was counted in each quadrant 
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under 40 x magnifications on a microscope. The bead count was determined by the following 
formula: grid 1 + grid 2+ grid 3 + grid 4 x 10 000/0.4 = number of beads/ml. The bead count 
should be between 1-1.27 x 10
7 
beads/ml, the number of beads was captured after each 
conjugation reaction. 
 
Measurement and quantification of DT, TT, PT, FHA and HBsAg specific IgG antibody 
concentration by Luminex assay 
The purpose of the method was to determine antigen specific IgG antibody concentration in 
serum samples. 
 
Reference serum, sample and control preparation 
In-house reference sera, serum samples and controls were brought to room temperature before 
use. The reference serum was diluted with assay buffer in duplicate with a starting dilution of 
1/50 in a seven step four fold dilution series. Serum samples were diluted with assay buffer in 
duplicate to 1/100. The positive control was diluted in assay buffer in duplicate to 1/2000 and the 
negative control was run as is. 
Working phase 
Ninety six well multiscreen HTS filter plate was wet with 100µl of assay buffer, and allowed to 
stand for 30 seconds, the excess liquid was filtered by placing the plate on the plate holder with 
vacuum pump at 5Hg (the pressure should not exceed 5Hg as there was a risk of puncturing the 
filter wells). Fifty microliters of activated beads at 5000 beads/region were added to each well. 
Fifty microliters of reference sera, sample and controls were added to each well in the following 
plate layout (Figure 5.4). 
 
 
 1  2  3  4  5  6  7  8  9  10  11  12  
A
  
B 
 
R4 
3200  
S 1  S 5  S 9  S 13  S 17  S 21  S 25  S 29  S 33  S 37  
B
  
B  R4 
3200  
S 1  S 5  S 9  S 13  S 17  S 21  S 25  S 29  S 33  S 37  
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C
  
R7 
204800 
R3  
800  
S 2  S 6  S 10  S 14  S 18  S 22  S 26  S 30  S 34  S 38  
D
  
R7 
204800  
R3  
800  
S 2  S 6  S 10  S 14  S 18  S 22  S 26  S 30  S 34  S 38  
E
  
R6  
51200  
R2  
200 
S 3  S 7  S 11  S 15  S 19  S 23  S 27  S 31  S 35  PC 2000 
F  R6  
51200 
R2  
200 
S 3  S 7  S 11  S 15  S 19  S 23  S 27  S 31  S 35  PC 2000  
G
  
R5  
12800  
R1  
50 
S 4  S 8  S 12  S 16  S 20  S 24  S 28  S 32  S 36  NC
 
H
  
R5  
12800  
R1  
50 
S 4  S 8  S 12  S 16  S 20  S 24  S 28  S 32  S 36  NC  
Figure 5.4: Multiplex Plate layout. B= blank; R= reference sera; S= sample, PC= Hebagam IM positive 
control; NC= negative control 
 
The plate was covered in foil and incubated for an hour in the orbital mixer at 600rpm.  The plate 
was washed three times with 100µl of washing buffer and vacuum filtered at 5Hg. R-PE 
conjugated anti-human IgG was diluted to 1/200 and 50l was added to each well and incubated 
as previously described for 30 minutes. Plate was washed three times as previously described, the 
beads were re-suspended in 130µl wash buffer and transferred to 96 well round bottom plates for 
analysis on the Bio-Plex 200 in combination with Bio-Plex manager software version 4.1.1 (Bio-
Rad Laboratories, Hercules, CA).  
 
Interpretation of results 
For each analyte, the median fluorescent intensity (MFI) was converted to IU/ml or mIU/ml by 
interpolation from a 5-parameter logistic standard curve (log-log) for every bead 
region/reference. The microsphere immunoassay (MIA) results were determined from the mean 
of the two sample dilutions if their MFI signals were on the linear part of the reference curve. 
 
5.3.6. Measurement of Haemophilus influenzae type b PRP-t antibodies with in-house 
ELISA 
Principle of the method  
The Hib ELISA is a solid phase indirect sandwich ELISA. The Hib antigen was pre-coated onto 
microtiter plates, which act as the solid phase. Hib specific antibodies in the sample were bound 
to the antigens on the surface of the well. The antibody-antigen complex was detected by adding 
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conjugate. Substrate was added to the antigen-antibody conjugate complex and measured 
colometrically at 405nm.  
 
 Chemicals and Reagents 
Listed in section 5.2, under the subtitle: List of chemicals and reagents for the Hob ELISA 
 
 Reagent preparation:  
a. The reference serum, anti-H.influenzae type b capsular polysaccharide serum, lot 1983 
(NIBSC) was dissolved in sterile, pyrogen free water (1ml/ampoule). The mixture was incubated 
overnight at 4°C to ensure complete dissolving of the reagent. The reference serum was stored in 
1ml aliquots at –20°C.  
b. Quality control plasma (Human anti-Hib polysaccharide), was reconstituted in 1ml sterile 
distilled water and stored at -20°C.  
c. The low positive control was an in-house pooled control serum which was stored at -20ºC in 
1ml aliquots. 
d. High positive control – Polygam (Natal Bioproducts Institute, Durban South Africa) was a 
preparation of purified IgG from pooled human serum. Packaged in vials of 1g of lyophilized 
powder and stored at –20°C. Polygam was reconstituted in 50ml of sterile saline/vial and agitated 
for 15 minutes to dissolve the powder and stored at –20°C. 
e. Hib polysaccharide conjugated to serum protein (HboHA) was reconstituted in 1ml of sterile 
water to a final concentration of 1 mg/ml. The mixture was incubated for 30 minutes at room 
temperature or until the HboHA was completely dissolved. The antigen was stored at -70ºC in 
aliquots.  
f. PBS-F was made by adding 10% thawed fetal bovine serum to sterile 1x PBS. The solution 
was stored for a maximum of 5 days at +2-8ºC and when it became cloudy it was discarded. 
g. An appropriate amount of pNPP substrate powder: p-nitrophenol phosphate disodium salt 
1mg/ml or p-nitrophenol phosphate disodium salt Hexahydrate 1.4mg/ml was weighed out. The 
substrate powder was added to 0.05M carbonate buffer (pH 9.8) and swirled to dissolve, substrate 
was prepared 10-15 minutes prior to use. 
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    Antigen coating of wells in the microtiter plates 
Ninety six well microtiter plates were coated with 1µg/ml HboHA antigen diluted in PBS-N. 
One hundred microliters of the diluted antigen was pipetted into each well, the plates were 
covered with clear plate cover tape and incubated at 37°C over night (Coated plates were 
stored at +2-+8°C for maximum of five days). The plates were washed with a Skanwasher 
400, using a programme that dispenses 300µl/well of PBS-T and washed four times 
 
 Blocking-step 
One hundred microliters of PBS-F was aliquoted into each well; the plates were then covered and 
incubated for one hour at 37°C. The plates were emptied by inverting the plates and the liquid 
poured out and the plates were patted dry with a hand towel. 
 
Working phase  
Reference sera, controls and samples were tested as true duplicates; two identical dilutions were 
made up, in separate tubes which were distributed into two wells in a row allocated to a 
patient/control/reference as a form of internal quality control to minimize dilution and pipetting 
errors. The starting dilution for samples was 1:100 in 1x PBS-F. The starting dilution for the high 
positive control was 1:300 and the low positive control starting dilution was 1:100. The plate 
layout is shown in figure 5.5. 
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Figure 5.5: Plate layout for sample dilution for Hib ELISA 
 
Samples and controls: 150µl/well of the starting dilution was added to the first sample rows and 
100µl/well of PBS-F to the other wells. Doubling dilutions using 50µl (creating a 1:3 dilution) 
leaving final volume of 100µl/well. The last 50µl removed from the last row was discarded with 
the tips.  
 
Reference serum: the starting dilution was 1:600, in the first two wells, 200µl of reference serum 
was dispensed, and in the remaining wells 100µl of PBS-F was dispensed. One hundred 
microliters from the first well was transferred to the next well to have the 2 fold dilution series. 
The 100µl from the last wells was discarded to have the final volume of 100µl/well. For reagent 
control (blank), PBS-F was distributed into the blank wells (100µl/well). Plates were then 
covered and incubated for two hours at 37°C. 
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Plates were washed four times with 300µl PBS-T on the Skanwasher 400, plates were patted dry. 
One hundred microliters of HboHA conjugate at 1:1000 dilution was distributed into each well, 
covered and incubated for two hours at 37°C. Plates were then washed three times with 
300µl/well of PBS-T and twice with distilled water on the Skanwasher 400. One hundred 
microliters of pNPP substrate was distributed into each well, the plates were incubated at room 
temperature in the dark for one hour. The reaction was stopped by the addition of 50µl/well of 
2M NaOH. The plates were read with a microtiter plate reader (Multiscan II plus) at a 
wavelength of 405nm.   
 
 Interpretation of results 
Results were calculated with the CDC programme ELISA for windows version 2.00 (U.S. 
Department of Health and Human Services, CDC, Atlanta).  The reference curve should give an 
OD reading of >0.2 and 2.5, the plate was discarded if the reference readings did not fall within 
the set limits. The sample was considered positive when the 1/100 dilution gave an OD reading 
>0.2. The control values should have been within the calculated alarm limits as set out by 
RMPRU in order to except serum results for the plate.  
 
5.3.7. Measurement of serum bactericidal activity specific for Haemophilus influenzae type 
b. 
 Principle of Assay 
This protocol was based on the original method by Schlesinger et al (1992) and later modified by 
Romero-Steiner et al (2001). It reproducibly measures the functionality of serum antibodies 
against Haemophilus influenzae type b. In this assay, serum samples were serially diluted in a 
microtitre plate, and a known concentration of live bacteria was added to each well. An active 
source of complement was added to induce killing of opsonized bacteria. After a fixed time point, 
the bacteria from each well were plated out to determine the viable count. The serum bactericidal 
activity was determined by the concentration of serum which was able to produce 50% killing of 
bacteria in relation to complement control. This assay measured functional binding, as opposed to 
ELISA which measures total binding. 
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Reagents  
Listed in section 5.2, under the subtitle: List of reagents and consumable for Hib bactericidal 
assay 
 
 Reagent preparation 
All reagents and media were brought to room temperature. 
a. Dilution buffer: 44.5ml HANKS with 0.5ml Ca
++ 
and Mg
++
 5ml 1% gelatin.  
b. Complement source: Baby rabbit serum was used as the complement source. Batches of 
complement were pre-screened for a batch that had a killing effect in the presence of anti-PRP 
antibodies, but had no killing effect on Hib in the absence of opsonising antibodies. Frozen 
stocks of complement were aliquoted in 1.2ml aliquots and stored at –70C. 
 
 Haemophilus influenzae type b frozen stock preparation.  
An overnight culture of Haemophilus influenzae Type b, strain GB3292 was prepared. One 
hundred millilitres of BHI broth was prepared and autoclaved at 121ºC for 15 minutes, it was 
allowed to cool and 2% Fildes Enrichment media was added.  From the overnight culture two to 
three colonies were isolated and inoculated into the Fildes enrichment BHI broth and incubated at 
37°C. The culture was checked regularly by measuring the optical density at 600nm, until the 
growth phase of the strain was 0.45 (mid-log growth phase). Once that phase had been reached 
15% glycerol was added to the broth and mixed well. Zero point five millilitres of the mixture 
was aliquoted into cryotubes and subsequently flash frozen in an ethanol bath and dry ice, the 
frozen aliquots were stored at -70°C.  Before use 50µl of the frozen culture was plated onto 
chocolate agar plates and incubated overnight at 37°C in 5% CO2, this was done to check the 
purity of the culture. After 24 hours at -70°C bacterial viability was calculated from the stored 
aliquots in order to determine loss of viability overtime.  
 
Viable counts 
Chocolate agar plates were dried for 30 minutes in an air circulating 37°C incubator, once dry the 
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plate was divided into six sectors and labelled with the appropriate dilution 100, 100
-1
, 10
-2
, 10
-3
, 
10
-4
 and 10
-5
. A sterile U-bottom 96 well plate was prepared by pipetting 180µl of sterile PBS 
into well B-F. Two hundred microliters of undiluted sample was aseptically pipette into well A as 
in Figure 5.6.  Twenty microliters of the mixture in well A was pipetted into well B and mixed 
four times resulting in a ten-fold dilution. The transfer of 20µl into the remaining wells was 
repeated as previously stated. Twelve samples could be run on one plate.  The bacterial dilutions 
were plated out onto labelled agar plates by dropping 20µl per drop from each dilution according 
to Figure 5.7. The plate was incubated overnight at 37°C; the colonies in each drop were counted 
the following day.  
 
Calculation of CFU/ml 
(Colony drop #1 + Colony drop  #2 + colony drop #3) x 50 x dilution factor 
  3 
 
Figure 5.6: Plate layout of 96 well U-bottom plate used for diluting bacterial strain for viable 
count. 
285 
 
 
Figure 5.7: Agar plate layout 
 
Quality control sera 
QC serum was serum with a known reproducible titer of PRP antibodies and was included in 
each assay; one QC sample was included in each plate.  
Sample preparation 
Serum samples were heat inactivated at 56C in a water bath for 30 minutes. The staring serum 
dilution was adjusted on the basis of ELISA antibody results as shown in the table below. When 
it was necessary samples were pre-diluted in dilution buffer. 
 
Serum IgG concentration in µg/ml and the reciprocal dilution. 
IgG concentration g/ml (EIA) Sample dilution  
0–4 1/1 
4-7 1/2 
7-10 1/4 
10-15 1/8 
15-30 1/16 
30-50 1/32 
> 50 1/64 
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Serum samples were tested at a starting dilution of 1:8 (in plate final dilution) and diluted in a 
two-fold dilution scheme as shown in Figure B8. Twenty microliters of serum was aliquoted into 
the first wells (A1, A2.....A10), in duplicate with the last two wells being reserved for QC sample 
(A11 and A12). The remaining wells were filled with 10µl of dilution buffer (B1-12 to H1-12), 
were two-fold serial dilutions of sample were made using a multichannel pipette by transferring 
10µl of sample and mixing well. Rows H9-12 was reserved for the complement control sample. 
All wells had a final volume of 10µl, row A was a 1:8 dilution once the remainder of the reagents 
were added. Row B=1:16, row C=1:32, row D=1:64, row E=1:128, row F=1:256, row G=1:512 
and row H=1:1024. G11 and G12 are 1:512 dilutions for the QC sera, whereas H9 through H12 
were the Complement control wells. The final volume per well at the end of the entire assay was 
80l. 
 
Serum Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 QC sera 
Dilution 1 2 3 4 5 6 7 8 9 10 11 12 
1:8 A  
All wells (except the Complement (C’) control wells) contain: 
 
                                   10 l Serum dilution 
                                   20 l Bacteria dilution 
                                   10 l Complement 
                                   40 l Dilution buffer 
 
C’ control wells contain: 
 
                                   10 l Dilution buffer 
                                   20 l Bacteria dilution 
                                   10 l Complement 
                                   40 l Dilution buffer 
1:16 B 
1:32 C 
1:64 D 
1:128 E 
1:256 F 
1:512 G 
1:1024 H 
 
C’ C’ C’ C’ 
Figure 5.8: microliter plate format for Hib Killing assay 
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Pre-opsonization: Dilution of frozen bacterial stocks 
The frozen bacterial stock was thawed at room temperature. It was then mixed well by vortexing. 
Dilutions were made (1 10 1 to 10- 4 bacteria/ml) in dilution buffer. The required concentration 
for working dilution was 2000 bacteria/20l in each well i.e. 105 bacteria/ml. The concentration 
of the bacteria stock was determined beforehand by viable counts. Plate T0 controls were 
prepared as follows in microcentrifuge tubes:  
 
      T0 plate: 20 l of the working dilution was added to 60l of dilution buffer. 
      T0 3   :  20 l of the 10 
2
 bacteria dilution was added to 60l of dilution buffer. 
      T04    :  20 l of the 10
3 
bacteria dilution was added to 60l of dilution buffer. 
  
The dilutions were mixed by vortexing followed by transferring 10l of the dilution onto three 
chocolate agar plates each labelled accordingly. This was repeated three to four times on the 
same plates. The plates were tilted at a 45° angle to allow the liquid to run slowly down the 
plates. The liquid was allowed to completely absorb into the agar plates before being inverted. 
The agar plates were incubated overnight at 37°C in 5% CO2.  Approximately 60 cfu/aliquot were 
expected on the T0 plate after 18-48 hours of incubation. The average colony count was recorded 
for each T0 control 
 
 Distribution to the wells 
A multi-channel pipette was set to 20l in order to add the diluted bacterial suspension to each of 
the 96 wells in the microtiter plate. A sterile reagent reservoir was used to hold the diluted 
bacterial suspension. The lid was replaced on the plate and the plate was incubated at  
37C in 5% CO2 for 15 minutes. This step allows the pre-opsonization of bacteria with diluted 
sera. 
 
Complement  
Vials of complement were thawed immediately before use and should be at 4°C before they were 
added to the plates. Following pre-opsonization, 10l of complement was added into each well. 
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Bacterial killing 
Immediately after the complement was added, 40 µl of dilution buffer was added into each well 
and tapped five times to allow for mixing of all reagents. The plate was covered and the plate 
incubated for one hour at 37°C in 5% CO2 without shaking. 
 
Viable counts 
The surface of chocolate agar plates was allowed to dry by placing the plates in a 37°C forced air 
incubator and plates were labelled. The mixture in the 96 well plates after the one hour 
incubation was carefully mixed. Using a multichannel pipette 5µl of solution in each well was 
released onto pre-warmed chocolate agar plates. This was repeated for all the remaining columns, 
resulting in 12 chocolate agar plates per 96 well plates. The spots were allowed to air dry for 5 
minutes; the plates were inverted and incubated at 37C in 5% CO2. A colony counter was used to 
count the colonies on the plates. Complement control counts and T0 plate counts were expected to 
be close to each other at  20%. 
 
Bactericidal titers 
The bactericidal titer was defined as the reciprocal of the serum dilution with at least 50% killing, 
when compared to the average growth in the complement control wells (H9 through H12). 
Occasionally, sera with high titers needed to be re-tested at higher initial dilutions than 1:8 to 
determine the opsonic titer. Serum samples with opsonic titers <8 were reported as a titer of 4 for 
purposes of data analysis. 
 
Quality Control 
a. Time zero (T0) control: ~60 cfu/aliquot are expected. 
b. Complement control: The average growth of the four complement control wells should be 
close to the T0 control a variation of  20% is acceptable. Occasional growth in the complement 
control wells (doubling) is preferable to killing. This control is prepared within the plate and at 
the same time that the samples are run. If the assay consists of several microliter plates, use the 
average of the complement control wells in each plate to calculate the opsonic titers. 
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c. Quality control serum: A serum with known titer should be included in each assay to control 
plate to plate and day to day variation. Include one QC serum per plate (wells A11 and A12). 
Any high volume serum (with a known reproducible titer) can be used as a QC serum. QC serum 
should yield results within  1 dilution of previous average values (corresponds to a coefficient of 
variation of approximately 30%). 
 
5.3.8. Quantitative measurement of measles virus specific antibodies with ENZYGNOST® 
anti-Masern-virus/ IgG 
 Principle of assay 
Immunoglobulin G (IgG) antibodies in the test sample which are specific for measles virus were 
bound to the antigen coated onto the wells of the test plates. Anti-human IgG/POD conjugate was 
added and bound to these specific antibodies. The enzyme component of the conjugate catalyzed 
the working chromogen solution thus producing a blue colour. This reaction was terminated by 
the addition of stopping solution POD during which the colour changed to yellow. The intensity 
of the yellow colour was proportional to the activity of measles virus IgG in the sample. The 
activity was quantified in international units by calculating using the -method. 
 
 Materials 
Components of Enzygnost® Anti-Masern-Virus/ IgG kit. 
Materials supplied Composition 
Enzygnost® Anti-Measles Virus/IgG test plate Microtitration plate coated with inactivated measles 
virus antigen. The wells in the left row of each test 
strip were coated with antigen derived from permanent 
simian kidney cells infected with measles virus. While 
the wells on the right row were coated with non-
infected cells (control antigen). 
 
Anti-human IgG/POD conjugate F(ab)‘ fragment of a rabbit antibody to human IgG, 
conjugated with peroxidase and contained in 0.05M 
Tris/HCL buffer solution, pH 7.2 with 0.5% 
polygeline. Dye max 60mg/L patent blue and max 
440mg/L tartazine, preservative phenol 1g/L. 
Conjugate buffer Microbial 37 mg EDTA in a litre of 0.01M phosphate-buffered 
solution, pH 7.2 with approximately 2% tetronic and 
~100mg/L gentamicin, ~6mg/L 5-chloro-2-methyl-
isothiazole-3-one and ~2mg/L 2-methyl-4-isothiazole-
3-one. 
Anti-Measles Virus reference P/N Human serum containing IgG antibodies to measles 
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virus antigens, contained in Tris buffer solution 
(20mmol/L), pH 7.4 with ~60% humanalbumin® 
(5%). Preservatives, ~5mg/L amphotericin B and 
~100mg/L gentamicin. 
Sample buffer POD 0.3M Tris/HCL buffer solution, pH8.0-8.2, ~0.1% 
Tween 20, ~1% polygeline and ~ 5% Boviserin®. 
Preservatives ~5mg/L amphotericin b and ~ 100mg/L 
gentamicin. 
 
 Reagent Preparation 
All reagents were brought to room temperature before the test procedure was initiated. 
a. Anti-human IgG/POD conjugate: was diluted 1:50 with conjugate buffer microbial, transfer 
250l of conjugate into a vial of 12.5ml of conjugate buffer microbial and shaken gently. 
b. Coloured sample buffer POD: 2.5ml of colour solution blue was added to 50ml of sample 
buffer POD and shaken gently. 
c. Washing solution POD: for each test plate 20ml of washing solution was added to 400ml of 
distilled water. 
d. Working chromogen solution: for each test plate 1ml of chromogen was added to 10ml of 
buffer/substrate TMB and stored protected from light. 
e. Specimen predilution: serum samples and anti-measles virus reference P/N were diluted in a 
ratio of 1:20 using coloured sample buffer POD. Therefore 20l of sample into a dilution tube 
and added into 400l of sample buffer POD and mixed well. 
 
Working phase 
Each well was filled with 200l of non-coloured sample buffer POD. Twenty microliters of pre-
diluted anti-measles virus reference P/N into the first pair of coated wells (A1= measles virus 
antigen; A2: Measles virus control antigen). Afterwards prediluted samples were added to the 
remaining wells. The plate was incubated at 37°C ±1°C for 60 minutes under humid conditions. 
Plates were washed 4 times with diluted wash buffer solution POD, they were not tapped dry. 
One hundred microliters of working anti-human IgG/POD was added to each well and sealed 
with foil and incubated at 37°C for 60 minutes under humid conditions. The wash step was 
repeated, after washing 100l of working chromogen solution was added to each well and the 
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plate was sealed with foil and incubated for 30 minutes at room temperature in the dark. One 
hundred microliters of stopping solution POD was added to each well, the reaction was read at 
450nm and referenced at 620nm. 
 
 Interpretation of results 
a. Internal quality control: for all evaluations the values used were the sample absorbance values 
in the antigen well minus those in the control antigen well. These difference values were stated as 
A. 
b. Validation criteria: For evaluation, each A value obtained per test with anti-measles virus 
reference P/N must be within the lot-dependent lower and upper margins stated on the barcode 
table of values. In addition, the individual A values must not differ by more than 20% from the 
mean value calculated from these values. If these conditions were not met the test was considered 
as invalid and had to be repeated. 
c. Measurement correction: For achieving optimal reproducibility of the results, the 
measurements require correction, both for the quantitative evaluation using the -method and for 
the qualitative evaluation of the test. First, calculate the mean A value for the Reference P/N. 
Then, divide the nominal value of the reference P/N by the calculated mean A value, this gave 
the correction factor. This value was used to multiply the A values. 
 
Correction factor =   nominal value/ Mean A of Reference P/N  
d. Qualitative evaluation: 
The following criteria were applied for qualitative evaluation: 
Anti-Measles Virus/IgG negative             A<0.100 (cut-off) 
Anti-Measles Virus/IgG positive              A>0.200 
Anti-Measles Virus/IgG equivocal           0.100A0.200 
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e. Quantitative evaluation using the -method: Samples with IgG antibody activities above the 
cut-off value were evaluated quantitatively with the aid of the -method. 
Log10 mIU/ml =  x A
 
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APPENDIX 5 
 
 
